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Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction. Various
therapeutic agents have been showed to halt disease progression in clinical studies. In this special
issue, we cover subjects from the periodontal condition of RA patients [1,2] to therapeutic strategies [3],
and patient related outcomes [4,5], accompanied by the most extensive review ever on methotrexate
(MTX) use in RA [6].
Eriksson et al. [1] describe that the subgingival plaque of RA patients with moderate/severe RA
was enriched with abundant bacteria of different bacterial strains typical for periodontitis. Interestingly,
ACPA also positivity correlated with moderate to severe periodontitis. Rinaudo-Gaujous et al. [2]
showed that MMP-3 (matrix metalloproteinase 3), a marker of periodontal disease and bone and
cartilage degradation, decreases subsequent to newly introduced infliximab therapy together with
a reduction of disease activity. The interesting question is whether periodontitis primarily improves
due to the reduction of disease activity, or whether improved arthritis leads to less pain during dental
brushing and improved dental care remains, so far, unsolved.
Köhler et al. [7] reviewed the available methods for treatment of RA, while Mueller et al. [3]
discussed how combination of the whole therapeutic armamentarium (new onset biologic agent,
intra-articular and oral glucocorticoids, and optimization of conventional synthetic DMARDs) leads to
a vastly improved outcome in a randomized clinical study. ACR 20, 50, and 70 response rates were
achieved in 90.5%, 76.2%, 71.4%, an outcome that has so far not been achieved in a clinical trial of
RA. The same group also reports the most extensive real-life experience of RA patients treated with
tofacitinib in this issue [8]
Taylor et al. [6] wrote the largest and most comprehensive review on MTX, covering the
pharmacology, the flexibility and efficacy and cost/benefit of the drug. Included among many other
topics are the potential toxicities of MTX.
Hirter et al. [9] reviewed the literature on pseudo-erosions and came to three conclusions:
(A) Pseudo-erosions may be related to normal anatomy or technical artefacts. (B) So-called calcified
zones can be part of classical anatomical structures, such as subchondral, sub-tendinous or -ligamentous
bone. (C) As a caveat, a real arthritic erosion can develop at the site of a pseudo-erosion.
In two post-hoc analyses of the RA BEAM Study Fautrel et al. [4] and Taylor et al. [5] demonstrated
that in RA patients with moderately to severely active RA despite MTX treatment, the addition of
baricitinib may be more effective in improving pain and physical function than placebo or addition
of adalimumab.
In summary, in this special issue the disease of RA and its therapy is described from different
angles to provide a broad and profound insight into the disease.
J. Clin. Med. 2020, 9, 2562; doi:10.3390/jcm9082562 www.mdpi.com/journal/jcm1
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Abstract: Rheumatoid arthritis is a chronic inflammatory disease characterized by the development
of osseous and cartilaginous damage. The correct differentiation between a true erosion and other
entities—then often called “pseudoerosions”—is essential to avoid misdiagnosing rheumatoid arthritis
and to correctly interpret the progress of the disease. The aims of this systematic review were as follows:
to create a definition and delineation of the term “pseudoerosion”, to point out morphological pitfalls
in the interpretation of images, and to report on difficulties arising from choosing different imaging
modalities. A systematic review on bone erosions in rheumatoid arthritis was performed based
on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
The following search terms were applied in PubMed and Scopus: “rheumatoid arthritis”, “bone
erosion”, “ultrasonography”, “radiography”, “computed tomography” and “magnetic resonance
imaging”. Appropriate exclusion criteria were defined. The systematic review registration number
is 138826. The search resulted ultimately in a final number of 25 papers. All indications for
morphological pitfalls and difficulties utilizing imaging modalities were recorded and summarized.
A pseudoerosion is more than just a negative definition of an erosion; it can be anatomic (e.g., a normal
osseous concavity) or artefact-related (i.e., an artificial interruption of the calcified zones). It can be
classified according to their configuration, shape, content, and can be described specifically with an
anatomical term. “Calcified zone” is a term to describe the deep components of the subchondral,
subligamentous and subtendinous bone, and may be applied for all non-cancellous borders of a bone,
thus representing a third type of the bone matrix beside the cortical and the trabecular bone.
Keywords: rheumatoid arthritis; pseudoerosions; hand; foot; ultrasonography; radiography;
computed tomography; magnetic resonance imaging
1. Introduction
Rheumatoid arthritis (RA) manifests with three types of structural joint damage: joint
space narrowing, erosions, and capsular abnormalities in the form of synovial proliferation and
subluxations [1–4]. The diagnosis of erosions and their quantification as part of radiographic scoring
systems is an accepted surrogate biomarker of structural progression of arthritis [4,5]. Erosions
in RA have been defined in consensus statements and in studies with high-resolution peripheral
quantitative computed tomography (HRpqCT) as cortical defects, breaks, or other discontinuities with
underlying trabecular bone loss and characteristic locations that can be identified with imaging [6–12].
On radiographs, according to the 2010 ACR/EULAR (American College of Rheumatology/European
J. Clin. Med. 2019, 8, 2174; doi:10.3390/jcm8122174 www.mdpi.com/journal/jcm3
J. Clin. Med. 2019, 8, 2174
League Against Rheumatism) rheumatoid arthritis classification criteria [13,14], erosions have to be
seen at least at three separate joints at the interphalangeal (PIP), metacarpophalangeal (MCP), wrist
(counted as one joint), or metatarsophalangeal (MTP) joints [15,16]. For ultrasound (US) and magnetic
resonance imaging (MRI), the operational OMERACT (outcome measures in rheumatology) definition
requests the abnormality being visible in two planes [17,18].
At the wrist, the most frequent locations are the capitate, ulna, lunate, triquetrum, and scaphoid [19–26],
at the ankle the distal fibular notch, the navicular, cuneiform and cuboid bones are often involved,
the talus and calcaneus less frequently [27,28]. Why erosions occur at these sites is commonly
explained by immunological and anatomical models [29–31]. The latter mainly refer to the thinning
of cartilage near capsular insertions at bones (bare areas) and to microdamage [32–36]. Following
immunologically-based concepts, erosion formation is explained by increased bone resorption and
decreased bone formation at certain locations in the subchondral bone [37]. Werner et al. [32] showed
a correlation between cortical micro-channels and the occurrence of bone erosions in bare areas.
Especially in early, preclinical or undifferentiated arthritis with small or no erosions, it is
necessary to differentiate a true rheumatic erosion from the various forms of normal erosion-simulating
concavities of the bony surface and therefor avoid false-positive statements [38,39]. Such so-called
pseudoerosions [40] have been described to be smooth and well demarcated on radiographs, ultrasound,
computed tomography (CT) and MRI [41]. The effect of misinterpreting a normal anatomic concavity
as an erosion or vice versa may be estimated from the intra- and inter-reader variations of scoring
systems and has been directly mentioned for the RAMRIS (rheumatoid arthritis MRI score) [42,43].
The spectrum of MRI “erosion-like” lesions is broad: Ejbjerg et al. [44] observed them in 1.9% of healthy
persons, whereas Olech et al. [45] saw them in 65%. Rothschild [46] questioned if such findings should
be interpreted as true erosions, old erosions from earlier diseases without clinical significance, or other.
For the US, a 30% false-positive rate of erosion detection has been reported [47]. The computer-assisted
assessment of erosions was considered helpful, but difficulties in discriminating those from normal
bony concavities were observed [48,49].
The aim of this systematic review was (1) to evaluate the frequency of specifically stated difficulties
arising in the interpretation of imaging modalitis in search for bone erosions, (2) to define the
characteristic anatomic appearances and patterns of pseudoerosions with respect to the potential
pitfalls in the diagnosis of RA as reported in the literature and (3) to develop an anatomic concept for
improving the accuracy and precision of imaging assessment.
2. Materials and Methods
A systematic review on bone erosions in RA was performed based on the guidelines of the
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and was
registered accordingly (No. 138826) [50].
2.1. Search Strategy
The search was performed in PubMed (Medline) and Scopus with the following search terms:
“rheumatoid arthritis”, “bone erosion”, “ultrasonography”, “radiography”, “computed tomography”
and “magnetic resonance imaging” (example for search in PubMed: “rheumatoid arthritis” AND bone
AND erosion AND (ultrasonography OR radiography OR “computed tomography” OR “magnetic
resonance imaging”). No specific date was defined as starting point, the end of search was 31 May
2019. English language was defined as a required criterium.
2.2. Selection Criteria
All original studies investigating the diagnosis of RA with X-ray, sonography, CT or MRI and
describing false positive diagnoses of bone erosions and erosion-like changes published before 31 May
2019 were included. Exclusion criteria were animal studies, feasibility studies, other inflammatory
diseases, clinical studies comparing therapeutic measurements in RA, studies comparing the sensitivity
4
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of imaging modalities without report of false positive diagnosed erosions or erosion-like lesions, surgical
procedures or longitudinal studies without direct reference to this topic, case reports and conference
papers. Additionally, all papers without full text availability were excluded from the analysis.
Data extraction was performed by using a standardized Excel (Microsoft Corporation, Redmont,
WA, USA) data extraction form: first author, year of publication, country, study population,
number of patients, imaging modality, joints evaluated, reported sensitivity of imaging modalities,
reported false positive or false negative diagnosis of bone erosions, reported limitations in image
interpretation with respect to anatomy, the differential diagnosis to other erosive diseases, artifacts and
signal-to-noise reduction.
3. Results
The search with the defined terms resulted in a total of 1487 results. An additional number
of 59 papers were added after reference-screening. The flow diagram of the literature review may
be seen in Figure 1. Ultimately, only 25 papers reported specifically on false-positive results or
erosion-like changes.
Records identified through 
database searching 
(n = 1487) 
Additional records identified 
through other sources 
(n =59) 
Removal of duplicates 
(n = 133) 
Records screened 
(n = 1413) 
Records excluded 
(n = 983) 
Full-text articles assessed 
for eligibility 
(n = 430) 
Full-text articles excluded, 
with reasons 
(n = 405) 
Studies included in 
qualitative synthesis 
(n = 25) 
Figure 1. Flow diagram of the literature review.
Based on the information gathered in the remaining papers, the false-positive results were
subdivided into anatomic pseudoerosions, if the explanation for the false-positive diagnosis was
5
J. Clin. Med. 2019, 8, 2174
described as a morphological phenomenon, and into artifact-related pseudoerosions, if the explanation
for the false-positive diagnosis was related to the respective imaging technique.
3.1. Anatomic Pseudoerosions
Anatomic pseudoerosions, i.e., normal concavities of a bone with a potential for misinterpreting
them as arthritis-related erosions, were described in twelve original papers and reviews and may be
classified into four types according to their anatomic form and configuration (Table 1): (1) a groove or
notch or its incomplete form, i.e., a jutty, (2) a sulcus as part of an osteofibrous channel, (3) a subcapital
neck on long bones, or (4) a nutritional channel or a zonal roughness [3,11,41,51–57]. According to their
shape, they may be grouped into (1) shallow or broad concavities and (2) subchondral cysts, if en-face
displayed on an image and occasionally with a small opening to the joint space, or (3) channel-like
structures (Figure 2a,c) [3,54,55]. The anatomic location of pseudoerosions is predominantly at the
carpal bones, the MCP- and the MTP-joints. Almost always they are linked to a ligament insertion
(Figure 2b), a mucosal fold fixation or the hood of a tendon sheath, and occur at the noncortical bone,
also known calcified zones (i.e., borders of the subchondral and enthesial calcified bone with the
adjacent underlying trabecular structures). The content of pseudoerosions is visible with US and MRI
and may be normal or degenerated ligament tissue, or blood vessels [44,56] and the development of
edematous changes [58]. With contrast media, a slight enhancement can be observed, however, in one







Figure 2. Examples of anatomical pseudoerosions. (a) Example of a sulcus like pseudoerosion of the
capitate bone (black circle) in a left hand of a 52 years old female patient. Referred for suspected
scaphoid fracture, which was not verified. (b) Example of a pseudoerosion at the level of the scaphoid
waist (black circle) in a right hand of a 66 years old female patient. Referred because of unspecific wrist
pain, which afterwards subsided without treatment after one week. (c) Scaphoid rim simulating an
erosion in a left hand of a 38 years old male patient (white circle). Referred because of presurgical
planning after fracture of the fifth metacarpal and luxation of the fourth and third metacarpal.
6
J. Clin. Med. 2019, 8, 2174
Table 1. Pseudoerosions.




Alasaarela et al., 1998
[58] Original research
Magnetic resonance imaging





in subchondral bone in MRI












Dohn et al., 2006 [53] Original research Sonography Erosion-likechanges
Metacarpophalangeal (MCP)
joints
Dohn et al., 2013 [57] Original research Sonography False positiveinterpretation
Cortical irregularities
(osteophytes, notches at the
metacarpal neck, subcortical
bone cysts)
Ejbjerg et al., 2004 [44] Original research MRI (1.0 T1 spin echo, STIR,T2 spin echo fat-suppressed
Erosion-like
changes Capitate, lunate
Martel et al., 1965 [3] Original research Plain radiography Carpalpseudoerosion
Normal deep groove in the
capitate in about 10%
McQueen et al., 2005 [51] Review article MRI (T1, T2 fat-saturated) False positiveinterpretation
Attachments of interosseous
ligaments of the wrist, articular
ligaments of the MCP joints,
nutrient foramina
Peluso et al., 2015 [52] Original research 3D sonography False positiveinterpretation
Arterial foramina
Osteophytes
Robertson et al., 2006
[56] Original research






Torshizy et al., 2008 [55] Original research CT Tarsalpseudoerosions
attachment site of joint capsule
ligament insertions
tendinous sulci
Wawer et al., 2014 [41] Original research Plain radiography Carpalpseudoerosions ligament insertions
STIR = Short TI Inversion Recovery, FSE = Fast Spin Echo, SPGR = Spoiled Gradient Recalled Echo.
3.2. Artifact-Related Pesudoerosions
Artifact-related pseudoerosions were mentioned in 18 original papers and reviews and may be
caused due to (1) partial volume artifacts of cross-sectional images or other modality-specific artifacts
(ultrasound diffraction or reflection, insufficient fat suppression with MRI), or (2) a low signal-to-noise
ratio (Table 2) [1,5,52,57–68].
Table 2. Imaging difficulties.
Citation Type of Article Imaging Modality Reported Problem
Alasaarela et al., 1998 [58]
Original research CT
Examination of a curvilinear object—the
more the reformat plane parallels the z-axis,
the more resolution of multiplanar
reformats is impaired. The partial volume
effect is harmful.
Plain radiography Information dependent on projections used
Albrecht et al., 2013 [1]
Original research Plain radiography 2D character of radiography
CT No simultaneous assessment ofinflammatory changes of RA
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Table 2. Cont.
Citation Type of Article Imaging Modality Reported Problem
Amin et al., 2012 [62] Original research Plain radiography Beam has to hit erosion tangentially toshow cortical break
Aurell et al., 2018 [63] Original research Plain radiography
Possibility of false negative evaluation, if
the orifice of the erosion is not hit
tangentially
Cimmino et al., 2002 [60] Original research MRI (T2 spin echo orgradient echo)
Failed fat suppression can mimic bone
marrow edema
Dohn et al., 2013 [57] Original research Sonography Some areas of hand and wrist areinaccessible for ultrasound beam
Dohn et al., 2008 [65] Original research MRI (0.6T T1 3D fastfield echo)
Overestimation of erosion size due to
difficult differentiation between cortical
bone and erosion
Ejbjerg et al., 2006 [64] Original research Plain radiography Up to 30% of an MCP joint bone has to beeroded before detection
Emond et al., 2012 [68] Original research MRI (1T 3D spoiledgradient echo)
Boundaries of erosions difficult to
differentiate
Foley-Nolan et al., 1991 [59] Original research Plain radiography Erosions only visible when large percentageof bone thickness has been destroyed
Forslind et al., 2003 [61]
Original research Plain radiography Delineation of erosions difficult in patientswith osteoporosis
MRI (1.0T 3D T2
gradient echo, T1 spin
echo with and without
fat-saturation)
False negative interpretation due to
contiguous looking erosions
Kleyer et al., 2016 [66] Original research MRI (1.5T T1) Small cortical breaks not seen onMRI—validation by HRpqCT
McQueen et al., 1998 [69] Original research
MRI (1.5T T1 and T2
with and without fat
suppression)
Partial volume artefacts may lead to false
positive indications of erosions
McQueen et al., 2001 [70] Original research Plain radiography Identification of erosions hampered by poorvisibility at the carpus
Peluso et al., 2015 [52] Original research Ultrasonography
Due to anatomical structure, multiplanar
distribution of bones that restricts the
ultrasound beam and alters the correct
visualization





False positive identification of erosions due
to motion artefacts, strong susceptibility
artefacts at tissue intersections
Weak differentiation of cortical bone
Wakefield et al., 2000 [5] Original research Plain radiography
Typical anatomical location of bone
erosions difficult to see until it lies in the
tangential plane of the radiographic beam.
Plain radiography Periarticular osteoporosis
Wawer et al., 2014 [41] Original research Plain radiography
Less density in subcortical cancellous bone
due to synovial and bony hyperemia,
overlapping of carpal bones, presence of
osteophytes
4. Discussion
From the viewpoint of imaging anatomy, a misinterpretation of erosions in RA may occur due
to (1) anatomic pseudoerosions, or (2) artifact-related pseudoerosions as a result of an inadequate
investigation technique. Pseudoerosions and erosions are commonly located at certain areas of the
surface outline of the calcified bone, also known as calcified zones. These may therefore, besides
cortical bone and trabecular bone, be regarded as a third type of organization of the bone matrix.
The term “calcified zones” (Figure 3) in this context is therefore proposed to describe the borders
of the subchondral and enthesial calcified bone with the adjacent underlying trabecular structures.
It may be extended for describing all parts of intraarticular bone apart from the cortex. With its
overlying tissue of hyaline cartilage, synovium or capsule-ligamentous structures it forms anatomic
units. The relationship between these zones and the adjacent tissues is so tight that the fibrous layers
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of tendon sheaths, bursae, periosteum or the cartilaginous zones of entheses or hyaline cartilage are
in direct continuation with the subjacent bone, thus providing direct contact with synovial tissue.
The concept of the subchondral zone was used by Dihlmann [71] to describe the mineralized zone of
hyaline cartilage as part of the subchondral bone. It may be extended to describe a subligamentous,
subtendinous or subbursal zone of the bone. Utilizing sub-millimeter spatial resolution CT, these
calcified zones can be displayed. Differentiating the normal calcified zone from erosional changes, i.e.,
irregular margins and sclerotic reaction, is the main challenge in differentiating true erosions from
pseudoerosions [72].
 
Figure 3. Example of a calcified zone. Thin ground section of the calcaneal tuberosity, the calcaneal
tendon and the calcaneal bursa—also a frequent location of bone erosions. The described calcified zone
as subchondral and enthesial calcified bone with adjacent underlying trabecular structures including
the overlying tissues is marked by the rectangle. The asterix marks the calcaneal bursa. A 5 mm scale is
included, the tissue was stained with Giemsa.
Pseudoerosions have to be differentiated from other pathologies as ganglion cysts, crystal-induced
arthropathies, tuberculosis or other infections, and from degenerative lesions in the form of
erosions, subchondral (pseudo)cysts or beak-shaped osteophytes as there are so many similarities
in location [38,60]. Intraosseous ganglion cysts are common and almost always have a continuity
with a ligament which underwent mucous degeneration [73,74]. Especially in the elderly population,
the more prevalent degenerative changes of the bone may be difficult to be differentiated from
RA-related erosions [38,75]. However, in children interpretational problems may arise. There, normal
concavities simulating erosions have been referred to as “bony depressions” at certain locations in the
wrist [76–78]. Such pseudoerosions in children may be big, indicating that size is not a reliable feature
for differentiating normal variants from true erosions.
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4.1. Anatomic Pseudoerosions
An anatomic pseudoerosion can be defined as a normal concavity of a bone outlined by a smooth
and thin calcified zone with the potential for a false-positive misinterpretation of an erosion. In this
form, the term pseudoerosion is more precise than “notch” or “bony depression” and may be preferred
as it contains a prognostic impact for the imaging assessment of arthritis. Such clinically oriented
annotations, examples are the scaphoid waist and the metacarpal neck as typical sites for fractures,
have been in use in traumatology and may be of help in the assessment of arthritis-related erosions,
too (list of described pseudoerosions in Table 3, an overview of anatomical pseudoerosions in the hand
may also be found in Figure 4).
Table 3. List of pseudoerosions with anatomic description.
Location Name Description
Scaphoid waist, palmar aspect Scaphoid waist Tendon hood of radial-sided carpal tunnel withradio-scapho-capitate ligament
Scaphoid, radial aspect of midpart Scapho-capsular ligament or mucosal foldinsertions
Capitate, distal ulnar portion [41] Ulnar capitate notch Intercarpal ligaments
Capitate, radial portion Radial capitate notch Intercarpal ligaments
Lunate, radial aspect Scapholuntate ligament
Hamate, distal radial portion [41] Insertion of capitatohamate ligament andcarpometacarpal ligaments
Hamate, distal ulnar portion [41] Insertion of carpometacarpal ligaments
Triquetrum, radial and dorsal aspect Radial triquetral notch Insertion of the radiotriquetral ligament
Triquetrum, ulnar and proximal aspect Insertion of the ulnotriquetral ligament
Metacarpal bases metacarpal base notches Insertion of intercarpal ligaments
Metacarpal or metatarsal neck and heads metacarpal or metatarsal headnotch
Insertion of metacarpophalangeal ligaments or
joint capsule
5th metatarsal head Slight normal varus angulation of metatarsalhead
Achilles tendon insertion Insertion jutty
 
Figure 4. Locations of anatomical pseudoerosions. Overview on possible locations of anatomical
pseudoerosions as summarized in Table 3. Right skeletal hand, on the left view from palmar, on the
right view from dorsal.
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Grooves due to ligament or tendon insertions have a varying appearance as described in the
enthesis concept by Benjamin and McGonagle [79]. Such prominent grooves can cause the appearance
of a pseudoerosion (Figure 2a). A groove may occur in three forms: (1) at a non-apophyseal direct
tendon or ligament attachment where the uncalcified components of the enthesis enters the bone, (2)
at an apophysis with overhanging edges, or (3) at an incomplete apophysis, a jutty, at the indirect
attachments of a tendon or ligament with a tangential transition into the periosteum. For example,
pseudoerosions resulting from the first form are the metacarpal ligament insertions at the bases of
the metacarpal bones [80]. At the dorsal aspect of the triquetral bone, such a pseudoerosion may be
formed by the distal insertion of the radiotriquetral ligament along with other components of the dorsal
radiocarpal ligament. On the capitate, on which several strong carpal ligaments have their insertion,
and many other carpal bones, intercarpal ligaments may cause pseudoerosions [51]. Examples for
the second form may be the non-spherical form of metacarpal and metatarsal heads, which can be
explained by the collateral ligament complexes running laterally and medially with smoothly outlined
shallow metacarpal grooves containing these structures. At the metacarpals, these grooves are bordered
by little tubercles for the proximal attachment of the collateral ligaments (Figure 4) [81]. Moraes do
Carmo et al. [54] identified three concavities in the first metacarpal head (intersesamoid, ulnar, and
radial) and two in those of the fingers (ulnar and radial). They described dorsal depressions of the
metacarpal heads due to the extensor digitorum tendons in one third of their anatomic specimens which
correlated with observations with ultrasound made by Boutry et al. [82,83]. A similar study was done
for defining pseudoerosions of the metatarsal heads by Torshizy et al. [55] who described anatomic
variations in the normal osseous concavities of the lateral and medial aspects of each metatarsal head.
Typical jutties, i.e., examples for the third form of grooves, are the small round or oval subcapsular
notches at the proximal phalangeal bases [80,84]. At the Achilles tendon insertion, proximal to its jutty
shallow irregularities beneath the calcaneal bursa may represent true erosions [85].
Osseous sulci are commonly roofed with a ligament, fascia or other fibrous tissue, thus forming
an osteofibrous channel for a tendon within a synovial tendon sheath. A subcapital neck of the distal
metacarpal and the metatarsal bones is a small metaphyseal narrowing that may cause a pseudoerosion
on projection radiographs, ultrasound or MRI [86]. At the distal fifth metacarpal bone, due to its slight
varus angulation this neck may be more prominent.
Nutritional channels may appear as pseudoerosion on MR if their orifice is displayed as a little
T2-weighted hyperintense spot [51]. Their superficial orifice is often located at a roughness of the
calcified zones which as a whole may simulate an erosion [11,34,87]. Some of these iuxtaarticular
surface roughnesses may be specified as crests or ridges that correspond to attachment sites for
redundant joint capsule [55]. Others, especially on carpal bones, may be due to indentations of
innominate ligamentous attachments or synovial folds [51]. Such typical structures visible between the
radial aspect of the scaphoid and the radial carpal collateral ligament may be called scapho-capsular
ligaments (Figure 2C). Roughness of the calcified zones may be visible at various sites and should be
differentiated from shallow extensive true erosions and from advanced cartilage degeneration [88].
4.2. Artefact-Related Pseudoerosions
Artefact-related pseudoerosions are defined as an interruption of the sharp outline of the calcified
zones. Important causes are a low signal-to-noise ratio, a partial volume artefact, or in case of ultrasound
irregular backscattering with artefacts on an incongruent or rough surface. A low signal-to-noise ratio
could be caused by over-penetration of the X-ray beam through the bone or due to insufficient spatial
or contrast resolution. This effect is more severe in cases with low calcium content in the calcified zones
or the subjacent trabecular bone, previously referred to as subchondral osteoporosis or as pre-erosions,
and may be enhanced by swelling of the overlying soft tissue. With ultrasound, diffraction or a complex
backscattering of the waves on a curved or irregular surface may cause various pseudo-effects on the
retrieved image [51,69,89].
11
J. Clin. Med. 2019, 8, 2174
Although X-ray is most commonly used in the diagnosis of RA it is CT which can be regarded as the
best imaging modality for differentiating pseudoerosions from true erosions [53,62,63,90–94]. Several
studies [34,95–98] describe a significant decrease of trabecular volume and number and an increased
trabecular heterogeneity in patients with rheumatoid arthritis by using HRpqCT. This trabecular
bone loss as the intramedullary component of bone erosions may contribute the largest part and may
therefore be a reason for misinterpretation of erosions or pseudoerosions in radiographs as this imaging
method is relatively insensitive to trabecular bone loss [60,99].
In addition, MRI and US are reported to be more sensitive than plain radiography [53,62,90–94],
but this especially seems to be dependent on the location investigated [88,100]. In some cases,
radiography may even be superior to MRI in detecting bony erosions despite its lack of three
dimensionality [1,3,5,58,99,101,102]. Through its high spatial resolution it can differentiate smaller
erosions which otherwise would present themselves as continuous on MRI [61,65].
Thus, it is important to recognize several parameters to achieve a decrease of cognitive diagnostic
errors especially in early arthritis. These include slight variations in the respective projection technique
and individual ligament laxity or postinflammatory scarring of ligaments. In addition, the roughness
of a calcified zone, and the transitional changes between normal bone and true inflammatory erosions
are until now not or only scarcely addressed. Even the projection of the joints, even if the relevant
anatomic landmarks are displayed according to the standards, is highly variable. One has also to
keep in mind that discrete forms of malalignment due to ulnar deviations or other forms of arthritic
subluxation, ligament laxity with a slight rotation of bones, and variations in their arrangement may
cause a more prominent appearance of a pseudoerosion [3,51,57,102].
4.3. Erosions-in-Pseudoerosions
Both anatomic and artefact-related pseudoerosions are located at sites with direct or indirect
contact to inflammatory tissue in arthritis, and therefore, are at higher risk for destruction. Areas of the
articular bone without any cartilage covering are more prone to erosive destructions by synovial tissue
and effusion [3,32]. Hence, in an anatomically preformed concavity a true inflammatory erosion may
develop. McQueen et al. [51] described these erosions-in-pseudoerosions (Figure 5) for the attachment
sites of the intercarpal ligaments. It may be observed at the site of ligamentous attachments covered by
synovial folds at the metacarpal or metatarsal heads or at the wrist. On the other hand, true erosions
may be classified as normal variants. It remains unclear whether these are incidental findings or
subclinical erosions [3,57,102].
 
Figure 5. Erosions within pseudoerosions. Example of the development of an erosion within a
pseudoerosion (black/white circle) in a left hand of a 65 years old female patient with longstanding
mild seropositive rheumatoid arthritis. Left: radiograph, right: MRI.
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4.4. Limitations
A limitation of this study was that the defined search terms resulted in a large quantity of papers,
which had to be screened. However, generally accepted terms for mimickers of true erosions do not
exist, are described in various forms and additionally with more equivocal definitions than expected at
the beginning of this project. Nonetheless, this wide search net allowed for the inclusion of all relevant
sources describing the phenomenon of pseudoerosions and minimized the possibility of excluding the
respective publications.
5. Conclusions
In conclusion, a pseudoerosion is more than just a negative definition of an erosion. It can be
defined as a normal osseous concavity (anatomic pseudoerosion) and/or an artefactual interruption of
the calcified zones (artefact-related pseudoerosion). It can be classified according to their configuration,
shape, content, and can be directly anatomically named. “Calcified zone” is a term to describe the
deep components of the subchondral, subligamentous and subtendinous bone and may be applied
for all non-cancellous borders of a bone, thus representing a third type of the bone matrix beside the
cortical and the trabecular bone. Anatomic pseudoerosions are almost always related to a ligament
insertion or the osteo-fibrous channel of a tendon sheath, therefore, being of high risk for microdamage
and the development of a “true” arthritic erosion. Understanding these peculiar aspects of the bony
surface with relation to ligament insertions and osteofibrous channels may be of help in improving the
assessment of erosions and for reducing over- and underdiagnosis of true erosions.
6. Take Home Message
1. Pseudoerosions may be subclassified into anatomic (normal osseous cavity) and artefact-related
(artefactual interruption of the calcified zone).
2. The term “calcified zone” describes the deep components of the subchondral, subligamentous
and subtendinous bone and may be applied for all non-cancellous borders of a bone.
3. Pseudoerosions can be regarded as anatomic sites at risk for the development of “true”
arthritic erosions.
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Abstract: Objectives: Th1.17 are highly polyfunctional, potentially harmful CD4+ effector T cells (Teff)
through IFN-γ and IL-17A coproduction. Th1.17 take part in the pathophysiology of rheumatoid
arthritis (RA) and psoriatic arthritis (PsA), in which their hyper activation results in part from defects
in negative regulation mechanisms. We recently demonstrated that the ecto-nucleotidase CD73
delineates a Th1.17-enriched Teff population and acts as an endogenous regulatory mechanism.
Because Methotrexate (MTX), used as first line treatment of RA and PsA, increases extracellular
concentrations of AMP and immunosuppressive adenosine, we investigated the modulation of CD73
by MTX treatment on Teff in RA/PsA patients. Methods: In a prospective cohort of 26 RA and 15 PsA
patients before or under MTX treatment, we evaluated CD73 expression on blood Teff subsets, their
cytokine production and AMPase functions. Results: We showed a decreased CD73 expression on
Th1.17 and Th1 in untreated patients compared to healthy donors that was partly restored under MTX.
This decrease in untreated patients leads to a halved Ado production by Th1.17 cells. CD73+ Teff
remained functional under MTX treatment, but their CD73 re-expression may contribute to control
their activation. Conclusion: Our study unveils uncovered mode of action of MTX on Teff subsets
modulation and in the adenosine-dependent termination of inflammation in RA and PsA.
J. Clin. Med. 2019, 8, 1859; doi:10.3390/jcm8111859 www.mdpi.com/journal/jcm21
J. Clin. Med. 2019, 8, 1859
Keywords: Th1.17; IL-17A; IFN-γ, CD73; adenosine; rheumatoid arthritis; psoriatic arthritis;
methotrexate; regulation
1. Introduction
Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) are chronic inflammatory disorders
characterized by tenderness and swelling of the joints. If not treated, both can lead to bone erosion,
resulting in joint destruction due to osteoclasts activation. RA is an autoimmune systemic disease
characterized by the presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor
(RF) [1]. PsA is usually associated with the skin condition psoriasis (Pso) [2]. In both cases, study
of the immune infiltrate of inflamed joints has shed light on particularly deleterious memory CD4+
T helper lymphocytes (Th): Th17 and Th1.17 [3–5]. These cells, found enriched at the inflamed
site, secrete high amounts of the pro-inflammatory cytokine IL-17A, responsible for many features
of both RA and PsA. IL-17A indeed contributes to the recruitment of pro-inflammatory monocytes
and neutrophils at the site of inflammation, and promotes the transformation of the fibroblast-like
synoviocytes present in the synovial lining toward a pro-inflammatory phenotype [6–8]. In the presence
of IL-17A, these cells secrete IL-6 and TNF [9] and high levels of RANKL, which in turn stimulate
osteoclast differentiation [10]. Therefore, IL-17A is implicated in the positive feedback loop at the roots
of the chronic inflammation and bone destruction observed in joints. Moreover, in RA and PsA, T cells
display reduced sensitivity to the diverse immune suppressive functions exerted by regulatory T cells
(Treg) [11]. Treg are involved in the modulation of extracellular purine derivatives levels, through
their membrane expression of the ecto-enzyme CD39, which degrades pro-inflammatory extracellular
ATP into AMP. AMP can, in turn, be degraded into immunosuppressive adenosine (Ado) by the
ecto-nucleotidase CD73. We recently demonstrated that in human, Treg express CD39, but no CD73;
therefore, third-party CD73 expressing cells are required for the degradation of AMP into Ado [12].
CD73 is in particular expressed by a fraction of non-regulatory CD4+ memory T cells (Teff) strongly
enriched in Th1.17 and Th17 [12]. We showed that CD73 expression by Teff renders them selectively
sensitive to Ado through their cooperation with CD39+ Treg for extracellular ATP degradation. In the
context of chronic inflammation, modulation of expression of these ecto-enzymes on Teff, and thus of
Ado production, may regulate T cell activation.
RA and PsA treatment options are mainly composed of an arsenal of disease modifying anti
rheumatic drugs (DMARDs), among which Methotrexate (MTX) is still largely used due to its efficiency,
low toxicity and cost effectiveness [13,14]. Its mode of action at low doses (5–20 mg/week) for RA
and PsA treatment remains incompletely understood. Apart from its role as anti-folate agent, other
mechanisms have been proposed to explain clinical improvement upon MTX treatment (reviewed
in [13]). Robust evidence suggests that MTX acts through the potentiation of Ado signaling. Indeed,
MTX inhibits the 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase enzyme
(ATIC) [13–15] resulting in increase in both intracellular AICAR levels and extracellular AMP and Ado
release. However, the majority of extracellular Ado is in fact generated from extracellular transport of
ATP and AMP degraded by CD39/CD73 that are required for MTX-induced immune suppression in
mouse models [16]. Extracellular Ado inhibits T cell activation and proliferation in a paracrine manner,
through the engagement of its A2A and A2B receptors which expression is upregulated on activated
Teff [12,17,18], and through the amplification of Treg expressing A2AR [19].
In this study, we evaluated the presence and distribution of CD73+ Teff among Th populations
in the blood of untreated RA and PsA patients. We also assessed the functionality of these cells in
patients in comparison to healthy donors’ blood. We demonstrated that loss of CD73 membrane
expression in untreated patients resulted in a lowered Ado production, potentially contributing to
impaired control of the inflammation. Under MTX treatment, CD73 was partially recovered on Teff,
which was associated with a restored capacity to degrade AMP into Ado.
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Therefore, CD73 expression level on Teffmay represent a therapeutic target worth considering




Patients aged ≥ 18 years, naive of biologics, with RA fulfilling the American College of
Rheumatology and European League Against Rheumatism 2009 criteria [20] or with PsA fulfilling
the Classification of PsA (CASPAR) criteria [21] were enrolled in the LADORIC study (NCT03953378)
after written informed consent, in accordance with the Declaration of Helsinki. The approval of the
ethics committee was not required in accordance with our institution’s policy. Clinical and biological
information was collected prospectively (Table 1).







Gender ratio (f/m, n) 19/7 9/6 8/4











Mean MTX treatment duration
(months) 9.3 (3–22) 6 (3–22) -
MTX doses (mg/week) (15–20) (15–20) -
RF detection (yes/no, n) 22/4 Not detected -
ACPA detection (yes/no, n) 24/2 Not detected -
Data presented as (range). RA. Rheumatoid Arthritis; PsA: Psoriatic Arthritis; DAS28: 28 joints activity score; RF:
Rheumatoid Factor; ACPA: antibodies against cyclic citrullinated peptides. Two RA patients under MTX treatment
also received cortancyl (7.5 mg).
Severity of the disease was assessed using the Disease Activity Score in 28 joints (DAS28-CRP) [22]
for RA and CRP for PsA at baseline visit and 3 or 6 months after MTX treatment onset. DAS28-CRP≥ 3.2
in untreated RA patients and CRP ≥ 6 mg/mL in untreated PsA patients were set as thresholds for
active disease. Samples of venous blood and, when available, synovial fluid (SF) were collected for
each patient before the onset of MTX (untreated patients) or during the course of MTX treatment
(MTX-treated patients). Blood samples from age- and sex-matched anonymous healthy donors (HD)
were obtained from the Etablissement Français du Sang.
2.2. Peripheral Blood Mononuclear Cells (PBMC) and Synovial Fluid Mononuclear Cells (SFMC) Isolation
Blood samples were centrifuged on a Ficoll (Eurobio, Les Ullis, France) density gradient to purify
PBMC. SF samples were diluted in HBSS (Life Technologies, Cailloux sur Fontaines, France) containing
10 mM EDTA (Sigma, Saint Quentin-Fallavier, France), and processed as blood samples to isolate SFMC.
2.3. Flow Cytometry Analyses
Multi-parametric Flow Cytometry (FC) staining were performed on PBMC or SFMC from RA and
PsA patients using different panels described in Table S1 (Panels A and B) to assess CD73 expression
on total memory T cells and within Th subsets. When specified, proliferation was assessed using an
anti-human anti-Ki67 antibody (Ki-67, Biolegend, Saint-Cyr-l’Ecole, CA, France). For FoxP3 intracellular
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staining to characterize Treg, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life
Technologies), according to manufacturer instructions. Samples were analyzed on a LSR-Fortessa (BD
Biosciences, Pont de Claix, France) with conserved settings throughout the entire study. Data were
analyzed using FlowJo Software (Tree Star v10.4, Franklin Lakes, NJ, USA).
2.4. Analysis of Cytokines Production Capacity after Reactivation
PBMC were activated with PMA and Ionomycin (Sigma-Aldrich) as previously described [12]
and intracellular cytokines (IL-17A, TNF-α, IFN-γ, IL-22) produced by CD73+ and CD73neg Teff were
analyzed using the specific panel described in Table S1 (Panel C). Stainings were analyzed on a
LSR-Fortessa and Teff polyfunctionality was evaluated using the Boolean method (FlowJo software)
and then processed using Pestle and SPICE v5.3 softwares, National Institute of Allergy and Infectious
Diseases, Bethesda, MD, USA.
2.5. CD73+ Teff Sorting and In Vitro Activation to Asses CD73 Dynamic Expression
Memory CD4+ T cells were purified from HD PBMCs using MagniSortTM Human CD4+ Memory
T Cell Enrichment Kit (LifeTechnologies). CD73+CD4+ Teff (CD4+CD45RAnegCD127+CD25negCD39neg
CD73+) and CD73negCD4+ Teff (CD4+CD45RAnegCD127+CD25neg CD39negCD73neg) were sorted from
purified memory CD4+ T cells by multi-parametric FC (FACSAria III, BD Biosciences) using antibodies
against CD25 (2A3, BD-Biosciences), CD45RA (2H4LDH11LDB9, Beckman-Coulter, Brea, CA, USA),
as well as CD127 (eBioRDR5), CD39 (eBioA1) and CD73 (AD2) (all from e-Bioscience), alongside a
viability marker (DAPI).
Sorted populations were stained with CellTrace Violet (CTV) (20 μM, LifeTechnologies)
proliferation markers before incubation with Expand beads (LifeTechnologies) (ratio 1:4) in
96-round-bottomed-well plates in 200 μL of complete RPMI medium for 4 days at 37 ◦C under
5% CO2.
After 4 days’ proliferation, part of the cells was stained for viability and CD73 expression with
anti-human anti-CD73 and cells were fixed with 2% Formaldehyde solution (Sigma) and stored at 4 ◦C.
The rest of the cells were washed and removed from Expand beads using a magnet. They were then
incubated for a 2-day period without TCR signal in 200 μL of complete RPMI medium containing IL-2
(50 UI, Chiron). Cells were then stained for viability and CD73 expression as well. All time points
were analyzed concomitantly by FC for viability, proliferation and CD73 expression (LSR Fortessa, BD
Biosciences).
2.6. Th1.17, Th1 and Th17 Sorting for In Vitro AMP Degradation Assay
Memory CD4+ Teffs were purified using MojoSort Human CD4+ Memory T Cell Isolation
Kit (Biolegend). Th1, Th17 and Th1.17 cells were sorted from purified memory CD4+ T cells by
multi-parametric FC (FACSAria III, BD Biosciences) based on chemokine receptors expression [23]
(Figure S1) using the combination of antibodies described in Table S1 (Panel D).
The capacity of 5 × 104 cells of each Th subpopulation of HD, RA untreated or MTX-treated
patients to degrade AMP was analyzed after 2 h incubation at 37 ◦C under 5% CO2 with labeled
AMP (AMP13C,15N, 37.5 μM, Sigma-Aldrich) in 200 μL of serum-free RPMI medium supplemented
with antibiotics and L-glutamine (Life Technologies). As a control, cells were pre-incubated with
a CD73 chemical inhibitor (APCP, 50 μM, Sigma) for 30 min before adding AMP13C,15N to assess
CD73-specific degradation.
2.7. Nucleotides and Nucleosides Quantification by Liquid Chromatography Coupled with Tandem Mass
Spectrometry (LC-MS/MS)
Cell supernatants were harvested, boiled at 65 ◦C for 5 s and frozen at −20 ◦C. AMP13C,15N and
Ado13C,15N were quantified in 50 μL of supernatant, after solid phase extraction, using a LC-MS/MS
method as described [12,24]. Concentrations of nucleotides in the supernatants were calculated using
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calibration curves of the corresponding labeled nucleotides (AMP15N and Ado13C). AMP13C and
Ado15N were used as internal standards. We also verified that APCP did not interfere with AMP and
Ado quantification.
2.8. Statistical Analysis
Data formatting and statistical tests were performed using Prism software (Graphpad Inc.,
San Diego, CA, USA). Kruskal-Wallis test, Mann-Whitney test and ANOVA2 were used when
comparing unpaired data according to the parameters considered. Wilcoxon test and ANOVA2 with
paired values were performed to analyze patients’ data follow up. We evaluated correlation between
biological parameters and activity of the disease (DAS28-CRP) using Spearman correlation tests.
3. Results
3.1. Activated Th1.17 from Peripheral Blood of Untreated RA and PsA Patients Express Low Levels of CD73
Total memory CD4+ and CD8+ T cells frequencies were not modified in peripheral blood of
untreated RA and PsA patients compared to HD (Figure S2A), neither were frequencies of Th
subpopulations based on their CCR6 and CXCR3 expression [23] (Figure 1A). Treg frequency was
unaltered in untreated RA and PsA patients’ blood (Figure 1B). However, in RA patients, Treg
displayed a higher frequency of CD39 expression compared to HD and PsA patients, although the
mean fluorescence intensity (MFI) of CD39 was not different (Figure 1C). Interestingly, we found a
significantly lower CD73 expression on total Teff population from RA and PsA patients compared to
HD (Figure 1D). Since we established that, in HD, CD73 is enriched in Th1.17 and Th17 phenotype [12],
we stratified our analysis on Th subpopulations based on CXCR3 and CCR6 expression that allows to
distinguish Th subsets with different cytokine pattern (Figure S1). CD73 expression was significantly
decreased on Th1.17 (by 1.5 and 1.4 fold on RA and PsA patients respectively) and Th1 (by 1.9 fold on
both RA and PsA patients) (Figure 1E).
Using CD39 [25,26], we demonstrated a significantly increased activation of blood-associated
Th1.17 and Th17 in RA and PsA patients compared to HD ones (Figure 1F). In parallel, we observed
that in vitro TCR stimulation was sufficient to decrease CD73 expression in sorted CD73+ Teff from HD
(Figure S2B). Taken together, these results indicate that loss of CD73 expression on Th1.17 associated
to high CD39 expression in untreated RA and PsA patients’ blood could reflect the activated state of
this population. The access to paired samples of PBMC and SFMC for RA and PsA patients before
treatment enabled us to show that the decrease of CD73 expression and CD39 up-regulation on total
Teffwas even more dramatic at the site of inflammation both in RA (Figure 1G) and in PsA (Figure S2C).
In addition, proliferating cells (identified as Ki67+ cells) were included within CD39+CD73neg Teff in
RA (Figure 1H and Figure S2E) and PsA (Figure S2D,F) SF, further highlighting the absence of CD73
expression by proliferating Teff.
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Figure 1. Unchanged Th populations but impaired CD73 expression on Th1 and Th1.17 from RA and
PsA patients. (A). Th subsets frequencies based on phenotypic analysis (CXCR3/CCR6 staining) among
memory CD4+ T cells. (B). Frequencies of FoxP3+ Treg among memory CD4+ T cells. (C). Frequencies
(left) and MFI (right) of CD39+ Treg among memory CD4+ T cells. (D). CD73 expression on total
Teff. (E). CD73 expression by Th subsets. (F). CD39 expression by Th subsets. (from A to F: analyses
performed on peripheral blood). (G,H). Flow cytometry plots on total Teff in peripheral blood and SF of
an untreated RA patient showing CD73/CD39 (G) and CD73/Ki67 (H) staining. (A–D): Kruskal-Wallis
test, (E,F): ANOVA-2. * p < 0.05, ** p < 0.001, *** p < 0.0001.
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In untreated RA patients, percentage of CD39+ Treg positively correlated (r = 0.68, p = 0.03)
with the severity of the disease evaluated through DAS28-CRP score. In contrast, no correlation was
noticed for CD39 percentage on Th1, Th1.17 and Th17 subsets (not shown). No correlation with the
severity of the disease was noticed for global CD73 expression on Teff nor global Th1, Th1.17 and Th17
proportions in blood. Moreover, the proportion of CD73 expressed by Th1 and Th1.17 populations
did not correlate with disease severity despite they were strongly reduced in untreated RA patients
compared to HD. In contrast expression of CD73 on Th17 and IL-17A production by CD73+ Teff tend
to inversely correlate with disease severity (r = −0.65, p = 0.06 and r = −0.63, p = 0.07, respectively)
(Figure S3). For PsA untreated patients no correlation was observed probably because either the
heterogeneity of the disease or too small cohort size to achieve robust correlations.
3.2. Untreated RA and PsA Patients’ Blood Teff are Polyfunctional but Express Lower Levels of CD73 among
IFN-γ/IL-17A Expressing Cells
We previously showed that CD73 marks polyfunctional Teff in blood but also in healthy (tonsil,
colon) and tumor (breast and ovarian) tissues [12]. In our setting, no striking modifications of the
polyfunctionality (IFN-γ, IL-17A, and TNF-α) of CD73+ and CD73neg Teffwas noticed in untreated RA
and PsA patients compared to HD (Figure 2A) and global levels of each cytokine were unchanged
(Figure S4A). Of note, CD73+ Teff, which were higher single IL-22 producers in HD [12] were an even
more important source of IL-22 in PsA (9.1 ± 2.6% versus 4.2 ± 1.3% of CD73+ Teff) (Figure S4B).
In line with phenotypic analyses (Figure 1E), the IFN-γ/IL-17A coproducing cells, corresponding to
Th1.17 (Figure S1), expressed significantly less CD73 (Figure 2B). Finally, Teff from untreated RA and
PsA patients according to their DAS28-CRP or CRP level, respectively, showed enhanced IFN-γ and
IL-17A production by CD73+ Teff in patients with active RA (DAS28-CRP ≥ 3.2), although not reaching
statistical significance (Figure 2C).
Figure 2. Cont.
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Figure 2. Polyfunctionality of Teff is not altered in RA and PsA patients but there are less CD73+ cells
identified in IL-17A/IFN-γ secreting Teff. (A): SPICE® representation of the cytokines secreted by either
CD73+ or CD73neg Teff from peripheral blood of HD, or untreated RA and PsA patients. (B): CD73
expression on Teff according to their secretion of IFN-γ, IL-17A and IL-22 in peripheral blood of HD or
untreated RA and PsA patients. (C): IFN-γ and IL-17A mono- or co-production by Teff according to
their CD73 expression in untreated RA and PsA patients stratified on DAS28-CRP score and CRP seric
level respectively. (B,C): ANOVA-2. * p < 0.05, ** p < 0.001, *** p < 0.0001.
3.3. Treatment of Patients with MTX Partially Restores CD73 Expression on Teff Resulting in an Enhanced
Ado Production
Due to the described MTX involvement in the regulation of purine metabolism [13,26], we also
analyzed the impact of MTX treatment on CD73 expression by Th subpopulations. We recently
demonstrated that exogenously added Ado on CD73+ Teff blocked their proliferation and cytokine
secretion [12]. Here, we evidenced that CD73+ Teff re-acquired CD73 expression after two days in
resting condition (no TCR signaling), demonstrating dynamic CD73 protein expression at the surface
of Teff (Figure S2B). In this context, we analyzed CD73 expression on Th subsets in MTX-treated RA
and PsA patients, considering that a gain of CD73 expression could reflect drug efficiency on these
populations and could contribute to its anti-inflammatory effects. MTX did not impact Th subsets
frequencies compared to untreated RA and PsA patients (Figure 3A). However, CD73 expression
on Teffwas increased in MTX-treated RA patients compared to untreated ones while no significant
variation was observed in PsA patients (Figure 3B). Interestingly, in RA patients, CD73 expression was
especially increased within Th1.17 (Figure 3C) and overall CD73 expression level tended towards those
observed in HD. Finally, the analysis of paired patients’ blood samples (for, respectively, four and seven
patients for RA and PsA) before and under MTX treatment showed significantly increased CD73 levels
on Th1 and Th1.17 subsets (Figure 3D), the two populations with significantly altered CD73 expression
in untreated patients compared to HD (Figure 1E). This impact of MTX was restricted to CD4+CD73+
Teff, as we did not notice striking variations in memory CD8+ T cell frequencies (Figure S5A) or in Treg
or CD39+ Treg frequencies (Figure S5B,C) even in paired samples (Figure S5D–F). Of note, CD39 levels
did not seem to be modulated by MTX treatment on Teff either (Figure S5G,H).
Among HD donors’ Th subsets, Th1.17 was the main subset able to degrade AMP into Ado
(Figure S6), in line with its strongest expression of CD73 (Figure 1E). This generation of Ado was
dependent on CD73, as demonstrated by the loss of Ado in the presence of APCP (Figure S6).
In comparison the quantities of Ado generated was four-fold lower for the Th1 subset. Interestingly, we
evidenced that reduced CD73 expression on Th1.17 and Th1 of untreated RA patients was associated
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with 50% decrease in Ado production (Figure 3E). Strikingly, upon MTX treatment, the level of Ado
production was restored to HD donor levels (Figure 3E).
Figure 3. MTX treatment restores CD73 levels on Teff populations in RA patients but not in PsA
patients. (A) Frequencies of Th subsets in peripheral blood of untreated versus MTX-treated RA (left)
and PsA (right) patients. (B) CD73 percentages on total Teff in peripheral blood of untreated versus
MTX treated RA (left) and PsA (right) patients. (C) CD73 percentages on Th subsets of untreated
versus MTX-treated RA (up) and PsA (down) patients. (D) Paired samples showing CD73 percentages
modulation in Th subsets upon MTX treatment in RA (n = 4) and PsA (n = 7) patients. (E) Fold change
of Ado produced by sorted Th1.17, Th17 and Th1 subsets from untreated (n = 3) and MTX-treated RA
(n = 3) patients. Cells were incubated for 2 h with AMP13C15N isotope (37.5 μM) +/− APCP (50 μM)
before Ado quantification in supernatants by LC-MS/MS. Ado production was normalized to the
production by Th1.17 from HD’s blood used as reference. A and C: ANOVA-2, B: Mann-Whitney test,
D: ANOVA-2 with paired values. * p < 0.05, ** p < 0.001.
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3.4. MTX Treatment Impacts Teff Polyfunctionality
Interestingly, we showed that CD73 expression was increased on cells coproducing IFN-γ and
IL-17A, corresponding to Th1.17, from MTX-treated RA patients (Figure 4A,B). These results mirror
the phenotypic analysis obtained for the Th1.17 subset (Figure 3C). In addition, we evidenced that
MTX treatment significantly increased CD73 frequency among IL-22 producing cells in RA patients
(Figure 4A). Of note, no major variation on global pattern of cytokines production was detected in
RA patients when comparing untreated and MTX-treated samples (Figure S7A) and a rather modest
increase of IL-17A+ and IFN-γ+/IL-17A+ coproducing cells was observed in MTX-treated PsA patients
compared to untreated ones (Figure S7B). CD73neg Teff functionality was not altered by MTX neither
in RA nor in PsA patients (Figure 4C,D). Surprisingly, CD73+ Teff displayed increased capacity to
produce IFN-γ in RA patients (Figure 4C) and to co-produce IFN-γ and IL-17A after MTX treatment in
both RA (Figure 4C) and PsA patients (Figure 4D).
Figure 4. Cont.
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Figure 4. Impact of MTX treatment on Teff polyfunctionality. (A,B). Analysis of CD73 expression
on cytokine secreting Teffmirrors phenotypic analysis in RA (A) and PsA (B) patients. (C,D). IFN-γ,
IL-17A producing and IFN-γ/IL-17A co-producers in RA (n = 4) (C) and PsA (n = 7) (D) patients before
initiation of MTX treatment and under MTX treatment. A,B: Mann-Whitney tests, C,D: ANOVA-2
paired samples * p < 0.05, ** p < 0.001.
4. Discussion
In this study, we demonstrated a dynamic expression of CD73 on Th populations in peripheral
blood of RA and PsA patients modulated by MTX treatment. Decreased CD73 levels were detected on
Th1, Th1.17, Th22 and to a lesser extent on Th17 cells in untreated patients compared to HD. The partial
restoration of CD73 levels on these Th effectors upon MTX treatment reveals a novel regulatory action
of this immunosuppressive drug.
The development of new therapeutic approaches for the treatment of RA and PsA is an ongoing
challenge that requires to decipher the pathologic modifications of immune cells at the roots of the
establishment of the chronic inflammatory state that characterizes these pathologies.
The diverse pro-inflammatory Th populations appear as good targets to breakdown the chronic
inflammation [27]. In the context of systemic inflammation, the monitoring of CD39/CD73 expression
levels in the peripheral blood of patients may therefore be a marker of Teff inflammatory potential, an
important parameter in the evaluation of disease activity. We focused our work on the polyfunctional
CD73+ Teff population that we recently described in human as enriched in Th1.17 and Th17 [12].
Since we previously showed that CD73 expression renders them selectively sensitive to the inhibition
by CD39+ Treg through autocrine Ado activity, we aimed at better understanding the dynamic of
CD73 expression on Th1.17 and Th17 that play a central role in RA and PsA [3,4,28]. FC analyses on
PBMC from untreated RA and PsA patients did not highlight any modification in Treg frequencies,
consistent with previous data [29]. However, we noticed up-regulated expression of CD39 on these
Treg in untreated RA, which was correlated to disease activity at odds to other studies focusing on
RA [3,28,30]. CD73 expression was significantly diminished on blood Teff in untreated RA and PsA
patients compared to HD. This decrease was even stronger in SFMC, indicating that blood CD73 levels
might mirror the extent of the inflammation in the affected joints as previously suggested in juvenile
idiopathic arthritis [31]. Dampened or inefficient Treg suppressive functions described by others in
RA and PsA patients [32] could partly result from this decreased expression of CD73 on activated
Teff, as it may impair CD39+ Treg and CD73+ Teff cooperation for self-inhibition through autocrine
Ado production that will act only in a nearby environment due its very short half-life. In line with
this, CD73 expression level on synovial lymphocytes was proposed as a marker of disease activity in
idiopathic juvenile arthritis [31] and could also be monitored in adults.
This decreased CD73 expression was particularly pronounced on Th1 and Th1.17 subsets compared
to HD. Considering the strong plasticity of Th differentiation and recent data showing that Th1.17
can shift to unconventional Th1 cells when exposed to inflammatory cytokines [3,33], we suggest
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this decreased CD73 expression observed on Th1 might comprise activated non-classical Th1 cells
phenotypically characterized by CXCR3 expression. Interestingly, this loss of CD73 expression was
associated with a decreased production of Ado by Th1.17 and Th1 cells from untreated patients.
Therefore, we propose that loss of CD73 expression on Teff might be a mechanism of escape to the
suppression exerted by Treg, thereby enabling them with uncontrolled proliferation and secretion of
pro-inflammatory cytokines. Although not reaching statistical significance, CD73 downregulation was
also observed on Th17 cells that highly express CD39, suggesting an activated state. In addition, the
only parameter that negatively correlated to disease activity in RA was CD73 expression by Th17 cells.
This suggests that CD73 expression on Th17 cells could contribute in RA to limit the aggressiveness
of the disease through the generation of Ado that could impair their own expansion but not IL-17A
production as we previously demonstrated the inability of Ado to alter IL-17A secretion in contrast to
other cytokines (IFN-γ, GM-CSF, IL-22, IL-10, IL-13) [12,30].
Considering the polyfunctionality of Teff in untreated patients, we did not notice significant
variations compared to HD in contrast to other studies reporting higher frequency of IL-17A producing
cells in peripheral blood of PsA patients [34,35]. These discrepancies may rely on the methodology
used to investigate IL-17A production, and also from patients’ medical history and sampling criteria.
These results remain however to be confirmed in a bigger cohort of untreated RA and PsA patients.
It would also be interesting to confirm that Teff from untreated patients display low or no alteration of
their cytokine production in presence of exogenous AMP because of their low expression of CD73
contrary to HD [12]. In addition, we evidenced that the frequency of single IL-22 producing cells is
higher in untreated PsA patients compared to HD and to untreated RA patients (Figure S4B). This is in
line with the high IL-22 production by Teff previously reported in blood of PsA patients [36]. CD73
expression could not precisely investigated on Th22 cells using as specific phenotypic markers are
lacking so far, but we demonstrated that single IL-22-producing cells were enriched among CD73+
Teff compared to CD73neg counterparts, although this population was decreased in untreated patients.
While IL-22 has been reported to contribute to Pso pathogenesis [37], there is, however, no clear
consensus as to whether this cytokine is deleterious in PsA. In our study, we reported no variation in the
proportion of single IL-22 producing cells between untreated and MTX treated PsA patients. From our
point of view, it is therefore important to evaluate the CD73 status of these IL-22 secreting cells to
determine if they can be regulated by Ado. A recent study on the contrary suggests a regulatory role
of IL-22 in PsA patients with a reported decreased IL-22+ cells frequency in PsA patients compared to
HD [38]. However, in this paper, treated and untreated patients have been pooled together, making the
interpretation more difficult. In RA, inflammation in the SF seems mediated by IL-17A independently
of IL-22 signaling [39]. Nevertheless, IL-22 can be found in high concentrations in RA patients due to
its production by Th17 and Th1.17 cells that are subsets highly active in the pathology.
In our study, MTX treatment of RA and PsA patients did not induce changes on Treg frequency
and CD39 MFI (Figure S5C,E,F). This contrasts with another study showing increased CD39+ Treg
frequencies in MTX responders [40]. However, in this study, the authors suggest the direct production
of Ado by Treg expressing both CD39 and CD73 which is in contradiction with observations we
and others have reported [12,41]. However, high CD39+ Treg frequency at baseline could correlate
with good MTX response, and CD39 is therefore suggested as a biomarker of the MTX response
in RA [40,42]. Our analysis of untreated and MTX-treated paired samples of RA and PsA patients
demonstrated a CD73 frequency in Th subsets closer to HD in MTX-treated patients. This could result
from an arrest in cell proliferation due to A2AR engagement by Ado released after MTX-induced
AICAR blockade [15]. We hypothesize that restoration of CD73 expression, through degradation of
AMP, in turn accentuates the Ado-mediated immunosuppression initiated by MTX. The loss of CD73
expression on Teff could indeed be necessary for their proliferation and pro-inflammatory features to
escape CD39+ Treg-mediated suppression through cooperative Ado production.
In MTX-treated PsA patients, up-regulation of CD73 on Teff appears less important than
in RA patients. This could rely on the fact that PsA is a joint affection mostly developing
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subsequently to established Pso, that is more heterogeneous in its characterization and symptoms.
The immune-biological regulation of PsA inflammation is therefore different from RA and joint
inflammation in PsA might be fueled by specific immune cells active in Pso, possibly interfering with
the biological effect of MTX. Indeed, auto-reactive CD8+ T cells have been shown to contribute to Pso
and should be considered.
We also showed an enhanced cytokine production capacity of CD73+ Teff in RA patients after
MTX treatment (IFN-γ, IL-17A, IL-17A/IFN-γ, IL-22). However, we can expect these cells to be less
pro-inflammatory in vivo, since they express higher level of CD73, favoring Ado production. We and
others have indeed previously showed that Ado strongly reduced CD73+ Teff cytokine pattern except
IL-17A and, to a lesser extent, IL-22 [12,30]. These data suggest a benefit of MTX treatment, which
may have synergistic effect with anti-IL-17A in contrast to TNF inhibitors in PsA [43]. Similarly,
in RA, although combination of MTX and anti-IL-6R such as Tocilizumab has not shown clinically
relevant short-term superiority over Tocilizumab monotherapy [44], concomitant MTX treatment with
Tocilizumab may have an interest in low Tocilizumab responders first under monotherapy. Indeed, we
evidenced down-regulation of IL-6R on CD73+ Teff compared to CD73neg Teff (unpublished results),
suggesting a reduced impact of anti-IL-6R on CD73+ Teff. Therefore, MTX could better neutralize
activated and proliferating CD73+ Teff, while anti-IL-6R might target CD73neg Teff; their combined
action provide a better regulation of the overall hyper activated Teff population in the contexts of
auto-immune disorders.
Purine metabolism and its regulation emerges as a pivotal regulator of immunity and inflammation,
Modulation of this pathway in combination with MTX therefore appears as a promising target for new
therapeutic strategies.
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Abstract: Introduction: Tofacitinib is an oral JAK inhibitor indicated for the treatment of rheumatoid
arthritis (RA). The efficacy and safety of tofacitinib have been shown in several randomized clinical
trials. The study presented here aimed to assess the clinical tolerability and effectiveness of tofacitinib
among RA patients in real life. Methods: Consecutive patients between January 2015 and April
2017 with RA who fulfilled the American College of Rheumatology (ACR)/European League Against
Rheumatism (EULAR) 2010 criteria were included in a prospectively designed analysis of retrospective
data. Patients were initiated on tofacitinib 5 mg bid. The primary objective was to analyze the safety
of tofacitinib in a real-life cohort. Safety was assessed by the reasons to stop tofacitinib during follow
up and changes of liver enzymes, hemoglobin, and creatinine. The secondary outcome was to analyze
the frequency of and time to achieve low disease activity (LDA) and remission as defined by 28 joint
count disease activity score (DAS28). Results: A total of 144 patients were treated with tofacitinib.
A total of 84.9% of patients were pre-exposed to at least one biological agent. The average DAS28 at
the initiation of tofacitinib was 4.43. A total of 50.0% of patients were positive for rheumatoid factor
and 49.0% for ACPA. The mean follow up was 1.22 years (range 10d–3.7a) after initiation of tofacitinib
treatment. A total of 94 (64.4%) patients remained on tofacitinib during follow-up. The average time
to stop tofacitinib was 190.0 days. Reasons to stop tofacitinib were: insufficient response (n = 23),
gastrointestinal symptoms (n = 18), infection (n = 5), myalgia (n = 2), remission (n = 2), headache
(n = 2), cough, blue finger syndrome, intolerance, heartburn, psoriasis, and increased liver enzymes
(all n = 1). Increased alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) > 2×
upper limit of normal (ULN) were detected in 3.3% and 4.4% of patients, respectively. Hemoglobin
decrease of >10% was detected in 15.1% of the patients and decreased lymphocytes <500/μL in 3.4%.
An increase of creatinine >20% was detected in 9.4% of patients. A total of 62.9% and 50.0% of
the patients achieved low disease activity (LDA) or remission after a median of 319 and 645 days,
respectively. These rates were significantly higher in patients naïve to biologic agents as compared
to patients pre-exposed to biologics (LDA: naïve 100% 92 d, pre-exposed 57.0% 434 d, p ≤ 0.001;
remission: naïve 86.7% 132 d, pre-exposed 44.1%, 692 d, p = 0.001). Conclusions: Tofacitinib is a safe
and effective treatment option for patients with RA. Tofacitinib may induce high rates of LDA and
J. Clin. Med. 2019, 8, 1548; doi:10.3390/jcm8101548 www.mdpi.com/journal/jcm37
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remission in patients with active disease, even after the use of one or more biologics, though the rate
appeared higher in patients naïve to biologics. Tofacitinib may be a valuable option in a treat-to-target
approach. Our data demonstrate that Janus kinase (JAK) inhibitors are safe and efficacious in real
life patients.
Keywords: tofacitinib; rheumatoid arthritis; oral
1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the inflammation
and destruction of joints. It may result in functional impairment, declining health status and reduced
quality of life for affected patients [1–3]. The principal goal in the treatment of RA is to achieve and
maintain remission, or, if that is not attainable, low disease activity (LDA) [4,5].
Conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs), especially
methotrexate (MTX), have long been the cornerstones of RA treatment. In the last 20 years, biologic
agents have broadened the clinical armamentarium [6]. Though biologics have revolutionized the
managing of RA [7–24], their effects are limited. Approximately 50% of RA patients treated with
biologics meet the criteria for low disease activity (28 joint count disease activity score (DAS28) ≤ 3.2) or
remission (DAS28 < 2.6), while a significant proportion of patients do not achieve an ACR 20 (American
College of Rheumatology) response [14,15]. Furthermore, patients on biologics may experience adverse
events (AEs) or loss of effectiveness over time [25], e.g., by developing anti-drug antibodies. To quantify
the unmet need for additional therapies, Drosos et al. performed a long-term, real-world observational
study of their cases with RA treated according to the European League Against Rheumatism (EULAR)
and American College of Rheumatology (ACR) recommendations. Approximately one-fifth of their
patients did not respond sufficiently to csDMARDs or bDMARDs (biological disease-modifying
anti-rheumatic drugs), substantiating the need for alternative treatments [26].
Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor indicated for the treatment of RA.
JAK inhibitors are small-molecule drugs that interfere with the activation of JAKs, a family of enzymes
implicated in the signaling of leukocytes. JAK signaling has been shown to play an essential role
in immune cell generation, differentiation and responses [27–29]. By inhibiting these signaling
mechanisms, JAK inhibitors such as tofacitinib have the potential to successfully interfere with immune
activation that is critical for RA [30–32] (Koehler, J. Clin. Med. 2019, 8, 938).
Phase II and III clinical trials have shown that the treatment of RA patients with tofacitinib,
either as a monotherapy or in combination with csDMARDs, is capable of significantly reducing
disease activity, as measured by ACR response rates, EULAR responses and HAQ-DI scores [33–39].
Studies comparing tofacitinib to other therapeutic strategies in the treatment of RA suggest that the
effectiveness of tofacitinib is similar to that of biologic agents [40–43]. The safety profile of tofacitinib
does not appear to differ significantly from biologics [34,39–44].
In 2012 and 2014, the FDA and the Swissmedic approved tofacitinib for adult patients with
moderate to severe RA who had a prior inadequate response to MTX. Approval from the European
Medicines Agency (EMA) was granted in 2017. With JAK inhibitors still representing a relatively novel
treatment option in the management of RA, there is a demand to use the experience gained through
using tofacitinib in a real-life, clinical setting, to further evaluate its safety and utility. In this study,
we aimed to analyze real-life data from routine clinical practice to compare our experience with the
results of controlled studies.
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2. Methods
2.1. Patient Recruitment
For this retrospective analysis of data, patients were recruited through a chart review of all RA
patients at the hospitals of St. Gallen and Aarau, Switzerland. Patients with a clinical diagnosis of RA
consistent with the current definition in the 2010 ACR/EULAR criteria were required [45] and initiation
of oral tofacitinib 5 mg bid followed. Exclusion criteria were ages younger than 18 years or older than
80 years at disease onset. All patient charts of the cohort from Aarau and St. Gallen were screened
sequentially for eligibility. Thus, selected patients were followed until tofacitinib administration was
terminated or until the last visit entered in the database. The decision to stop tofacitinib and all other
decisions concerning treatment were at the discretion of the treating clinician. Ethical approval for the
collection of patient data was given by the regional review board.
2.2. Study Design
This was a longitudinal, retrospective chart review conducted between April 2013 and September
2017 within the St. Gallen and Aarau RA cohorts. The pre-defined primary endpoints were the
incidence of adverse events, changes in laboratory values (increase in alanine amino transferase (ALAT)
or aspartate amino transferase (ASAT) > 1.2 or 2.0 above the upper limits of normal), decrease in
hemoglobin of >10%, lymphocytes <500 or <1000/μL, increase in creatinine >20%, and adverse events
leading to the termination of tofacitinib treatment. The pre-defined secondary clinical endpoint was
longitudinal disease activity as measured by DAS28 and the achievement of LDA (DAS28 ≤ 3.2) and
remission (DAS28 < 2.6). Data were analyzed for the entire cohort of 144 patients, and, as a secondary
analysis, separately for patients who had prior exposure to biologic agents and patients who were
naïve to biologic agents.
2.3. Statistical Methods
Summary statistics are reported as median (range) or n (%). Kaplan–Meier curves were plotted,
and Kaplan–Meier estimates with 95% confidence intervals based on a log–log transformation were
computed for the endpoints. Time to LDA and remission was compared between patients with
and without prior exposure to biologics with a log-rank test. All analyses were performed in the R
programming language (R Foundation, Vienna, Austria, version 3.3.3, R Core Team 2013).
3. Results
3.1. Baseline Demographics
A total of 144 patients from the rheumatology units of the St. Gallen and Aarau rheumatology
divisions fulfilled the inclusion criteria and were included in the cohort. The mean age at initiation
of tofacitinib was 59.7 years and mean disease duration was 9.1 years. The majority of patients were
female (69.4%). A total of 50% were positive for rheumatoid factor (RF), and 48.6% were positive for
anti-citrullinated protein antibodies (ACPAs), as described in the records. No additional testing for RF
and/or ACPA prior or under tofacitinib treatment was conducted. A total of 56% of the patients were
either RF and/or ACPA positive.
Disease activity among the patient cohort was moderate, with a mean DAS28 of 4.43 at the
initiation of tofacitinib. A total of 63.3% had a disease classified as erosive. All patients were initiated
on a baseline dose of tofacitinib 5 mg bid. Regarding other medications, the mean number of previous
csDMARDS was 1.9. A total of 84.7% of patients had been previously exposed to at least one biologic
agent; the mean number of previous biologics was 2.2. Mean follow-up was 1.22 years (range
10 days–3.7 years) after initiation of tofacitinib (Table 1).
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Table 1. Patient demographics.
All Stopped Remained on Naïve to After
Patients Tofacitinib A Biologic Agent
Number (n) 144 57 87 22 122
Gender (%, female) 69.4 64.9 72.4 72.7 68.8
Age at initiation tofacitinib (years,
mean) 59.7 59.6 59.8 58.8 59.8
Tofacitinib applied in
monotherapy (n, %) 65 22 43 14 51
Concomitant medication
- Methotrexate 36 (25.0) 16 (28.1) 20 (23.0) 5 (22.7) 31 (25.4)
- Sulfasalazine 7 (4.9) 4 (7.0) 3 (3.4) 0 (0) 7 (5.7)
- Leflunomide 25 (17.3) 6 (10.5) 19 (21.8) 3 (13.6) 22 (18.0)
- Hydroxychloroquine 11 (7.6) 5 (8.8) 6 (6.9) 0 (0) 11 (9.0)
- Prednisolone or equivalent 48 (33.3) 16 (28.1) 32 (36.8) 4 (18.2) 44 (36.1)
Disease duration (years, mean) 9.1 9.9 8.7 2.6 10.3
Comorbidities of special interest
Cardiovascular
- Coronary heart disease 10 2 8 1 9
- Arterial hypertension 29 13 16 3 26
- Dysipoproteinemia 5 2 3 1 4
- Valvular heart disease 2 1 1 1 1
- Adipositas 12 6 6 0 2
- PAD 3 1 2 0 3
Osteoporosis 39 15 24 4 25
After a biologic agent (%) 84.7 87.2 83.5 0 100
Previous biologic agents (n, mean) 2.2 2.3 2.2 0 2.6
Previous csDMARDs (n, mean) 1.9 1.9 1.8 1.4 1.9
ACPA pos. (%) 48.6 42.8 52.3 50.0 48.3
Rheumatoid factor pos. (%) 50.0 51.1 48.2 40.9 51.7
Erosive disease (%) 63.3 60.9 66.7 45.5 66.7
DAS28 (mean) 4.4 4.4 4.5 3.7 4.6
ESR (mean) 17.2 18.5 16.6 18.8 16.9
CRP (mean, ULN < 5mg/L) 8.5 8.0 8.8 8.9 8.4
n: number. DAS28: 28 joint count disease activity score. DMARDs: disease modifying drugs. ACPA:
anti-citrullinated peptide antibody. ESR: erythrocyte sedimentation rate. CRP: C-reactive protein. pos.: positive.
ULN: upper limit of normal. PAD: peripheral artery disease.
3.2. Disease Activity
For all patients, the mean DAS28 decreased significantly from 4.4 at baseline to 3.59, 3.22, 3.18,
and 3.13 at 90, 180, 270, and 360 days (Figure 1). In total, 53% of patients achieved LDA and 48% DAS28
defined remission. The median time to LDA and remission was 319 days and 645 days, respectively.
The rates of LDA and remission under tofacitinib were higher in patients naïve to biologics
compared to patients who had been previously exposed: 100% of naïve patients achieved LDA,
and 83.3% achieved remission, as compared to 53.3% and 44.9% of pre-exposed to biologics patients.
Also, the duration of tofacitinib treatment until LDA or remission was shorter in patients naïve to
biologics. Patients in this cohort achieved LDA after a median 92 days and remission after a median
132 days, while medians for achieving LDA and remission among patients pre-exposed to biologic
agents amounted to 434 days and 692 days, respectively. In both cases, the difference between naïve
and pre-exposed patients was statistically significant (Figure 2, p < 0.001).
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Figure 1. Disease activity: The average disease activity score (DAS28) level is shown for all rheumatoid
arthritis (RA) patients treated with tofacitinib with a 95% confidence interval.
Figure 2. Disease activity: Time to remission (left panel) and low disease activity (LDA, right panel)
is shown for all RA patients treated with tofacitinib. Patients previously exposed to biologic agents are
shown in green, and patients naïve to biologics in red.
3.3. Discontinuation
A total of 89 (61.8%) patients remained on tofacitinib during follow-up. The median time to
stop tofacitinib was 95 days (range: 4–1106). A total of 21 patients (14.6%) stopped tofacitinib due to
insufficient responses and 35 patients (23.6%) stopped due to adverse events (AEs, Table 2). Of these,
the most frequent reasons for discontinuing tofacitinib were gastrointestinal symptoms (n = 18),
followed by infection (n = 5), myalgia (n = 2), remission (n = 2), headache, cough, blue finger syndrome,
intolerance, heartburn, psoriasis, and increased liver enzymes (all n = 1). The median time to stop
tofacitinib treatment due to ineffectiveness was 204 days (Figure 3). The median time to stop treatment
due to AEs ranged from 10 to 290 days (Figure 3). None of the demographic parameters at baseline
was a significant predictor for stopping tofacitinib.
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Table 2. Reasons for stopping tofacitinib.
Reason Number Time to Stop Tofa
Inefficacy/flare n = 22 median d204, range d21–d1106
Gastrointestinal n = 18 median d28, range d4–d265d
Infection n = 5 median d154, range d85–d877
Myalgia n = 2 range d92–d171
Remission n = 2 range d106–d379
Headache n = 2 d30
Cough n = 1 d22
Blue finger syndrome n = 1 d10
Intolerance n = 1 d42
Heartburn n = 1 d39
Psoriasis n = 1 d287
Increased liver enzymes n = 1 d290
d: day. n: number.
Figure 3. Time to discontinuation of tofacitinib was analyzed for all patients (n = 57 out of 144 total
patients, blue line). Patients stopping for ineffectiveness (n = 22, green line) or adverse events (n = 35,
red line) are shown separately.
3.4. Laboratory Values
Laboratory values including liver enzymes, creatinine, lymphocyte count, and hemoglobin were
followed during tofacitinib treatment. Increased ALAT or ASAT > 2× ULN were detected in 3.3% and
4.4% of patients, respectively. These changes were transient in 50% and 60% of cases, respectively.
Hemoglobin decrease of >10% was detected in 15.1% of patients and decreased lymphocytes <500/μL
in 3.4%. An increase in creatinine >20% was detected in 9.4% (Figure 4).
Figure 4. Patients were followed for laboratory changes under treatment with tofacitinib. Data are
shown for patients with at least one in- or decrease in one of these parameters during follow-up.
Percentages were calculated on patients with available data. ALAT: alanine amino transferase. ASAT:
aspartate amino transferase.
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4. Discussion
This study retrospectively analyzed real-life data from a cohort of 144 RA patients treated with
tofacitinib 5 mg bid, with the aim of assessing the effectiveness and tolerability of tofacitinib in a
clinical setting.
4.1. Effectiveness
Among the patient cohort, tofacitinib significantly reduced disease activity, with 58.2% of
patients achieving LDA and 49.5% achieving remission at follow-up. This is a little higher
than in published phase I–III clinical trials. In these clinical trials, the overall proportion of
RA patients achieving DAS28 defined as was LDA 5.7%–47.5% [34,37,43,46,47] and remission
7.2%–23.1% [34,36,37,43,46–49], depending on the exposure to and efficacy of previous treatments.
Essentially, our findings corroborate those of previous studies that have shown tofacitinib to be effective
in the management of RA [33–37,48,50].
A total of 15.9% of our patients stopped tofacitinib due to ineffectiveness. Percentages of inefficacy
were not published in the pivotal clinical trials, especially as this is not a defined outcome. Therefore,
the best approximation may be missing an ACR 20 response. The ACR 20 response was not reached in
33.9% of the MTX-IR (methotrexate incomplete responders) patients and 48.2% of the TNF-IR (tumor
necrosis factor incomplete responders) patients [51] in the phase II and III program for tofacitinib and
28.7% of naïve patients [47]. In a long-term extension study, 20.4% of patients did not achieve ACR 20
after 24 months and 21.5 after 96 months [52]. Importantly, not achieving ACR 20 does not necessarily
mean that a patient or a treating physician considers the therapeutic response to, e.g., tofacitinib,
ineffective in a clinical setting. Thus, the rate of 15.9% of patients stopping tofacitinib for ineffectiveness
appears to be somewhat lower than observed in the clinical studies and long-term extension studies.
However, because, as outlined above, missing an ACR 20 response does not necessarily reflect inefficacy,
we think that these rates are comparable.
Although tofacitinib demonstrated effectiveness across all patient demographics, a significant
difference was observed between patients naïve to biologic agents and patients who had previously
been exposed to biologics: naïve patients had a trend of a higher rate of achieving LDA and remission
compared to pre-exposed patients. Also, the duration of tofacitinib treatment until LDA and remission
was significantly shorter in patients naïve to biologics. However, the small number of patients naïve to
biologics have to be taken into account. These patients naïve to biologics had a shorter mean duration
of disease at initiation of tofacitinib and lower mean baseline DAS28, which may have influenced the
results. Shorter disease duration [53–55] and lower disease activity at initiation of treatment [56–59]
have both been shown to correlate with higher rates of LDA and remission in RA patients. However, the
indication that previous biologic therapies are associated with a reduced clinical response to tofacitinib
is consistent with recent studies: a meta-analysis of phase II and III clinical trials of tofacitinib in RA
patients published in 2016 showed that patients who were naïve to biologics had a numerically better
clinical response compared to patients with a prior inadequate response to biologics [60]. This finding
was confirmed by a direct comparison study [61] In the 2015, ACR guidelines for the treatment of
RA tofacitinib were still recommended as a second-line drug after treatment with biologic agents
resulted in an inadequate response or intolerance [62]. In the EULAR guidelines, tofacitinib is already
recommended for RA that has inadequately responded to one or more csDMARDs [63].
This is reflected in the patient cohort of the present analysis, in which only 15.2% of patients were
biologic-naïve. However, this and other studies suggest that there is a benefit to be gained from using
tofacitinib early in the treatment of RA, before the initiation of biologics, which may call into question
the position of tofacitinib as a second-line drug.
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4.2. Adverse Events
Few AEs leading to the discontinuation of tofacitinib treatment were observed in this study.
Among the AEs that lead to stopping tofacitinib, the most frequent were gastrointestinal AEs, followed
by infections. Patients experienced no severe or life-threatening AEs under tofacitinib. The safety
profile was comparable to published data, except for a single case of blue finger syndrome [64].
Following initiation, patients developed an increase in LDL cholesterol, which has been established
as a side effect of tofacitinib treatment in previous studies [65,66]; however, a tofacitinib-induced
increase in cholesterol does not appear to be associated with a higher incidence of cardiovascular AEs
in patients [60,65,67].
It is interesting that AEs are the main reason for stopping tofacitinib in the period directly
following initiation of treatment, later superseded by insufficient therapeutic responses. Treatment
had to be stopped for AEs, if necessary, usually rather early in the course of treatment, considering
that the average time of follow up was 1.22 years and the mean time to stop tofacitinib was 183 days.
Most patients (23%) discontinued treatment for AEs as early as within the first month (Figure 3).
We found no increase in AEs with longer disease duration. Non-tolerability of the drug seems to
become apparent rather early after initiation of treatment.
The rate of 24.3% of patients stopping tofacitinib for adverse events in our study is comparable to
the rate of 25% published in the 9.5 year long-term extension study published by Wollenhaupt et al. [52].
4.3. Limitations
A significant limitation of this study is that it deals with real-life data. Follow-ups in real-life
practice are not as frequent or consistent as in clinical studies. The size of the patient cohort was also
limited, and there was a considerable size difference between the sub-cohorts of patients naïve to
biologics and patients with prior exposure. However, the design as a retrospective, whole population
real-life analysis also constitutes a strength of this study, as its results reflect the variability of patient
populations in medical practice more than data on selected patients in controlled clinical trials.
5. Conclusions
The efficacy and safety of tofacitinib have been established in clinical trials. This retrospective
analysis of real-life data shows that tofacitinib is also effective and safe in a real-life setting. Over 50%
of the patient cohort achieved LDA or remission on a dose of tofacitinib 5 mg bid, with a higher rate of
patients naïve to biologic agents achieving either LDA or remission. The safety profile of tofacitinib
was generally consistent with previous studies. In conclusion, our results support the use of tofacitinib
in the treatment of RA to achieve a more successful clinical outcome.
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Abbreviations
ACPA anti-citrullinated protein antibody
ACR American College of Rheumatology
AE adverse event
AGREE
Abatacept study to gauge remission and joint damage progression in methotrexate-naïve
patients with early erosive rheumatoid arthritis
CAMERA Computer Assisted Management in Early Rheumatoid Arthritis
COMET
Comparison of methotrexate monotherapy with a combination of methotrexate and
etanercept in active, early, moderate to severe rheumatoid arthritis
CRP C-reactive protein
Cs Conventional synthetic
DAS Disease Activity Score
DMARD disease-modifying antirheumatic drug
ESR erythrocyte sedimentation rate
EULAR European League Against Rheumatism
GI gastrointestinal
LDA low disease activity
MTX methotrexate
PREMIER
A multicenter, randomized, double-blind clinical trial of combination therapy with
adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in





SWEFOT Swedish Farmacotherapy Trial
TEAR Treatment of Early Aggressive Rheumatoid Arthritis
TEMPO Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes
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Abstract: Patients with rheumatoid arthritis (RA) may experience residual pain and functional
impairment despite good control of disease activity. This study compared improvements in pain
and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib,
adalimumab or placebo in the 52-week RA-BEAM phase III study. Adults with active RA and
inadequate response to methotrexate received baricitinib 4 mg once daily, adalimumab 40 mg every
two weeks or placebo, with background methotrexate. Patients (N = 1010) were categorised as in
remission, in remission or low disease activity, or not in remission or low disease activity at week 24.
For patients in remission or low disease activity (n = 310), improvements in mean pain and physical
function scores at week 24 were significantly greater with baricitinib than placebo (p < 0.001 and
p < 0.01, respectively) and adalimumab (p < 0.05 for both). For both outcomes, differences between
adalimumab and placebo were not significant. The proportions of patients in remission or low
disease activity with minimal or no pain and with normalised physical function were numerically
greater with baricitinib than placebo. Baricitinib 4 mg once daily provided enhanced improvement in
pain and physical function in patients with well-controlled RA, suggesting it may produce effects
beyond immunomodulation.
Keywords: rheumatoid arthritis; baricitinib; pain; recovery of function; fatigue; productivity
1. Introduction
A major goal in the contemporary treatment of rheumatoid arthritis (RA) is to achieve remission
or low disease activity, with the aim of reducing inflammation to prevent joint damage and physical
disability [1,2]. However, achieving this objective target is not always associated with a corresponding
improvement in disability (Health Assessment Questionnaire (HAQ)) scores and other patient-reported
outcomes (PROs): In a study of the Leiden Early Arthritis Clinic cohort, for example, patients with
J. Clin. Med. 2019, 8, 1394; doi:10.3390/jcm8091394 www.mdpi.com/journal/jcm51
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RA were now diagnosed after a shorter duration of symptoms and with less inflammation than they
were 20 years ago, but HAQ results remained stable over this time while PROs worsened [3]. Indeed,
residual pain and functional impairment can persist despite ongoing treatment and can negatively
affect quality of life [4,5]. Control of pain and maintenance of physical function are priorities for
patients with RA [5–9]. Improvement in PROs should, therefore, be considered an important treatment
goal, in addition to reducing inflammation, for improving the health outcomes of such patients [10].
Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 [11], which are essential
for the intracellular signalling of various cytokines associated with inflammation in RA [12,13]. It is
approved for the treatment of moderately to severely active RA in adults in over 50 countries, including
the USA, Europe and Japan [14–16]. The efficacy and safety of baricitinib as a treatment for RA were
established in four phase III, randomised, double-blind, multicentre studies in patients with active
disease [17–20].
The objective of these post-hoc analyses was to compare improvements in pain, physical function,
fatigue and work productivity/loss between baricitinib, adalimumab and placebo, all given with
background methotrexate, in patients with well-controlled RA (in remission or low disease activity) at
week 24 in RA-BEAM.
2. Materials and Methods
2.1. RA-BEAM Study Design
RA-BEAM (NCT01710358) was a phase III, double-blind, placebo- and active-controlled study in
which patients with active RA were randomised to treatment with baricitinib 4 mg, adalimumab or
placebo in addition to background methotrexate for 52 weeks (24 weeks for placebo). All patients had
an inadequate response to stable doses of methotrexate before study entry. The study design has been
described in detail previously [20]. In brief, 1305 adult patients (aged ≥18 years) with moderately to
severely active RA were randomised and treated with either baricitinib 4 mg once daily (N = 487),
adalimumab 40 mg once every two weeks (N = 330) or once-daily placebo (N = 488) for 52 weeks
(24 weeks for placebo) in addition to stable background methotrexate.
RA-BEAM was conducted in accordance with the ethical principles of the 1964 Declaration of
Helsinki and its later amendments, and Good Clinical Practice guidelines, and was approved by
each centre’s institutional review board or ethics committee. Informed consent was obtained from all
individual participants included in the study.
2.2. Outcomes Relevant to the Post-Hoc Analyses
Pain was assessed throughout the study, including at week 24, using a pain visual analogue
scale (VAS, 0–100 mm), whereas physical function was assessed using the HAQ-Disability Index
(HAQ-DI) [21]. Additional PROs assessed at baseline and week 24 included fatigue, measured using the
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale [22], and work absenteeism,
presenteeism, productivity loss and activity impairment, measured using the Work Productivity and
Activity Impairment Questionnaire-RA [23].
2.3. Statistical Analysis
Patients from all treatment groups were categorised as being in remission, being in remission or
low disease activity, or not being in remission or low disease activity at week 24 (Table 1). Remission was
defined as Disease Activity Score for 28-joint count with erythrocyte sedimentation rate (DAS28-ESR)
<2.6 and low disease activity as DAS28-ESR ≥2.6 and ≤3.2. Not being in remission or low disease
activity was defined as DAS28-ESR >3.2 based on observed data. Changes from baseline to week 24 in
pain VAS, HAQ-DI and FACIT-F scores and work-related outcomes were compared between baricitinib,
adalimumab and placebo according to remission or low disease activity status. Comparisons were
made using analysis of covariance (ANCOVA) adjusted for randomisation variables (region and
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baseline joint erosion status (1–2 or ≥3)) and baseline score. The proportions of patients achieving
minimal or no pain and those achieving normalisation of physical function at week 24 were also
compared descriptively between treatment groups according to remission status. Minimal or no
pain was defined as a VAS score of ≤10 mm, and normalisation of physical function was defined as
a HAQ-DI score of <0.5 (including patients with a baseline HAQ-DI score of <0.5). For all outcome
measures, missing values were imputed using modified last observation carried forward (mLOCF) as
per the original predefined study analyses [20]. Analyses were not controlled for multiple testing.
For changes from baseline to week 24 in pain and HAQ-DI scores, sensitivity analyses were
conducted for patients in remission or low disease activity according to DAS28 with high-sensitivity
C-reactive protein (DAS28-hsCRP), Simplified Disease Activity Index (SDAI) or Clinical Disease
Activity Index (CDAI) criteria (Table 1).
Table 1. Remission and remission or low disease activity rates at week 24 in patients with moderately
to severely active rheumatoid arthritis from RA-BEAM [14,20].
Treatment ¥ BARI 4 mg ADA 40 mg Q2W Placebo
n 487 330 488
Remission rates (%)
DAS28-ESR <2.6 18 *** 18 *** 5
DAS28-hsCRP <2.6 34 *** 32 *** 8
SDAI ≤3.3 16 *** 14 *** 3
CDAI ≤2.8 16 *** 12 *** 4
Remission or low disease activity rates (%)
DAS28-ESR ≤3.2 32 *** 34 *** 10
DAS28-hsCRP ≤3.2 52 *** 48 *** 19
DAS28-ESR ≥2.6 and ≤3.2 14 16 5
DAS28-hsCRP ≥2.6 and ≤3.2 18 16 11
SDAI >3.3 and ≤11 35 34 17
CDAI >2.8 and ≤10 34 36 16
¥ Patients remained on background methotrexate throughout the study; all patients were bDMARD naïve.
*** p < 0.001 vs. placebo. ADA adalimumab, BARI baricitinib, CDAI Clinical Disease Activity Index, bDMARD
biologic disease-modifying antirheumatic drug, DAS28-ESR Disease Activity Score for 28-joint count with erythrocyte
sedimentation rate, DAS28-hsCRP Disease Activity Score for 28-joint count with high-sensitivity C-reactive protein,
Q2W once every two weeks, SDAI Simplified Disease Activity Index.
3. Results
Baseline characteristics of 1305 randomised and treated patients in RA-BEAM are shown in Table 2.
Characteristics were similar across the treatment groups, including the proportions taking steroids
and/or concomitant conventional synthetic disease-modifying antirheumatic drugs. Of these patients,
1010 were included in the current analyses—168 (baricitinib, n = 87; adalimumab, n = 57; placebo,
n = 24) were in remission, 310 (baricitinib, n = 154; adalimumab, n = 110; placebo, n = 46) were in
remission or low disease activity and 700 (baricitinib, n = 267; adalimumab, n = 157; placebo, n = 276)
were not in remission or low disease activity at week 24, according to DAS28-ESR criteria.
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3.1. Change in Pain VAS Scores
For patients in remission, change from baseline in mean pain VAS score at week 24 with baricitinib
was significantly greater than that with placebo (p < 0.01) and greater than that achieved with
adalimumab, although the difference between baricitinib and adalimumab was not statistically
significant (Figure 1). There was no significant difference between adalimumab and placebo.
For patients in remission or low disease activity, change from baseline in mean pain VAS score
at week 24 was significantly greater with baricitinib than with placebo (p < 0.001) and adalimumab
(p < 0.05). The difference between adalimumab and placebo was not statistically significant. Results
of sensitivity analyses using other disease activity measures were consistent with these findings.
For patients not in remission or low disease activity, change from baseline in mean pain VAS score at
week 24 was significantly greater with baricitinib and adalimumab than with placebo (p < 0.0001 and
p = 0.0130, respectively). There was no significant difference between baricitinib and adalimumab.
***
Figure 1. Change from baseline in pain VAS score at week 24 by remission status in patients from
RA-BEAM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. placebo; ‡ p < 0.05 vs. adalimumab. Error bars
indicate standard deviation. Change in pain VAS score based on numbers of patients from RA-BEAM
in remission (DAS28-ESR <2.6): PBO+MTX n = 24, BARI+MTX n = 87, ADA+MTX n = 57; in remission
or low disease activity (DAS28-ESR ≥2.6 and ≤3.2): PBO+MTX n = 46, BARI+MTX n = 154, ADA+MTX
n = 110; and not in remission or low disease activity: PBO+MTX n = 276, BARI+MTX n = 266,
ADA+MTX n = 157. One patient was missing from the BARI+MTX group for patients not in remission
or low disease activity. ADA adalimumab, BARI baricitinib, DAS28-ESR Disease Activity Score for
28-joint count with erythrocyte sedimentation rate, PBO placebo, MTX methotrexate, VAS visual
analogue scale.
3.2. Change in HAQ-DI Scores
For patients in remission, change from baseline in mean HAQ-DI score at week 24 was significantly
greater with baricitinib and adalimumab than with placebo (p< 0.01 and p< 0.05, respectively) (Figure 2).
The difference between baricitinib and adalimumab was not statistically significant. For patients in
remission or low disease activity, change from baseline in HAQ-DI score at week 24 was significantly
greater with baricitinib than with placebo (p< 0.01) and adalimumab (p< 0.05). There was no significant
difference between adalimumab and placebo. Results of sensitivity analyses using other disease activity
measures were consistent with these findings (data not shown). For patients not in remission or low
disease activity, change from baseline in mean HAQ-DI score at week 24 was significantly greater with
baricitinib and adalimumab than with placebo (p < 0.0001 and p = 0.0014, respectively). The difference
between baricitinib and adalimumab was not statistically significant.
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**
Figure 2. Change from baseline in HAQ-DI score at week 24 by remission status in patients from
RA-BEAM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. placebo; ‡ p < 0.05 vs. adalimumab. Error bars
indicate standard deviation. Change in HAQ-DI score based on numbers of patients from RA-BEAM in
remission (DAS28-ESR <2.6): PBO+MTX n = 24, BARI+MTX n = 87, ADA+MTX n = 57; in remission or
low disease activity (DAS28-ESR ≥2.6 and ≤3.2): PBO+MTX n = 46, BARI+MTX n = 154, ADA+MTX
n = 110; and not in remission or low disease activity: PBO+MTX n = 276, BARI+MTX n = 266,
ADA+MTX n = 156. One patient was missing from the BARI+MTX group and one from the ADA+MTX
group for patients not in remission or low disease activity. ADA adalimumab, BARI baricitinib,
DAS28-ESR Disease Activity Score for 28-joint count with erythrocyte sedimentation rate, HAQ-DI
Health Assessment Questionnaire-Disability Index, MTX methotrexate, PBO placebo.
3.3. Proportion of Patients Achieving Minimal or No Pain and Proportion Achieving Normalisation of
Physical Function
The proportion of patients in remission who achieved minimal or no pain at week 24 was
65.5% (57/87) for baricitinib, 61.4% (35/57) for adalimumab and 41.7% (10/24) for placebo (Figure 3a).
The proportion of patients in remission who achieved normalised physical function at week 24 was
75.9% (66/87) for baricitinib, 70.2% (40/57) for adalimumab and 50.0% (12/24) for placebo (Figure 3b).
Trends were the same, although proportions achieving these endpoints were slightly lower, for patients
in remission or low disease activity.
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(a) (b) 
Figure 3. Patients from RA-BEAM with (a) minimal/no pain and (b) normalised physical function
at week 24, by remission status. Proportions of patients from RA-BEAM with (a) minimal or no
pain (pain VAS ≤10 mm) and (b) normalised physical function (HAQ-DI <0.5) based on numbers of
patients in remission (DAS28-ESR <2.6): PBO+MTX n = 24, BARI+MTX n = 87, ADA+MTX n = 57;
in remission or low disease activity (DAS28-ESR ≥2.6 and ≤3.2): PBO+MTX n = 46, BARI+MTX n = 154,
ADA+MTX n = 110; and not in remission or low disease activity (DAS28-ESR >3.2): PBO+MTX n = 276,
BARI+MTX n = 266, ADA+MTX n = 156. One patient was missing from the BARI+MTX group and
one from the ADA+MTX group for patients not in remission or low disease activity. For the pain
analysis, the number of patients not in remission or low disease activity was PBO+MTX n = 276,
BARI+MTX n = 210, ADA+MTX n = 120. ADA adalimumab, BARI baricitinib, DAS28-ESR Disease
Activity Score for 28-joint count with erythrocyte sedimentation rate, HAQ-DI Health Assessment
Questionnaire-Disability Index, MTX methotrexate, PBO placebo, VAS visual analogue scale.
3.4. Changes in Other Patient-Reported Outcomes
Despite meeting DAS28-ESR criteria for remission or low disease activity, patients continued
to experience fatigue, although FACIT-F scores were <36 in all treatment groups (Figure 4).
Work productivity of working patients generally improved in all treatment groups, including those
not in remission or low disease activity (Supplementary Table S1). For working patients in remission,
improvements in work-related measures were numerically greater with both active treatments than
with placebo. For those in remission or low disease activity, improvement in activity impairment was
significantly greater with baricitinib than placebo, whereas the difference between adalimumab and
placebo was not statistically significant. For working patients not in remission or low disease activity,
improvements in the proportion of patients present at work, productivity loss and activity impairment
were significantly greater with both active treatments than with placebo.
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(a) (b) 
Figure 4. FACIT-F scores in patients from RA-BEAM by remission status (a) at baseline and (b) change
at week 24. Error bars indicate standard deviation. FACIT-F scores at baseline and change in FACIT-F
scores based on numbers of patients from RA-BEAM in remission (DAS28-ESR <2.6): PBO+MTX n = 24,
BARI+MTX n = 87, ADA+MTX n = 57; in remission or low disease activity (DAS28-ESR ≥2.6 and ≤3.2):
PBO+MTX n = 46, BARI+MTX n = 154, ADA+MTX n = 110; and not in remission or low disease activity
(DAS28-ESR >3.2): PBO+MTX n = 276, BARI+MTX n = 266, ADA+MTX n = 156. One patient was
missing from the BARI+MTX group and one from the ADA+MTX group for patients not in remission
or low disease activity. ADA adalimumab, BARI baricitinib, DAS28-ESR Disease Activity Score for
28-joint count with erythrocyte sedimentation rate, FACIT-F Functional Assessment of Chronic Illness
Therapy-Fatigue, MTX methotrexate, PBO placebo.
4. Discussion
Residual pain and impaired function persist in many patients with RA despite the achievement of
disease control [4,5,24]. This residual pain may be non-inflammatory in origin, caused by sensitisation
of nociceptors or peripheral joint damage; or it may be due to central sensitisation [25–27]. Results
of the post-hoc analyses reported here suggest that, in patients with moderately to severely active
RA and an inadequate response to methotrexate, addition of baricitinib may be more effective than
adalimumab and placebo in improving pain and physical function in patients with a good level of
disease control (i.e., in remission or low disease activity). Among patients in remission, significantly
greater improvements in pain and physical function were observed with baricitinib than with continued
methotrexate alone (placebo group). Among patients in remission or low disease activity, greater
improvements in pain and physical function were observed with the addition of baricitinib than with
the addition of adalimumab or with continued methotrexate alone. Notably, both active treatments
were significantly more effective than placebo at improving pain and physical function in patients who
did not achieve controlled disease during the study (not in remission or low disease activity).
Another analysis of data from RA-BEAM also showed that, among patients with varying levels of
inflammation, patients treated with baricitinib achieved consistent pain relief regardless of the CRP level
at week 24 [28]. Furthermore, patients treated with baricitinib achieved greater and more rapid pain
relief than those receiving adalimumab or placebo. Using CRP levels as a surrogate for inflammation,
baricitinib plus methotrexate was associated with greater relief from the non-inflammatory component
of RA-associated pain than adalimumab plus methotrexate or placebo plus methotrexate [28].
The mechanisms underlying the effect of baricitinib on non-inflammatory pain are not
understood. As reviewed by Taylor et al. [28], it is possible that inhibition of JAK1 and JAK2
also produces anti-nociceptive effects that are not related to inflammation, such as inhibition of the
JAK2-dependent cytokine granulocyte-macrophage colony-stimulating factor, which may be involved
in the pathophysiology of pain [29], and/or inhibition of the JAK2-dependent signal transducer and
activator of transcription (STAT)3 phosphorylation pathway [30]. Further studies to elucidate the
underlying mechanisms are warranted.
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Both greater disease activity and longer disease duration have been shown to increase the likelihood
of a patient retiring early or stopping work because of RA [31]. In RA-BEAM, work productivity
generally improved in all working patients, including those who did not achieve remission or low
disease activity, but not all work-related problems were resolved (Supplementary Table S1). Control
of all aspects of the disease, including reduction of pain and fatigue and maintenance of function,
is an important goal of RA treatment, and patients generally consider these specified outcomes more
essential than control of inflammation [10]. Pain and physical function have been identified as key
unmet needs, both clinically and for patients themselves, that can adversely affect a patient’s ability to
function normally and their overall well-being [5].
Control of pain in patients with RA is important, since pain has been shown to contribute to worse
long-term outcomes. For example, high pain levels at disease onset have been identified as a risk factor
for being in the most disabled tertile of RA patients 5–18 years after disease onset [32]. High baseline
pain scores were also shown to predict suboptimal mental health (p = 0.02) in a cohort of South African
patients with early RA [33].
Maintenance of normal physical function is also important in patients with RA. Data from the
Dutch DREAM registry showed that having better physical function (measured using the HAQ-DI)
was associated with work participation (odds ratio (OR) 0.32, p = 0.000) and with starting work after 2
years of treatment with tumour necrosis factor inhibitors (OR 0.58, p < 0.1) [34]. Similarly, a survey of
patients with RA from France showed a high correlation between deteriorating function and work
capacity, such that only 15% of patients with a HAQ score of ≥2 were working, compared with 63% of
patients with a HAQ score of <1 [35]. Poor physical function can also affect health-related quality of
life [33].
The assessment of PROs, such as pain and function, in RA should help clinicians to focus more on
the impact of the disease on patients themselves and how they are feeling rather than solely on the
inflammatory component of the disease [10]. This is likely to aid in shared decision-making discussions
between patients and clinicians, enabling clinicians to provide more effective and efficient patient
care [25]. Indeed, it has been recommended that assessment of the PROs of pain and physical function
(HAQ) be added to the current core set of treatment targets to achieve greater patient involvement
in the RA treatment process [10]. Our results suggest that patients who do not respond to treatment,
as measured using inflammation-associated endpoints, may still experience treatment benefit, and may,
therefore, choose to continue with treatment.
Despite major advances in the treatment of RA, predicting remission a priori at the start of
disease-modifying treatment remains a clinical conundrum. Nevertheless, in line with recent treatment
recommendations for a treat-to-target approach, the aim of any treating rheumatologist should be to
help their patients achieve remission or at least low disease activity [1,2]. With respect to this, it could
be of clinical relevance to know if differences exist between agents in treating residual symptoms (such
as pain) once inflammation is well controlled. Since baricitinib has demonstrated more effective pain
control than adalimumab [28], we were interested in investigating whether this benefit persists even
when a good level of disease control has been achieved. The post-hoc analyses reported here are not,
on their own, intended to inform clinical practice, but to help towards better defining current evidence
for the pain-relieving benefits of baricitinib compared to tumour necrosis factor inhibitors.
Limitations of the current analysis include that post-hoc analyses are exploratory by nature,
aimed at creating hypotheses rather than clearly demonstrable facts; the sample sizes for patients
achieving remission or low disease activity and working patients were small; and generalisability of
the results to patients in routine care who receive baricitinib or adalimumab is uncertain. In addition,
analyses were not adjusted for multiple testing.
5. Conclusions
Treatment with baricitinib 4 mg once daily or adalimumab 40 mg every other week resulted in
improvements in pain, physical function, fatigue and work productivity/impairment in patients with
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RA, independent of the impact on inflammation, measured using DAS28-ESR. Among patients in
remission or low disease activity, greater improvements in pain and physical function were observed
with baricitinib than with adalimumab and placebo. Research to better understand the role of
JAK1/JAK2 pathways in the control of pain beyond the regulation of inflammation is underway to help
clarify the differential effects of baricitinib relative to adalimumab on pain.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/9/1394/s1,
Table S1: Work-related patient-reported outcomes at week 24 according to remission status in working patients
from RA-BEAM.
Author Contributions: Conceptualisation, Methodology and Formal Analysis, C.G., A.Q., B.Z., I.d.l.T., F.D.L.
and P.C.T.; Data Curation, B.Z.; Investigation, B.F., B.K., J.E.P.; T.T., C.G., A.Q., B.Z., I.d.l.T., F.D.L. and P.C.T.;
Writing—Original Draft Preparation, P.C.T.; Writing—Review and Editing, B.F., B.K., J.E.P., T.T., C.G., A.Q., B.Z.,
I.d.l.T., F.D.L. and P.C.T.; Supervision, I.d.l.T.; Project Administration, F.D.L.
Funding: RA-BEAM and these post-hoc analyses were funded by Eli Lilly and Company.
Acknowledgments: The authors would like to acknowledge JS Smolen for critical review of the manuscript,
and Sue Chambers and Caroline Spencer (Rx Communications, Mold, UK) for medical writing assistance with the
preparation of this manuscript, funded by Eli Lilly and Company. PCT would like to acknowledge support from
the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and from Arthritis
Research UK.
Conflicts of Interest: B.F. reports grants from AbbVie, Eli Lilly and Company, MSD, and Pfizer, and personal
fees from AbbVie, Biogen, BMS, Celgene, Janssen-Cilag, Eli Lilly and Company, Medac, MSD, NORDIC Pharma,
Novartis, Pfizer, Roche, Sanofi-Aventis, SOBI and UCB. B.K. reports grants and personal fees from Eli Lilly and
Company, Janssen, Novartis and UCB. T.T. reports grants and personal fees from Astellas Pharma Inc., Chugai
Pharmaceutical Co. Ltd., Daiichi Sankyo Co., Takeda Pharmaceutical Co. Ltd., AbbVie GK, Asahikasei Pharma
Corp., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Eisai Co. Ltd., AYUMI Pharmaceutical Corporation,
Nipponkayaku Co. Ltd., Novartis Pharma K.K., Bristol–Myers K.K., Astra Zeneca K.K., Eli Lilly Japan K.K.,
Taisho Toyama Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., UCB Japan Co. Ltd. and Taiho Pharmaceutical
Co. Ltd. C.G. is an employee and stockholder of Eli Lilly and Company. A.Q. is an employee and stockholder of
Eli Lilly and Company. I.d.l.T. is an employee and stockholder of Eli Lilly and Company. B.Z. is an employee
and stockholder of Eli Lilly and Company. F.D.L. is an employee and stockholder of Eli Lilly and Company.
P.C.T. reports grants from Eli Lilly and Company, and Galapagos, and personal fees from Eli Lilly and Company,
AbbVie, Gilead, and Pfizer.
References
1. Singh, J.A.; Saag, K.G.; Bridges, S.L., Jr.; Akl, E.A.; Bannuru, R.R.; Sullivan, M.C.; Vaysbrot, E.; McNaughton, C.;
Osani, M.; Shmerling, R.H.; et al. 2015 American College of Rheumatology guideline for the treatment of
rheumatoid arthritis. Arthritis Rheumatol. 2016, 68, 1–26. [CrossRef]
2. Smolen, J.S.; Landewé, R.; Bijlsma, J.; Burmester, G.; Chatzidionysiou, K.; Dougados, M.; Nam, J.; Ramiro, S.;
Voshaar, M.; Van Vollenhoven, R.; et al. EULAR recommendations for the management of rheumatoid
arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum.
Dis. 2017, 76, 960–977. [CrossRef]
3. Nieuwenhuis, W.P.; De Wit, M.P.; Boonen, A.; Van Der Helm-Van Mil, A.H. Changes in the clinical presentation
of patients with rheumatoid arthritis from the early 1990s to the years 2010: Earlier identification but more
severe patient reported outcomes. Ann. Rheum. Dis. 2016, 75, 2054–2056. [CrossRef]
4. Ishiguro, N.; Dougados, M.; Cai, Z.; Zhu, B.; Ishida, M.; Sato, M.; Gaich, C.; Quebe, A.; Stoykov, I.; Tanaka, Y.
Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc
analyses of overall and Japanese results from two phase 3 clinical trials. Mod. Rheumatol. 2018, 28, 950–959.
[CrossRef]
5. Taylor, P.C.; Moore, A.; Vasilescu, R.; Alvir, J.; Tarallo, M. A structured literature review of the burden of
illness and unmet needs in patients with rheumatoid arthritis: A current perspective. Rheumatol. Int. 2016,
36, 685–695. [CrossRef]
6. Gossec, L.; Dougados, M.; Rincheval, N.; Balanescu, A.; Boumpas, D.T.; Canadelo, S.; Carmona, L.; Daurès, J.P.;
de Wit, M.; Dijkmans, B.A.; et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease
(RAID) score: A EULAR initiative. Ann. Rheum. Dis. 2009, 68, 1680–1685. [CrossRef]
60
J. Clin. Med. 2019, 8, 1394
7. Khan, N.A.; Spencer, H.J.; Abda, E.; Aggarwal, A.; Alten, R.; Ancuta, C.; Andersone, D.; Bergman, M.;
Craig-Muller, J.; Detert, J.; et al. Determinants of discordance in patients’ and physicians’ rating of rheumatoid
arthritis disease activity. Arthritis Care Res. 2012, 64, 206–214. [CrossRef]
8. Wen, H.; Ralph Schumacher, H.; Li, X.; Gu, J.; Ma, L.; Wei, H.; Yokogawa, N.; Shiroto, K.; Baker, J.F.; Dinnella, J.;
et al. Comparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology
clinic visits: A pilot, multicenter, international study. Int. J. Rheum. Dis. 2012, 15, 380–389. [CrossRef]
9. Van Tuyl, L.H.; Sadlonova, M.; Hewlett, S.; Davis, B.; Flurey, C.; Goel, N.; Gossec, L.; Brahe, C.H.; Hill, C.L.;
Hoogland, W.; et al. The patient perspective on absence of disease activity in rheumatoid arthritis: A survey
to identify key domains of patient-perceived remission. Ann. Rheum. Dis. 2017, 76, 855–861. [CrossRef]
10. Fautrel, B.; Alten, R.; Kirkham, B.; De La Torre, I.; Durand, F.; Barry, J.; Holzkaemper, T.; Fakhouri WTaylor, P.C.
Call for action: How to improve use of patient-reported outcomes to guide clinical decision making in
rheumatoid arthritis. Rheumatol. Int. 2018, 38, 935–947. [CrossRef]
11. Fridman, J.S.; Scherle, P.A.; Collins, R.; Burn, T.C.; Li, Y.; Li, J.; Covington, M.B.; Thomas, B.; Collier, P.;
Favata, M.F.; et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: Preclinical
characterization of INCB028050. J. Immunol. 2010, 184, 5298–5307. [CrossRef]
12. O’Shea, J.J.; Kontzias, A.; Yamaoka, K.; Tanaka, Y.; Laurence, A. Janus kinase inhibitors in autoimmune
diseases. Ann. Rheum. Dis. 2013, 72, ii111–ii115. [CrossRef]
13. Choy, E.H.S.; Miceli-Richard, C.; González-Gay, M.A.; Sinigaglia, L.; Schlichting, D.E.; Meszaros, G.;
de la Torre, I.; Schulze-Koops, H. The effect of JAK/JAK2 inhibition in rheumatoid arthritis: Efficacy and
safety of baricitinib. RMD Open 2019, 5, e000798. [CrossRef]
14. European Medicines Agency. Olumiant 2 mg and 4 mg Film-Coated Tablets. Summary of Product
Characteristics. 2018. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/004085/WC500223723.pdf (accessed on 11 April 2018).
15. Food and Drug Administration. Olumiant (Baricitinib) Tablets, for Oral Use. Prescribing Information; 2018.
Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf (accessed
on 21 June 2018).
16. Pharmaceutical and Medical Devices Agency. Report on the Deliberation Results. Olumiant Tablets 2 mg,
Olumiant Tablets 4 mg. 2017. Available online: http://www.pmda.go.jp/files/000226301.pdf (accessed on 21
June 2018).
17. Genovese, M.C.; Kremer, J.; Zamani, O.; Ludivico, C.; Krogulec, M.; Xie, L.; Beattie, S.D.; Koch, A.E.;
Cardillo, T.E.; Rooney, T.P.; et al. Baricitinib in patients with refractory rheumatoid arthritis. N. Engl. J. Med.
2016, 374, 1243–1252. [CrossRef]
18. Dougados, M.; van der Heijde, D.; Chen, Y.C.; Greenwald, M.; Drescher, E.; Liu, J.; Beattie, S.; Witt, S.;
de la Torre, I.; Gaich CRooney, T. Baricitinib in patients with inadequate response or intolerance to
conventional synthetic DMARDs: Results from the RA-BUILD study. Ann. Rheum. Dis. 2017, 76,
88–95. [CrossRef]
19. Fleischmann, R.; Schiff, M.; van der Heijde, D.; Ramos-Remus, C.; Spindler, A.; Stanislav, M.; Zerbini, C.A.;
Gurbuz, S.; Dickson, C.; de Bono, S.; et al. Baricitinib, methotrexate, or combination in patients with
rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis
Rheumatol. 2017, 69, 506–517. [CrossRef]
20. Taylor, P.C.; Keystone, E.C.; van der Heijde, D.; Weinblatt, M.E.; del Carmen Morales, L.; Reyes Gonzaga, J.;
Yakushin, S.; Ishii, T.; Emoto, K.; Beattie, S.; et al. Baricitinib versus placebo or adalimumab in rheumatoid
arthritis. N. Engl. J. Med. 2017, 376, 652–662. [CrossRef]
21. Fries, J.F.; Spitz, P.W.; Young, D.Y. The dimensions of health outcomes: The health assessment questionnaire,
disability and pain scales. J. Rheumatol. 1982, 9, 789–793.
22. Cella, D.; Yount, S.; Sorensen, M.; Chartash, E.; Sengupta, N.; Grober, J. Validation of the Functional
Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with
rheumatoid arthritis. J. Rheumatol. 2005, 32, 811–819.
23. Reilly, M.C.; Zbrozek, A.S.; Dukes, E.M. The validity and reproducibility of a work productivity and activity
impairment instrument. Pharmacoeconomics 1993, 4, 353–365. [CrossRef]
24. Ishida, M.; Kuroiwa, Y.; Yoshida, E.; Sato, M.; Krupa, D.; Henry, N.; Ikeda, K.; Kaneko, Y. Residual
symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity:
A systematic literature review. Mod. Rheumatol. 2018, 28, 789–799. [CrossRef]
61
J. Clin. Med. 2019, 8, 1394
25. Taylor, P.; Manger, B.; Alvaro-Gracia, J.; Johnstone, R.; Gomez-Reino, J.; Eberhardt, E.; Wolfe, F.;
Schwartzman, S.; Furfaro, N.; Kavanaugh, A. Patient perceptions concerning pain management in the
treatment of rheumatoid arthritis. J. Int. Med. Res. 2010, 38, 1213–1224. [CrossRef]
26. Walsh, D.A.; Mcwilliams, D.F. Mechanisms, impact and management of pain in rheumatoid arthritis. Nat.
Rev. Rheumatol. 2014, 10, 581–592. [CrossRef]
27. Boyden, S.D.; Hossain, I.N.; Wohlfahrt, A.; Lee, Y.C. Non-inflammatory causes of pain in patients with
rheumatoid arthritis. Curr. Rheumatol. Rep. 2016, 18, 30. [CrossRef]
28. Taylor, P.C.; Lee, Y.C.; Fleischmann, R.; Takeuchi, T.; Perkins, E.L.; Fautrel, B.; Zhu, B.; Quebe, A.K.;
Gaich, C.L.; Zhang, X.; et al. Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab
plus methotrexate: Results from the RA-BEAM trial. J. Clin. Med. 2019, 8, 831. [CrossRef]
29. Cook, A.D.; Pobjoy, J.; Steidl, S.; Dürr, M.; Braine, E.L.; Turner, A.L.; Lacey, D.C.; Hamilton, J.A.
Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and
disease development. Arthritis Res. Ther. 2012, 14, R199. [CrossRef]
30. Dominguez, E.; Rivat, C.; Pommier, B.; Mauborgne, A.; Pohl, M. JAK/STAT3 pathway is activated in spinal
cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J.
Neurochem. 2008, 107, 50–60. [CrossRef]
31. Capron, J.; De Leonardis, F.; Fakhouri, W.; Burke, T.; Rose, A.; Jacob, I. The impact of rheumatoid arthritis
(RA) on a patient’s ability to stay in work and level of pain experienced. Value Health 2017, 20, A531–A532.
[CrossRef]
32. Malm, K.; Bergman, S.; Andersson, M.; Bremander, A.; BARFOT Study Group. Predictors of severe
self-reported disability in RA in a long-term follow-up study. Disabil. Rehabil. 2015, 37, 686–691. [CrossRef]
33. Hodkinson, B.; Musenge, E.; Ally, M.; Meyer, P.W.; Anderson, R.; Tikly, M. Functional disability and
health-related quality of life in South Africans with early rheumatoid arthritis. Scand. J. Rheumatol. 2012, 41,
366–374. [CrossRef]
34. Manders, S.H.; Kievit, W.; Braakman-Jansen, A.L.; Brus, H.L.; Hendriks, L.; Fransen, J.; van de Laar, M.A.;
van Riel, P.L. Determinants associated with work participation in patients with established rheumatoid
arthritis taking tumor necrosis factor inhibitors. J. Rheumatol. 2014, 41, 1263–1269. [CrossRef]
35. Kobelt, G.; Woronoff, A.S.; Richard, B.; Peeters, P.; Sany, J. Disease status, costs and quality of life of patients
with rheumatoid arthritis in France: The ECO-PR study. Jt. Bone Spine 2008, 75, 408–415. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Next-Generation Sequencing Profiles of the
Methylome and Transcriptome in Peripheral Blood
Mononuclear Cells of Rheumatoid Arthritis
Chia-Chun Tseng 1,2, Yuan-Zhao Lin 1, Chia-Hui Lin 1, Ruei-Nian Li 3, Chang-Yi Yen 4,
Hua-Chen Chan 5, Wen-Chan Tsai 5, Tsan-Teng Ou 5, Cheng-Chin Wu 5, Wan-Yu Sung 5 and
Jeng-Hsien Yen 1,5,6,7,*
1 Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University,
Kaohsiung 80708, Taiwan
2 Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 80145, Taiwan
3 Department of Biomedical Science and Environmental Biology, College of Life Science, Kaohsiung Medical
University, Kaohsiung 80708, Taiwan
4 Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan
5 Division of Rheumatology, Department of Internal Medicine, Kaohsiung Medical University Hospital,
Kaohsiung 80754, Taiwan
6 Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan
7 Department of Biological Science and Technology, National Chiao-Tung University, Hsinchu 30010, Taiwan
* Correspondence: jehsye@kmu.edu.tw; Tel.: +886-7-3121101 (ext. 6088)
Received: 23 July 2019; Accepted: 19 August 2019; Published: 22 August 2019
Abstract: Using next-generation sequencing to decipher methylome and transcriptome and
underlying molecular mechanisms contributing to rheumatoid arthritis (RA) for improving
future therapies, we performed methyl-seq and RNA-seq on peripheral blood mononuclear cells
(PBMCs) from RA subjects and normal donors. Principal component analysis and hierarchical
clustering revealed distinct methylation signatures in RA with methylation aberrations noted across
chromosomes. Methylation alterations varied with CpG features and genic characteristics. Typically,
CpG islands and CpG shores were hypermethylated and displayed the greatest methylation variance.
Promoters were hypermethylated and enhancers/gene bodies were hypomethylated, with methylation
variance associated with expression variance. RA genetically associated genes preferentially displayed
differential methylation and differential expression or interacted with differentially methylated
and differentially expressed genes. These differentially methylated and differentially expressed
genes were enriched with several signaling pathways and disease categories. 10 genes (CD86,
RAB20, XAF1, FOLR3, LTBR, KCNH8, DOK7, PDGFA, PITPNM2, CELSR1) with concomitantly
differential methylation in enhancers/promoters/gene bodies and differential expression in B cells
were validated. This integrated analysis of methylome and transcriptome identified novel epigenetic
signatures associated with RA and highlighted the interaction between genetics and epigenetics in
RA. These findings help our understanding of the pathogenesis of RA and advance epigenetic studies
in regards to the disease.
Keywords: rheumatoid arthritis; methylation; next-generation sequencing
1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease manifested by sustained chronic inflammation
resulting in joint damage and severe disability. Numerous therapies based on our knowledge of RA
were developed over the past two decades and helped improve outcomes for those suffering from the
disease [1]. Despite the increasing number of treatment strategies, many patients are refractory to their
J. Clin. Med. 2019, 8, 1284; doi:10.3390/jcm8091284 www.mdpi.com/journal/jcm63
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current treatments, some patients see their clinical response diminish, while others suffer from adverse
events from therapy. As such, there is a necessity to develop an improved strategy to treat RA [2].
Engrafting peripheral blood mononuclear cells (PBMCs) of RA patients into severe combined
immunodeficient (SCID) mice resulted in a reconstituted synovitis characteristic of human RA [3].
Additionally, these cells secreted numerous inflammatory cytokines, such as interleukin (IL)-6 and
tumor necrosis factor-alpha (TNF-α) [4,5] which orchestrated inflammation, radiographic progression of
RA and were, therefore, therapeutic targets of current RA management [6]. These findings highlight the
critical role of PBMCs in RA pathogenesis. Therefore, a more comprehensive understanding of PBMCs
in RA holds promise in unraveling the complexity of RA and identifying novel therapeutic targets.
In past decades, tremendous efforts have been devoted to exploring RA genetics. However,
in recent years, DNA methylation is emerging as one key pathogenic player of RA. DNA methylation
acts as a composite measure of environmental exposures [7], making it an intriguing candidate for
the investigation of diseases that involve environmental factors, such as RA. Traditionally, DNA
methylation has been thought of as being involved in gene silencing but recent work has shown a more
complex picture [8]. Most studies investigating the role of DNA methylation in RA utilized the Illumina
450K microarray for methylation profiling and focused on methylation alone. Studies integrating
DNA methylation with gene expression at a whole-genome manner to investigate the relationship
between methylation, expression and RA, the associations of genomic contexts and DNA methylation
and the interaction between differentially methylated genes and genetic at-risk loci in RA remain
somewhat limited.
To decipher the methylation signatures involved in RA PBMCs, we performed next generation
sequencing to compare the methylome and transcriptome landscape in PBMCs from RA patients and
healthy donors, detect changes to the methylome and transcriptome, elucidate the relationship between
methylation and expression and interaction between genetically associated genes and epigenetically
associated genes. These results offered a map to the PBMCs methylome and shed light on the
pathophysiology of RA.
2. Methods
After adjusting for cell types and batch effects (Figure 1), methylome data went through principal
component analysis (PCA) and hierarchical clustering (HC) (Figure 1, Step 1), OmicCircos visualization
(Figure 1, Step 2), CpG features mapping (Figure 1, Step 3), genic characteristics annotation (Figure 1,
Step 4), integration with transcriptome for methylation-expression correlation (Figure 1, Step 5)
and identification of concomitantly differentially methylated (false discovery rate (FDR) <0.05) and
differentially expressed genes (FDR < 0.05) (Figure 1, Step 6–7). Genes with concomitantly differential
methylation and differential expression underwent genetic–epigenetic interaction investigation
(Figure 1, Step 8), Ingenuity Pathway Analysis (IPA) (Figure 1, Step 9), and upstream regulator
deduction (Figure 1, Step 10). GEO dataset were downloaded for further validation (Figure 1, Step 11).
For detailed methods, see Supplementary Files. The study was conducted in accordance with the
Helsinki Declaration and was approved by the ethics committee of the Kaohsiung Medical University
Hospital (KMUHIRB-G(II)-20180031). All subjects gave their informed consent for inclusion before
they participated in the study.
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Figure 1. Schematic representation of the next-generation sequencing data analytical workflow.
After adjusting for cellular composition and batch effects, methyl-seq data first underwent Principal
component analysis (PCA) and hierarchical clustering (HC) (Step 1), OmicCircos visualization (Step 2),
CpG features mapping (Step 3), and genic characteristics annotation (Step 4). Methylation and
expression profiles were then integrated for methylation-expression correlation (Step 5). Differentially
methylated genes (FDR < 0.05) and differentially expressed genes (FDR < 0.05) were identified
(Step 6a–6b) and intersected to yield genes with concomitant expression and methylation changes in
enhancer/promoter/gene body (Step 7). These differentially methylated and differentially expressed
genes underwent genetic–epigenetic interaction investigation (Step 8), IPA (Step 9), and upstream
regulator deduction (Step 10). GEO dataset validation (Step 11) confirmed concomitant differential
methylation and expression of 10 genes.
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3. Results
3.1. Differential Methylation of PBMCs in RA
After adjusting for cellular composition and batch effects, we first profiled DNA methylation
alterations between RA and healthy donors with PCA and HC (Figure 1, Step 1). As shown in
Figure S2a, RA samples were characterized by distinct methylation profiles compared with healthy
donors. We also performed molecular stratification of samples using HC of methylation profiles
(Figure S2b). Based on methylation profiles, two distinct groups were identified, with the results
reaffirming the classification of RA and healthy donors.
3.2. Distribution of Methylation According to Genome Locations
For a visual representation of the analysis results, the R package Omiccircos was used to draw the
circos-plot. Supplementary Figure S3 depicted the methylation differences between RA and healthy
donors according to chromosome locations. Generally, methylation alterations were scattered across
nuclear genomes. No clear concentration of methylation changes was identified.
3.3. CpG Features Mapping
Past studies suggest methylation alterations depended on CpG features [9]. However, whether
similar phenomena existed in RA remained unexplored. Traditionally, CpG sites are classified into
four classes according to their CpG features. CpG islands are genomic regions of>200 bp with a CG
content of>50% and an observed/expected CpG ratio of>60%. CpG shores are located within 2 kb
from CpG island). CpG shelves include regions 2–4 kb from CpG island. The remaining regions >4 kb
from CpG island are defined as open seas [10]. To clarify whether methylation variations differed with
respective CpG features, we classified CpG into CpG islands, CpG shores, CpG shelves, and open
seas adopting similar classification schemes (Figure 1, Step 3). On average, CpG islands and CpG
shores were hypermethylated in RA, and CpG shelves and open seas were hypomethylated in RA
and methylation difference differed with respect to CpG features (Figure 2a). Overall, the methylation
variance was most pronounced in CpG islands, CpG shores, followed by open seas and CpG shelves
(p < 0.001) (Figure 2b).
3.4. Genic Characteristics Annotation
In addition to CpG features, evidence suggested methylation alterations differed with respect
to genic characteristics [9]. To test these possibilities in RA, we annotated every CpG to enhancers,
promoters, gene bodies, and intergenic regions (Figure 1, Step 4). Generally, CpG in promoters were
hypermethylated and CpG in enhancers, gene bodies and intergenic regions were hypomethylated
in RA, with significant methylation differences between different genic characteristics (Figure 2c).
Furthermore, the methylation variance was most striking in enhancers, followed by promoters and
intergenic regions, decreased in gene bodies (p < 0.001) (Figure 2d). When we further stratified
CpG located in promoters according to their distance to transcription start sites, the results showed
preferential methylation alterations near the transcription start sites (Figure S4).
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Figure 2. Methylation differences according to CpG features and genic characteristics. The bar charts
showed the methylation difference (rheumatoid arthritis (R) minus healthy donor (H)) in CpG island,
CpG shore, CpG shelf, open sea (a) and variance of methylation according to respective CpG features
(b). Methylation difference in intergenic region, enhancer, promoter, gene body (c) and variance of
methylation in respective genic characteristics (d) were also presented. * p < 0.001 for methylation
difference and variance of methylation between different CpG features and genic characteristics.
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3.5. Methylation Variation Linked to Transcription Variation
Since transcription is regulated through epigenetic marks, we subsequently set upon determining
whether the presence of methylation alterations was linked to alterations in gene expression (Figure 1,
Step 5). We divided CpG into high variance (methylation variance above mean methylation variance)
and low variance (methylation variance below mean methylation variance). Enhancer CpG with high
methylation variance was associated with greater variation in transcript abundance compared with
enhancer CpG with low methylation variance (p < 0.001, Figure S5a,b). Promoter CpG with high
methylation variance was associated with greater variation in transcript abundance compared with
promoter CpG with low methylation variance (p < 0.001, Figure S5c,d). We next focused our analysis on
CpG located in gene bodies. Again, a higher variance of gene expression was significantly associated
with gene body CpG with higher methylation variance (p < 0.001, Supplementary Figure S5e,f).
3.6. Integration of Methylation and Expression Profiles
After confirming the association between methylation variation and expression variation,
we interrogated methylation and expression profiles to identify differentially methylated genes
and differentially expressed genes. We first identify genes with differentially-methylated regions
(FDR < 0.05) (Figure 1, Step 6a). In the same time, differentially expressed genes (FDR < 0.05) were
found (Figure 1, Step 6b). Since enhancer/promoter methylation was associated with decreased
gene expression and gene body methylation was associated with increased gene expression [8,11],
we intersected differentially methylated genes and differentially expressed genes to obtain genes
with concomitant expression and methylation changes in enhancer/promoter/gene body (Step 7) for
following analysis.
3.7. RA Genetically Associated Genes and Their Targets Preferentially Displaying Differential Methylation and
Differential Expression
A growing body of literature suggested interaction of genetic loci and differentially methylated
loci in phenotype determination [12]. To examine whether there was similar genetic–epigenetic
interaction in RA, we utilized GWAS results on RA and non-RA traits and protein-protein interaction
information from BioGRID to characterize genetic–epigenetic interaction in RA (Figure 1, Step 8;
Figure S1). RA genetically associated genes and their interacting targets are more likely to exhibit
differential methylation and differential expression than non-RA genetically associated genes and their
interacting targets (Figure S6). This finding highlighted interaction of genetically associated genes and
epigenetically associated genes in RA pathogenesis.
3.8. Ingenuity Pathway Analysis
To identify pathways and diseases associated with the differential methylation and differential
expression in RA compared with healthy donors, we performed a pathway analysis using IPA. Dendritic
cell maturation, inflammasome pathway, iNOS signaling, LPS/IL-1 mediated inhibition of RXR function,
neuroinflammation signaling pathway, NF-κB signaling, PPAR signaling, Toll-like receptor signaling,
TREM1 signaling and type 1 diabetes mellitus signaling were identified as enriched pathways (Figure S7,
Table S3). Differentially methylated and differentially expressed genes were enriched for genes of
atherosclerosis, atopic dermatitis, hematopoietic neoplasm, inflammation of joint, juvenile rheumatoid
arthritis, polyarticular juvenile rheumatoid arthritis, rheumatic disease, rheumatoid arthritis, systemic
autoimmune syndrome and viral infection as disease annotation (Figure S8, Table S4).
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3.9. Upstream Regulator Deduction
Since altered DNA methylation in differentially methylated regions may contribute to
transcriptional dysregulation through altered transcription factor binding [13], to gain insight into
involved transcription factors, a network of transcription factors and their targets was constructed using
iRegulon (Figure 1, Step 10). iRegulon revealed 13 transcription factors (CEBPA, CEBPB, ETS2, FOS,
FOSL2, FOXM1, HLCS, NAP1L1, NFIC, NFKBI, NXPH3, RXRA, SNAI1) with significant enrichment
of target genes in the network of genes with concomitant differential methylation and differential
expression (Figure 3). These transcription factors had well-established roles in inflammation and
immune cells development (Table S5).
 
Figure 3. Transcription factors identified through iRegulon analysis. The bubble chart showed the
transcription factors associated with differentially methylated and differentially expressed genes
identified by iRegulon. Y-axis label represented normalized enrichment score. The sizes of the bubbles
were proportional to the number of regulated genes with concomitant differential methylation and
differential expression for each transcription factor.
3.10. Validation of Differential Methylation and Differential Expression in RA
To validate the results from next-generation sequencing, we retrieved previously reported
methylation and expression patterns of RA CD4 T cells and B cells, both of which were major cellular
subsets of PBMCs, from GEO (Figure 1, Step 11) (methylation and expression profiles of CD8 and
monocyte unavailable). The magnitude of methylation aberrations across all validated genes was similar
to previous studies [14] (Figures 4–6). 10 genes with methylation alteration and expression deregulation
were validated in B cells, including three (CD86, RAB20, XAF1) with enhancer hypomethylation and
expression upregulation (Figure 4), one (KCNH8) with promoter hypermethylation and expression
downregulation, two (FOLR3, LTBR) with promoter hypomethylation and expression upregulation
(Figure 5), and four (DOK7, PDGFA, PITPNM2, CELSR1) with gene body hypomethylation and
expression downregulation (Figure 6).
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Figure 4. Validation of genes with differential methylation in enhancer and differential expression.
(a) The results of methylation and expression obtained from next-generation sequencing (NGS meth,
NGS exp), the cell subsets of validation dataset (Cell), the dataset of validation (Meth dataset, Exp
dataset), and the probes of validation dataset (CpG probe, Exp probe). (b) Visualization of the
methylation levels obtained from NGS in rheumatoid arthritis (RA) and healthy donors (HD) and
location of validated CpG probe and enhancers. (c) Volcano plot of the −log10(false discovery rate) on
the Y-axis versus expression change (log2ratio) on the X-axis. Of validated genes, (d) Methylation and
(e) Expression levels of corresponding probes in the validation dataset.
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Figure 5. Validation of genes with differential methylation in promoter and differential expression.
(a) The results of methylation and expression obtained from next-generation sequencing (NGS meth,
NGS exp), the cell subsets of validation dataset (Cell), the dataset of validation (Meth dataset, Exp
dataset), and the probes of validation dataset (CpG probe, Exp probe). (b) Visualization of the
methylation levels obtained from NGS in RA and healthy donors (HD) and location of validated CpG
probe superposed onto the genomic locations of genes. (c) Volcano plot of the -log10(false discovery rate)
on the Y-axis versus expression change (log2ratio) on the X-axis. Of validated genes, (d) Methylation
and (e) Expression levels of corresponding probes in the validation dataset.
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Figure 6. Validation of genes with differential methylation in gene body and differential expression.
(a) The results of methylation and expression obtained from next-generation sequencing (NGS meth,
NGS exp), the cell subsets of validation dataset (Cell), the dataset of validation (Meth dataset, Exp
dataset), and the probes of validation dataset (CpG probe, Exp probe). (b) Visualization of the
methylation levels obtained from NGS in RA and healthy donors (HD) and location of validated CpG
probe superposed onto the genomic locations of genes. (c) Volcano plot of the -log10(false discovery rate)
on the Y-axis versus expression change (log2ratio) on the X-axis. Of validated genes, (d) Methylation
and (e) Expression levels of corresponding probes in the validation dataset.
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4. Discussion
Here we reported a comprehensive analysis of methylome and transcriptome in RA. By combining
methyl-seq and RNA-seq data, this study provided a global map of the methylation profile in RA.
Methylation alterations occurred across human genomes (Figure S3), varied with CpG features and
genic characteristics (Figure 2) and associated with gene expression (Figure S5). RA genetically
associated genes and their interacting targets preferentially displayed differential methylation and
differential expression compared with non-RA genetically associated genes (Supplementary Figure S6).
These methylation and transcription aberration associated with several autoimmune and infectious
diseases (Figure S8, Table S4). Additionally, we identified several transcription factors as potential
regulators (Figure 3). Moreover, 10 genes (CD86, RAB20, XAF1, KCNH8, FOLR3, LTBR, DOK7, PDGFA,
PITPNM2, and CELSR1) with concomitant methylation and expression alterations in B cells were
validated (Figures 4–6). These results highlighted potential roles played by these genes in RA.
The scale of methylation differences across all validated genes was not large, similar to those
reported in previous studies [14–16]. Studies suggested that traits-associated methylation changes
were predominantly of small magnitude [16,17], tended to be subtle and long-lasting, with stronger
but short-lived gene expression alterations [15]. Accumulating evidence further suggested functional
consequences of such subtle methylation changes, with halving or doubling of gene transcription
accompanying every 1% change in methylation [17]. These collectively supported the biological
relevance of methylation alterations validated in this study.
Generally, PCA and HC based on the methylation levels revealed a clear phenotype-driven
distinction between RA and healthy donors (Figure S2a,b), supportive of the potential of methylation as
diagnostic marker. Similar conclusions were made in other autoimmune diseases, including SLE [18].
However, difference of methylation profiles between RA patients was also noted (Figure S2a), suggesting
epigenetic heterogeneity of RA patients. Epigenetic alteration varies with different manifestations of
autoimmune disease [18]. Evidence suggests genetic and clinical heterogeneity of RA [19], though it has
not been fully defined and warrants further study. Since different serology status implied contrasting
genetic architecture and transcriptome changes [20,21], it is tempting to speculate on the roles of
autoantibodies in the difference of methylome, as one of patients was positive for anti-citrullinated
protein antibodies (ACPA) and the other negative for ACPA. Large scales of studies combining clinical
status, immunopathology, methylomics and transcriptomics analysis from ACPA+ vs ACPA- patients
will provide valuable insight into the relationship between autoantibodies and epigenetic subsets of
RA. This needed to be explored in future studies.
When we characterized methylation variation according to CpG features, CpG islands displayed
the highest methylation variation compared with other CpG features (Figure 2b). Since CpG islands
had the most pronounced correlation with gene expression level [22], this suggested that despite small
methylation differences, there may be more biologically relevant regions of the genome.
In this study, we observed differential enhancer, promoter and gene body methylation between
RA and healthy donors (Figure 2c). On average, promoter hypermethylation and enhancer and
gene body hypomethylation were noted. Promoter hypermethylation has also been demonstrated
in other autoimmune diseases, such psoriasis [23]. Interestingly, promoter hypermethylation was
often correlated with gene downregulation [8]. These changes in promoter and gene body DNA
methylation might be related to inadequate immune regulation [24] and exemplified by polycyclic
forms of RA-asymptomatic during interepisodic period but flare-up intermittently [25].
With regards to methylation variation within promoters, increased methylation variation was
noted in the vicinity of transcription start site (Figure S4). Since transcription factor binding sites were
enriched in transcription start site [26], the presence of more dynamic DNA methylation in the vicinity
of transcription start site provided higher flexibility for different transcription factor bindings under
different conditions and thus transcription plasticity.
Our study highlighted that RA genetically associated genes and their interacting targets are more
likely to exhibit differential methylation and differential expression than non-RA genetically associated
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genes (Figure S6). Although evidence of genetic–epigenetic interaction existed in past literature [12],
interaction of genetically associated genes and epigenetically associated genes in autoimmune diseases
such as RA was largely uncharacterized. Furthermore, interaction of genetically associated genes and
epigenetically associated genes in RA raised the possibility of cooperation of these two interacting
systems to facilitate gene regulation in RA pathogenesis. It is possible that both methylation and
genetic alterations were necessary for RA development and altered DNA methylation may be a second
hit contributing to penetrance as demonstrated by complex multifactorial traits [27] and supported by
past studies of autoimmune diseases [28].
Pathway analysis of methylation and expression alterations suggested significantly multiple
upregulated inflammatory pathway (including TREM1 signaling) and one downregulated pathway
(PPAR signaling) (Figure S7). TREM1 was expressed in monocyte and amplified production of IL-6
and TNF-α, both critical players in RA pathogenesis [29]. With regards to PPAR, PPAR activation
downregulated NF-κB signaling, primed monocytes into anti-inflammatory properties, and exerted
therapeutic effects on RA [30–32]. These findings support the importance of DNA methylation on the
regulation of implicated pathways in RA.
In the diseasome analysis, genes with significantly different DNA methylation and expression
alterations were associated with several diseases, including atherosclerosis, atopic dermatitis,
hematopoietic neoplasm, inflammation of joint, juvenile rheumatoid arthritis, polyarticular juvenile
rheumatoid arthritis, rheumatic disease, rheumatoid arthritis, systemic autoimmune syndrome and
viral infection (Figure S8). Numerous reports linked RA with juvenile idiopathic arthritis, atopic
dermatitis, atherosclerosis and lymphoma [33–36]. Viral infection also associated with RA in past
epidemiology study [37]. However, it is previously unknown whether these diseases are also linked to
RA epigenetically. This study was the first to suggest an epigenetic relationship between these diseases
and RA.
When we applied iRegulon to decipher potential upstream regulator, several transcription factors
were singled out (Figure 3). All these transcription factors were involved in various aspects of
immunological responses (Table S5). Thus, it was conceivable that they participated in regulation of
differentially methylated and differentially expressed genes in RA.
During validation with B cell microarray profiles, upregulated CD86, RAB20, XAF1, FOLR3, LTBR
and downregulated KCNH8, DOK7, PDGFA, PITPNM2, CELSR1 with corresponding methylation changes
in enhancers/promoters/gene bodies were identified (Figures 4–6). CD86 activated B cell proliferation
and immunoglobulin secretion [38]. Moreover, CD86 was increased in RA B cells and correlated
with disease activity [39,40]. Thus, upregulated CD86 may contribute to immune activation in RA
(Figure S9). Considering RAB20, RAB20 was upregulated by Crohn’s disease-associated polymorphism
and vaccination and increases during B cell transformation (Table S3 of [41], Supplementary material S1
of [42,43]). It may be possible that increased RAB20 contributes to B cell activation and facilitates RA
development (Figure S9). Regarding XAF1, XAF1 was one risk gene of sarcoidosis which implicated
dysregulated immune responses [44]. Moreover, XAF1 was downregulated during lymphocyte
immortalization and sensitized lymphocyte to apoptosis [45,46]. As a result, XAF1 has the potential to
be involved in RA pathogenesis (Figure S9).
KCNH8 was almost exclusively expressed in B cells [47] and KCNH8 region was associated with
susceptibility to autoimmune diseases, including Crohn’s disease and psoriasis [48]. However, its
function in B cells remained unexplored. FOLR3 was a member of folate receptor family. FOLR3 was
associated with hepatitis C virus clearance [49] and folate receptor-mediated STAT3 activation [50].
Therefore, upregulated FOLR3 may contribute to immune activation (Figure S9). With regards to LTBR,
LTBR activated NFkB and blockade of LTBR impaired humoral immune response and ameliorated
arthritis in the animal model [51–53]. Thus, upregulated LTBR potentially activates humoral immunity
and facilitated arthritis development (Figure S9).
DOK7 belonged to a family of docking protein and DOK7 inhibited malignant cell proliferation
and increased leukemia patient survival [54,55]. DOK7 downregulation may lead to increased B cell
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proliferation and aggravated RA (Figure S9). PDGFA was part of PDGF family and PDGF family
members stimulated B cell growth [56]. Whether downregulated PDGFA represents one mechanism to
counteract excessive inflammation is unknown (Figure S9). PITPNM2 was implicated as a risk locus of
multiple sclerosis [57] and allergic diseases [58] which were all linked to RA [34,59]. Furthermore, risk
protective alleles of allergic disease and drug with anti-inflammatory effects in autoimmune diseases
both increased PITPNM2 expression (Supplementary Table 27 of [58,60]). As a result, decreased
PITPNM2 might enhance RA pathogenesis (Figure S9). CELSR1 was part of the apoptosis network [61],
inhibited proliferation of neural progenitor [62] and decreased in non-nodal mantle cell lymphoma [63].
Therefore, decreased CELSR1 might facilitate B cell proliferation and therefore sustain immune
responses in RA (Figure S9).
In this study, we detected methylation and transcription perturbations in CD86. Notably, abatacept,
one approved treatment option for RA, decreased CD86 expression in B cells [64]. It was possible that
genes with differential methylation and differential expression identified in this study hold therapeutic
promises for RA in the future. These should be addressed by further studies.
Limitations of this work include the relatively small sample size due to the high cost of
next-generation sequencing and failure to validate methylation results in CD4 T cells. This may
be a result of potentially more aberrant methylation of B cells than CD4 T cells, as demonstrated in
another autoimmune disease, Sjogren’s syndrome [65]. Future work was needed to fully characterize
additional RA samples by next-generation sequencing with additional cell types.
In past decades, progress in understanding the molecular bases of disease pathogenesis and
the application of new technologies greatly transformed our treatment of diseases [1]. Integration
with multiomic data identified several novel genes and pathways as potential relevant therapeutic
avenues that may be important dysregulated mediators at the interface of genetics, epigenetics, and
RA pathogenesis. These results may be useful for the development of new, more effective biomarkers
and therapeutics. With that goal in mind, future studies are necessary in order to characterize precisely
the molecular mechanisms, the functional consequences, and the interactions between differential
methylation and genetic risk factors in RA pathogenesis.
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Abstract: This study aimed to investigate the regulatory effect of SKI306X, a mixed extract of
three herbs, in T helper (Th)17 cytokine-induced inflammation and joint destruction in rheumatoid
arthritis (RA). Synovial fibroblasts were isolated from RA patients and cultured with Th17 cytokines
including interleukin (IL)-17, IL-21, and IL-22 and SKI306X, and tumor necrosis factor (TNF)-α,
IL-1β, and receptor activator of nuclear factor kappa-B ligand (RANKL) expression and production
were investigated using real-time PCR and ELISA of culture media. After peripheral blood (PB)
cluster of differentiation (CD)14+ monocytes were cultured in media supplemented with Th17
cytokines and SKI306X, tartrate-resistant acid phosphatase positive (TRAP+) multinucleated giant
cells (mature osteoclasts) were enumerated and gene expression associated with osteoclast maturation
was assessed via real-time PCR analysis. After PB monocytes were co-cultured with IL-17-stimulated
RA synovial fibroblasts in the presence of SKI306X, osteoclast differentiation was assessed. When RA
synovial fibroblasts were cultured with IL-17, IL-21, and IL-22, TNF-α, IL-1β, and RANKL
expression and production were increased; however, SKI306X reduced cytokine expression and
production. When PB monocytes were cultured in media supplemented with Th17 cytokines,
osteoclast differentiation was stimulated; however, SKI306X decreased osteoclast differentiation
and osteoclast maker expression. When PB monocytes were co-cultured with IL-17-stimulated RA
synovial fibroblasts, osteoclast differentiation was increased; however, SKI306X decreased osteoclast
differentiation and osteoclast maker expression. SKI306X reduced Th17 cytokine-induced TNF-α,
IL-1β, and RANKL expression and osteoclast differentiation, providing novel insights into adjuvant
therapy for regulating inflammation and joint destruction in RA.
Keywords: rheumatoid arthritis; synovial fibroblasts; cytokine; osteoclast; herbal medicine
1. Introduction
A few decades ago, Korean patients with rheumatoid arthritis (RA) received herbal medication and
acupuncture before they visited rheumatologic clinics. They believed the herbal therapies could cure RA
without any adverse effects. By the time these patients visited rheumatologists, they already had joint
destruction and disability because of delayed treatment with disease-modifying antirheumatic drugs
(DMARDs). RA is currently considered an autoimmune inflammatory disease requiring treatment
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with DMARDs, which has led to an increase in rheumatologic consultations. However, DMARDs do
not always have therapeutic effects in RA, they can display adverse effects and are highly expensive [1].
Hence, some patients prefer complementary and alternative medication, primarily including herbal
medication [1,2]. According to the Korean RA registry (KORONA), 10.5% of patients received
complementary and alternative medicines de novo and among them, 17% received herbal medication
and 55% received acupuncture [3].
SKI306X, a mixed extract of three herbs, is a purified extract prepared from a mixture of
three Oriental herbal plants, Clematis mandshurica, Trichosanthes kirilowii, and Prunella vulgaris [4].
According to the Donguibogam, i.e., ‘Principles and Practice of Eastern Medicine’ written in 1610,
Clematis mandshurica effectively reduces lower back and knee pain, Trichosanthes kirilowii reduces febrile
sensations and dry mouth, and Prunella vulgaris effectively reduces lymphadenitis, abscess, and ulcers.
The anti-inflammatory effects of SKI306X have been reported previously.
SKI306X inhibits tumor necrosis factor (TNF)-α, leukotriene B4, and nitric oxide (NO)
production in macrophages and cyclooxygenase-2 expression [5]. It inhibits TNF-α, prostaglandin E2,
and interleukin (IL)-1β production by stimulated peripheral blood (PB) mononuclear cells [6] and is
commonly used to treat osteoarthritis owing to its chondroprotective effects. SKI306X inhibits the
IL-1β-induced production of proteoglycans, NO, matrix metalloproteinases (MMPs) and degradation of
glycosaminoglycan by cartilage [4,6]. A preclinical animal study reported that SKI306X protects against
osteoarthritis. Collagenase injection at the knee joint of rabbits led to osteoarthritis-like degeneration of
articular cartilage and development of synovial tissues; however, SKI306X reduces osteoarthritis-like
histological changes [4]. In chondrocytes cultured in media supplemented with IL-1α, the cumulative
activity of MMP-3 and MMP-13 increased; however, SKI306X significantly reduced their activities and
inhibited the activation of the proenzyme MMP-3 to the active MMP-3 [7]. In clinical trials of knee
osteoarthritis, SKI306X treatment resulted in greater changes in pain and function than the placebo [8,9].
The change in cartilage volume and thickness of the lateral tibia were reportedly greater after treatment
with SKI306X than the placebo [8].
Two studies have reported that SKI306X has similar effects in controlling for pain and disease
activity and has greater cardiovascular safety than celecoxib in RA. When SKI306X was compared
with celecoxib among RA patients, SKI306X was not inferior to celecoxib with regards to pain score
(visual analog scale), American College of Rheumatology (ACR) 20 response rate, frequency of rescue
medication, and drug-related adverse effects [10]. Unlike celecoxib, SKI306X does not have a higher
risk of cardiovascular events in patients with RA and osteoarthritis [11]. However, the limitation
of this clinical study was that celecoxib is not a DMARD and it cannot prevent joint destruction.
Thus far, no study has investigated the anti-inflammatory and joint protective effects of SKI306X in
RA. Therefore, this study aimed to investigate the regulatory effect of SKI306X in T helper (Th)17
cytokine-induced inflammation and bone destruction in RA.
2. Methods
2.1. Patients
Informed consent was obtained from all patients, and the experimental protocol was approved
by the Institutional Review Board for Human Research, Konkuk University Hospital (KUH1010186,
approved on January 22nd 2010). Synovial tissues were isolated from eight RA patients (mean age
63.4 ± 4.6 years, range 38–76 years) undergoing total knee and hip replacement surgery.
2.2. Isolation of Synovial Fibroblasts
Synovial fibroblasts were isolated by enzymatic digestion of synovial tissues, as described
previously [12,13]. Synovial fibroblast cell lines were prepared from synovectomized tissue of RA
patients undergoing joint replacement surgery. To set up cell lines, synovial tissues were minced into
2–3 mm pieces and treated for 4 h with 4 mg/mL type 1 collagenase (Worthington Biochemicals, Freehold,
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NJ, USA) in Dulbecco’s modified Eagle’s medium (DMEM) at 37 ◦C in 5% CO2. Dissociated cells were
centrifuged at 500× g and were resuspended in DMEM supplemented with 10% fetal calf serum (FCS),
2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Suspended cells were plated in
75 cm2 culture flasks and cultured at 37 ◦C in 5% CO2. Medium was replaced every 3 days, and once
the primary culture reached confluence, cells were split weekly. Cells at passages 5 to 8 contained a
homogeneous population of synovial fibroblasts (<2.5% CD14 positive, <1% CD3 positive, and <1%
CD19 positive in flow cytometric analysis).
2.3. Reagents
Recombinant human IL-17 (20 ng/mL), IL-21 (20 ng/mL), IL-22 (20 ng/mL), and macrophage
colony-stimulating factor (M-CSF) (25 ng/mL) were purchased from R&D Systems (Minneapolis, MN,
USA). SKI306X (at 0 μg/mL, 1 μg/mL, 5 μg/mL and 10 μg/mL) were generously provided by the Life
Science R&D Center of SK Chemicals (Seongnam, Korea). Anti-TNF-α, anti-IL-1β and anti-RANKL
antibodies were purchased from R&D Systems.
2.4. Real-Time PCR
Synovial fibroblasts were stimulated with IL-17, IL-21, or IL-22. Synovial fibroblasts were
incubated in the presence or absence of SKI306X for 3 h before the addition of IL-17, IL-21, or IL-22.
After incubation for 72 h, mRNA was extracted using RNAzol B (Biotex Laboratories, Houston, TX,
USA) according to the manufacturer’s instructions.
2.5. Enzyme-Linked Immunosorbent Assay (ELISA)
TNF-α, IL-1β, IL-8 and soluble receptor activator of nuclear factor kappa-B ligand (sRANKL)
levels in the culture supernatants from RA synovial fibroblasts were measured using a sandwich ELISA
according to R&D System’s instructions.
2.6. Osteoclast Formation
PB monocytes were prepared from heparinized blood by Ficoll–Hypaque (GE Healthcare,
Pittsburgh, PA, USA) density gradient centrifugation. Monocytes were added to the IL-17-pretreated
RA synovial fibroblasts with fresh media. Monocytes were co-cultured for 3 weeks in α-minimal
essential medium and 10% fetal bovine serum (FBS) in the presence of 25 ng/mL recombinant
human macrophage-colony stimulating factor (rhM-CSF). On day 21, tartrate-resistant acid
phosphatase (TRAP)-positive cells were identified using a leukocyte acid phosphatase kit according to
Sigma-Aldrich’s protocol [14].
2.7. Statistical Analysis
The data are expressed as means ± standard deviation (SD). Statistical difference was assessed
using Mann–Whitney U test for analyzing two groups or one-way analysis of variance (ANOVA) with
Bonferroni’s multiple comparison post-hoc test for analyzing more than three groups. A p value < 0.05
was considered statistically significant.
3. Results
3.1. Regulatory Effect of SKI306X on Th17 Cytokine-Induced TNF-α Expression and Production in RA
Synovial Fibroblasts
When RA synovial fibroblasts were cultured in media supplemented with IL-17, IL-21, or IL-22,
TNF-α was upregulated; however, SKI306X reduced Th17 cytokine-induced TNF-α expression
(Figure 1A), TNF-α production was increased upon IL-17 stimulation in culture media, and SKI306X
reduced TNF-α production (Figure 1B).
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Figure 1. The inhibitory effect of SKI306X, a mixed extract of three herbs, in T helper (Th)17
cytokine-induced tumor necrosis factor (TNF)-α expression and production by synovial fibroblasts
in rheumatoid arthritis (RA). (A) RA synovial fibroblasts were cultured in media supplemented with
interleukin (IL)-17, IL-21, and IL-22 in the presence of various doses of SKI306X, and TNF-α was
examined using real-time PCR, normalized to that of beta-actin and reported in relative expression
units. (B) RA synovial fibroblasts were cultured with IL-17, IL-21, and IL-22 in the presence of various
concentrations of SKI306X, and TNF-α production in culture media was determined using ELISA.
The data represent the mean ± standard deviation (SD) values from six independent experiments.
* p < 0.05, ** p < 0.01 and *** p < 0.001 compared with the nil condition (white bars). # p < 0.05,
## p < 0.01 and ### p < 0.001 compared with the Th17 cytokine stimulating condition (gray bars).
3.2. The Regulatory Effect of SKI306X on Th17 Cytokine-Induced IL-1β Expression and Production in RA
Synovial Fibroblasts
When RA synovial fibroblasts were cultured in media supplemented with IL-17 or IL-22, IL-1β was
upregulated; however, SKI306X reduced Th17 cytokine-induced IL-1β expression. Stimulation with
IL-21 resulted in a similar, albeit non-significant, effect (Figure 2A). Furthermore, IL-1β production
was increased after IL-17 or IL-21 supplementation in culture media, and SKI306X reduced IL-1β
production (Figure 2B).
However, IL-21 and IL-22 did not promote IL-8 expression and production. Although IL-17
induced IL-8 expression and production, SKI306X inhibited IL-17-induced IL-8 production in RA
synovial fibroblasts but did not affect IL-17-induced IL-8 expression.
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Figure 2. The inhibitory effect of SKI306X in Th17 cytokine-induced IL-1β expression and production
in synovial fibroblasts in RA. (A) RA synovial fibroblasts were cultured in medium supplemented with
IL-17, IL-21, and IL-22 with various concentrations of SKI306X, and IL-1β expression was examined
using real-time PCR, normalized to beta-actin and reported in relative expression units. (B) RA synovial
fibroblasts were cultured in medium supplemented with IL-17, IL-21, and IL-22 in the presence of
various doses of SKI306X, and IL-1β production in the culture media was determined via ELISA.
The data represent mean ± SD values from six independent experiments. * p < 0.05 and ** p < 0.01
compared with the nil condition (white bars). # p < 0.05, ## p < 0.01 and ### p < 0.001 compared with
the Th17 cytokine stimulating condition (gray bars).
3.3. Regulatory Effect of SKI306X on Th17 Cytokine-Induced RANKL Expression and Production in RA
Synovial Fibroblasts
On culturing RA synovial fibroblasts in media supplemented with IL-17 or IL-22, RANKL was
upregulated; however, SKI306X reduced Th17 cytokine-induced RANKL expression (Figure 3A).
Furthermore, RANKL production was increased upon IL-17 supplementation in culture media,
and SKI306X reduced IL-17-induced RANKL production (Figure 3B).
3.4. Regulatory Effect of SKI306X on Th17 Cytokine-Induced Osteoclast Differentiation from PB Monocytes
When CD14+ monocytes isolated from the PB of healthy donors were cultured in media
supplemented with IL-17 and monocyte colony stimulating factor (M-CSF), TRAP-positive
multinucleated osteoclasts were differentiated, and SKI306X reduced osteoclast differentiation in
a dose-dependent manner. Osteoclast markers including TRAP, cathepsin K, and dendritic cell
specific transmembrane protein (DC-STAMP) were upregulated upon IL-17 stimulation, and SKI306X
downregulated these factors (Figure 4A). Monocyte stimulation with IL-21 or IL-22 yielded a
similar pattern as IL-17 during osteoclast differentiation. On culturing CD14+ monocytes in media
supplemented with IL-21 or IL-22 and M-CSF, TRAP-positive multinucleated osteoclasts differentiated,
and SKI306X reduced osteoclast differentiation in a dose-dependent manner. Osteoclast markers
including TRAP, cathepsin K, DC-STAMP, and ATP6v0d2 were also upregulated upon IL-21 and IL-22
stimulation, and SKI306X reduced their expression (Figure 4B,C).
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Figure 3. The inhibitory effect of SKI306X in Th17 cytokine-induced receptor activator of nuclear
factor kappa-B ligand (RANKL) expression and production in synovial fibroblasts in RA. (A) RA
synovial fibroblasts were cultured in medium supplemented with IL-17, IL-21, and IL-22 with various
concentrations of SKI306X, and RANKL expression was examined using real-time PCR, normalized to
beta-actin and reported in relative expression units. (B) RA synovial fibroblasts were cultured in
medium supplemented with IL-17, IL-21, and IL-22 with various concentrations of SKI306X, and RANKL
production in the culture media was examined using ELISA. The data represent mean ± SD values from
six independent experiments. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared with the nil condition
(white bars). # p < 0.05, ## p < 0.01 and ### p < 0.001 compared with the Th17 cytokine stimulating
condition (gray bars).
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Figure 4. Regulatory effect of SKI306X on Th17 cytokine-induced osteoclast differentiation in peripheral
blood (PB) monocytes. PB cluster of differentiation (CD)14+ monocytes were cultured in medium
supplemented with (A) IL-17, (B) IL-21, or (C) IL-22 and various concentrations of SKI306X in the
presence of 25 ng/mL of monocyte colony stimulating factor. After 21 days of culturing, TRAP-positive
multinucleated cells were enumerated. The figures represent one of three independent experiments and
the bars represent mean ± SD values. The expression of osteoclast markers including tartrate-resistant
acid phosphatase (TRAP), cathepsin K, dendritic cell specific transmembrane protein (DC-STAMP),
and ATP6v0d2 was quantified using real-time PCR, normalized to beta-actin and reported in relative
expression units. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared with the nil condition (white
bars). # p < 0.05, ## p < 0.01 and ### p < 0.001 compared with the Th17 cytokine stimulating condition
(gray bars).
3.5. Regulatory Effect of SKI306X on Osteoclast Differentiation from PB Monocytes Co-Cultured with
IL-17-Stimulated RA Synovial Fibroblasts
CD14+ monocytes isolated from PB were co-cultured with IL-17-prestimulated RA synovial
fibroblasts in media supplemented with M-CSF, and TRAP-positive multinucleated osteoclasts were
differentiated and compared with non-stimulated RA synovial fibroblasts. SKI306X reduced osteoclast
differentiation (Figure 5A). Furthermore, osteoclast markers including TRAP, cathepsin K, and nuclear
factor of activated T-cells, cytoplasmic 1 (NF-ATc1) were upregulated when osteoclast precursors were
co-cultured with IL-17-prestimulated RA synovial fibroblasts, and SKI306X reduced their expression
(Figure 5B).
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Figure 5. The regulatory effect of SKI306X on osteoclast differentiation in co-cultures of PB monocytes
and IL-17-stimulated synovial fibroblasts (SF) in RA. (A) After PB monocytes were co-cultured with
IL-17 stimulated RA synovial fibroblasts in the presence of monocyte colony stimulating factor and
SKI306X for 21 days, the TRAP-positive multinucleated cells were enumerated. The figures represent
one of three independent experiments and the bars represent mean ± SD values. (B) The expression of
osteoclast markers including TRAP, cathepsin K, DC-STAMP, and nuclear factor of activated T-cells,
cytoplasmic 1 (NF-ATc1) was quantified using real-time PCR, normalized to beta-actin and reported in
relative expression units. * p < 0.05 and *** p < 0.001.
4. Discussion
In some Asian countries, herbal medicines are commonly used for treating arthritis. Although many
patients do not receive prompt diagnosis and treatment for RA, some patients have experienced
therapeutic effects using herbal medication [1,3]. SKI306X is widely used to manage osteoarthritis in
Korea; however, no study has reported the efficacy of herbal medication in RA. This study aimed to
investigate the anti-inflammatory and osteoprotective effects of SKI306X in Th17 cytokine-induced
inflammation and osteoclast differentiation in RA.
To determine the anti-inflammatory effect of SKI306X, we examined Th17 cytokine-induced
TNF-α and IL-1β expression in RA synovial fibroblasts. We selected synovial fibroblasts and Th17
cytokines in this study because they are primary targets in RA pathogenesis; however, they are very
active effector cells, which can induce and aggravate inflammatory processes [15,16]. We previously
reported that IL-21, IL-22, and IL-17 stimulate RA synovial fibroblasts to produce inflammatory
cytokines [13,17,18]. Moreover, Th17 overproduction and the differentiation of Th17-positive cells
are one of the major events in RA pathogenesis; hence, reduction of the Th17 response regulates
inflammation and joint destruction in RA [19,20]. IL-17, IL-21, and IL-22 upregulated TNF-α and
IL-1β in RA synovial fibroblasts and SKI306X effectively reduced their expression. A previous study
reported that SKI306X reduces lipopolysaccharide (LPS)-induced TNF-α and IL-1β production in
human peripheral blood mononuclear cells (PBMCs) [20]. Another study reported that SKI306X
inhibits TNF-α release from LPS-stimulated human whole blood; however, it does not affect IL-1β
release [5]. LPS is a nonspecific stimulant in the inflammatory processes. In this study, we used
RA synovial fibroblasts, which represent target cells, and stimulated them with Th17 cytokines as
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specific stimulators and LPS as a non-specific cellular stimulator. Thus, we replicated pathological
conditions in vitro and investigated the therapeutic effect of SKI306X. Reduction of Th17-induced
TNF-α and IL-1β expression and production by SKI306X indicates that SKI306X plays a potential
anti-inflammatory role in Th17-induced inflammation in RA.
Furthermore, we determined the bone protective role of SKI306X in RA. In RA, loss of cartilage
and bone erosion cause joint destruction and subsequent joint disability. Bone erosion is caused by
bone resorption of synovial osteoclasts, which in turn are activated by RANKL and other inflammatory
cytokines. They originate from synovial tissues, subchondral bone, and circulating monocytes in
inflammatory conditions [21]. We examined the dual roles of SKI306X in the reduction of RANKL
production from synovial fibroblasts and in the inhibition of osteoclast differentiation. Because synovial
fibroblasts are major sources of RANKL [13,22,23], SKI306X inhibited Th17 cytokine-induced RANKL
expression and production in RA synovial fibroblasts. These findings suggest that SKI306X potentially
ameliorates bone destruction because RANKL is a very important molecule in osteoclast activation.
In recent clinical trials, denosumab, an anti-RANKL antibody, inhibited the progression of joint
destruction in RA patients [24,25]. Although denosumab does not reduce inflammation, combinatorial
treatment with conventional or biologic DMARDs can effectively reduce both inflammation and
joint destruction.
Finally, we examined the inhibitory effect of SKI306X in osteoclast differentiation. RA treatment
is primarily aimed at preventing joint destruction; hence, inhibition of osteoclastogenesis is critical
for treatment. Circulating CD14+ monocytes are precursors of osteoclasts and they upregulate
RANK on the cell surface and interact with RANKL that is primarily produced by RA synovial
fibroblasts and Th17 cells [26]. Th17 cytokines independently induce osteoclast differentiation from
their precursor [17,18,27]. In this study, when PB monocytes were cultured in media supplemented
with Th17 cytokines and SKI306X, SKI306X reduced Th17 cytokine-induced osteoclast differentiation.
The underlying mechanism of action of this drug is unclear; hence, further studies are required to
determine the cell receptors and signaling pathways involved herein.
Monocytes express various chemokine receptors including C-C chemokine receptor type 2 (CCR2)
and (C-X3-C motif) chemokine receptor 1 (CX3CR1) and interact with chemokine ligands expressed by
synovial fibroblasts. Their interaction promotes cellular activation, migration, and recruitment into the
synovium of RA patients [26]. To investigate their interactions, we co-cultured monocytes with RA
synovial fibroblasts under osteoclast-differentiating conditions. RA synovial fibroblasts can potentially
augment osteoclastogenesis [28], and TNF-α- or IL-17-stimulated synovial fibroblasts are more effective
at osteoclastogenesis [17]. Osteoblast differentiation was augmented when RA synovial fibroblasts
were stimulated with IL-17 and then co-cultured with monocytes rather than non-stimulation with
IL-17. However, SKI306X restored IL-17-augmented osteoclast differentiation in stimulated synovial
fibroblasts. These results suggest that SKI306X reduces osteoclastogenesis through its effects on both
osteoclast precursors and cellular interactions with synovial fibroblasts.
There are only two clinical studies of SKI306X in RA; however, the studies have limitations
regarding the assessment of the clinical efficacy of SKI306X in RA patients. One study is a six-week,
double blinded noninferiority study for assessment of pain relief and tolerability of SK1306X compared
with celecoxib. The duration of the study is too short to assess clinical efficacy and protective effect
of joint destruction. Because SKI306X is compared with celecoxib rather than DMARDs, the disease
modifying effect of SKI306X for RA cannot be assessed [10]. The other study evaluated cardiovascular
risk associated with SKI306X use in RA patients which was compared with celecoxib and naproxen.
A total of 27,253 patients were studied and the incidence of major cardiovascular events was highest for
celecoxib (15.4%), followed by SKI306X (8.6%) and naproxen (8%). SKI306X did not have a higher risk
of cardiovascular events than naproxen. This study is a retrospective observational study using data
from National Health Insurance Service–National Sample Cohort and it does not assess the therapeutic
efficacy of SKI306X. However, this study has a meaningful result because the cardiovascular risk is
high in RA patients and it influences their survival [11]. RA is associated with high cardiovascular risk,
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affecting patient survival, and inflammation and atherosclerosis are closely linked; the pathological
features are similar in both disease states and they share common risk factors [29]. Furthermore,
the overall risk of metabolic syndrome is higher in patients with RA than in healthy controls and
RA is associated with body weight changes, dyslipidemia, adipokine profile changes and insulin
resistance in metabolic syndrome [30]. Although IL-17 has a double-sided effect in atherosclerosis,
IL-17 could be involved in the process of atherosclerosis of RA. It induces the release of chemokines and
their ligands (chemokine (C-X-C motif) ligand (CXCL)1, CXCL2, CXCL8 and CXCL10), which recruit
neutrophils and monocytes to the atherosclerotic lesion. IL-17 simulates monocytes to produce IL-6,
TNF-α and IL-1β, which enhance plaque instability [31,32]. In early atherosclerosis, increased carotid
intima-media thickness is associated with the IL-17-related chemokine eotaxin [33], and in RA patients,
IL-17 is the main predictor of microvascular function and arterial compliance, suggesting a significant
role for IL-17 in increased cardiovascular risk in RA [34].
This study is the first to report that SKI306X regulates RANKL production and osteoclast
differentiation in RA. The mechanism of action of SKI306X is unclear, unlike that of conventional
DMARDs. Recently, targeted or biologic DMARDs have been preferred in treating active RA; however,
their usage in combination with SKI306X potentially results in in additional therapeutic effects.
There have been no clinical or experimental studies of the comparison between SKI306X and other
DMARDs such as methotrexate or hydroxychloroquine. There are only comparative clinical studies of
SKI306X for assessment of pain relief, tolerability and cardiovascular risk. Based upon the results of this
study, a comparison study of the therapeutic effects of SKI306X versus DMARDs and the assessment
of combination effects of SKI306X with DMARDs in RA patients should be performed in the future.
5. Conclusions
SKI306X reduced both inflammation and osteoclast differentiation in RA, reducing Th17 cytokine-
induced TNFα and IL-1β expression and production in RA synovial fibroblasts during inflammation.
SKI306X ameliorated RANKL production in synovial fibroblasts and osteoclast differentiation in
circulating monocytes. SKI306X is thus a potential novel therapeutic agent to prevent inflammation
and joint destruction in RA.
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Abstract: Background: Switching from reference infliximab (RI) to biosimilar infliximab (BI) had no
detrimental effects on efficacy and safety. However, long-term follow-up data is missing. Objective:
To evaluate patients with Ankylosing Spondylitis (AS) in clinical remission who were switching from
RI to BI, in terms of the safety and efficacy of this, in a long-term fashion. Methods: One hundred
and nine consecutive unselected AS patients were investigated. All were naïve to other biologics and
were followed-up at predefined times receiving RI. Patients in clinical remission were asked to switch
from RI to BI. Those who switched to BI were compared with a matched control-group receiving
continuous RI. During follow-up, several parameters were recorded for at least 18 months. Disease
activity was measured using the Bath Ankylosing Spondylitis disease activity index (BASDAI), and the
Ankylosing Spondylitis disease activity score (ASDAS), using the C-reactive protein. Remission was
defined as BASDAI < 4 and ASDAS < 1.3. Results: Eighty-eight patients were evaluated (21 excluded
for different reasons). From those, 45 switched to BI, while 43 continued receiving RI. No differences
between groups regarding demographic, clinical and laboratory parameters were observed. All patients
were in clinical remission. During follow-up, five patients from the BI-group and three from the
maintenance-group discontinued the study (4 patients nocebo effect, 1 loss of efficacy). After 18 months
of treatment, all patients in both groups remained in clinical remission. No significant adverse events
were noted between groups. Conclusion: BI is equivalent to RI in maintaining AS in clinical remission
for at least 18 months.
Keywords: ankylosing spondylitis; infliximab; biosimilar; switching
1. Introduction
CTP-13 (Inflectra®, Remsima®) the biosimilar infliximab (BI) has been granted all indications,
including Ankylosing Spondylitis (AS), of the reference infliximab (RI) in several countries [1].
Clinical evidence for the approval of BI has been obtained from pivotal studies on patients with AS
(PLANETAS) [2] and rheumatoid arthritis (RA) (PLANETRA) [3]. Switching from RI to its biosimilar
had no detrimental effects on efficacy, safety or immunogenicity compared with continuous RI
therapy [4,5]. Therefore, BI is an efficacious alternative to RI in patients with inflammatory arthritis [6].
On the other hand, there are reports emphasizing the role of shared-decision making with patients
when it comes to switching to a biosimilar product in order to achieve a better acceptance and higher
retention rate, minimizing the nocebo effect [5]. However, long-term follow-up data is missing. The aim
of our study was to investigate if BI is equivalent to RI to maintain patients with AS in clinical remission
compared with continuing RI in a long-term fashion.
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2. Materials and Methods
This is a single-center prospective observational cohort study with a total number of 109 consecutive
unselected patients with AS who were treated with RI in a tertiary university center. All patients were
followed-up at predefined times receiving RI (5 mg/kg/8 weeks) intravenously and were naïve to
previous biologic treatments. Patients who were in clinical remission were asked to switch from RI to
BI using the same therapeutic dose after shared-decision making. The allocation of the patients was
done randomly using an internet-based allocation program in order to minimize any selection bias
(Random.org). Patients switched to BI were compared with a matched control group receiving continuous
RI. The switching period was from January 2017 until June 2017 and patients were followed-up until
December 2018. During follow-up, the demographic, clinical, and laboratory parameters as well as
comorbidities were all recorded for at least 18 months. In addition, all adverse events as well as
serious adverse events according to the Food and Drug Administration (FDA.gov) were also recorded.
Disease activity was measured using the Bath Ankylosing Spondylitis Activity Index (BASDAI) [7] and
the Ankylosing Spondylitis Activity Score (ASDAS) [8,9] using the C-reactive protein (CRP). Clinical
remission was defined if patients had BASDAI < 4 and ASDAS < 1.3. Statistical analysis was performed
using SPSS statistics version 20.0 (IBM Corporation, Armonk, NY, USA) We used the paired samples
t-test for variables with normal distribution and Wilcoxon signed ranks test for variables which were
not normally distributed. A p-value < 0.05 was considered statistically significant. Written informed
consent was obtained from all patients, and the study has been approved by the clinical Research Ethic
Committee of the University Hospital of Ioannina, according to the principles in the Declaration of
Helsinki (197/2-12-2016).
3. Results
Twenty-one patients were excluded: 9 because they were not in clinical remission and 12 refused
to switch from RI to its biosimilar. Thus, the final results comprise 88 patients. From these patients,
45 switched to BI, while 43 continued receiving RI (Figure 1). The demographic and clinical characteristics
of our patients are depicted in Table 1. There were no differences between groups regarding the
demographic, clinical and laboratory parameters. All patients were in clinical remission with low
BASDAI and low ASDAS for approximately 3 years. During the follow-up period, 5 patients from
the switched group and 3 from the continuing group discontinued the study (Figure 1). Four patients
receiving BI presented nocebo effects after the second infusion while one had recurrent urinary tract
infections. The patients with nocebo effects experienced nonspecific, subjective complaints such as
headache, somnolence, dizziness, arthralgias, fatigue and pain. The clinical examination of these
patients was unremarkable, and the acute phase reactants were within normal limits. These patients
were switched to RI. Three responded well, while the fourth did not, and was changed to interleukin-17
(IL-17) inhibitor with good results. On the other hand, from the patients who continued receiving
the RI, two patients presented recurrent upper respiratory tract infections while one had a disease
flare-up. These patients were treated with an IL-17 inhibitor and responded very well. After 18 months
of follow-up, all patients in both groups remained in clinical remission with low BASDAI, low ASDAS
as well as low erythrocyte sedimentation rate (ESR) and CRP (Table 2). No significant adverse events,
serious adverse events or any comorbidities were noted between the studied groups (Table 3).
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Figure 1. Flow chart of AS patients treated with infliximab.






Mean age (years) (SD) 36.1 (4.6) 35.7 (4.3) NS
Male/female 39/6 40 (3) NS
Mean disease duration (years) (SD) 7.8 (3.0) 7.6 (2.8) NS
Mean follow-up (years) (SD) 7.0 (1.1) 6.9 (0.9) NS
BMI (kgr/m2) >25 5 (11.1) 4 (9.3) NS
Current smokers n (%) 10 (22.2) 8 (18.6) NS
Ex-smokers n (%) 9 (20) 9 (20.9) NS
Mean treatment with BI/RI 6.4 (0.9) 6.5 (0.8) NS
Mean treatment with RI and clinical
remission (years) (SD) 3.6 (0.8) NS
Axial disease n (%) 45 (100) 43 (100) NS
Peripheral disease n (%) 4 (9) 3 (7) NS
Methotrexate intake n (%) 3 (7) 2 (5) NS
Mean BASDAI (SD) 3.7 (0.2) 3.6 (0.4) NS
Mean ASDAS (SD) 1.0 (0.2) 1.1 (0.2) NS
Mean ESR mm/h (SD) 18.5 (2.2) 19.3 (1.7) NS
Mean CRP mg/L (SD) 6.0 (0.8) 5.8 (0.6) NS
BI, biosimilar infliximab; RI, reference infliximab; SD, standard deviation; BMI, body mass index; BASDAI, bath
ankylosing spondylitis activity index; ASDAS, ankylosing spondylitis disease activity score; ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein; NS, non-statistical.
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Table 2. Response to treatment in AS patients switched to BI versus those continuing RI.
Parameters Switched Group (BI) Continued Group (RI) p-Value
At switching
BASDAI (SD) 3.7 (0.2) 3.6 (0.4) NS
ASDAS (SD) 1.0 (0.2) 1.1 (0.2) NS
ESR mm/h (SD) 18.5 (2.2) 19.3 (1.7) NS
CRP mg/l (SD) 6.0 (0.8) 5.8 (0.6) NS
End of the study
BASDAI (SD) 3.7 (0.4) 3.8 (0.2) N5
ASDAS (SD) 1.0 (0.2) 1.1 (0.1) NS
ESR mm/h (SD) 19.5 (1.5) 20.0 (1.6) NS
CRP mg/l (SD) 6.0 (1.0) 6.1 (1.1) NS
BI, biosimilar infliximab; RI, reference infliximab; SD, standard deviation; BASDAI, bath ankylosing spondylitis
activity index; ASDAS, ankylosing spondylitis disease activity score; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; NS, non-statistical.
Table 3. Adverse events during follow-up in AS patients switched to BI versus those continuing RI.
Adverse Events * n (%) Switched Group (BI) Continued Group (RI) p-Value
Upper respiratory tract infections 3 (6.6) 2 (4.6) NS
Urinary tract infections 2 (4.4) 2 (4.6) NS
Skin infections 2 (2.2) 1 (2.3) NS
Increased liver enzymes 2 (4.4) 2 (4.6) NS
Diarrhea 1 (2.2) 2 (4.6) NS
Viral infections 2 (4.4) 1 (2.3) NS
Headache 1 (2.2) 0 (0) NS
Hypertension 1 (2.2) 1 (2.3) NS
*, not requiring discontinuation; BI, Biosimilar Infliximab; RI, Reference Infliximab; n, number of patients;
NS, Non-statistical.
4. Discussion
Biosimilars represent an important new generation of drugs in a rheumatologist’s armamentarium [10].
Biosimilars have been approved by the European Medical Association (EMA) for rheumatologic
indications and those for which the biological originator is no longer patent-protected. CTP-13, under
the commercial name Inflectra/Remsima, was the first biosimilar approved by the EMA in 2013 [1].
Approval of BI was based on findings from two pivotal trials in AS [2] and RA [3]. Data from open-label
extension studies of the original trials for AS have been reported [5]. Current data supports the proposal
that it was possible to switch from RI to BI without any detrimental effects on safety and efficacy [5].
In addition, all available data regarding switching from RI to its biosimilar are reassuring. Switching is
also recommended in the European League Against Rheumatism (EULAR) guidelines [11]. Indeed,
a 52-week double-blind trial supports the efficacy and safety of the switch from RI to its biosimilar
in patients with stable disease [12]. However, long-term follow-up data are required to confirm the
efficacy and safety of the switch. The present study tries to cover this gap.
In our study, 88 AS patients receiving RI who were in clinical remission were asked to switch to
BI. Half of them received BI, while the rest continued receiving RI. After 18 months of follow-up, no
differences of clinical efficacy and safety were found between groups. Both groups remained in clinical
remission. Our findings are in line with the PLANETAS study despite the fact that they used different
tools in assessing disease activity [2]. Five patients from the BI group and three from the RI group
discontinued the treatment. In the switched group, four patients discontinued the treatment due to
nocebo effects. Nocebo effects are complex and individualized clinical phenomena that can induce new
worsening pain, nonspecific subjective complaints such as malaise, fatigue, headache, weakness and
others which are mainly induced by the patients’ negative expectations [13]. Thus, physicians should
be aware of the potential appearance of nocebo effects which may hinder the transition to biosimilars in
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some patients [14]. Our patients responded very well to switching from RI to its biosimilar. The reason
for this could be the clinical state of the patients that are in clinical remission. Our results are in line with
those of other investigators who reported a high retention rate of switching to biosimilars if the patients
are stable [5,12]. Another reason could be that the switching was after discussion and decision-making
with the patients. Evidence-based recommendations are available for several conditions in order to guide
physicians in the switching process with biologics. Data suggests that shared-decision making leads to
a better therapeutic response with fewer nocebo effects in contrast to non-medical switching [15,16].
The limitation of our study is that we included a small number of patients. On the other hand, the
strength of our study is that it is the longest comparative study regarding switching from the RI to BI
in AS.
When biosimilars appeared in the market, they not only had a lower price but also led to the
price erosion of the reference products. In our study, there were no differences between the studied
groups, and despite the fact that we did not make a cost-effectiveness analysis, we assume that the cost
of the BI per patient is lower than that of the RI. Our study offers the promise of substantial savings
relative to the RI product, enabling more AS patients to access biological therapy and reducing the cost
associated with expensive biological treatment [17].
5. Conclusions
This is the first study in which AS patients in clinical remission receiving RI who were switched
to BI remained in clinical remission for at least 18 months. We demonstrated that BI is equivalent to RI
in maintaining AS patients in clinical remission.
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Abstract: The purpose of the study was to assess the proportion of patients who achieve pain
relief thresholds, the time needed to reach the thresholds, and the relationship between pain
and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response
to methotrexate in RA-BEAM (NCT0170358). A randomized, double-blind trial was conducted,
comparing baricitinib (N = 487), adalimumab (N = 330), and placebo (N = 488) plus methotrexate.
Pain was evaluated by patient’s assessment on a 0–100 mm visual analog scale (VAS). The following
were assessed through a 24-week placebo-controlled period: the proportion of patients who achieved
≥30%, ≥50%, and ≥70% pain relief, the time to achieve these pain relief thresholds, remaining pain
(VAS ≤ 10 mm, ≤20 mm, or ≤40 mm), and the relationship between inflammation markers and pain
relief. Baricitinib-treated patients were more likely (p < 0.05) to achieve ≥30%, ≥50%, and ≥70% pain
relief than placebo- and adalimumab-treated patients, as early as Week 1 vs. placebo and at Week 4
vs. adalimumab. A greater proportion of baricitinib-treated patients achieved ≤20 mm or ≤40 mm
remaining pain vs. placebo- and adalimumab-treated patients. Baricitinib-treated patients tended to
demonstrate consistent pain relief independent of levels of inflammation control. In RA patients with
an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than
adalimumab and placebo. Analyses suggest the relationship between inflammation and pain may be
different for baricitinib and adalimumab treatments.
Keywords: baricitinib; disease-modifying antirheumatic drugs; pain perception; outcomes research;
patient perspective; rheumatoid arthritis
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1. Introduction
Rapid, sustained pain control is a foremost goal for many patients with rheumatoid arthritis (RA);
notably, in a survey approximately two-thirds of patients responded that pain was their treatment
priority [1]. Many patients with RA who have achieved control of inflammation associated with good
clinical response with RA therapy continue to report pain, including at levels described as moderate to
severe [1–4]. This remaining pain may be a result of the multifactorial nature of pain associated with
RA, which is not solely a result of inflammation; rather it may also be associated with structural damage,
peripheral sensitization, or central amplification [2,5,6]. For other patients, despite a treat-to-target
approach, the desired goal of remission cannot be attained. For these patients, ongoing pain is often a
predominant symptom.
In RA-BEAM, a Phase 3 clinical trial of baricitinib, an oral, selective inhibitor of Janus kinase (JAK)1
and JAK2, baricitinib plus methotrexate (MTX) was associated with significant clinical improvements
compared to patients treated with adalimumab plus MTX or placebo plus MTX. Baricitinib- and
adalimumab-treated patients demonstrated similar improvement in swollen joint count (SJC), with both
groups demonstrating significantly greater improvement relative to the placebo group beginning at
Week 1 that was maintained through the placebo-controlled period (Week 24). For patient-reported pain,
however, baricitinib-treated patients reported significantly greater improvements as early as Week 1
compared to placebo-treated patients, and as early as Week 2 when compared with adalimumab-treated
patients. These statistical differences in pain relief between the active treatment arms were maintained
through the duration of RA-BEAM (Week 52) [7]. This observation prompted us to explore differences
in pain relief with baricitinib- and adalimumab-treated patients in RA-BEAM.
Publications of clinical trials in RA traditionally evaluate pain improvement only as central
tendencies (i.e., mean change from baseline). To our knowledge, no prior reports have more fully
characterized treatment effects or explored the relationship between the control of pain and inflammation
with treatment. The objectives of this analysis were two-fold: first, to use the RA-BEAM data to assess
the proportion of patients who achieve pain relief thresholds and the time needed to achieve these
thresholds, and second, to investigate the relationship between inflammation and patient-reported pain.
2. Patients and Methods
2.1. Trial Design
The design and procedure of RA-BEAM have been described previously [7,8]. Briefly,
RA-BEAM was a randomized, double-blind, double-dummy, placebo-controlled and active-controlled,
parallel-arm, 52-week study conducted at 281 centers in 26 countries between 2012 and 2015
(ClinicalTrials.gov: NCT01710358). A total of 1305 patients on stable background MTX were randomly
allocated (3:2:3) to placebo, adalimumab 40 mg, or baricitinib 4 mg. At Week 16, those patients
considered non-responders received open-label rescue treatment with baricitinib 4 mg. After Week 16,
patients may have received rescue treatment at investigator discretion. At Week 24, placebo-treated
patients were switched to baricitinib. The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol
was approved by each center’s institutional review board or ethics committee. All patients provided
written informed consent.
2.2. Patients
Patients were ≥18 years old with active RA (≥6/68 tender and ≥6/66 swollen joints; serum
high-sensitivity C-reactive protein (CRP) ≥6 mg/L). Patients had an inadequate response to MTX and
either ≥3 joint erosions (based on radiographs), or ≥1 joint erosion with seropositivity for rheumatoid
factor or anti-citrullinated peptide antibodies [7].
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2.3. Pain Measures
Pain was measured with the patient’s assessment of pain visual analog scale (VAS), consisting
of one question, “How much pain are you currently having because of your rheumatoid arthritis?”
Responses range from 0 mm (no pain) to 100 mm (worst possible pain). The pain VAS was administered
at every study visit.
Pain Thresholds
Our initial observation of differential pain response between baricitinib and adalimumab was based
on mean change from baseline. We wanted to understand if these differences persisted when pain relief
was evaluated against various thresholds of success, as is typical for other patient-reported outcomes
in RA. Because there are no established, standard pain thresholds in RA, we reviewed the literature and
selected two approaches. First, we applied percent change from baseline threshold recommendations
from the general chronic pain literature, specifically those from the Initiative on Methods, Measurement,
and Pain Assessment in Clinical Trials (IMMPACT), a multidisciplinary organization with the mission
to develop consensus reviews and recommendations and to improve clinical trials of treatments for
pain [9,10]. A 30% improvement threshold is described as “much improved, meaningful differences”
and 50% represents “very much improved, substantial improvement” in chronic pain conditions.
A 70% improvement threshold, although not defined in IMMPACT, was also evaluated because it is
analogous to American College of Rheumatology response endpoints and was observed with patients
in RA-BEAM. Second, while relative improvement is important, so is absolute pain; thus we evaluated
thresholds of remaining pain (i.e., the absolute value of patient-reported pain) of ≤10 mm, ≤20 mm,
or ≤40 mm, at Week 24. The ≤10 mm threshold reflects limited pain to no pain and is extrapolated
from data by Wells et al. [11]. The ≤20 mm threshold represents a threshold when satisfaction with
health is not negatively affected by pain [11,12]. The ≤40 mm threshold was derived from observed
cut-off points between the pain VAS and the Patient Acceptable Symptom State (PASS) [13].
2.4. Outcomes
The proportion of patients achieving ≥30%, ≥50%, or ≥70% improvement from baseline by Week
24 was assessed, as was the median time when 50% of patients achieved these thresholds of pain relief.
The proportion of patients achieving remaining pain VAS values of ≤10 mm, ≤20 mm, or ≤40 mm was
assessed at Week 24. To evaluate if the differences in pain response were associated with inflammation,
we assessed the relationship between levels of inflammation and pain relief at Week 24.
2.5. Statistical Analyses
All analyses were conducted with an intention-to-treat approach in which data from patients who
received ≥1 dose of study drug were assessed, regardless of whether they completed the trial. Missing
values were imputed with modified last observation carried forward for all analyses where applicable.
Analyses were not adjusted for multiplicity.
Comparisons were made on the percent change in pain VAS from baseline to Week 24 using
analysis of covariance (ANCOVA) and on the proportion of patients achieving pain relief at Week 24
between treatment arms using logistic models, adjusted for randomization factors (region, baseline
joint erosion status (1–2 erosions plus seropositivity vs. ≥3 erosions)) and baseline pain VAS score.
The median time needed for patients to achieve these pain relief thresholds were assessed through
Week 24 using the cumulative incidence estimate with ‘competing risks’ which included rescue or
discontinuation due to lack of efficacy before reaching the pain relief threshold. The Cox proportional
hazards model with ‘competing risks’ (proportional sub-distribution hazards model) [14,15] was used
to obtain the hazard ratio.
Remaining pain was analyzed across treatment groups with logistic regression models. Pain relief
at Week 24 by CRP was evaluated using ANCOVA.
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A mediation analysis with multiple mediators was conducted to evaluate the relationship between
levels of inflammation and pain relief. The effects of change in inflammatory factors (CRP, erythrocyte
sedimentation rate (ESR), SJC) as multiple mediators on change in pain outcome for each treatment
over placebo during the 24-week period were evaluated in this analysis [16]. The total treatment effect
on pain relief over placebo that can be accounted for by changes in CRP, ESR, and SJC in the mediation
analysis is the ‘indirect’ or mediation effect, while the total treatment effect that cannot be accounted for
by the ‘indirect’ effect is called the ‘direct’ effect. Observed data were used for the mediation analysis.
Statistical analyses were performed in SAS (SAS Institute; Cary, NC, USA, version 9.4). A two-sided
p value < 0.05 was considered statistically significant.
3. Results
3.1. Pain Relief
As noted by Taylor et al. [7], patients had established and active RA. The mean baseline pain
scores were well matched across treatment groups in this study and ranged from 60 to 62 mm with the
median baseline pain of 62 mm [7]. Other baseline characteristics were well-balanced between the
treatment arms [7]. A detailed description of the safety of baricitinib and adalimumab is available in
the RA-BEAM publication [7]. In brief, adverse events were more frequent with baricitinib (71%) and
adalimumab (68%) than with placebo (60%) through Week 24. Rates of serious adverse events through
Week 24 were 5% with placebo, 5% with baricitinib, and 2% with adalimumab.
As early as Week 1, significantly greater improvement in pain relief was observed between
baricitinib and placebo (25% for baricitinib vs. 4% for placebo, p < 0.0001). At Week 24, the mean
percentage reduction in pain from baseline for baricitinib, adalimumab, and placebo, respectively,
were 51%, 39%, 17% (p = 0.001 for baricitinib and adalimumab vs. placebo and p = 0.030 for baricitinib
vs. adalimumab).
A greater proportion of patients treated with baricitinib or adalimumab achieved the ≥30%,
≥50%, or ≥70% pain relief thresholds compared with placebo-treated patients at Week 1 (Figure 1).
Compared with adalimumab-treated patients, a greater proportion (p < 0.05) of baricitinib-treated
patients achieved ≥30% and ≥50% pain relief as early as Week 4 and ≥70% pain relief at Week 8.
Differences between baricitinib and adalimumab for ≥50% and ≥70% pain relief were maintained
through Week 24 (Figure 1).
At Week 24, for the placebo-, adalimumab-, and baricitinib-treated patients, respectively, the
proportion of patients who achieved ≥30% pain relief were 49%, 69%, and 74%; for ≥50% pain relief,
the values were 32%, 52%, and 61%; and for ≥70% pain relief, the values were 16%, 32%, and 41%.
The median time to achieve the ≥30% pain relief threshold was 2 weeks for baricitinib- and
adalimumab-treated patients and 5 weeks for those on placebo (Figure 2). For ≥50% pain relief, the
median time was 4 weeks for baricitinib, 8 weeks for adalimumab, and 14 weeks for placebo (Figure 2).
For ≥70% pain relief, the median time was 12 weeks for baricitinib, 20 weeks for adalimumab, and
>24 weeks for placebo (Figure 2). Compared with placebo, baricitinib-treated patients were more
likely to achieve ≥30%, ≥50%, or ≥70% pain relief with Hazard Ratio (HR) values of 1.7, 1.9, and 2.5,
respectively (p ≤0.001). Compared with adalimumab, baricitinib-treated patients were more likely to
achieve ≥50% or ≥70% pain relief; the HR values for the ≥30%, ≥50%, or ≥70% pain relief thresholds,
respectively, were 1.1 (p = 0.145), 1.2 (p = 0.032), and 1.3 (p = 0.003).
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Figure 1. Percentage of patients who achieved pain relief thresholds from baseline, as measured by the
pain VAS. *** p ≤ 0.001 vs. placebo; † p ≤ 0.05; †† p ≤ 0.01, ††† p ≤ 0.001 vs. adalimumab. Abbreviations:
VAS = visual analog scale. Number of respondents who answered the pain question by week: placebo,
n = 481 at Week 1 and n = 483 at all other weeks; adalimumab, n = 325 at Week 1 and n = 327 at all
other weeks; baricitinib, n = 482 at all weeks.
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The median time (weeks) for patients to 
attain pain VAS improvement ≥30% was 
1.9 weeks for baricitinib, 2.0 weeks for 
adalimumab, and 4.6 weeks for placebo. 
Compared with placebo, baricitinib-
treated patients were more likely to 
achieve ≥30% pain relief with Hazard 
Ratio (HR) of 1.7 (p ≤ 0.001). 
The median time (weeks) for patients to 
attain pain VAS improvement ≥50% was 
4.0 weeks for baricitinib, 7.9 weeks for 
adalimumab, and 14.0 weeks for placebo. 
Compared with placebo, baricitinib-
treated patients were more likely to 
achieve ≥50% pain relief with an HR of 1.9 
(p ≤ 0.001). Compared with adalimumab, 
baricitinib-treated patients were more 
likely to achieve ≥50% pain relief with an 
HR of 1.2 (p = 0.032). 
The median time (weeks) for patients to 
attain pain VAS improvement ≥70% was 
12.4 weeks for baricitinib, 20.0 weeks for 
adalimumab, and >24.0 weeks for placebo. 
Compared with placebo, baricitinib-
treated patients were more likely to 
achieve ≥70% pain relief with an HR of 2.5 
(p ≤ 0.001). Compared with adalimumab, 
baricitinib-treated patients were more 
likely to achieve ≥70% pain relief; the HR 
value was 1.3 (p = 0.003). 
Figure 2. Time course for patients attaining pain relief thresholds.
3.2. Remaining Pain
The differences in the proportion of patients who achieved the ≤40 mm, ≤20 mm, and ≤10 mm
remaining pain thresholds were significantly greater for baricitinib and adalimumab compared with
placebo as early as Week 1 (Table 1). Compared with adalimumab-treated patients, a greater proportion
of baricitinib-treated patients achieved the ≤40 mm threshold (p ≤ 0.001) at Week 4, and a difference
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was observed between the active treatment groups at the ≤20 mm threshold by Week 12 (p ≤ 0.001;
Table 1). Differences were maintained through Week 24. The percentage of patients who achieved
the ≤10 mm remaining pain threshold was greater for baricitinib compared to adalimumab, but the
difference reached statistical significance only at Week 12.
Table 1. Percentage of patients who met the thresholds of remaining pain (VAS) over time by treatment
groups. *** p ≤ 0.001 vs. placebo; † p ≤ 0.05; ††† p ≤ 0.001 vs. adalimumab.
Threshold of Remaining Pain
at Each Time Point (Week)
Placebo n (%) Adalimumab n (%) Baricitinib n (%)
≤40 mm
1 150 (31) 132 (41) *** 208 (43) ***
4 193 (40) 169 (52) *** 298 (62) ***,†††
12 225 (46) 202 (62) *** 335 (69) ***,†
24 236 (49) 218 (66) *** 351 (73) ***,†
≤20 mm
1 51 (11) 64 (20) *** 90 (19) ***
4 80 (17) 93 (28) *** 158 (33) ***
12 103 (21) 120 (37) *** 209 (43) ***,†
24 105 (22) 121 (37) *** 239 (49) ***,†††
≤10 mm
1 20 (4) 32 (10) *** 40 (8) ***
4 29 (6) 49 (15) *** 88 (18) ***
12 52 (11) 63 (19) *** 124 (26) ***,†
24 56 (12) 86 (26) *** 144 (30) ***
3.3. Relationship between Inflammation and Pain Relief
At Week 24, among patients with varying levels of inflammation, as measured by CRP as
an objective marker of inflammation, baricitinib-treated patients tended to demonstrate consistent
pain relief regardless of the CRP levels. In contrast, patients treated with adalimumab and placebo
demonstrated less pain relief at higher CRP levels (Figure 3).
Figure 3. Pain improvement by remaining inflammation (CRP, mg/L) at Week 24. * p≤ 0.05, *** p ≤ 0.001
vs. placebo; †† p ≤ 0.01 vs. adalimumab. Abbreviations: CRP = C-reactive protein.
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While the total effect of baricitinib on pain relief over placebo at Week 24 was greater than that for
adalimumab, changes in inflammation accounted for approximately 40% of the pain improvement
with baricitinib and 50% of pain improvement with adalimumab (Figure 4; Table S1). In this analysis,
the direct effects (i.e., those not associated with these markers of inflammation) of drug on pain relief
were higher for baricitinib than for adalimumab after accounting for indirect inflammatory effects
(Figure 4).
Figure 4. Relative contribution of inflammatory control to pain control.
4. Discussion
In the RA-BEAM trial, patient-reported improvements in disease activity, physical function, and
pain were greater for baricitinib plus MTX than for adalimumab plus MTX within 4 weeks of starting
treatment and were maintained throughout the 52-week observation period [7]. In this analysis, we
further explored pain relief experienced by patients. Baricitinib demonstrated greater and more rapid
achievement of clinically significant levels of pain relief than adalimumab or placebo through Week 24.
Furthermore, this differential effect became more marked as the pain relief thresholds increased, with
approximately 40% of the patients receiving baricitinib achieving ≥70% pain relief from baseline by
Week 24.
Another striking feature of this analysis was the rapid onset of effective mean pain relief at a
cohort level with baricitinib plus MTX. Here, we show that for those patients achieving ≥50% or ≥70%
pain relief, baricitinib had a shorter median time to achieving these pain relief thresholds than placebo
or adalimumab. Specifically, for ≥50% pain relief, the 4 weeks needed for baricitinib was approximately
half that of adalimumab treated patients (8 weeks). For patients achieving ≥30% pain relief, baricitinib
and adalimumab had similar median time to onset (approximately 2 weeks).
Remaining pain is commonly reported by patients with RA despite achieving satisfactory
disease control by adopting the treat-to-target approach in disease management. A threshold of
≤20 mm remaining pain is considered to represent a point where health satisfaction is not adversely
affected [11,12]. In our study, we found that patients treated with either baricitinib plus MTX or
adalimumab plus MTX were significantly more likely to achieve ≤10 mm, ≤20 mm, and ≤40 mm
thresholds for remaining pain compared to placebo plus MTX. Baricitinib separated from adalimumab
by Week 4 for the ≤40 mm and by Week 8 for the ≤20 mm threshold.
To explore the relative contribution of anti-inflammatory and other mechanisms of pain relief
obtained with either baricitinib or adalimumab, we explored relationships between changes in
patient-reported pain and an objective marker of inflammation, namely CRP. This analysis suggests
that the difference in pain relief between baricitinib and adalimumab cannot be solely accounted for by
differential effects on inflammation.
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While it is clear from multiple clinical studies that baricitinib has a profound anti-inflammatory
effect, as would be expected of a multi-cytokine inhibitor, these observations imply that JAK1 and
JAK2 inhibition also has anti-nociceptive effects that are independent of at least certain aspects of
the inflammatory process [17]. A rodent model indicated that treatment with baricitinib attenuates
complete Freund’s adjuvant-induced joint deficits, a surrogate measure of joint pain [18]. At present, the
mechanisms by which baricitinib modulates the pain experience independently of at least some generic
features of inflammation is unknown. One possible mechanism could involve granulocyte-macrophage
colony-stimulating factor (GM-CSF). GM-CSF is a cytokine that signals through JAK2 homodimers.
In a rodent collagenase-induced instability model of osteoarthritis, pain was shown to be GM-CSF
dependent, and therapeutic neutralization of GM-CSF rapidly and completely abolished arthritis
pain [19]. Another possible pathway is through phosphorylation of signal transducer and activator of
transcription 3 (STAT3). In rodent models of neuropathic pain following spinal nerve ligation, STAT3
phosphorylation was induced centrally in the dorsal spinal cord with upregulation of interleukin-6
(IL-6) mRNA in the dorsal root ganglia and elevated IL-6 concentrations in the dorsal spinal cord.
Intrathecal administration of a JAK2 inhibitor blocked this STAT3 phosphorylation pathway with
accompanying attenuation of both mechanical allodynia and thermal hyperalgesia [20]. It is known that
the JAK-STAT3 system is activated through IL-6 signaling in spinal microglia and that this transduction
pathway participates in development of pain associated with nerve alteration. However, it is not
known whether such mechanisms have relevance to pain in established RA.
In rodent arthritis models, autoantibodies to citrullinated proteins (ACPA) are reported to induce
joint pain independent of inflammation via a chemokine-dependent mechanism [21]. However, this is
unlikely to account for the differences in pain relief between TNF blockade and JAK inhibition in our
study as we did not observe statistically significant differences in ACPA change from baseline between
baricitinib and adalimumab at Week 24.
This analysis has limitations. Specifically, the present findings represent post hoc analyses in
which patients were not randomized according to their baseline pain. Pain studies may be complicated
by the subjective experience of pain and the inherent limitations of a VAS as an instrument to measure
pain experience. Additionally, the pain relief thresholds and remaining pain values are not yet firmly
established for RA [12,13]. Further, some concomitant medication use (e.g., glucocorticoids) are
controlled within a clinical trial, precluding assessment of any potential relationship between pain
improvement and medication changes.
Pain relief with treatment may have clinical and holistic implications. Patients who experience
pain relief are likely to report clinically significant improvements in other patient-reported outcomes,
such as the Patient’s Global Assessment of Disease Activity and functional disability [22,23]. More
broadly, reductions in pain have been associated with improvements in daily activity and work
productivity [24]. In this analysis, we have presented evidence that baricitinib rapidly provides pain
relief in patients with active RA on concomitant MTX to a magnitude greater than that observed with
the TNF inhibitor, adalimumab. We have expanded prior research through a new and detailed analysis
of the range of magnitude and kinetics of pain relief in a head-to-head study of baricitinib versus
adalimumab and by exploring the relationship between the control of pain and inflammation with
treatment. We observed that the inhibition of JAK1/JAK2 or TNF similarly ameliorate inflammatory
markers, but the overall pain and the non-inflammatory component are faster and more markedly
improved by baricitinib. Our findings merit further investigation into the biological mechanisms
underlying pain relief.
The observations from this analysis may be of importance in managing the unmet needs of
adequate pain relief in RA, whether in patients attaining the treatment targets of remission or low
disease activity or in those who are unable to achieve these targets with biologic anti-TNF treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/6/831/s1,
Table S1: Multiple mediator analysis coefficients for adalimumab vs. placebo and baricitinib vs. placebo at
Week 24.
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Abstract: Objective: Rheumatoid arthritis and periodontal disease are associated together, but the
effect of therapy provided for one disease to the second one remained under-investigated. This study
investigated effect of infliximab therapy used to treat rheumatoid arthritis (RA) on various biomarkers
of periodontal disease (PD) severity including serologies of Porphyromonas gingivalis and Prevotella
intermedia and matrix metalloproteinase 3. Methods: Seventy nine RA patients were enrolled at the
time to start infliximab therapy and the 28 joint disease activity score (DAS28), anti-cyclic citrullinated
petides 2nd generation (anti-CCP2), anti-P. gingivalis antibody, and Matrix metalloproteinase 3
(MMP-3) were monitored before and at 6 months of infliximabtherapy. Joint damage and severe
periodontal disease were assessed at baseline. Anti-CCP2, anti-P. gingivalis antibody, and MMP-3
weredetermined by enzyme-linked immunosorbent assay (ELISA). Results: At baseline, anti-CCP2
titers were associated with anti-P. gingivalis lipopolysaccharide (LPS)-specific antibodies titers
(p < 0.05). Anti-P. gingivalis antibodies were not significantly correlated with clinical, biological,
or destruction parameters of RA disease. At 6 months of infliximab therapy, MMP-3 level decreased
(from 119 ± 103 ng/mL to 62.44 ± 52 ng/mL; p< 0.0001), whereas P. gingivalis antibody levels remained
at the same level. DAS28 and inflammation markers C-reactive protein (CRP) and Erythrocyte
sedimentation rate (ESR) also decreased significantly during infliximab therapy (p< 0.05) as anti-CCP2
levels (p < 0.001). Only high MMP-3 level at baseline was associated with infliximab efficacy (p < 0.01).
Conclusion: MMP-3 level can be a useful marker of the efficacy of infliximab in RA patients.
The treatment did not affect anti-P. gingivalis antibodies.
Keywords: Rheumatoid arthritis; Porphyromonas gingivalis; periodontal disease; matrix
metalloproteinase 3; infliximab
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1. Introduction
Rheumatoid arthritis (RA) is the most frequently chronic inflammatory joint disease characterized
by synovial hypertrophy and inflammation with joint and subchondral bone destruction,
which correlates with disability and loss of function [1]. Epidemiological studies suggest an
association between RA and periodontal disease (PD) and confirmed by a recent meta-analysis [2].
Both diseases (RA and PD) share important similarities in their pathogenesis involving similar genetic
background [3] or production of large amount of proinflammatory cytokines such as tumor necrosis
factor alpha (TNF) [4]. In, P.D., inflammation is initiated and perpetuated by a subset of bacteria,
including Porphyromonas gingivalis (P. gingivalis) and Prevotella intermedia (P. intermedia), two specific
gram-negative anaerobic bacteria, which colonize the gingival sulcus and proliferate in the gingival
plaque. The resulting chronic inflammatory response by the host induces destruction of the supporting
structures of the teeth defining severe PD. P. gingivalis presence seems to be specific of severe PD.
This was reinforced by recent data from an experimental rat model confirming the specific involvement
of P. gingivalis in arthritis onset [5]. Furthermore, bacterial colonization was also described in the gut of
RA patients [6].
Anti-citrullinated protein antibodies (ACPA) are the highest specific biomarker for RA diagnosis
or prognosis and are now included in the new RA criteria [1]. Endogenous or exogenous
peptidyl-arginine deiminases (PADs) induced citrullinated proteins by conversion of peptidyl-arginine
to peptidyl-citrulline. This is part of many physiological processes [7]. However, smoking or P. gingivalis
infection could induce excess of citrullination in some conditions [8]. Since ACPA occurred some years
before RA clinical onset [9], P. gingivalis infection could precede RA onset and be a key player for
initiation and maintenance of the autoimmune inflammatory responses in RA [10]. P. gingivalis is the
unique known pathogen to have a specific enzyme PAD (PPAD) [11], which induce citrullination of
proteins [12] and could provide a rupture of tolerance with ACPA induction.
Indirect presence of P. gingivalis by serology demonstrated that high concentrations of
anti-P. gingivalis antibody in established [12] or early RA patients [13]. This indirect biomarker
of P. gingivalis correlated with the gingival bacteria load assessed by polymerase chain reaction [13,14].
PD is related to many other anaerobic periodontal pathogens including P. intermedia, which was also
detected in both the serum and synovial fluids of RA patients [15].
Matrix metalloproteinase 3 (MMP-3) is one of the major MMPs expressed in rheumatoid synovial
tissue [16]. MMP-3 is mainly involved in bone and cartilage degradation in RA or bone destruction
in PD [17]. Thus, MMP-3 is already considered as a biomarker for RA and PD destruction [18]. In,
P.D., a MMP-3 polymorphism was described as associated to PD [19]. Furthermore, strategy based on
MMP-3 monitoring improved clinical response and reduced joint destruction in RA [20]. In both PD
and, R.A., production of proinflammatory cytokines, as TNF., is increased and specific blocking of TNF
improves two-third of RA patients [21]. Only few studies have reported predictive factors of response
to infliximab in RA [21], but no relevant clinical or biological markers can be used in the daily practice.
In only one previous study, PD was related to be a predictive factor for a non-response to TNF blocker
therapy in RA patients [22]. Persistence of P. gingivalis in gingival tissue could participate to maintain
local and systemic inflammation in relation with treatment resistance [23]. Only few studies explored
therapeutic effect for PD on RA [24] and vice versa [25].
Since both diseases are associated at the susceptibility and severity level [24], therapy from
one disease should be efficient to the second one. This concept was recently reinforce by the first
demonstration of PD severity on RA activity [26]. We already reviewed previously [24] impact of some
biologic disease modifying anti-rheumatic drugs (bDMARDs) on PD. Infliximab treatment worsened
the gingival inflammation, but decreased the gingival destruction of bone [25]. A the opposite,
rituximab [27] or tocilizumab [28] decreased gingival inflammation or gingival bone destruction related
to the PD. Accordingly, in case of severe PD B-cell blocker or IL-6 receptor blockers could be considered
preferentially compared to TNF blocker. At the opposite, some non-surgical PD therapy reported
decreased of anti-P. gingivalis antibodies without effect on ACPA level [29].
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Thus, our aim in this study was to correlate marker of PD severity (MMP-3, anti-P. gingivalis and
anti-P. intermedia antibodies) and to assess effect of infliximab therapy on PD severe biomarkers in
RA patients. In addition, the usefulness of these biomarkers was assessed for prediction of clinical
response to infliximab therapy.
2. Patients and methods
2.1. Patients and Controls
Seventy nine RA patients treated with methotrexate with active disease and starting infliximab
therapy were included consecutively. Following clinical parameters were recorded: Age, sex, disease
duration, patient’s global assessment of disease activity, 28 tender and swollen joint counts, and the
28 joint disease activity score (DAS28). Joint damage and severe PD were defined by a right Larsen
wrist score ≥ 2 and Hugoson and Jordan criteria, respectively as previously used [3]. Wrist X-rays
were examined by the same reader (HM) as panoramic X-rays (PF). Clinical response to infliximab
was defined by a decrease of DAS28 > 1.2. Blood samples were collected before and at 6 months of
infliximab therapy to assess anti-cyclic citrullinated peptide second generation (CCP2), rheumatoid
factor (RF), MMP-3, and antibodies against P. gingivalis and P. intermedia. Sera from two control groups
were used in this study. We enrolled 27 healthy blood donors as control healthy volunteers and
28 patients with inflammatory bowel disease (IBD) and 35 patients with systemic lupus erythematosus
(SLE), as inflammatory disorders controls. Local clinical ethics committee approved the protocol and
all patients gave their written informed consent.
2.2. Methods
Determination of anti-P. gingivalis and anti-Escherichia coli LPS-specific antibodies by enzyme-linked
immunosorbent assay (ELISA). To optimise our evaluation anti-P. gingivalis antibody assessed by
ELISA., we performed two standardised ways for coating: Whole extract or lipopolysaccharide (LPS)
components. LPS from P. gingivalis (InvivoGen, Toulouse, France) was coated on 96-well plates (Nunc,
Dominique Dutscher, Brumath, France) at 10 μg/mL (diluted in carbonate buffer, pH 9.6) and incubated
overnight at 4 ◦C. We used LPS from Escherichia coli (E. coli, InvivoGen, Toulouse, France) as control with
the same dilution. Wells were washed three times with phosphate buffered saline (PBS)-Tween (0.005%).
Plasma were diluted to 1:600 in PBS containing 1% of bovine serum albumin (BSA) and incubated
(in duplicate) for 2 h at room temperature. Plates were washed as described above and incubated
with peroxidase-conjugated goat anti-human IgG H + L (Jackson ImmunoResearch, West Grove, PA,
USA) (diluted 1:50 000 in PBS) for 2 h at room temperature. After a final wash, detection was made by
tetramethylbenzidine substrate (R&D Systems, Minneapolis, MN., USA). The reaction was stopped by
the addition of H2SO4 (1M) solution and absorbances were measured at 450 nm.
2.2.1. Determination of Anti-P. gingivalis and Anti-P. intermedia Whole Extract Antibodies by ELISA
P. gingivalis strain ATCC 33277 and P. intermedia CIP 103607 were grown on sterile non-selective
agar containing defibrinated sheep blood, supplemented with 0.0002% menadione sodium bisulfite
and 0.4% hemin chloride. Cultures were then placed in an anaerobic chamber for 7 days at 37 ◦C. Then,
colonies were recovered in a sterile water solution and centrifuged for 20 min at 5000× g. Pellets were
diluted in sterile PBS at 50 mg/mL and were frozen at −20 ◦C until use. P. gingivalis or P. intermedia
solution was then washed twice with carbonate buffer (pH 9.6) and diluted in the same buffer to obtain
a solution of 1 McFarland (DensiCHEK plus, Biomérieux, Craponne, France). The solution was heated
to 60 ◦C for 45 min, filtered (0.22 μm), diluted 1:10, coated on a 96-well plate and then incubated
overnight at 4 ◦C. Plasma were diluted to 1:900 in PBS containing 1% BSA. Following steps are identical
to those described for the LPS-specific ELISA. Cut-off values for seropositivity to P. gingivalis (LPS and
whole extract) and P. intermedia were determined by concentrations higher than the 95th percentile in
27 healthy blood donors.
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A calibration curve was systematically done for each plate with dilutions of a pool of positive
plasma diluted six times from 1:100 to 1:16200 to correct for plate-to-plate variation. Two plasma
controls (high and low positives) were included on all plates. All intra assay coefficients of variation
(CV) were below 6.5%. Inter assay CV for the high positive control were 13%, 8%, and 28% for
P. gingivalis whole extract, LPS assay and P. intermedia assay, respectively. Results are expressed in
Arbitrary Units (AU) defined by the pool dilution (10 AU = 1:16200 to 2430 AU = 1:100).
Furthermore, determination of citrullinated proteins in P. gingivalis whole extract or LPS was
assessed by using the specific anti-CCP2 detection antibody (Phadia, Thermo Fisher Scientific,
Uppsala, Sweden).
2.2.2. Assessments of ACPA, R.F., and MMP-3
MMP-3 blood concentrations were determined by a commercial ELISA method
(AESKU.diagnostics, Wendelsheim, Germany). ACPA was assessed by anti-CCP2, and RF (IgA and
IgM) were measured by ELIA method on ImmunoCap 250 (Phadia, Thermo Fisher Scientific, Uppsala,
Sweden). Anti-CCP2 was considered to be positive at a cut off value of 10 U/mL., RF IgA at 14 IU/mL
and RF IgM at 3.5 IU/mL, as recommended by the manufacturer.
2.3. Statistical Analysis
Since data were not normally distributed, they were expressed as median and interquartile range
25–75% (IQR 25–75) or number (%). Correlations were performed by Spearman tests. Comparisons
between controls and RA patients were performed by Mann Whitney test. Comparisons between
baseline and 6 months of infliximab treatment were performed by Wilcoxon test. Statistics were




Our RA population had the main characteristics of RA patients treated with TNF inhibitors as
reported in the Table 1. In this cohort, severe PD was present in 51 RA patients and severe PD was
associated with joint damage (χ2 test = 4.4; p = 0.0276).
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Table 1. Characteristics of rheumatoid arthritis (RA) patients at baseline and after infliximab therapy.
Baseline 6 Months p Values
Sex (female/male) 63/16
Age, years 52.8 (43.3–59.4)
Disease duration (years) 9 (5–13)
No destruction, n (%) 12 (15.2%)
Wrist destruction, n (%) 56 (70.9%)
Periodontal disease, n (%) 51 (64.6%)
DAS28 5.1 (4.1–5.7) 3.5 (2.7–4.3) <0.0001
ESR (mm/h) 34 (20–49) 18 (10–32) <0.0001
CRP (mg/L) 18 (7–33) 7 (2–17) <0.05
Anti–CCP2 (U/mL) 97 (9–275) 43 (5–189) <0.001
RF IgM (IU/mL) 38 (11–96) 22 (6–66) <0.0001
RF IgA (IU/mL) 25 (10–61) 17 (8–47) 0.0001
MMP–3 (ng/mL) 90 (40–177) 45 (24–91) <0.0001
Anti–P. gingivalis whole extract (AU) 238 (148–377) 274 (173–557) <0.01
Anti–P. gingivalis LPS (AU) 86 (67–146) 97 (77–152) NS
Anti–P. intermedia whole extract (AU) 390 (131–1558) 436 (246–853) <0.05
Values are indicated as number of patients (%) or median (1st and 3rd quartiles). DAS28: Disease Activity Score
28; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; Anti-CCP2: anti-cyclic citrullinated peptides
2nd generation; RF: rheumatoid factor; MMP-3: Matrix metalloproteinase-3; LPS: lipopolysaccharide; U: unit;
IU: international units; AU: arbitrary units, NS: non-significant.
3.2. Immunity Against Oral Pathogens is Related to Established RA
Anti-P. gingivalis whole extract antibodies were more frequently positive in established RA
patients (97.5%) than in healthy blood donors (5%) with higher concentrations of anti-P. gingivalis
antibody in established RA patients (238 (148–377) AU) than in healthy blood donors (43 (24–79) AU;
Figure 1A; p < 0.001). Similar results were observed for anti-P. gingivalis LPS specific antibody (data not
shown). Analogous pattern was also observed for anti-P. intermedia whole extract antibodies with
more positive in established RA patients (84.8%) than in healthy blood donors (17.8%; Figure 1A;
p < 0.001). Anti-P. intermedia antibody concentrations were also higher in established RA patients
(390 (131–1558) AU) than in healthy blood donors (96 (67–179) AU; Figure 1A; p< 0.001). Thus immunity
against oral pathogens was higher in established RA patients than in healthy blood donors reinforcing
association between RA and PD. Furthermore, the two ways for anti-P. gingivalis antibody determination
strongly correlated together (Figure 1B; p < 0.0001) and also correlated with anti-P. intermedia antibody
concentrations (Figure 1C; p < 0.0001). Since we observed a correlation between immunity against
these two bacteria from the oral cavity, we investigated the specificity of our assay. For this purpose,
we tested the same plasma for anti-LPS fraction of E. coli, another commensal bacterium of the gut.
Only one patient has serum with anti-E. coli antibody without anti-P. gingivalis antibody. At the
opposite, many patients had anti-P. gingivalis antibody without anti-E. coli antibody, demonstrating
the absence of crossreaction between these two antibodies (Figure 1D). As P. gingivalis whole extract
may contain citrullinated proteins, we then investigated a putative crossreactivity between anti-CCP2
and anti-P. gingivalis antibodies. Presence of citrullinated proteins was not observed in the whole
P. gingivalis extract by using the monoclonal antibody to detect anti-CCP2 (data not shown).
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Figure 1. Evaluation of the measure of anti-P. gingivalis whole extract and LPS specific antibodies
by ELISA. Anti-P. gingivalis and anti-P. intermedia (A) whole extract antibodies were measured in
healthy blood donors and RA patients. Correlations between both anti-P. gingivalis LPS and whole
extract (two ways to assess the same germ; (B); anti-P. intermedia and anti-P. gingivalis whole extract
(assessment of two oral germs; (C) in RA patients. No correlation between anti-P. gingivalis and anti-E.
coli LPS antibodies in RA patients (assessment of one oral germ and on commensal gut germ; (D).
Anti-P. gingivalis (E) and anti-P. intermedia (F) whole extract antibodies were measured in SLE., IBD.,
and RA patients. From the bottom up, the bars indicate the interquartile range and the median. AU:
arbitrary units; r: Spearman correlation coefficient; LPS: lipopolysaccharide; RA: rheumatoid arthritis;
SLE: systemic lupus erythematosus; IBD: inflammatory bowel disease; ***: p < 0.001.
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3.3. Anti-P. gingivalis and anti-P. Intermedia Antibodies and RA Specificity
To assess the specificity of these antibodies to, R.A., we then assessed them in IBD and SLE.,
two other inflammatory auto-immune diseases. Anti-P. gingivalis and anti-P. intermedia antibody
concentrations were lower in IBD and SLE patients and established RA patients (Figure 1E,F; p < 0.001
for P. gingivalis and P. intermedia in RA and SLE vs. IBD ).Thus high antibody concentrations against
oral pathogens were specific for RA or SLE diseases involving joint.
3.4. Differential Implication of P. Gingivalis and P. Intermedia Antibodies in Immune Response in RA Patients
Since high antibody concentrations against P. gingivalis and P. intermedia were observed in RA
patients, association of these antibodies with clinical and biological RA parameters was investigated.
RF IgA concentrations were correlated with DAS28 at baseline (Figure 2A; p < 0.01). Furthermore,
anti-CCP2 concentrations correlated with both anti-P gingivalis (whole extract and LPS) antibody
concentrations (Figure 2B,C; p < 0.001 and p < 0.01; respectively), without correlation with IgM
RF concentrations. Interestingly, anti-P intermedia antibody concentrations correlated with IgM RF
concentrations (Figure 2D; p < 0.05), but not with anti-CCP2 concentrations. Since only anti-P gingivalis
concentrations correlated with anti-CCP2 concentrations, these data reinforced the association between
P. gingivalis and citrullination in RA.
Figure 2. Correlation between clinical and biological parameters at baseline. Correlations between
RF IgA and DAS28 (A); anti-CCP2 and anti-P. gingivalis whole extract antibodies (B); anti-CCP2
and anti-P. gingivalis LPS specific antibodies (C); and RF IgG and anti-P. intermedia antibodies (D).
RF: rheumatoid factors; IU: international units; DAS28: disease activity score 28; AU: arbitrary
units; anti-CCP2: anti-cyclic citrullinated petides 2nd generation; r: Spearman correlation coefficient;
LPS: lipopolysaccharide; U: Unit; IU: International unit; NS: non-significant.
3.5. Clinical Response to Infliximab Therapy and Joint or Periodontal Destructions
As expected, DAS28 and inflammation markers (CRP and ESR) strongly decreased at 6 months
of infliximab treatment (Table 1). DAS28 improvement was similar in RA patients with or without
severe PD (1.9 (0.7–3.0) vs. 1.7 (0.5–2.5); not significant) and according to the joint damage status.
Interestingly, anti-CCP2 concentrations decreased significantly during infliximab therapy (Figure 3A;
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p < 0.001) as IgM RF concentrations (Figure 3B; p < 0.001). As expected, all RA parameters decreased
during infliximab therapy.
 
Figure 3. Effect of infliximab treatment on biological markers. Anti-CCP2 (A), RF IgM (B), anti-P.
gingivalis antibodies (C), anti-P. intermedia antibodies (D), and MMP3 (E) were evaluated at baseline
and after 6 months of infliximab therapy. Dots represent results for each patient, with values at baseline
in round and at 6 months of infliximab therapy in square. From the bottom up, the bars indicate
the interquartile range and the median. Anti-CCP2: anti-cyclic citrullinated petides 2nd generation;
RF: rheumatoid factor; MMP-3: metalloproteinase 3; AU: arbitrary units; IU: International units;
*: p < 0.05; ***: p < 0.001; ****: p < 0.0001.
3.6. Dissociated Effect of Infliximab Therapy on PD Biological Markers
Anti-P. gingivalis whole extract antibody concentrations slightly increased at 6 months of infliximab
therapy (Figure 3C; p < 0.05) with the same trend for anti-P. intermedia antibody concentrations
(Figure 3D; p = 0.052). During infliximab therapy, MMP-3 concentrations strongly decreased from
90 (14–259) ng/mL to 45 (10–160) ng/mL (Figure 3E; p < 0.0001). Thus, infliximab therapy induced a
strong reduction of MMP-3, but slightly increased concentrations of antibodies against P. gingivalis and
P. intermedia.
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3.7. Biological Markers and Prediction of Clinical Response
Among biomarkers assessed in this study, baseline MMP-3 concentrations were higher in patients
with a good response to infliximab (111 (49–187) ng/mL) compared to non-responders (57 (29–110)
ng/mL; p < 0.05; Figure 4A). However, neither baseline anti-CCP2 concentrations (Figure 4B; NS) nor
anti-P. gingivalis and anti-P. intermedia antibody concentrations (data not shown) were not associated
with clinical response to infliximab. Furthermore, reduction of MMP-3 during infliximab therapy was
higher in responders than in non-responders patients (Figure 4C; p < 0.05). Only a trend was observed
for higher reduction of anti-CCP2 in responders compared to non-responders to infliximab (Figure 4D;
p = 0.09).
Figure 4. Predictive factors for clinical response to infliximab therapy. Baseline values of MMP-3 (A)
and anti-CCP2 (B) were represented. Delta MMP-3 (C) and delta anti-CCP2 (D) represent difference
of MMP-3 and ACPA (baseline value minus 6 month value) and are shown according to clinical
response to infliximab. Dots represent results for each patient, with responders in square () and
non-responders in round (). From the bottom up, the bars indicate the interquartile range and
the median. Response to infliximab treatment was defined by an improvement > 1.2 of DAS28
at 6 months. MMP-3: matrix metalloproteinase-3; anti-CCP2: anti-cyclic citrullinated petides 2nd
generation; *: p < 0.05; NS: non significant.
4. Discussion
We confirmed a higher prevalence of PD in established RA patients (64.5%) than in the general
population (30–40%) [30], as previously reported in early RA [31]. PD is related to many anaerobic
periodontal pathogens including P. intermedia, P. melaninogenica, or T. forsythia. Antibodies against
these periodontal pathogens were also more frequently detected in the serum from RA patients
than controls [32]. We first confirmed higher concentrations of antibodies against P. gingivalis and
P. intermedia in established RA than in healthy blood donors [32] or in two other inflammatory
diseases (SLE and IBD). This is in link with a recent review considering high P. gingivalis antibody as
a biomarker of RA [33]. Serology determination is the easiest way to assess presence of P. gingivalis
and indirectly presence of severe PD. Gingival presence of P. gingivalis detected by polymerase chain
reaction is strongly correlated with concentrations of anti-P. gingivalis antibody [13,14]. Previous
studies have explored antibodies against P. gingivalis in RA patients by using either LPS or whole
extract [12]. Here, we observed a correlation between these two assessments (LPS and bacterial
extract) of antibodies against P. gingivalis, suggesting that LPS should be the easiest way to assess
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anti-P. gingivalis. Furthermore, antibody concentrations against P. gingivalis and P. intermedia correlated
together, which was not surprising since both are involved in PD pathogenesis [34]. Despite the quite
high r value for the correlation between antibodies against P. gingivalis LPS and against E. coli, we still
believe that each antibody is specific due to absence of high level of antibodies for both pathogens.
Our assay to detect antibodies against P. gingivalis LPS or E. coli LPS without crossreaction. This was
not surprising since LPS from P. gingivalis has a specific structure compared to other bacteria with the
ability to activate TLR2 and TLR4 [35], whereas LPS from E. coli activates mainly TLR4 [35].
Anti-P. gingivalis antibody concentrations correlated with anti-CCP2 concentrations without
correlation with RF concentrations [15]. We did not expected crossreacticvity between P. gingivalis
and anti-CCP2 due to LPS structure containing only sugars and lipids and absence of detection
of citrullinated proteins in P. gingivalis extracts by using the monoclonal detection antibody from
anti-CCP2 assay. Contrary to anti-P. gingivalis antibodies, anti-P. intermedia antibodies were not
correlated with anti-CCP2, but with RF IgM concentrations, as previously described in a human [36] or
in a rat model [5]. This suggested different mechanisms of action between these two bacteria in immune
response induction. Assessment of several oral bacteria is required to have a discriminate role for each
pathogen. For instance, recent data suggested high anti-P. intermedia antibodies in clinical remission RA
patients with persistent PD US activity [23]. On the other hand, Aggregatibacter actinomycetemcomitans
(A. actinomycetemcomitans), a periodontal pathogen associated with PD severity, has been suspected
to be the culprit of the association of RA and PD [37] without confirmation since. Taken all together,
our data support the specific implication of P. gingivalis compared to P. intermedia in RA pathogenesis
with induction of anti-CCP2 in response to gingival citrullinated proteins, as suggested by a recent
rodent model [5].
MMP-3 is a biomarker of both destruction in RA [38] and in PD [39]. So, we confirmed the
reduction of inflammatory markers (ESR., CRP) and MMP-3 over infliximab treatment, as previously
described with infliximab [40] or other TNF blocker [41].
Despite the growing interest for P. gingivalis in, R.A., this was the first observation that
anti-P. gingivalis and P. intermedia antibodies were increasing over time during infliximab therapy.
Only a recent study observed a stability of anti-P. gingivalis antibody concentrations in 50 early
RA patients mainly treated with methotrexate [42]. As previously reported with methotrexate
therapy [42], no patient developed seroconversion for P. gingivalis or P. intermedia with combination
of infliximab and methotrexate. Despite the growing interest for P. gingivalis pre-existing immunity
in RA patients, this was the first observation that serum anti-P. gingivalis antibodies were increasing
over time during infliximab therapy or bDAMRDS. It is not surprinsing that bDMARD promotes
infections including gingival infection. Our results are in line with previous report with infliximab
showing increasing of gingival inflammation during infliximab therapy [25]. However, this increasing
of gingival inflammation was not observed with rituximab or tocilizumab, two other bDMARDs
targeting B cell and IL-6, respectively [27,28]. On the contrary, some studies investigated the effect
of periodontal therapy on RA activity. A recent metaanalysis suggested a small effect of periodontal
therapy (full-mouth scaling and root planning) on RA disease activity [43]. Reduction of ACPA during
infliximab therapy was also already described [44]. Despite increased of anti-P. gingivalis antibody
concentrations during infliximab therapy, a trend for a reduction of anti-CCP2 during infliximab
therapy was observed in our study. This kind of dissociation response was also observed after
non-surgical therapy for periodontal disease with a decreased of anti-P. gingivalis levels without effect
on anti-CCP2 levels [29]. This dissociated response to infliximab of anti-P. gingivalis and anti-CCP2
concentrations reinforced role of P. gingivalis only in anti-CCP2 induction.
Prediction of TNF response remains a huge challenge and to date no biomarkers can be used
in daily practice [21]. Here, we observed that high baseline MMP-3 concentrations were associated
with a good clinical response. This emphasizes the role of MMP-3 for RA management strategy [20].
However, baseline MMP-3 concentrations were similar in 47 good responders vs. 29 non-responders
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according to response assessed earlier than in our study at 14 weeks [45]. Further studies are needed
before to consider MMP-3 as a validate biomarker to predict clinical response in the daily practice [21].
Our study also has some weakness. PD assessment was only performed at baseline on panoramic
X-rays without clinical assessment. Clinical PD assessment was not planned in this study. However,
clinical severe PD was already extremely reported [2] with a dissociated effect of infliximab therapy.
In fact, infliximab treatment worsens the gingival inflammation, but decreases the gingival destruction
of bone [25]. Panoramic X-rays was not repeated due to low variation of bone loss.
5. Conclusions
Concentrations of anti-P. gingivalis antibody, a biomarker of PD severity correlated with anti-CCP2
concentrations in one hand and anti-P. intermedia antibody concentrations in another hand. Besides,
anti-P. intermedia antibody concentrations correlated only with RF concentrations suggesting different
immunologic response induced by both oral bacteria. Whereas MMP-3 is strongly decreased
by infliximab therapy, serology against oral pathogen slightly increased. Furthermore, MMP-3,
another biomarker of PD and RA severity, is a predictive biomarker of response to infliximab therapy.
Our data reinforce interest of PD in RA pathogenesis and RA therapeutic management. They also
confirm the possible involvement of P. gingivalis in RA physiopathology due to the correlation
with ACPA.
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Abstract: This study aimed to investigate the periodontal health of patients with established
rheumatoid arthritis (RA) in relation to oral microbiota, systemic and oral inflammatory mediators,
and RA disease activity. Forty patients underwent full-mouth dental/periodontal and rheumatological
examination, including collection of blood, saliva, gingival crevicular fluid (GCF) and subgingival
plaque. Composition of plaque and saliva microbiota were analysed using 16S rRNA sequencing and
levels of inflammatory mediators by multiplex-immunoassay. The majority of the patients (75%) had
moderate or severe periodontitis and the rest had no/mild periodontitis. Anti-citrullinated protein
antibody (ACPA) positivity was significantly more frequent in the moderate/severe periodontitis
(86%) compared to the no/mild group (50%). No significance between groups was observed for RA
disease duration or activity, or type of medication. Levels of sCD30/TNFRSF8, IFN-α2, IL-19, IL-26,
MMP-1, gp130/sIL-6Rß, and sTNF-R1 were significantly higher in serum or GCF, and April/TNFSF13
was significantly higher in serum and saliva samples in moderate/severe periodontitis. The microbial
composition in plaque also differed significantly between the two groups. In conclusion, the majority
of RA patients had moderate/severe periodontitis and that this severe form of the disease was
significantly associated with ACPA positivity, an altered subgingival microbial profile, and increased
levels of systemic and oral inflammatory mediators.
Keywords: rheumatoid arthritis; periodontitis; periodontal disease; anti-citrullinated protein
autoantibodies; rheumatoid factor; smoking; medication; Porphyromonas gingivalis
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1. Introduction
An increased risk of periodontitis has been reported in patients with rheumatoid arthritis (RA) as
compared to healthy controls [1] and conversely, an association between chronic periodontal infection
and risk of developing RA has been suggested [2,3]. The relationships between periodontitis and
RA include similar pathological mechanisms of chronic inflammation and bone destruction [4–7],
increased production of cytokines, prostaglandins and matrix-degrading enzymes, as well as shared
risk factors where cigarette smoking is the most highlighted [2,4–6,8–10]. In periodontitis, the chronic
inflammation, which results in the destruction of tooth-supporting structures, is initiated by periodontal
pathogens such as Porphyromonas gingivalis and a dysbiotic microbial community surrounding the
periodontium [11].
The underlying etiological processes in RA are not fully understood, although ever since the
identification of antibodies to citrullinated protein antigens (ACPAs) as specific markers predictive for the
development of RA, associated also with disease severity and joint destruction [12], increased attention
has been given to the etiological mechanisms of ACPA production. These antibodies are directed against
post-translationally modified proteins containing the amino acid citrulline generated by the enzyme
peptidyl arginine deiminase (PAD) during the process of citrullination [12,13]. Some recent studies
suggest that immunity against citrullinated proteins may be initiated at a mucosal site (e.g., the lung or
gingiva), and others point to a cross-reactivity scenario between microbial amino acid sequences and
citrullinated self-proteins resulting in ACPA production [11,14,15]. The periodontal pathogens P. gingivalis
and Aggregatibacter actinomycetemcomitans have been suggested to be involved in the generation of
citrullinated antigens and the subsequent production of ACPA. Interestingly, A. actinomycetemcomitans
was reported to induce hypercitrullination in host neutrophils, with hypercitrullination patterns similar
to those observed in synovial fluid of RA patients [16]. P. gingivalis, on the other hand, has for some
time been implicated in RA autoimmunity because of its unique ability to express a microbial PAD
enzyme (P. gingivalis PAD, PPAD), which has the ability to citrullinate proteins, similar to the human
PAD enzymes [2,17]. By citrullinating proteins in the periodontium, PPAD could trigger the production
of ACPAs, which through epitope spreading may cross-react with citrullinated proteins in the joints
resulting in a chronic inflammation and eventually joint destruction [2].
A relationship between periodontitis and RA has recently been supported by a systematic review
and meta-analysis [1]. One of the largest studies that report an association (OR = 1.16; 95% CI: 1.12–1.20)
between these two diseases was based on a register study including 13,779 Taiwanese patients with
newly diagnosed RA and 137,790 controls [18]. A significant association between RA and periodontitis
(OR = 1.17; 95% CI: 1.15–1.19, p < 0.001) was also reported in a Korean population based registry study
comprising 57,024 patients with RA out of which 26,320 had periodontitis [19]. However, none of these
studies were able to account for smoking, which is an important risk factor for periodontitis, as well as
RA, and the studies lacked information about autoantibody status. Thus, the strength of the relationship
between periodontitis and RA is still an area of interest for researchers and clinicians, as several studies
have also failed to report an association between these two diseases. For example, in the largest
prospective study conducted to date where 81,132 female nurses (292 RA and 80,840 controls) were
followed for more than 12 years, no association was found between RA and periodontal surgery and/or
tooth loss [20]. Likewise, in our recently published study of 6682 Swedish patients with established RA
and matched healthy controls included in the Epidemiological Investigation of Rheumatoid Arthritis
(EIRA) registry, we reported no increased prevalence of periodontitis diagnosis in patients with RA as
compared to controls, and no differences in periodontitis prevalence based on ACPA or rheumatoid
factor (RF) status [21]. Importantly, however, in that study, we were not able to assess the severity of
the periodontal diagnosis in patients with RA using clinical parameters of periodontal disease. The aim
of this study was, therefore, to investigate the severity of periodontitis (defined as severe, moderate or
no/mild) [22] in Swedish patients fulfilling the 2010 American College of Rheumatology (ACR) criteria
for RA in relation to autoantibody status (ACPA and RF), inflammatory mediators, RA disease activity
and medication as well as the microbiota in saliva and subgingival plaque.
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2. Experimental Section
2.1. Study Population
A total of forty-five volunteers (age 29 to 80) with chronic arthritis (mean disease duration
11 years) were recruited from two Rheumatology clinics at Karolinska University Hospital in Solna
and Huddinge (Stockholm, Sweden) between January 2016 and January 2017. Five participants were
excluded from the study due to not fulfilling the inclusion criteria for RA (the 2010 ACR Criteria
for RA) [23], or having other types of chronic arthritis. The recruited participants underwent a full
mouth dental and periodontal examination (third molars not included), performed by a single dentist
(KE) calibrated by a periodontist (LJ). The examiner (KE) did not have information about the patients
periodontal or rheumatological measurements (clinical or laboratory) beforehand. Based on the
results from the dental examinations, the patients were divided according to their periodontal status,
following the standardised clinical definition of periodontitis (intended for use in population-based
studies) established by the Centers for Disease Control and Prevention and the American Academy
of Periodontology [22]. All patients completed a health screen questionnaire including information
about comorbidities, medication, smoking and alcohol habits, body mass index (BMI) as well as
questions regarding education and place of birth. The participants had not received any periodontal
treatment for at least 3 months prior to the dental examination. Exclusion criteria included pregnancy,
lactation, other forms of arthritis as well as the use of antibiotics the last 3 months prior to examination.
This study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2009/792-31/4 and
2015/766-32) and a written informed consent was obtained from all participants.
2.2. Clinical Assessments
The RA disease activity was assessed by using the DAS28 CRP (Disease Activity Score in
28-joints) [24] measuring total tender- and swollen- joint count (ranging from 0–28 joints), C-reactive
protein (CRP, mg/dL), as well as the patient’s global assessment of health on a 10 cm visual analogue
scale. A DAS28 score of >5.1 was considered high disease activity, whereas <3.2 equaled low disease
activity and ≤2.6 reflected remission [25]. Patients’ self-reported functional status was measured using
the Health Assessment Questionnaire (HAQ) [26], where functional ability was assessed by addressing
eight general component categories (reach, grip, hygiene, dressing and grooming, eating, arising,
walking and common daily activities). In the HAQ disability index, each question was scored from 0
to 3, corresponding to “without any difficulty” (score 0), “with some difficulty” (score 1), “with much
difficulty” (score 2) and “unable to do” (score 3).
The periodontal condition was assessed by probing pocket depth (PPD), clinical attachment level
(CAL) and bleeding index (BI) determined at 6 sites per tooth, and the presence of supragingival plaque
(PI) at 4 sites per tooth. Stimulated salivary flow rate, number of missing and mobile teeth as well as the
number of multirooted teeth with furcation involvement were also recorded. Periodontitis, defined by
following international consensus criteria, was based on the interproximal measurements of CAL and
PPD, excluding the third molars [22]. The severity of the disease was defined as severe (corresponding
to ≥2 interproximal sites with CAL ≥ 6 mm, not on the same tooth, and ≥1 interproximal sites with
PPD ≥ 5 mm), moderate (corresponding to ≥2 interproximal sites with CAL ≥ 4 mm, not on the same
tooth, or ≥2 interproximal sites with PPD ≥ 5 mm) or no/mild (corresponding to neither severe nor
moderate criteria) [22]. In addition to the periodontal status, the examination also included assessment
of soft tissue pathologies and the number of decayed, missing and filled permanent teeth and tooth
surfaces (DMFT/DMFS) describing the amount of dental caries, where the DMFT can range from 0 to
28 and the DMFS from 0 to 128 [27].
2.3. Collection and Preparation of Gingival Crevicular Fluid, Plaque, Saliva and Blood Samples
Gingival crevicular fluid (GCF) was collected by inserting two paper strips (Periopaper,
Proflow Inc., Amityville, NY, USA) until slight resistance, at both the mesiobuccal and the distobuccal
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sites of the teeth with the deepest pockets. The paper strips were left within the gingival crevice for
30 s, pooled together and frozen at −80 ◦C until processing [28].
Subgingival plaque samples were collected from the deepest pockets by inserting four sterile
paper points (Nordenta, Enköping, Sweden), two at the distolingual and two at the mesiallingual sites
of the tooth, and left for 20 s [29]. Before the paper points were inserted supragingival plaque was
removed by using cotton pellets and the tooth surface was dried with air. The samples from the same
tooth were pooled together and frozen at −80 ◦C awaiting analysis.
Stimulated saliva samples were collected by using paraffin wax (1g, Ivoclar Vivadent,
Liechtenstein), which the participants were instructed to chew on for a duration of 2 min. The volume
of collected stimulated saliva was determined, the salivary flow rate recorded and the samples kept on
ice until processing. Saliva samples were then centrifuged at 500× g for 10 min at 5 ◦C and supernatants
collected and stored at −80 ◦C until analysis [28].
Blood samples were collected in BD Vacutainer SST tubes (MediCarrier AB, Stockholm, Sweden).
Tubes were left standing at room temperature for at least 30 min before storing, in order to remove cells
and clotting factors by allowing a clot to form. The samples were then centrifuged at 200× g for 10 min
at 20 ◦C and the serum stored at −80 ◦C until analysis. The preparation of the samples is described in
the Supplementary Methods (Preparation of samples).
2.4. Immunoassay Analysis
Serological markers of RA (ACPA and RF antibody status) were analysed using a multiplex
immunoassay (Bio-Plex® 2200 system, Bio-Rad, Hercules, CA, USA) for ACPA and nephelometry for
RF (Karolinska University Hospital Laboratory, Sweden). Results were interpreted as ACPA-positive/
RF-positive following the cut-off values for seropositivity (3 E/mL for ACPA and 20 E/mL for RF).
Levels of CRP in serum (measured between intervals 0.2–380 mg/L) were analysed at Karolinska
University Hospital Laboratory using a near-infrared particle immunoassay (NIPIA) method and
Beckman reagents on Synchron LX20 automated equipment (Beckman Coulter, Fullerton, CA, USA) [30].
Concentrations of CRP in saliva and GCF samples were analysed via commercially available ELISA kit
(USCN Life Science, Wuhan, China), according to the manufacturer’s instructions. Briefly, PBS-diluted
saliva (diluted 1:3) and GCF samples (diluted 1:2) were incubated with biotinylated CRP antibodies,
followed by incubation with horseradish peroxidase conjugate. CRP-antibody levels were detected
with tetramethylbenzidine reagent and the concentrations expressed as pg/ml. The detection limit of
the CRP ELISA was 19.2 pg/ml with <12% inter-assay and <10% intra-assay variation.
Immunoassay kits (37-Plex inflammation panel, Bio-Rad, Hercules, CA, USA) were used to
investigate the cytokine profile in serum (diluted 1:4), saliva and GCF (undiluted), according
to manufacturer’s protocol. The analysed cytokines (sensitivities in pg/ml, in brackets) were
APRIL/TNFSF13 (190), BAFF/TNFSF13B (34.7), sCD30/TNFRSF8 (1.0), sCD163 (16.8), Chitinase 3-like
1 (10.3), gp130/sIL-6Rβ (16.9), IFN-α2 (0.7), sIL-6Rα (1.5), IL-8 (2.7), IL-10 (0.6), IL-11 (0.05), IL-12
(p70) (0.1), IL-19 (0.2), IL-20 (3.6), IL-22 (1.1), IL-26 (1.2), IL-27 (p28) (0.1), IL-29/IFN-λ1 (1.6), IL-32
(12.3), IL-34 (51.9), IL-35 (3.7), LIGHT/TNFSF14 (10.2), MMP-1 (33.7), MMP-2 (39.7), MMP-3 (28.5),
Osteocalcin (23.4), Osteopontin (91.3), Pentraxin-3 (0.8), sTNF-R1 (0.2), sTNF-R2 (3.2), TSLP (0.8) and
TWEAK/TNFSF12 (0.5). The mean concentrations were expressed as pg/ml and the inflammatory
mediators that were below the detection limit were excluded.
2.5. 16S rRNA Sequencing and Quantitative Polymerase Chain Reaction (qPCR)
The amount of bacterial DNA from saliva and subgingival plaque samples of the 40 included
patients was determined by using the 7500 Fast Real-Time qPCR System (Applied Biosystems,
Foster City, CA, USA). Ten samples with less than in total 0.5 ng/μL DNA were excluded from qPCR
analysis, whereas 3 samples with less than 0.5 ng/μL DNA were excluded from 16S rRNA gene
sequencing. For the preparation of the 16S rRNA amplicon libraries, 2 ng genomic DNA (gDNA)
from each saliva and plaque sample were used as template to amplify the V3-V4 regions of the 16S
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rRNA gene, with final concentrations for PCR reactions being 1X KAPA HotStart ReadyMix (KAPA
Biosystems, Wilmington, MA, USA), 1.0 μM 341′F primer (CCTAHGGGRBGCAGCAG), 1.0 μM 805R
primer (GACTACHVGGGTATCTAATCC) [31,32] and 0.1 ng/μL gDNA. The PCR during amplification
was programmed as follows, initial incubation at 98 ◦C for 2 min, 26 cycles of 98 ◦C for 20 s, 54 ◦C for
20 s, 72 ◦C for 15 s, followed by an elongation step of 72 ◦C for 2 min. The samples were then purified
with Polyethylene Glycol 6000 (Merck Millipore, Darmstadt, Germany) and carboxylic acid beads
(Dynabeads® MyOne™, Thermo Fisher Scientific, Waltham, MA, USA) [33]. For indexing the sample
amplicons, 12 μL of the purified product, 0.4 μM forward and reverse indexing primers and KAPA
HotStart ReadyMix (KAPA Biosystems, Wilmington, MA, USA) were mixed for PCR amplification.
The indexing step followed the PCR programme: 98 ◦C for 2 min, 10 cycles of 98 ◦C for 20 s, 62 ◦C
for 30 s, 72 ◦C for 30 s and a final elongation step of 72 ◦C for 2 min. Equimolar amounts of indexed
samples were mixed and sequenced on the Illumina MiSeq platform (Illumina Inc, San Diego, CA,
USA) at NGI/SciLifeLab Stockholm. Three samples were excluded due to their low number of reads
(cutoff 10,000 reads). The median depth of sequencing, after exclusion of low-depth libraries, was
188,600 reads per sample (IQR: 166,669–209,905 reads).
For the qPCR analysis of subgingival plaque samples, two sets of primers were used for bacteria
detection, one species-specific pair for P. gingivalis and the other pair targeting the bacterial 16S
rRNA gene [34,35]. The qPCR analyses were performed as described in the Supplementary Methods
(Quantitative Polymerase Chain Reaction, qPCR).
2.6. Sequence Count Data Processing and Analysis
To process the sequencing data the DADA2 pipeline [36] was used. Amplicon reads with low
quality and primers were trimmed and filtered. The remaining reads were then dereplicated, the
sequence variants were inferred, and the paired-end reads were merged by requiring 30 bp overlap with
no mismatches. Results of two sequencing runs were then merged and a sequence table was constructed,
followed by removal of chimeras. The reads were taxonomically assigned using RDP training set
14 [37]. A phylogenetic tree was constructed using the scripts align_seqs.py, filter_alignment.py, and
make_phylogeny.py, as provided by QIIME [38]. The sequence table, taxonomic assignment, and
phylogenetic tree were used to create a phyloseq object [39], which was used in all subsequent analyses.
In total 6538 taxa were identified from the merged sequencing table. The final dataset included
1090 taxa, after removing the sequence variants that only present in 5% or less of the samples.
The analysis of differential abundance of microbes, reported as genus species (sp.), between saliva
samples and plaque samples as well as between samples from RA patients with no/mild and
moderate/sever periodontitis was performed using DESeq2 [40]. All statistical analyses were conducted
in R, version 3.3.3 (R Core Team 2015. R Foundation for Statistical Computing, Vienna, Austria).
2.7. Statistical Analysis
The characteristics of patients with moderate/severe periodontitis were compared to the subjects
with no/mild periodontal disease. Mann–Whitney U test or independent two-sample t-test was
performed for comparing ordinal and continuous variables. For dichotomous variables, Chi-square
test or Fisher’s exact test was used. The association between ACPA status, periodontitis severity and
periodontal bacteria, estimated as odds ratio (OR) with 95% Confidence Interval (CI), was analysed
using logistic regression analysis and adjusted for gender, age and smoking habits. All analyses were
performed using the IBM SPSS Statistics 21.0 (IBM Corp., Armonk, NY, USA) package. Statistical
significance was determined at p value < 0.05.
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3. Results
3.1. Characteristics of the Study Population
The characteristics of the RA study population are summarised in Table 1. The group consisted
of 40 patients fulfilling the ACR criteria for RA. The mean age of the total study population was
60 ± 11 years and the majority of the participants were women (88%). With regard to the periodontal
health, the majority, 75%, of the included subjects had moderate/severe periodontitis (n = 30), with
the rest (n = 10) having no/mild periodontal disease. Based on periodontal diagnosis, there were no
significant differences between the two groups with regard to gender, BMI, RA disease duration, place
of birth, alcohol consumption or the level of education. The groups were also comparable with respect
to comorbidities and medications. Subjects with moderate/severe periodontitis were significantly
(p = 0.010) older (mean age 64 ± 7.8 years) compared to those with no/mild periodontal disease (mean
age 50 ± 14 years). With regard to smoking, there were significantly (p = 0.014) more never smokers in
the group with no/mild disease as compared to the group with moderate/severe periodontitis (60%
and 17%, respectively).
Table 1. Characteristics of subjects with rheumatoid arthritis (RA) in relation to periodontal diagnosis.
Characteristics
No/Mild
Periodontitis (n = 10)
Moderate/Severe
Periodontitis (n = 30) p Value
Gender, no (%)
Female 10 (100) 25 (83)
Male 0 (0) 5 (17) 0.306
Age, mean (±SD) 50 (14) 64 (7.8) 0.004
BMI, mean (±SD) 26 (6.8) 24 (5.6) 0.325
RA duration in years, mean (±SD) 12 (11) 10 (10) 0.406
Comorbidities, no (%)
Diabetes 0 (0) 2 (6.7) 1.000
Cardiovascular disease 3 (30) 8 (27) 1.000
High blood pressure 2 (20) 5 (17) 1.000
Gastrointestinal disorders 1 (10) 6 (20) 0.739
Osteoporosis 0 (0) 3 (11) 0.552
Asthma 0 (0) 5 (17) 0.306
Sjögren’s syndrome 0 (0) 2 (7.4) 1.000
TMJ 4 (40) 8 (27) 0.451
Medication, no (%)
Analgesics 6 (60) 13 (43) 0.473
NSAIDs 1 (10) 10 (33) 0.233
DMARDs 6 (60) 22 (73) 0.451
Biological DMARDs 5 (50) 11 (37) 0.482
Glucocorticoids 5 (50) 18 (60) 0.717
Bisphosphonates 1 (10) 1 (3.0) 0.442
Smoking habits, no (%)
Current smokers 0 (0) 5 (17) 0.306
Ex-smokers 4 (40) 19 (73) 0.119
Never smokers 6 (60) 5 (17) 0.014
Alcohol consumption, no (%)
Monthly 7 (70) 20 (67) 1.000
Weekly 5 (50) 14 (47) 1.000
Daily 0 (0) 3 (10) 0.560
Never 2 (20) 3(10) 0.584
Education, no (%)
University degree 4 (40) 13 (46)
No university degree 6 (60) 5 (54) 1.000
Place of birth, no (%)
Sweden 10 (100) 24 (83)
Other 0 (0) 5 (17) 0.302
RA, rheumatoid arthritis; BMI, body mass index; TMJ, disorders involving the temporomandibular joint; NSAIDs,
non-steroidal anti-inflammatory drugs; DMARDs, disease-modifying antirheumatic drugs; SD, standard deviation.
Differences between the groups were analysed by Chi-square test or Fisher´s exact test for categorical variables, and
Mann–Whitney U-test continuous demographics. p value < 0.05 was considered statistically significant.
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3.2. Periodontal and Dental Characteristics in Relation to Periodontitis Severity
During the periodontal and dental examinations, variables such as PI, BI, PPD, CAL, number
of missing teeth, mobile and furcation involved teeth, DMFT/DMFS as well as stimulated salivary
flow rate were recorded. The subjects with moderate/severe periodontitis had significantly higher
(p values demonstrated in Supplementary Table S1) frequencies of most of the investigated variables,
including PPD ≥ 4 mm, interproximal sites with PPD ≥ 5 mm, sites with CAL 1–2 mm, 3–4 mm or
≥ 5 mm, interproximal sites with CAL ≥ 4 mm or ≥ 6 mm, as well as significantly higher numbers
of missing, mobile and furcation involved teeth, as compared to patients with no/mild periodontal
disease (Supplementary Table S1). The group with no/mild periodontitis had no interproximal sites
with PPD ≥ 5 mm or CAL ≥6 mm. Moreover, subjects with no/mild periodontitis had significantly
less DMFT and DMFS as compared to those with moderate/severe disease. There were, however, no
significant differences in PI or BI between the two groups, and also no differences in salivary flow rate
(Supplementary Table S1).
3.3. Rheumatological Characteristics in Relation to Periodontal Status
The periodontal status in relation to rheumatological characteristics was also investigated.
The majority (75%) of the study participants were ACPA-positive. When dividing the patients with
regard to periodontitis severity, ACPA positivity was significantly (p = 0.032) more frequent in patients
with moderate/severe periodontitis (86%), compared to the group with no/mild disease (50%) (Table 2).
In addition, RF positivity showed a similar trend, although did not reach statistical significance.
There were no significant differences between no/mild and moderate/severe periodontitis with regard
to self-reported HAQ score, the DAS28 score reported by the patients rheumatologists or the CRP-levels
in serum, saliva or GCF. With regard to RA disease activity, most of the participants had moderate
disease activity (5 in the no/mild and 9 in moderate/severe group) or were in remission (4 and 10,
respectively), irrespective of periodontal status (Table 2).
Table 2. Rheumatological and serological characteristics in relation to periodontal diagnosis.
Characteristics
No/Mild
Periodontitis (n = 10)
Moderate/Severe
Periodontitis (n = 30) p Value
ACPA status, no (%)
ACPA-positive 5 (50) 25 (86)
ACPA-negative 5 (50) 4 (14) 0.032
RF status, no (%)
RF-positive 5 (50) 22 (73)
RF-negative 5 (50) 8 (27) 0.246
HAQ score (range 0–3), mean (±SD) 0.7 (0.5) 0.9 (0.6) 0.380
DAS28 score (range 1-10), mean (±SD) 2.7 (1.5) 3.3 (1.4) 0.411
Disease activity (DAS28 score), no (%)
Remission (score < 2.6) 4 (44) 10 (37) 1.000
Low activity (score 2.6–3.2) 0 (0) 4 (15) 0.553
Moderate activity (score 3.2–5.1) 5 (56) 9 (33) 0.432
High activity (score >5.1) 0 (0) 4 (15) 0.553
Serum CRP (ng/mL), mean (±SD) 5100 (7300) 4300 (5200) 0.353
Salivary CRP (ng/mL), mean (±SD) 1.4 (1.9) 2.1 (5.4) 0.749
GCF CRP (ng/mL), mean (±SD) 2.2 (3.6) 2.3 (5.4) 0.617
ACPA, anti-citrullinated protein antibodies; RF, rheumatoid factor; HAQ, health assessment questionnaire; DAS28,
28-joint disease activity score; CRP, C-reactive protein; GCF, gingival crevicular fluid; SD, standard deviation.
Differences between the groups were analysed by chi-square test or Fisher´s exact test for categorical variables, and
Mann–Whitney U-test for ordinal or continuous demographics. p value< 0.05 was considered statistically significant.
In the next series of studies, the participants were also analysed with regard to ACPA status.
The ACPA-positive patients were taking significantly (p = 0.040) more non-steroidal anti-inflammatory
drugs (NSAIDs) compared to the ACPA-negative subjects with RA (37% versus 0%, respectively)
(Supplementary Table S2). There were, however, no differences in other medications (analgesics,
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DMARDs, biological DMARDs, glucocorticoids or bisphosphonates) based on ACPA status. Moreover,
in the ACPA-positive group there were significantly (p = 0.038) more ex-smokers, as compared
to the ACPA-negative group. In contrast, the ACPA-negative participants were mostly never
smokers (p = 0.032). There were no significant differences in gender, age, BMI, RA disease duration,
comorbidities, alcohol consumption, education or place of birth based on ACPA status (Supplementary
Table S2). Moreover, based on ACPA status, there were no significant differences between the groups
regarding plaque index (ACPA-positive 51% ± 19%; ACPA-negative 40% ± 18%) or bleeding index
(ACPA-positive 32% ± 22%; ACPA-negative 41% ± 14%).
3.4. Levels of Inflammatory Mediators in Serum, Saliva and GCF Samples
The levels of inflammatory mediators were analysed in serum, saliva and GCF samples from RA
patients with no/mild and moderate/severe periodontitis (Figure 1 and Table 3). In serum, RA subjects
with moderate/severe periodontitis had significantly higher levels of APRIL (TNFSF13) (p = 0.013),
sCD30 (TNFRSF8) (p = 0.048) and gp130 (sIL-6Rß) (p = 0.01) compared to patients with no/mild form
of periodontitis (Figure 1A–C). Similarly, patients with moderate/severe periodontitis had significantly
higher salivary levels of APRIL (p = 0.048) compared to those no/mild periodontal disease (Figure 1D).
In contrast, the salivary levels of Chitinase 3-like 1 were significantly (p = 0.041) lower in patients with
moderate/severe periodontitis compared to no/mild periodontitis group (Figure 1E). In GCF samples,
significantly (p < 0.05) higher levels of IFN-α2, IL-19, IL-26, MMP-1 and sTNF-R1 were observed in RA
patients with moderate/severe periodontitis compared to corresponding RA subjects with no/mild
periodontitis (Table 3). However, there were no significant differences in total protein concentrations
determined in saliva or GCF samples (Figure 1F and Table 3, respectively) between the two groups.
Table 3. Levels of inflammatory mediators (mean ±SD) and total protein (mg/mL) in gingival crevicular





Periodontitis (n = 29) p Value
APRIL (TNFSF13) 5289 (2451) 4584 (935) 0.652
BAFF (TNFSF13B) 2229 (736) 2982 (1767) 0.440
sCD30 (TNFRSF8) 9.0 (11) 21 (18) 0.077
sCD163 2980 (2727) 3678 (2835) 0.400
Chitinase 3-like 1 7284 (3881) 12,885 (9084) 0.118
gp130 (sIL-6Rß) 585 (424) 713 (828) 0.823
IFN-α2 20 (27) 43 (31) 0.036
sIL-6Rα 456 (339) 786 (594) 0.175
IL-8 761 (372) 1274 (995) 0.345
IL-10 2.0 (1.6) 4.3 (5.5) 0.104
IL-11 1.9 (2.1) 2.6 (4.4) 0.692
IL-12 (p70) 2.9 (3.2) 3.8 (4.4) 0.635
IL-19 14 (13) 32 (37) 0.035
IL-20 68 (51) 76 (26) 0.718
IL-22 6.6 (4.5) 10 (9.1) 0.353
IL-26 15 (11) 36 (62) 0.046
IL-27 (p28) 21 (11) 21 (10) 0.810
IL-29 (IFN-γ1) 52 (61) 103 (186) 0.198
IL-32 103 (55) 140 (92) 0.319
IL-34 205 (127) 184 (101) 0.436
LIGHT (TNFSF14) 269 (93) 314 (117) 0.328
MMP-1 897 (636) 1294 (534) 0.049
MMP-3 394 (298) 489 (371) 0.579
Pentraxin-3 375 (261) 429 (272) 0.718
sTNF-R1 259 (130) 523 (361) 0.015
sTNF-R2 2075 (5013) 1976 (5322) 0.311
TSLP 24 (20) 25 (15) 0.796
TWEAK (TNFSF12) 27 (17) 38 (16) 0.074
Total protein concentration 0.2 (0.2) 0.3 (0.3) 0.503
GCF, gingival crevicular fluid; RA, rheumatoid arthritis; SD, standard deviation. Differences between the groups
were analysed by Mann–Whitney U-test. p value < 0.05 was considered statistically significant.
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Figure 1. Levels of inflammatory mediators in serum and saliva samples. Mean (±SD) serum
concentrations of APRIL/TNFSF13 (A), sCD30/TNFRSF8 (B) and gp130/sIL-6Rß (C); mean (±SD) saliva
concentrations of APRIL/TNFSF13 (D), Chitinase 3-like 1 (E) and levels of total protein in saliva (F) from
RA patients with no/mild and moderate/severe periodontitis. The differences between the groups
were analysed by Mann–Whitney U-test. * p value < 0.05 was considered statistically significant.
Circle indicates outlier and star indicates far outlier.
3.5. Microbial Profile of Subgingival Plaque and Saliva Samples
The oral microbial profiles of the RA patients were analysed by 16S rRNA gene sequencing plaque
and saliva samples. The most highly differentially abundant microbes in plaque samples compared
to saliva samples, irrespective of periodontal status, are demonstrated in Figure 2. The ten most
significantly (p > 0.05) enriched microbes detected in plaque compared to saliva were Actinomyces
meyeri, Prevotella nigrescens, Treponema socranskii, Treponema sp., Eubacterium infirmum, Prevotella oris,
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Actinomyces massiliensis, Catonella sp. and two non-identified species (NA spp.). In contrast, in saliva
samples the most enriched microbes included Butyrivibrio sp., Atopobium parvulum, Prevotella pallens,
Solobacterium moorei, Centipeda sp., two Veillonella spp., as well as three Prevotella spp. (Figure 2). The oral
microbial profiles of patients with RA were also investigated in relation to periodontal status (Figure 3).
The results showed that patients with moderate/severe periodontitis had significantly (p < 0.05) higher
abundance of Desulfobulbus sp., Prevotella sp., Bulleidia sp., Capnocytophaga sp., Tannerella forsythia and a
NA sp. in plaque, when compared to RA with no/mild periodontitis. In contrast, Prevotella oris and a
Porphyromonas sp. were more abundant in patients with no or mild periodontitis (Figure 3). In saliva,
there were no significant differences in the detected bacterial species based on periodontal diagnosis
(Supplementary Table S3).
Figure 2. Most highly differentially abundant bacterial species in plaque compared to saliva samples.
The graph demonstrates log2 Fold Change (FC) for the ten most enriched as well as the ten most depleted
bacteria in plaque compared to saliva from patients with RA irrespective of periodontitis. Negative
log2 FC indicates higher abundance in plaque samples (orange bars) and positive values indicate
higher abundances in saliva samples (blue bars). NA, genome reference not available. The differences
between the groups were analysed using DESeq2 [40]. *Adjusted p value < 0.05 was considered
statistically significant.
Subgingival plaque samples of patients were also analysed for the presence and quantity of
P. gingivalis using qPCR. The results showed that P. gingivalis was present in higher degree (62%) in the
moderate/severe periodontitis group compared to no/mild periodontitis group (50%), although the
difference was not significant (Supplementary Table S4).
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Figure 3. Most highly differentially abundant bacteria in plaque from patients with RA in relation to
periodontitis severity. The graph demonstrates log2 Fold Change (FC) for the most highly enriched
and depleted bacteria in plaque from RA patients with no/mild and moderate/severe periodontitis.
Negative log2 FC indicate higher abundance in patients with no/mild periodontitis (light orange bars)
and positive values indicate higher abundances in those with moderate/severe periodontitis (dark
orange bars). NA, genome reference not available. The differences between the groups were analysed
using DESeq2 [40]. *Adjusted p value < 0.05 was considered statistically significant.
4. Discussion
The objective of this study was to investigate the severity of periodontitis in relation to
RA-associated clinical and immunological parameters, medication and comorbidities in patients
with established RA. In this well-defined cohort, our results show that moderate/severe periodontitis is
common in patients with RA, especially in ACPA-positive RA. In addition, we identified significantly
enriched/differentially abundant bacteria in subgingival plaque of RA patients with moderate/severe
periodontitis compared to those with no or mild periodontal disease. Moreover, the levels of both
systemic and oral (saliva and GCF) inflammatory mediators were significantly higher in RA with
moderate/severe periodontitis. Notably, the proliferation-inducing ligand APRIL (TNFSF13), a member
of the TNF-receptor superfamily, was significantly increased in serum and saliva samples.
ACPAs are important diagnostic and prognostic serological markers in RA, and their presence is
known to predict the development of RA [41]. In the current study, our results showed that ACPA
positivity was significantly more common in RA patients with moderate/severe periodontitis when
compared to those with no/mild form of disease. In agreement with our results, a more severe form
of periodontitis (indicated by higher percentage of sites with alveolar bone loss) was reported in
ACPA-positive patients with RA, in an American cohort [42]. Conversely, in a recent study, ACPA
positivity only correlated with the gingival inflammation markers bleeding on probing and gingival
index, but not with the severity of periodontitis assessed by CAL or PPD [43]. In our study, we
found no differences in oral hygiene or gingival inflammation based on ACPA status. One possible
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explanation for this might be that the ACPA-positive patients in our cohort were taking significantly
more NSAIDs, which may reduce and mask the signs of gingival inflammation [44].
Using 16S rRNA gene sequencing, previous studies have investigated the subgingival microbiome
of patients with RA and compared the results of subjects with osteoarthritis and healthy controls
without periodontitis [45,46]. These studies did neither report subgingival profiles/compositions
discriminating between RA and osteoarthritis [45], nor did they demonstrate differences between
RA and controls without periodontitis with regard to the periodontal pathogens P. gingivalis
or A. actinomycetemcomitans [46]. In our study, investigating the oral microbial composition
in RA based on periodontitis severity, the subgingival microbial profile differed significantly
between patients with moderate/severe and no/mild periodontitis. The species observed in higher
abundance in moderate/severe periodontitis were Desulfobulbus sp., Prevotella sp., NA sp., Bulleidia sp.,
Capnocytophaga sp. and Tannerella forsythia, and two were more abundant in no/mild periodontitis
(Prevotella oris and a Porphyromonas sp.). Similarly, in Norwegian RA cohort, the microbial composition
of subgingival plaque also differed in relation to periodontal severity measures (such as gingival
bleeding and PPD) [47]. However, in that study, RA disease status and medication (glucocorticosteroids)
were found to be associated with different microbiome composition [47], in contrast to our study where
no differences were found between no/mild and moderate/severe periodontitis group in terms of these
potential confounding factors, therefore likely not affecting our results. Moreover, the prevalence of
the periodontal pathogen P. gingivalis, assessed in 50 - 62% of the patients in our study, is in line with
previous reports showing that this bacterium was present in 47% of patients with established RA and
in 55% of newly-diagnosed RA patients [48]. We did not observe any significant differences in the
prevalence of P. gingivalis in subgingival plaque based on the severity of periodontitis. In a previous
study by Scher et al., P. gingivalis was reported to be more prevalent in newly-diagnosed treatment
naïve RA patients with advanced periodontitis as compared to a corresponding group of RA without
periodontitis [48]. This discrepancy could potentially be explained by the use of RA-medications,
supported by the finding that DMARDs may modulate the microbiome in patients with RA [49]. It has
been hypothesised that microbiome changes are partly driven by systemic inflammation and can
be modulated by DMARDs, abating the inflammatory response [50]. Even though there were no
differences in type of medications used between the groups in our study, we did not investigate the
use of specific subgroups of DMARDs or biological DMARDs. Moreover, as proposed by Zhang et al.,
the differences in modulation of the oral microbiome could also be due to differences among RA
patients [49], or possibly differences in response to RA-medication, which may explain why prevalence
of P. gingivalis did not differ between RA patients with no/mild and moderate/severe periodontitis
despite similar use of DMARDs therapy in the groups.
Inflammatory mediators play a central role in the pathogenesis of chronic inflammatory diseases
such as periodontitis and RA, promoting autoimmunity and maintaining a chronic inflammation
that collectively contribute to tissue and bone destruction [5,51]. Persistently increased levels of
various pro-inflammatory cytokines (e.g., TNF-α and IL-6) have been well documented in RA and
periodontitis, and several cytokine-targeting therapies are successfully used in RA treatment [52,53].
In the present study, the levels of sCD30 (TNFRSF8), sTNF-R1, gp130 (sIL-6Rß), IL-19, IL-26 and MMP-1
were increased in serum, saliva or GCF samples from subjects with moderate/severe periodontitis as
compared to no/mild disease. Interestingly, RA patients with moderate/severe periodontitis also had
increased levels of APRIL both in serum and in saliva samples. APRIL, also known as TNFSF13, is a
proliferation ligand and a member of the TNF-receptor superfamily [54]. This cytokine has together
with BAFF an important role in the survival and maturation of B-cells [54], and could therefore
potentially be important for the production of antibodies in RA. The overexpression of APRIL in
serum has been reported in several autoimmune diseases including RA [54], and increased expression
of APRIL mRNA has also been detected in gingival tissue from patients with periodontitis when
compared to non-periodontitis controls [55]. However, to our knowledge this is the first study reporting
significantly different levels of APRIL both in serum and saliva samples of RA patients with different
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degrees of periodontal disease. Thus, given that overexpression of APRIL/BAFF is suggested to
contribute to the autoimmune diseases [54,56], this system may be a key mediator involved in the
link between RA and periodontitis. Only one protein, Chitinase 3-Like-1 (also known as YKL-40),
was significantly reduced in saliva of patients with moderate/severe periodontitis. Although, this
protein is a potential inflammatory biomarker in arthritis, its role as a marker for disease diagnosis is
debated [57]. In RA, circulating levels of Chitinase 3-Like-1 reflect cartilage degradation and synovial
inflammation [57,58], and in osteoarthritis this cartilage glycoprotein have been suggested as a potential
target for treatment [59]. To our knowledge, this is the first study reporting the levels of Chitinase
3-Like-1 in saliva, both in RA and periodontitis. In serum, increased levels of this cytokine have
previously been reported in both diseases and seem to correlate with disease activity at least in RA
subjects [60,61]. The duration of treatment with RA medication, however, may have different effects
(both increase and decrease) on the levels of Chitinase 3-Like-1 in patients with RA. Knudsen et al.
showed that the serum levels of the protein is reduced after 4-, 8- and 12 weeks of methotrexate
therapy, but not after 16 weeks [62]. Although the levels of serum and salivary cytokines do not always
correlate [63], one explanation for the decreased levels of Chitinase 3-Like-1, observed in our study,
might be due to potential differences in the duration of methotrexate therapy between the groups.
Unfortunately, we were not able to investigate this due to lack of information about the duration of
different RA therapies.
In this study, we did not observe any association between periodontitis severity and RA disease
activity in terms of DAS28, the self-assessed health (HAQ-score) or in the levels of CRP (serum, saliva or
GCF). In agreement with these findings, several studies report no impact of the severity of periodontitis
on RA disease activity or on RA-associated serological markers [64–66]. For example, in a cohort of
100 RA patients and 112 matched controls, no association was found between RA disease activity
(assessed by DAS28 score) and periodontitis severity [65]. In contrast, some studies have detected an
association between periodontitis/alveolar bone loss and measurements of RA disease activity/severity
such as DAS28, CRP, HAQ, tender joint count and/or joint space narrowing scores [42,67–69]. Three of
these studies, conducted in the same cohort of 287 RA subjects, reported an association between
periodontitis diagnosis/alveolar bone loss or self-reported “loose teeth” and higher DAS28-/HAQ-score
and tender/swollen joint count [42,68,69]. The inconsistent results from different studies and the lack of
association between periodontitis and RA may be due to RA medication. For example, DMARDs and
biological DMARDs could be confounding factors potentially masking an association by decreasing RA
disease activity or periodontitis severity [70–73]. In our study, however, there were no differences in
type of medication used based on periodontitis, suggesting that the type of medication alone may not
explain the lack of association between periodontitis and RA disease activity in this study. It is, however,
plausible that the patients may respond differently to RA medication, or that different subtypes of
DMARDs/biological DMARDs may affect periodontitis differently. In addition, the contrasting results
between the different studies may also be due to the lack of uniformity in defining periodontitis [74].
One of the strengths of the current study is the well-characterised RA cohort and data set,
including information on several potential confounding factors for RA and periodontitis, such as RA
disease duration, BMI, comorbidities, type of RA medication used, smoking, alcohol consumption
and education. In addition, the gender distribution also reflected the general RA population as
the majority of the participants were women [75]. Furthermore, despite the limited number of
patients in this pilot study (especially in the no/mild periodontitis group), our results still indicate
that cigarette-exposure is associated with the ACPA-positive RA subset as well as with the severity
of periodontitis, in agreement with previous findings [76,77]. A limitation of this study is the higher
age of the patients with moderate/severe periodontitis compared to no/mild disease. Since age is
known to be strongly correlated with periodontitis disease severity [76], this might potentially affect
the results. On the other hand, no differences in age were detected between the groups based on ACPA
status, showing an increased frequency of ACPA positivity among patients with moderate/severe
periodontitis. Nevertheless, the results should be interpreted with caution due to limitations of the
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study including small samples size and the lack of information about the duration of different RA
medications. Furthermore, data about the levels of ACPA and RF were lacking, and we have instead
used a positive/negative antibody classification following the ACR classifications criteria for RA.
Additional studies using the levels of antibodies, particularly the fine specificities of anti-CCP/ACPA
antibodies, in relation to the disease outcome could be relevant.
5. Conclusions
In conclusion, our findings demonstrate that patients with ACPA-positive RA have more severe
forms of periodontitis, irrespective of DMARD therapy or the presence of subgingival P. gingivalis.
Moreover, our data show a different subgingival microbial profile in RA patients with moderate/severe
periodontitis versus no/mild periodontal disease. In addition, we also report, to our knowledge for
the first time, that RA subjects with moderate/severe periodontitis have increased serum and salivary
levels of the proliferation-inducing ligand APRIL. This cytokine, known to be important for B-cell
survival and maturation, could potentially be involved in the association between RA and periodontitis,
although additional studies including larger number of patients are required for confirmation of
this finding.
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Abstract: Background: Treatment of rheumatoid arthritis (RA) includes the use of conventional (cs),
biologic (b) disease-modifying anti-rheumatic drugs (DMARDs) and oral, intramuscularly, intravenous,
or intraarticular (IA) glucocorticoids (GCs). In this paper, we analysed whether a treat-to-target
(T2T) strategy optimizing csDMARD, oral, and IA-GC treatment as an adjunct new therapy to a new
certolizumab pegol (CZP) therapy improves the effectivity in RA patients. Methods: 43 patients with
active RA (≥6 tender, ≥6 swollen joints, ESR ≥ 20 mm/h or CRP ≥ 7mg/L) despite csDMARD treatment
for ≥ 3 months and naïve to bDMARDs were randomized to CZP (200 mg/2 weeks after loading with
400 mg at weeks 0–2–4) plus a treat-to-target strategy (T2T, n = 21), or to CZP added to the established
csDMARD therapy (fixed regimen, n = 22). The T2T strategy consisted of changing the baseline csDMARD
therapy (1) SC-methotrexate (dose: 15 ≥ 20 ≥ 25 mg/week, depending on the initial dose) ≥ leflunomide
(20 mg/d) ≥ sulphasalazine (2 × 1000 mg/d) plus (2) oral GCs (prednisolone 20–15–12.5–10–7.5–5–2.5–0
mg/d tapered every five days) and (3) injections of ≤5 affected joints with triamcinolone. DMARD
modification and an addition of oral GCs were initiated, depending on the achievement of low disease
activity (DAS 28 < 3.2). The primary objective was defined as the ACR 50 response at week 24. Results:
ACR 50 was achieved in 76.2% of the T2T, as compared to 36.4% of the fixed regimen patients (p = 0.020).
ACR 20 and 70 responses were achieved in 90.5% and 71.4% of the T2T patients and 59.1% and 27.3% of
the fixed regimen patients, respectively (p = 0.045 and p = 0.010, respectively). The adverse event rate was
similar for both groups (T2T n = 51; fixed regimen n = 55). Conclusion: Treat-to-target management with
the optimization of csDMARDs, oral, and IA-GCs of RA patients in parallel to a newly established CZP
treatment was safe and efficacious in comparison to a fixed regimen of csDMARDs background therapy.
Keywords: rheumatoid arthritis; treat-to-target; certolizumab pegol; csDMARDs; glucocorticoids;
intra-articular injections; DAS 28; ACR response; HAQ-DI
J. Clin. Med. 2019, 8, 302; doi:10.3390/jcm8030302 www.mdpi.com/journal/jcm143
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1. Introduction
Present treatment strategies for rheumatoid arthritis (RA) use conventional synthetic (cs), targeted
synthetic (ts), and bDMARDs (biological disease modifying drugs). All of these classes of drugs have
been shown to halt disease progression to a certain extent in clinical studies [1–7]. In general, therapy of
RA is initiated with csDMARDs with or without concomitant glucocorticoids (GCs). If disease activity
is not controlled under csDMARD treatment, ts or bDMARDs are added to treatment, as described,
e.g., the EULAR (European League Against Rheumatism) guidelines [8]. In real life, a physician
has more options than just adding the new ts/bDMARD. They can modify or optimize the therapy
with concomitant csDMARDs, and oral or IA-GC (intraarticular glucocorticoids) can be added to the
treatment regimen. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel
optimization of the csDMARD and GC treatment. In clinical studies with new compounds, on the
other hand, the drug under examination is, in general, tested with a more or less fixed regimen of the
pre-study csDMARDs, mostly methotrexate (MTX), and of GCs.
Strategic trials for the treatment of RA are rare [9–12]. In the TICORA (Tight Control of Rheumatoid
Arthritis) trial [13], patients with early RA were treated, in the tight control arm, with a therapeutic
strategy consisting of monthly visits, optimization of the therapeutic strategy (csDMARDs), and joint
injections with GCs (triamcinolone acetonide). Not only was the efficacy, as measured by ACR
(American College of Rheumatology) 20/50/70 responses, significantly higher in the patients in the
tight control arm of the trial, as compared to the conventionally treated patients in the control arm of
the study, but the rate of adverse events was also lower. A similar effect was repeated in the Camera
study, where intensive treatment determined by a computerized decision program was superior to
a conventional strategy [10]. This program forced the treating physician to increase the MTX dose
and, as further escalation, add ciclosporine in early RA patients on a monthly basis, depending on the
therapeutic response. This approach was shown to be superior to a conventional strategy with visits
every three months. Goekoop-Ruiterman et al. demonstrated in the BeSt study that a treat-to-target
approach was only superior with a step up to a bDMARD as compared to switching or adding more
csDMARDs. Similarly, as shown in the Guepard study, the therapeutic efficacy under the guidance
of tight control with MTX and step up to adalimumab was equally effective as compared to initial
combination therapy of MTX and adalimumab after 12 months [14]. An ultrasound-guided step
up of a therapeutic algorithm in early arthritis patients of the TaSer and the ARCTIC (Aiming for
Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical
TIght Control regimen) study did not lead to a significant amelioration of the clinical findings as
compared to therapeutic escalation based on clinical assessment [11,12]. All these studies follow the
idea of therapeutic escalation from cs to bDMARDs starting early in the course of the disease. In the
EULAR recommendations, a therapeutic adjustment including the “optimization of csDMARDs dose
or route of administration [15] or intra-articular injections of GCs” is recommended [8]. The European
guidelines’ authors state that they did not want to “capture several current ways of GC application”
independently of the dosage or route of application. In clinical trials, however, the doses of csDMARD
are not always optimized. In the Oral Standard Study, the average dosage of MTX, which could
not be increased during the trials, was 12.7 mg per week [16], and 16.5 mg per week in the Armada
trial [17], suggesting that the dosage of csDMARD before and after the start of b or tsDMARDs
had not been optimized. We hypothesize that the treating physicians may think that if one or more
csDMARDs have failed, although the drug was not optimized, no additional effect of csDMARDs in
the therapeutic algorithm can be expected. As in clinical trials, the doses of MTX are low; we estimate
that csDMARDs are, in general, not optimized before or during a new b or tsDMARD treatment in
real life, independently of what has been recommended by national or international organizations.
During these trials [16,17], modification of the concomitant therapy with csDMARD and GCs was not
allowed, as in almost every comparable trial.
Certolizumab pegol (CZP) is a PEGylated Fab’ fragment of a humanized anti-TNF (tumor necrosis
factor) antibody with high affinity for TNF. CZP is an effective treatment, approved for moderate to
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severe RA in many countries, when given in combination with MTX, and has been demonstrated to
be effective and safe in the treatment of RA in several phase III trials [18–21]. In the Rapid 1 trial,
the ACR 20/50/70 responses to CZP were 59%, 37%, and 21%, respectively, at week 24 (week 52 was
comparable) in combination with fixed regimen MTX and GC [20]. In comparison, in the TICORA
study, an ACR 20/50/70 response was found in 91%, 84%, and 71%, respectively, of the patients in the
tight control arm at 18 months.
Trials to date, involving CZP and other biologic agents, have primarily been controlled trials with
placebo comparisons. This trial design has resulted in a lack of data concerning the use of bDMARDs
in a setting closer to real-life, where treatment strategies are more adaptive based on the patient’s
signs and symptoms. This trial was aimed at comparing the use of CZP in patients with moderate
to severe RA, when administered in conjunction with an intensive, adaptive treatment program,
versus a fixed regimen approach, as seen in the previous clinical trials. We hypothesized that an
adaptive treat-to-target (T2T) strategy, in parallel to a new initiation of CZP, will lead to an improved
outcome of RA patients with active disease despite csDMARD treatment, as compared to patients
treated with a regimen of fixed csDMARDs and GC.
2. Methods
2.1. Patients
This study was conducted at four sites in Switzerland and Liechtenstein. Between March 2014
and December 2017, we recruited patients above 18 years of age suffering from RA and fulfilling the
2010 ACR/EULAR criteria [22] (NCT02293590). All patients had active disease despite csDMARD
treatment prior to the baseline for ≥three months, at a stable dose for ≥4 weeks for oral glucocorticoids
≤10 mg daily prednisolone or equivalent and csDMARDs, defined by ≥6 tender and ≥6 swollen joint
defined active disease out of the 66/68 joint count and an ESR (erythrocyte sedimentation rate) ≥ 20
mm/h or a CRP (C reactive protein) ≥ 7 mg/L. Key exclusion criteria included: previous treatment
with a bDMARD; missing anti-conception in fertile patients; untreated, active, or latent bacterial
(e.g., tuberculosis) or viral infections; or malignant diseases within the last five years.
This study was conducted in compliance with the ethical principles described in the Declaration
of Helsinki and Good Clinical Practice. Approval of the Institutional Review Boards designated by
each study site was obtained. All patients signed a written informed consent form.
2.2. Procedures
All patients were started on CZP (400 mg subcutaneously at weeks 0-2-4, and then 200 mg every
two weeks to week 24). Patients were randomly assigned to either the T2T group or the group with
the fixed regimen of the background treatment with csDMARDs and GCs. Both groups were started
on CZP after randomization. Randomization at week 0 was performed centrally using the Secutrial
system (interActive SystemsGmbH, Berlin, Germany, also used as clinical research form). This system
used for assigning eligible subjects to a treatment regimen was based on a predetermined schedule
for minimization. Minimization was conducted with respect to DAS (disease activity score, based on
28 joints) 28 ≥ 5.1 vs. <5.1, age ≥ 55 vs. <55, and male vs. female gender.
Patients were reviewed for their disease activity at weeks 4, 8, 12, 18, and 24 to determine their
treatment strategy and to document the proportion of patients classified as treatment responders.
The efficacy assessments included the number of swollen and tender joints (66/68 joint count); DAS 28;
the patient’s global assessment of disease activity and pain; the physician’s global assessment of disease
activity; CRP, ESR, and HAQ-DI (health assessment questionaire disability index) scores; and ACR
20/50/70 responses.
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Efficacy as a basis for adaption of the therapeutic strategy during the trial (outlined below)
was defined by a DAS 28 reduction of ≥1.2 since the last visit or achievement of LDA (low disease
activity, DAS 28 ≤ 3.2). Therapy was modified if these criteria were not fulfilled. In the case of
treatment-emergent adverse events, the DMARD could be tapered stepwise.
2.3. Therapeutic Strategies
2.3.1. T2T csDMARD Strategy
At the study start and during the study, patients who did not reach a sufficient treatment response,
as outlined in the previous chapter, or who developed treatment-emergent adverse events, were taken
to the next step or drug according to the therapeutic algorithm. For example:
Step 1: 15 mg MTX/week (MTX was always employed SC (subcutaneous) in the T2T arm);
Step 2: 20 mg MTX/week;
Step 3: 25 mg MTX/week;
Step 4: 20 mg leflunomide/d;
Step 5: sulphasalazine (target dose 2 × 1000 mg/d).
If a drug of this therapeutic algorithm had already been stopped before study entry because of
intolerance, this drug was left out, and csDMARD treatment was directly continued with the next
drug. This algorithm is illustrated in Figure 1.
Figure 1. The treatment strategy arms: Flow diagram for treatment for escalation of disease-modifying
anti-rheumatic therapy in RA patients. Patients were randomized into two arms: Fixed regimen (grey)
or T2T (treat-to-target, black). Patients with both therapeutic arms were treated with certolizumab pegol
(CZP). Fixed regimen arm: Baseline GCs and csDMARDs were continued at a stable dose throughout
the study. T2T arm: Depending on the csDMARD used before the study (shown as a striped arrow),
the csDMARD therapy was modified. In parallel, a cycle of oral GCs was initiated, and up to five
tender and/or swollen joints were injected with triamcinolone. The response criteria for the patients in
the T2T arm are listed below. If these response criteria were not met, therapy was modified according
to the mechanism described, and a new cycle of oral GCs was initiated. Joint injections were always
conducted independently of achieving the pre-set goal of the T2T strategy if they were tender and/or
swollen. Lef, leflunomide; MTX-SC, subcutaneous methotrexate; SSZ, sulphasalazine.
2.3.2. T2T GC Strategy
At the study start, all T2T patients were started on an oral dose of prednisolone 20 mg once daily,
which was then tapered down every five days at the following increments: 20 mg, 15.0 mg, 12.5 mg,
10 mg, 7.5 mg, 5 mg, 2.5 mg, and 0 mg once daily. If the DAS 28 had not improved by ≥1.2 or LDA
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was not reached at the subsequent visit, prednisolone was started again at 20 mg once daily, followed
by the same tapering schedule as noted above.
Starting at week 0, up to five synovitic joints had to be injected. The maximum cumulative
triamcinolone dose was 100 mg/visit.
Doses of triamcinolone and lidocaine for joint injections were:
• Small joints: metacarpophalangeal (MCP), proximal interphalangeal (PIP), metatarsophalangeal
joints (MTP): distal interphalangeal joints (DIP), sternoclavicular joint, acromioclavicular joint,
tarsus, and distal interphalangeal joints of the feet (IP): 10 mg triamcinolone;
• Intermediate joints: carpus, elbow, ankle: 20 mg triamcinolone with 0.5 mL 1% lidocaine; big
joints: knee, shoulder, hip: 40 mg triamcinolone with 4 mL 1% lidocaine.
If more than five synovitic joints were found to be painful and/or tender, the physician selected
the joints mostly affecting daily life activities based on the patient’s judgment.
2.3.3. Fixed Regimen Strategy
Patients continued to receive their stable weekly dose of csDMARD and GC (≤10 mg prednisolone
or equivalent), as noted at study entry, for the duration of the study (24 weeks, Figure 1).
2.4. Primary Objective
The primary objective was to determine the number of patients exhibiting at least a 50% improvement
of the disease activity, as determined by the ACR 50 response following 24 weeks of treatment of CZP,
when given as part of an intensive adaptive treatment plan (T2T), in comparison to a therapy with fixed,
continued, csDMARDs and GCs with unchangeable doses (fixed regimen).
2.5. Anti-Drug Antibodies
Sera from patients were collected at baseline and at four and 24 weeks of the study. Samples
at weeks 4 (because a first exposure to the drug was needed to measure CZP levels) and 24 were
used to measure CZP drug levels. Samples taken at baseline and at week 24 were analysed for
anti-drug antibodies. Analyses were conducted at Sanquin Research (Department of Immunopathology,
Amsterdam, The Netherlands), as previously described [23].
2.6. Data and Statistical Methods
2.6.1. Power Calculation
To detect an increase in ACR 50 from 37% assumed in the fixed regimen group [20] to 84% in the
T2T group [13], 21 patients were required in each group, if a chi-square test was used, to achieve 90%
power, if the two-sided significance level was 0.05.
2.6.2. Statistical Analyses
Demographic variables and baseline characteristics of the disease activity were summarized
using descriptive statistics. For ACR 20/50/70; DAS 28; and HAQ-DI, the chi-square test was
used. Missing values on the ACR responses were calculated as “not reached” (worst-case analysis).
Missing values of the DAS 28 and HAQ-DI were not imputed for the calculations (per protocol).
The chi-square test compared the proportion of the two groups of patients in remission. Time to
DAS 28, CDAI (clinical disease activity index), and Boolean defined remission was summarized using
Kaplan-Meier curves and compared using the log-rank test. The cumulative corticosteroid dose was
compared for the two patient groups using the Mann-Whitney U-test. Safety outcomes, including
treatment-emergent adverse events, were summarized in a table by type and severity and reported for
all patients receiving at least one dose of CZP. Anti-drug antibodies and CZP levels were measured at
the last visit, using the Mann-Whitney U-test.
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3. Results
3.1. Patient Demographics/Characteristics
We pre-screened 107 patients for the study (first patient in 27 March 2014; last patient out 22
December 2017); after exclusions and two withdrawn consents before randomization, 21 patients were
assigned to the T2T, and 22 to the fixed regimen arm of the study. Of these, 19 patients (90.5%) in the
T2T arm and 21 patients (95.5%) in the fixed regimen arm completed the 24-week study (Figure 2).
Two patients dropped out of the T2T group: one because of an adverse event and one because the
initial diagnosis of RA (inclusion criterion) had to be revised and a new primary diagnosis was
established. One patient of the fixed regimen arm dropped out for persistent disease activity. Baseline
characteristics and measures of disease activity in the two groups were balanced (Table 1). Mean DAS
28 (ESR) was 5.89 ± 0.98 for T2T and 6.16 ± 0.86 for fixed regimen patients. Small differences in
baseline measures of disease activity were deemed not to be clinically relevant. Median RA duration
(time from the first diagnosis) was approximately one year in both groups. Bone erosions on hands
and/or feet were described in 26.3% of the T2T patients and 30.0% of the fixed regimen patients.
Table 1. Demographics and disease activity at screening.
T2T (n = 21) Fixed Regimen (n = 22)
Age (a, mean) 56.3 ± 15.4 56.8 ± 14.8
Gender (% female) 66.7% 63.6%
BMI (Kg/m2, mean) 28.6 ± 4.4 28.7 ± 5.6
ACPA pos. (%) 47.6% 47.6%
RF pos. (%) 66.7% 81.0%
Erosive disease (%, defined by treating physician) 26.3% 30.0%
Disease duration (a, median, range) 0.99, 3 months–10 years 0.85, 3 months–18 years
Concomittant DMARD at baseline
MTX 10 mg/w, n = 2
MTX 15 mg/w, n = 9
MTX 20 mg/w, n = 4
MTX 25 mg/w, n = 3
Lef 20 mg/d, n = 3
MTX 10 mg/w: n = 2
MTX 15 mg/w n = 6
MTX 20 mg/w n = 3
MTX 25 mg n = 5
MTX + HCQ, n = 2 15 mg/w + 200
mg/d; 20 mg/w + 400 mg/d
SSZ n = 2
Lef n = 2
Concomitant GC (mean dose *, number of patients) 4.7 mg/d; n = 8 6.3 mg/d; n = 10
Disease activity score (DAS 28) 5.89 ± 0.98 6.16 ± 0.86
Tender joint score (0–68) 20.7 ± 10.3 23.2 ± 13.7
Swollen joint score (0–66) 18.9 ± 7.6 18.6 ± 10.9
Pain score (0–100) 65.3 ± 20.8 60.2 ± 21.0
Patient global assessment 70.1 ± 16.0 64.2 ± 16.9
Physician global assessment (0–100) 71.8 ± 8.8 67.0 ± 19.0
C-reactive protein (mg/L) 13.0 ± 16.2 17.1 ± 18.8
Erythrocyte sedimentation rate (mm/h) 28.7 ± 19.9 35.1 ± 25.2
Health assessment questionnaire score * (0–3) 0.84 ± 0.62 0.85 ± 0.64
* assessed on patients treated with glucocorticoids; Lef: leflunomide; SSZ: sulphasalazine; MTX: methotrexate;
HCQ: hydroxychloroqine, T2T: treat to target, BMI: body mass index, ACPA: anti-citrullinated protein antibodies,
RF: rheumatoid factor, pos.: positive, DMARD: disease modifying anti rheumatic drugs, GC: glucocorticoids, DAS:
disease activity score.
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Figure 2. Patient disposition: T2T: treat-to-target, ITT: intention to treat, ESR: erythrocyte sedimentation
rate, CRP: C reactive protein, SAE: serious adverse event.
3.2. Clinical Responses
Treatment of RA with CZP plus T2T background therapy significantly reduced signs and
symptoms as compared with CZP plus fixed regimen background therapy. At 24 weeks, the ACR
50 response rate (primary endpoint) was achieved in 16 out of 21 T2T patients (76.2%), as compared
to eight out of 22 fixed regimen patients (36.4%; Chi2: 5.355, p = 0.020, Figure 3A). ACR 20 and
70 responses were achieved in 90.5% and 71.4% of the T2T patients, and in 59.1% and 27.3% of the
fixed regimen patients, respectively (p = 0.045 and p = 0.010, respectively, Figure 3A).
 
Figure 3. Response to treatment: (A) Percentage of patients achieving an ACR 20/50/70 response was
demonstrated at week 24 (ITT analysis). T2T is shown in black, and fixed regimen in grey. (B) Average
disease activity score in 28 joints (DAS 28) at baseline and during follow up until week 24. (C) Average
health assessment questionnaire disability index (HAQ-DI) at baseline and during follow up until
week 24. All data are shown for the two patient groups as means with the 95% confidence interval:
T2T solid black line, and fixed regimen as a striped line; ACR: American college of rheumatology, ITT:
intention to treat, T2T: treat to target.
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The improvement in disease activity, as assessed by DAS 28, developed more rapidly within the
first four weeks of treatment and remained after that at sustained lower levels until week 24 (Figure 3B)
in the CZP plus T2T treated patients, as compared to the patients treated with the fixed regimen
co-therapy. In more detail, DAS 28 levels decreased to 2.62 and 1.91 at weeks 4 and 24 in the T2T group,
as compared to 4.21 and 3.77 in the fixed regimen group, respectively (p < 0.001 for all time points,
Figure 3B).
In parallel, higher remission rates were found for CZP and T2T treated patients independently of
the definition of remission employed. DAS-defined remission (DAS 28 < 2.6) was found in 68.4% vs.
28.6% (Log-rank test p < 0.001), CDAI defined remission (CDAI ≤ 2.8) in 78.9% vs. 23.8% (Log-rank
test p < 0.001), and Boolean remission in 47.4% vs. 19.1% (Log-rank test p = 0.031) of the T2T and fixed
regimen therapy patients, respectively, at week 24 (data shown as Supplementary Materials).
3.3. Patient-Related Outcomes
The improvement in the HAQ-DI as a patient-related outcome developed more rapidly within
the first four weeks of treatment, and remained after that at sustained lower levels until week 24
(Figure 3C) in the CZP plus T2T treated patients, as compared to the patients treated with the fixed
regimen co-therapy. The mean reduction in HAQ-DI was markedly higher in the T2T group than in
the fixed regimen group; however, significance was not reached (week 24: T2T 0.17 vs. fixed regimen
0.6, p = 0.06). Similarly, the changes in the patient’s pain score and in patient’s global assessment of
disease activity were not significantly different at week 24 (Table 2).
Table 2. Improvement of ACR core components at week 24.
T2T Fixed Regimen p-Value
Patient’s pain score −53.34 −50.51 n.s.
Patient’s global assessment −56.21 −49.59 n.s.
Physician’s global assessment −64.62 −31.74 <0.001
Tender joint count (68) −19.67 −9.9 <0.001
Swollen joint count (66) −17.89 −8.76 <0.001
ESR (mm/h) −12.83 −17.86 <0.001
CRP (mg/L) −3.03 −7.64 <0.001
HAQ-DI −0.68 −0.25 n.s.
CDAI −33.81 −21.9 <0.001
T2T: treat to target, n.s.: not significant, ESR: erythrocyte sedimentation rate, CRP: C reactive protein, HAQ-DI:
health assessment questionaire disability index, CDAI: clinical disease activity index.
3.4. Adverse Events
Of the 43 patients in this study, 18 (76.2%) patients in the T2T and 16 (72.7%) in the treatment
fixed regimen reported at least one adverse event (AEs). The most common AEs were infections.
Most reported AEs were of mild or moderate severity (98.1% T2T and 98.0% fixed regimen). Only three
patients reported serious AEs (SAE: n = 2 T2T; n = 1 fixed regimen). The SAEs were: insufficiency of
the adrenal gland, cardiovascular infarction (both SAEs were T2T), and bursitis infra-patellaris of the
right knee (fixed regimen). All SAEs were resolved (Table 3). The most frequent AEs were infections.
Thirteen T2T patients and 10 fixed regimen patients had infections during the study. In detail, we found
bursitis (n = 1), a nail infection (n = 1), lip blisters (n = 3), pyelonephritis (n = 1), an upper respiratory
infection (n = 3), and a urinary tract infection (n = 1) in fixed regimen patients and cutaneous mucositis
(n = 1), parondontitis (n = 1), a gastrointestinal infection (n = 1), Herpes Labialis, (n = 1) mycosis (n = 1),
pneumonia (n = 1), a skin infection (n = 1), and an upper airway infection (n = 6) in T2T patients.
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Table 3. Adverse events.
Fixed Regimen T2T
Total (n) 51 55
Patients with AEs (n) 16 18
Intensity (mild/moderate/severe, n) 49/1/1 50/4/1
SAE (n) 1 * 2 **
Related (Not, unlikely/possibly/
probably/definitely, n) 22/3/21/4/1 33/3/19/0/1
Cardiovascular (n) 2 7
Dermatological (n) 6 4
Gastrointestinal (n) 3 4
General (n) 1 4
Hepatology (n) 2 1
Infection 10 13
Injection site reaction to CZP (n) 4 3
Injury (n) 5 2
Joint injection reaction (n) - 3
Musculoskeletal (n) 4 3
Neurological (n) 11 10
Ophthalmological (n) 1 1
Psychology (n) 2 1
n: number; (S) AE: (serious) adverse events; CZP: Certolizumab pegol; * bursitis infrapatellaris; ** insufficiency of
adrenal gland, cardiovascular infarction; T2T: treat to target.
3.5. Cumulative Steroid Dose
For the T2T group, the cumulative oral corticosteroid dose was calculated by counting the number
of GC cycles: One patient required three cycles of oral GC, four patients two cycles, and all the other
T2T patients only one cycle. In total, an average of 471.2 mg prednisolone (SD (standard deviation)
± 207.1) was used in the T2T patients. Additionally, 10.2 (mean, SD ± 7.1) joints were injected
with triamcinolone per T2T patient. Furthermore, 7.2 small, 1.7 intermediate, and 1.0 large joints
were injected per patient. In total, a mean of 149.1 mg triamcinolone (SD ± 109.3) was injected
into the joints of T2T patients. This adds up to a cumulative average GC dose (equivalence dose
prednisolone:triamcinolone = 1:1.2) in T2T patients of 666.9 mg (SD ± 309.5) prednisolone/patient or
equivalent [24] over the whole study period.
Among the fixed regimen patients, three patients were continuously treated with 10 mg
prednisolone/d, two with 7.5 mg/d, seven with 5 mg/d, two with 2.5 mg/d, and eight without
concomitant prednisolone. This adds up to a cumulative average GC dose in fixed regimen patients of
792.5 mg prednisolone/patient or equivalent (SD ± 594.5) over the whole study period. The cumulative
GC doses did not differ significantly between both groups (Mann-Whitney test, p = 0.723, Figure S1).
3.6. Therapeutic Changes of the csDMARD Protocol
Only two patients required two modifications of their baseline T2T csDMARD regimen. All other
patient required only one optimization of the csDMARD. Two patients required a step up from 10 mg
to 15 mg MTX/week, nine from 15 mg to 20 mg MTX/week, six from 20 to 25 mg MTX/week, two from
25 mg MTX/week to 20 mg leflunomide/d, three from 20 mg leflunomide/d to 15 mg MTX/week,
and one from 20 mg leflunomide/d to 2 × 1000 mg sulphasalazine/day.
3.7. ADA (Anti Drug Antibodies) Antibodies
Blood serum CZP levels were analysed at week 4 and after 24 weeks and for anti-CZP antibodies
at baseline and after 24 weeks. Anti-CZP antibodies were not detectable at baseline, but were detected
after 24 weeks of treatment in 8/19 patients of the T2T group (42.1%) and in 10/19 patients of the
fixed-dose group (52.6%). This difference in frequencies was not significant (chi2 = 0.106, p = 0.745).
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There was, however, a trend of lower anti-CZP antibodies levels in the T2T group (T2T: 139.1 ± 138.8
vs. fixed regimen: 197.1 ± 170.0 AU (arbitrary units)/mL, Mann-Whitney test, p = 0.439, Figure S2).
CZP levels decreased from week 4 (46.5 ± 19.4 mg/mL) to week 24 (29.5 ± 12.6 mg/mL, Wilcoxon
signed-rank test, p < 0.001), but did not differ between treatment groups (Mann-Whitney test, week 4:
p = 0.857, week 24: p = 0.977).
4. Discussion
Treat-to-target management with the optimization of csDMARDs, oral, and of IA-GC (T2T) in
parallel to new CZP treatment was safe and led to a substantial decrease of disease activity, as compared
to new CZP with a fixed regimen of csDMARDs and GCs, in RA patients with an inadequate response
to previous csDMARDs.
The idea of treating to target has been around since the late 90s for the treatment of RA patients.
The study employing a modification of csDMARDs and IA-GCs had much influence on how we treat
RA to target nowadays [13]. The arrival of TNF antagonists and the other biologics had an even more
profound impact on the treatment of RA. As mentioned in the introduction, the underlying principle of
these T2T strategies is that if a class of drugs (e.g., csDMARDs) has failed to reach the target, mostly due
to low disease activity or even remission, a step up to the next class of therapeutics (bDMARDs) is
immediately necessary. Thus, an assumption is made that the csDMARD that has failed cannot add any
additional efficacy to the treatment of this patient. The novelty of our protocol is that the therapeutic
strategy is optimized by four parallel actions: first bDMARD (TNF antagonist), csDMARD with dose
adjustment, and additional oral and IA-GCs. Adaptation of concomitant medication is generally not
allowed in clinical phase II/III studies for a new compound in RA. The superiority of a combination of
the treat-to-target idea, as suggested by the TICORA study, with the addition of a biologic treatment
at a level that has never been reached for any biologic agents, in csDMARD-IR patients, is the real
novelty of this study.
Over the last two decades, various compounds have been tested for efficacy and safety:
combination therapy of csDMARDs, TNF antagonists, other biologic agents, and targeted synthetic
DMARDs. Efficacy, as assessed by ACR response rates, was always comparable: 60% for ACR 20, 40%
for ACR 50, and 20% for ACR 70, in MTX-incomplete, responding patients [16,20,25–27].
Every method available to improve an RA patient’s health, i.e., csDMARD dose adjustment,
in addition to oral and IA-GCs and bDMARD, should be applied to improve these response rates.
It seems likely that the effects demonstrated here for a T2T strategy in combination with a parallel start
of CZP can be generalized for all bDMARDs and tsDMARDs in csDMARD-IR patients. Whether a
similar effectiveness could also be achieved after an inadequate response to b or tsDMARDs would
have to be confirmed in other trials with a design similar to ours.
This publication has several limitations: Firstly, the differences found for efficacy (ACR response,
DAS28, CDAI) could not be demonstrated at a significance level for HAQ-DI and other patient-related
outcomes (PROs), but a strong tendency towards superiority of the T2T-regimen was found. Little is
known about the response of HAQ-DI in a treat-to-target clinical trial setting. The only publication
with a comparable design, where Hirano et al. demonstrated a reduction of HAQ-DI from 1.4 to 1.0
when following the Brazilian therapeutic recommendations, had no control group and the observation
period was much longer [28]. As a consequence, we did not have any data to calculate the power for
significant changes in HAQ-DI for the design of our study. Considering that 84% of the T2T patients
achieved an HAQ-DI < 0.5, and 65% of the patients with a fixed regimen, a sample size of two times
81 patients would have been necessary to reach a power of 0.8 with an alpha of 0.05. It has to be
considered, that in the face of the impressive results regarding efficacy, we would have treated an
additional 60 patients according to the fixed regimen protocol with a significantly lower clinical efficacy.
In summary, we think that this would have been ethically controversial. Psychological effects of RA
are well-described. Such phenomena may influence PROs [29,30]. Strand et al. [31] have described that
PROs improve with CZP treatment. Interestingly, this improvement had the lowest correlation with
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DAS 28 or ACR 20 response levels. It seems likely that regression towards the mean may be a reason
why the PROs in this study did not reflect the outstanding results of the efficacy parameters [32].
Secondly, changes in radiographic progression were not analysed. The reasons for this were the
sample size and that the study was only planned for 24 weeks. Concerning these two restrictions,
we did not expect to find any differences in the radiographic progression during the study. The low rate
of radiographic progression usually found in comparable patient populations was another reason not
to consider it as an outcome parameter: an increase of 0.4 Sharp units over only 52 weeks, or 0.2 over
24 weeks, was found in patients treated with CZP and MTX in the 0.2 units for RAPID 2 and 0.4 for
RAPID 1.
Thirdly, a double blind, randomized study is superior to an open study like ours. On the other
hand, studies with the combined therapeutic treat-to-target approaches, especially involving IA-GCs,
are difficult to blind. In the TICORA [13] and CAMERA [10] studies, which, like our study, also used
joint injections, the two therapeutic arms were not blinded.
5. Conclusions
In conclusion, this study shows that a T2T approach in the treatment of RA patients with an
inadequate response to csDMARDs, using the full armamentarium of the therapeutic possibilities,
has a high potential to improve disease activity in parallel to the start of a bDMARD, in our case, CZP.
We feel strongly that this approach is transferable to the start of other b or tsDMARDs. We are aware
of the fact that designing clinical studies for the demonstration of effectivity/effectiveness of new
drugs with dynamic background therapies is difficult. This, however, should not influence our daily
approach to ameliorate the situation for our patients.
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Figure S1: Cumulative GC (glucocorticoids) dose during the study period. The average cumulative GC dose was
calculated separately for patients treated with T2T or with fixed regimen. The average cumulative GC dose was
standardized for prednisolone or equivalent, Figure S2: (A) CZP (certolizumab pegol) levels and were measured
at week 4 and week 24. (B) CZP anti-drug antibodies were measured at the baseline and week 24. Patients treated
with CZP + T2T are shown in dark grey and CZP + fixed regimen in light grey. Data are shown as medians with
the 25th and 75th percentile and the standard deviation as error bars. Outliers are implemented as dots; w: week,
AU/mL: arbitrary units per milliliter, T2T: treat to target.
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Abstract: (1) Background: We evaluated the prevalence and fracture risk of osteoporosis in
patients with rheumatoid arthritis (RA), and compared the fracture risk assessment tool (FRAX)
criteria and bone mineral density (BMD) criteria established by the World Health Organization
(WHO). (2) Methods: This retrospective cross-sectional study, which included 479 RA patients
in 5 hospitals, was conducted between January 2012 and December 2016. The FRAX criteria for
high-risk osteoporotic fractures were calculated including and excluding the BMD values, respectively.
The definition of high risk for fracture by FRAX criteria and BMD criteria by WHO was 10-year
probability of ≥ 20% for major osteoporotic fracture or ≥ 3% for hip fracture, and T score ≤ −2.5 or
Z score ≤ −2.0, respectively. (3) Results: The mean age was 61.7 ± 11.9 years. The study included
426 female patients (88.9%), 353 (82.9%) of whom were postmenopausal. Osteoporotic fractures were
detected in 81 (16.9%) patients. The numbers of candidates for pharmacological intervention using
the FRAX criteria with and without BMD and the WHO criteria were 226 (47.2%), 292 (61%), and
160 (33.4%), respectively. Only 69.2%–77% of the patients in the high-risk group using the FRAX
criteria were receiving osteoporosis treatments. The following were significant using the WHO
criteria: female (OR 3.55, 95% CI 1.46–8.63), age (OR 1.1, 95% CI 1.08–1.13), and BMI (OR 0.8, 95%
CI 0.75–0.87). Glucocorticoid dose (OR 1.09, 95% CI 1.01–1.17), age (OR 1.09, 95% CI 1.06–1.12), and
disease duration (OR 1.01, 95% CI 1–1.01) were independent risk factors for fracture. (4) Conclusions:
The proportion of RA patients with a high risk of osteoporotic fractures was 33.4%–61%. Only
69.2%–77% of candidate patients were receiving osteoporotic treatments while applying FRAX
criteria. Independent risk factors for osteoporotic fractures in RA patients were age, the dose of
glucocorticoid, and disease duration.
Keywords: osteoporosis; fracture; fracture risk assessment tool; rheumatoid arthritis
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1. Introduction
Osteoporosis is one of the most well-known complications in patients with rheumatoid arthritis
(RA). RA is a disease that presents a state of chronic inflammation that is known to cause an increase
in osteoclastic differentiation and an inhibition of osteogenesis [1]. Furthermore, the treatment with
glucocorticoids then increases the imbalance which already existed due to the disease. Moreover, this
association may be due to a lack of mobility and frequent occurrences of RA during menopause as well
as systemic inflammation of RA and the use of corticosteroids [1–3]. The prevalence of osteoporosis
in patients with RA was reported to be approximately twice as high as in the general population [4].
The frequency of osteoporosis in patients with RA has been reported to be 6.3% to 36.3% in the hip,
and 12.3% to 38.9% in the spine [4–6]. Compared with controls, the fracture risk in patients with RA
also increased for the hip (relative risk (RR): 2) and spine (RR: 2.4) [7]. Moreover, hip and vertebral
osteoporotic fractures are known to be associated with an immediate and long-term (up to 20 years)
increased risk of mortality [8]. Excess mortality during the first year after a hip fracture ranged from
8.4% to 36%, and the risk of mortality following hip fracture was estimated to be more than 2 times
higher than that of the general population [9]. Therefore, it is very important to accurately assess the
risk of osteoporotic fractures in RA patients.
The fracture risk assessment tool (FRAX) criteria and the bone mineral density (BMD) criteria
established by the World Health Organization (WHO) are widely used for the risk assessment of
osteoporotic fractures. The WHO criteria, using BMD measured by dual-energy X-ray absorptiometry
(DXA), are the most widely used in the diagnosis of osteoporosis [10]. The management guidelines
for the prevention and treatment of osteoporosis, developed by an expert committee of the National
Osteoporosis Foundation (NOF), are also based on BMDs [11]. In 2008, a WHO task force introduced
the FRAX tool to evaluate the 10-year probability for hip and major osteoporotic fractures [12]. The
FRAX model contains various risk factors for osteoporotic fractures including country, age, sex, weight,
height, smoking, previous fracture, family history of fracture, glucocorticoid treatment, alcohol intake,
and BMD, if available [13]. In particular, RA is the only disease risk factor in the FRAX model, even
though the input for RA is just a dichotomous variable.
In clinical settings, physicians determine the proper medications to prevent osteoporotic fractures
based on these criteria [11,14]. However, when assessing the risk of osteoporotic fractures in patients
with RA, the relevance and benefits among the three assessment methods (WHO osteoporosis criteria
and FRAX criteria with BMD and without BMD) have not been clearly studied. Therefore, in this
multicenter study, we aimed to evaluate the incidence among a high-risk group for osteoporotic
fracture and to identify the risk factors of osteoporotic fractures in patients with RA by comparing




In this retrospective cross-sectional study, we assessed 479 Korean patients with RA in 5 university
hospitals between January 2012 and December 2016. All recruited patients were over the age of 18
and satisfied the 1987 American College of Rheumatology (ACR) criteria or the 2010 ACR/European
League Against Rheumatism (EULAR) criteria for RA [15,16]. Recorded data using a medical chart
review included age, sex, body mass index (BMI), menopausal status, hormone supplement therapy in
postmenopausal women, fracture history, history of parental hip fracture, daily alcohol intake, smoking
status, autoantibody status, erythrocyte sediment rate (ESR), C-reactive protein (CRP), and the presence
of secondary osteoporosis. The standard of BMI was 25 kg/m2 using validated BMI categorization for
the Korean population [17]. Therapeutic medication lists for the treatment of RA including current
glucocorticoid use, cumulative glucocorticoid dose, and conventional and biological disease-modifying
anti-rheumatic drugs, as well as pharmacological intervention for osteoporosis, such as bisphosphonate,
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selective estrogen receptor modulators (SERM), vitamin D and calcium, were also obtained. The study
was approved by the Institutional Review Board (IRB) of each Hospital (C2015163 (1621), 2015-09-026,
AJIRB-MED-MDB-15-285, 3-32100191-AB-N-01, and DSMC2015-12-017-007). Informed consent was
waived by the IRB.
2.2. Evaluation of Osteoporosis by BMD Criteria
Candidates for pharmacological interventions to prevent osteoporosis were assessed using the
WHO osteoporosis criteria [10]. All BMD measurements were done using the same technique. The
BMD of the lumbar vertebrae (L1–L4) and both hips were measured using DXA (GE Lunar, Madison,
WI, USA). t- and z-scores were calculated with the referent BMD of 5 hospitals. According to the WHO
criterion, patients with osteoporosis and osteopenia were defined having a value of the t-score that
was −2.5 or less, and from −2.5 to −1, respectively, for postmenopausal women or men ≥50 years old.
For the evaluation of premenopausal women or men <50 years old, z-scores ≤ −2 were considered
as osteoporosis.
2.3. Osteoporotic Fracture Risk Evaluation by FRAX
The 10-year probability of major osteoporotic and hip fractures was calculated by the FRAX tool,
based on medical chart reviews and questionnaires. The FRAX criteria for high risk of osteoporotic
fracture were defined as a 10-year probability of ≥20% for major osteoporotic fracture or ≥3% for
hip fracture. We calculated two kinds of FRAX values using the Korean model (http://www.shef.ac.
uk/FRAX/tool.aspx?country=25); FRAX with BMD was calculated including the femur neck BMD
(g/cm2) value.
2.4. Risk Factors for Fracture
Information regarding previous fractures was obtained through patient self-reporting
questionnaires during routine clinic visits and spinal x-ray evaluations. Potential factors associated
with osteoporotic fractures were collected by patient interviews, physical examinations, and
laboratory tests. Patient baseline characteristics, including clinical variables, RA medications, and
osteoporosis-related factors, were investigated at enrollment. The dose of glucocorticoid was calculated
on the basis of prednisolone. Glucocorticoid use was grouped as ≥5 mg/day prednisolone equivalent
and <5 mg/day prednisolone-equivalent. Candidates for pharmacological interventions preventing
osteoporotic fracture were identified using the WHO osteoporosis or the FRAX criteria. We evaluated
osteoporotic medications, such as bisphosphonate and SERM, to obtain the ratio of high-risk patients
currently undergoing osteoporosis treatments.
2.5. Statistical Analysis
All measurements were expressed as means ± SD. Values that were not normally distributed
were represented as medians (IQR). A Student’s t-test was used for the comparison of mean
values. A Pearson’s χ2 test was used to compare the differences between categorical variables
for analyzing correlations. Multiple linear analysis, including glucocorticoid dose, age, sex, BMI,
smoking, and disease duration, was used to identify factors affecting the FRAX values and BMD
scores. Glucocorticoid dose, age, BMI and disease duration were continuous variables in this model.
A multivariable logistic regression analysis using glucocorticoid dose, age, sex, BMI, and disease
duration was performed to obtain the respective odds ratios, and all the variables except sex were
continuous variables in this model. In all analyses, a p value of <0.05 was considered statistically
significant. All statistical analyses were conducted using the SPSS version 20 (IBM Corp, Armonk,
NY, USA).
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3. Results
3.1. Baseline Characteristics of the Study Participants
The baseline characteristics of the participants are summarized in Table 1. The data of baseline
characteristics in Table 1 were based on the time of BMD test, except for rheumatoid factor and
anti-citrullinated protein antibody. The average age of the 479 subjects was 61.5 ± 11.5 years. Study
participants included 426 female patients (88.9%) with 353 (82.9%) being postmenopausal. The median
disease duration was 53 (33–72) months. The median ESR and CRP levels were 15 (7–29) mm/h and 0.18
(0.05–0.79) mg/L, respectively. The proportion of patients who were using glucocorticoids was 92.3%
(442/479), and the median dose was 2.5 mg/day prednisolone-equivalent. The number of patients with
biological disease-modifying anti-rheumatic drug (DMARD) use was 56 (11.7%); 13 (2.7%) etanercept,
10 (2.1%) infliximab, 9 (2.9%) adalimumab, 3 (0.6%) golimumab, 11 (2.3%) tocilizumab, 6 (1.3%)
abatacept, 2 (0.4%) rituximab, and 2 (0.4%) tofacitinib. A total of 262 (54.7%) patients were receiving
osteoporosis treatments: 189 (39.5%) patients were treated with bisphosphonate, and 98 (20.5%) were
using SERM. Among all the participants, 81 (16.9%) patients (7 male and 74 postmenopausal females;
mean age of 69.5 ± 9.3 years) had fractures, all of which were vertebral.
Table 1. Baseline characteristics of the study participants.
Variables RA Patients (N = 479)
Age (year) 61.8 ± 11.5
Sex (female) 426 (88.9%)
Menopause 353 (82.9%)
Weight (kg) 55.4 (49.2–62.8)
Height (cm) 155.3 (150.1–160)
BMI (kg/m2) 23.1 (20.9–25)
Smoking 33 (6.9%)
Alcohol 41 (8.6%)
Disease duration (month) 53 (33–72)
1987 ACR criteria 377 (78.7%)
2010 ACR/EULAR criteria 418 (87.2%)
RF titer (IU/mL) 67.2 (24–165.2)
ACPA titer (U/mL) 78 (0.4–179.1)
RF positive 380 (79.3%)
ACPA positive 295 (61.6%)
ESR (mm/h) 15 (7–29)
CRP (mg/L) 0.18 (0.05–0.79)
Medications
Glucocorticoid 442 (92.3%)
Prednisolone-equivalent dose (mg/day) 2.5 (1.25–5)
NSAID 341 (71.2%)
Biologics 56 (11.7%)
Vitamin D 228 (47.6%)
Calcium 195 (40.7%)
Proton pump inhibitor 123 (25.7%)
Treatment for osteoporosis 262 (54.7%)
Bisphosphonate 189 (39.5%)
SERM 98 (20.5%)
Vertebral fracture 81 (16.9%)
Age (year) 69.5 ± 9.3
Male 7 (8.6%)
Postmenopausal woman 74 (91.4%)
BMI, body mass index; ACR, American college of rheumatology; EULAR, European League Against Rheumatism;
RF, rheumatoid factor; ACPA, anti-citrullinated protein antibody; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; NSAID, non-steroidal anti-inflammatory drug; SERM, selective estrogen receptor modulator.
Values were represented as mean ± standard deviation. Values that were not normally distributed are represented
as medians (IQR).
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3.2. Distribution of Candidates for Pharmacological Intervention Using the FRAX and the WHO
Osteoporosis Criteria
The number of patients with osteoporosis according to the WHO criteria was 160 (33.4%), and
the number of candidates for pharmacological intervention using the FRAX criteria with and without
BMD was 226 (47.2%) and 292 (61%), respectively. There were significant differences among these
three groups (Table 2). When men, women, and postmenopausal women were analyzed separately, the
number of candidates for pharmacological intervention was the highest for the FRAX criteria without
BMD, followed by the FRAX criteria with BMD, and finally, the WHO osteoporosis criteria (Table 2).
The numbers of candidates for pharmacological intervention of women were higher than those of
men using the FRAX criteria with BMD (p = 0.014) and when using the WHO osteoporosis criteria
(p = 0.011); however, there were no significant differences when using the FRAX criteria without BMD
(p = 0.077). The proportion of patients with a BMD < −1.0 was 216/226 (95.6%) among those eligible
for FRAX criteria with BMD, and 265/292 (90.8%) for FRAX without BMD.
3.3. Proportion of Patients Receiving Osteoporosis Treatment in the High-Risk Group According to the FRAX
Criteria and the WHO Osteoporosis Criteria
Table 3 shows the proportion of the patients currently receiving osteoporosis treatments
(bisphosphonate or SERM) in the high-risk group, based on the FRAX criteria with or without BMD
and the WHO osteoporosis criteria. Of the patients in the high-risk group using the FRAX criteria
with BMD, only 77% were receiving osteoporosis treatments, which was similar to the percentages in
sex and menopause subgroup analyses (men, 64.7%; women, 78%; postmenopausal women, 78.6%).
The proportion of patients undergoing osteoporosis treatment among the high-risk group using the
FRAX criteria without BMD was similar (overall, 69.2%; men, 55.6%; woman, 70.6%; postmenopausal
women, 71.1%, respectively). However, when applying the WHO osteoporosis criteria, more than 90%
of patients were receiving osteoporosis treatments in all patient groups or subgroups (overall, 91.3%;
men, 90%; woman, 91.3%; postmenopausal women, 91.3%).
Table 3. Current osteoporosis treatments in high-risk groups according to the FRAX criteria and the
WHO osteoporosis criteria.
Patient Groups FRAX with BMD FRAX without BMD WHO Osteoporosis
Overall 174/226 (77%) 202/292 (69.2%) 146/160 (91.3%)
Men 11/17 (64.7%) 15/27 (55.6%) 9/10 (90%)
Women 163/209 (78%) 187/265 (70.6%) 137/150 (91.3%)
Premenopausal 0/3 (0%) 0/2 (0%) 1/1 (100%)
Postmenopausal 163/206 (78.6%) 187/263 (71.1%) 136/149 (91.3%)
FRAX, fracture risk assessment tool; BMD, bone mineral density; WHO, World Health Organization.
3.4. Fracure Risk for the FRAX Criteria, the WHO Osteoporosis Criteria and Fractures
Table 4 shows which dichotomous factors were related to the FRAX criteria with BMD and without
BMD, the WHO criteria, and incidence of fractures. Patients with high fracture risk by FRAX with
BMD were more likely to be female, especially postmenopausal women (female, p = 0.019; menopause,
p < 0.001), with alcohol use, glucocorticoid use, and proton pump inhibitor use (p = 0.042, p = 0.007,
p = 0.018, and p < 0.001, respectively), and also with lower BMI (<25 kg/m2) (p = 0.042). Patients with
high fracture risk by FRAX without BMD had lower BMI and longer disease duration, and were more
likely to be menopausal women, alcohol users, glucocorticoid users and proton pump users than
patients who were not at high risk by FRAX without BMD (p = 0.004, p = 0.007, p < 0.001, p = 0.005,
p < 0.001, and p < 0.001, respectively).
The results of frequency comparison for WHO osteoporosis criteria were similar to those for
the FRAX criteria with BMD except for glucocorticoid use (female, p = 0.017; menopause, p < 0.001;
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BMI < 25 kg/m2, p < 0.001; alcohol use, p = 0.002; proton pump inhibitor use, p = 0.008). Biologic use,
seropositivity, and ESR elevation did not show any significant difference for all the criteria.
The number of patients meeting the FRAX criteria with BMD was significantly higher in the
higher dose with ≥5 mg/day prednisolone group in contrast to the lower dose with < 5mg/day
prednisolone group (76/127; 59.8% vs. 136/307; 44.3%, p = 0.003).
Multiple linear analyses were implemented to identify factors affecting the FRAX criteria and BMD
scores (Table 5). The 10-year probability percentage for hip fractures and that for major osteoporotic
fractures in the FRAX with BMD, the 10-year probability percentage for major osteoporotic fractures in
the FRAX without BMD, and total hip BMD scores, were significantly associated with glucocorticoid
dose, age, female sex, BMI, and disease duration. However, the 10-year probability percentage for hip
fractures in the FRAX without BMD was only associated with age and BMI.
Multivariable logistic regression analyses were performed to identify the fracture risk for the FRAX
criteria and the WHO osteoporosis criteria, and fractures in patients with RA (Table 6). Glucocorticoid
dose (odds ratio (OR) 1.15, 95% confidence interval (CI) 1.03–1.28, p = 0.016), age (OR 1.17, CI 1.13–1.2,
p < 0.001), female sex (OR 4.22, CI 1.8–9.9, p = 0.001), and BMI (OR 0.92, CI 0.85–0.99, p = 0.002) were
independent fracture risk for the FRAX criteria with BMD. Age (OR 1.65, CI 1.47–1.84, p < 0.001),
female sex (OR 8.23, CI 2.27–29.88, p = 0.001), and BMI (OR 0.6, CI 0.5–0.72, p < 0.001) were associated
with the FRAX criteria without BMD. Likewise, age (OR 1.1, CI 1.08–1.14, p < 0.001), female sex (OR
3.55, CI 1.46–8.63, p = 0.005), and BMI (OR 0.8, CI 0.75–0.87, p < 0.001) were associated fracture risk for
the WHO criteria. Furthermore, independent risk factors for fracture are glucocorticoid dose (OR 1.09,
95% CI 1.01–1.17, p = 0.02), age (OR 1.09, 95% CI 1.06–1.12, p < 0.001) and disease duration (OR 1.01,
95% CI 1–1.01, p = 0.002).
Table 4. Comparison of the frequencies for the high-risk of osteoporotic fractures according to FRAX













Sex (female) 48.6%, 0.019 62.2%, 0.077 35.2%, 0.017 17.6%, 0.457
Menopause 57.2%, <0.001 71.1%, <0.001 41.9%, <0.001 21%, <0.001
BMI < 25 kg/m2 50%, 0.042 64.9%, 0.004 39%, <0.001 17.3%, 0.868
Disease duration > 2 years 48.9%, 0.098 63.7%, 0.007 35.1%, 0.081 18.6%, 0.063
Seropositivity 46.5%, 0.970 61.4%, 0.170 35.3%, 0.118 17.5%, 0.129
ESR elevation 52.5%, 0.052 65.4%, 0.100 37.4%, 0.196 16.9%, 0.950
Smoking 30.3%, 0.092 45.5%, 0.109 21.2%, 0.209 18.2%, 0.855
Alcohol use 24.4%, 0.007 36.6%, 0.005 9.8%, 0.002 10.3%, 0.239
Glucocorticoid use 49%, 0.018 63.8%, <0.001 33.9%, 0.532 17.3%, 0.81
Biologics use 46%, 0.785 60%, 0.378 40%, 0.137 20.8%, 0.574
PPI use 62.6%, <0.001 77.2%, <0.001 43.1%, 0.008 19%, 0.524
FRAX, fracture risk assessment tool; BMD, bone mineral density; WHO, World Health Organization; BMI, body
mass index; ESR, erythrocyte sedimentation rate; PPI, proton pump inhibitor.
163
J. Clin. Med. 2018, 7, 507
Table 5. Multiple linear risk analyses using the FRAX criteria and the WHO osteoporosis criteria.
Variable β p Value Adjusted R2
FRAX with BMD %
10-year probability for hip fracture
Constant −13.464 0.309





Disease duration 0.01 0.114
FRAX with BMD %
10-year probability for major
osteoporotic fracture
Constant −24.341 0.407





Disease duration 0.025 0.001
FRAX without BMD %
10-year probability for hip fracture
Constant −8.455 0.326





Disease duration 0.004 0.722
FRAX without BMD %
10-year probability for major
osteoporotic fracture
Constant −26.833 0.630





Disease duration 0.025 <0.001
Table 5. Cont.


















Disease duration −0.004 <0.001
FRAX, fracture risk assessment tool; BMD, bone mineral density; WHO, World Health Organization; BMI, body
mass index.
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4. Discussion
In this study, we compared both the WHO and the FRAX criteria to estimate the risk of osteoporotic
fractures and to determine candidates for pharmacological treatments. As a result, 33.4% of patients
were eligible for the WHO osteoporosis criteria, 47.2% for the FRAX criteria with BMD, and 61% for
the FRAX criteria without BMD, with statistically significant differences in each high-risk group for
osteoporotic fractures (Table 2). When we performed subgroup analyses separated by men, women,
and postmenopausal women, all except premenopausal women showed a similar tendency.
We found that there was a significant difference between the WHO criteria and the FRAX criteria
with or without BMD, as well as between the FRAX criteria with BMD and those without BMD, which
is different from the previous assertion that there is a high degree of agreement [12,18]. A significant
difference in the number of high-risk groups for osteoporotic fractures according to the criteria applied
is a serious problem, since both the FRAX and WHO criteria are widely used in clinical practice, and
drugs used to prevent osteoporotic fractures have several side effects [11,12,14]. Therefore, it is very
important to determine which of the three criteria should be used. To accomplish this, we had to
determine the objective standard in order to evaluate all three criteria; however, it was not easy to set
standards to which everyone could agree. Ultimately, the goal of osteoporosis treatment is to prevent
fractures, so in order to select the best criteria, it may be advantageous to compare the incidences of
actual fractures in each criterion. Unfortunately, our study was only a retrospective cross-sectional
study, and patients with actual fracture histories were confined to compression fractures of the spine,
thereby limiting the prevalence of actual fractures used to evaluate the best criteria.
Recently, a study comparing the FRAX without BMD and BMD alone was published [19]. In that
study, the FRAX probability of a major osteoporotic fracture in 50-year-old women was approximately
two-fold higher than that for women of the same age, but with an average BMD. The authors concluded
that intervention thresholds based on BMD alone do not optimally target women at higher fracture risk
than age-matched individuals without clinical risk factors [19]. However, the FRAX with BMD was not
evaluated in that study, and there is no comparative study in RA patients. As shown in our study, the
WHO criteria may have less actual risk reflected in high-risk disease such as RA [7]. Conversely, the
FRAX value may be artificially elevated because RA itself is regarded as one of the major risk factors
in FRAX calculations [12].
Table 3 shows that the number of patients actually receiving pharmacological treatments for
osteoporosis (bisphosphonate or SERM) was only 69.2%–77% based on the FRAX with or without
BMD. Interestingly, more than 90% of patients were receiving medication for osteoporosis when the
WHO criteria were applied. This is probably due to the fact that insurance, covering the treatment of
osteoporosis in Korea, is based on the WHO criteria.
Osteoporotic fracture, especially hip fracture, can increase mortality rate, so there are attempts
to further expand the definition of osteoporosis. For example, while osteoporosis has traditionally
been diagnosed based on t-score of less than −2.5, osteoporosis can be clinically diagnosed if there is a
low-trauma fracture in the absence of other metabolic bone disease, independent of the BMD (t-score)
value [14]. However, there is no clear evidence that the WHO criteria reflect osteoporotic fractures
better than the FRAX criteria. Considering that the FRAX criteria are calculated with BMD values and
various clinical aspects of osteoporosis patients, the importance of FRAX criteria in predicting the risk
of osteoporotic fracture is increasingly emphasized [19,20], making the decision to treat osteoporosis
merely on the basis of WHO osteoporosis criteria problematic. Furthermore, as shown in Table 2, the
number of candidates for pharmacological intervention based on the WHO osteoporosis criteria is less
than those based on the FRAX criteria; therefore, candidates in need of pharmacological treatment
might be missed or their numbers underestimated when applying the WHO criteria. Alternately, we
may also consider the new criteria suggested by the National Bone Health Alliance, that osteoporosis
may be diagnosed in patients with osteopenia and increased fracture risk using FRAX country-specific
thresholds [21]. This is a kind of compromise between FRAX criteria and WHO criteria. In our study,
however, almost all patients who met the FRAX criteria had a BMD of −1.0 or less (FRAX criteria with
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BMD, 95.6%; FRAX criteria without BMD, 90.8%). This result implies that applying the above criteria
gives almost the same result as applying the FRAX criteria at least in patients with RA.
Therefore, further study is needed on how to apply the FRAX and WHO criteria in diagnosing
and treating osteoporosis, or how to combine these two criteria. In addition, since FRAX criteria with
BMD and without BMD may be different, as we have seen in our study, which of these tools is better
must be clarified in the future research. Ultimately, osteoporosis treatment should aim for precision
medicine. In order to do this, it is necessary to evaluate and approve the risk factors of individual
patients. In particular, considering that there is a high risk of osteoporosis in RA patients and that the
risk of osteoporotic fracture may be overestimated by FRAX tool in RA patients, more prospective
studies involving large populations are required to clarify which assessment tool can precisely estimate
osteoporotic fractures in patients with RA.
Nevertheless, it is clear that more than half of postmenopausal women with RA are included in
the high-risk group for osteoporotic fractures. The numbers of the high-risk group for osteoporotic
fractures in RA patients with postmenopausal woman were higher than those in total RA patients,
regardless of which criteria were applied (WHO criteria, 40.3% vs. 33.4%; FRAX criteria with BMD,
55.7% vs. 47.2%; FRAX without BMD, 71.1% vs. 61%, respectively) (Table 2).
The independent risk factors for pharmacological treatments to prevent osteoporotic fractures
were female sex, menopause, alcohol use, glucocorticoid use, and proton pump inhibitor use
(Table 4). In multiple linear analyses, female sex, older age, lower BMI, longer disease duration,
and glucocorticoid dose were associated with a higher probability of osteoporotic fractures (Table 5).
In multivariable logistic regression analyses, the OR of female sex was 3.55 and those of age and
BMI were 1.1 and 0.8, respectively for the WHO osteoporosis criteria (Table 6). These findings agreed
with previous studies [11]. Although smoking has been known to be a major risk factor in many
studies [11,22], it was not a statistically significance factor in our study, which was probably due to the
fact that the majority of patients enrolled in our study were postmenopausal women with a smoking
rate of only 6.9%. Our results showed that the use of biologics, seropositivity, and the levels of acute
phase reactants were not associated with an increased risk of osteoporotic fractures. Regarding the
use of glucocorticoids, the number of patients meeting the FRAX criteria with BMD was higher in
the higher dose with ≥ 5 mg/day prednisolone group. The OR of prednisolone dose was 1.15 in the
FRAX criteria with BMD and 1.09 for fractures. These results suggest that no use of glucocorticoid is
important in RA patients for the prevention of osteoporotic fractures, and if used, glucocorticoid use
should be at a dosage of <5 mg/day.
There are some limitations to this study. The first is that it was conducted not on all RA patients,
but on RA patients who had a BMD. There may be many patients who had been tested for BMD, given
that BMD is not a routine evaluation in RA patients, which could cause a selection bias in this study.
The prevalence of the high-risk group of osteoporotic fractures in patients with RA was 33.4%–61.0%
in this study, which was higher than the prevalence of osteoporosis in the general population of the
United States and Korea [23,24]. However, these results may be overestimated considering selection
bias. There are some studies dealing with the incidence and risk factors of osteoporotic fractures
in patients with RA [25–27]. In a study conducted using the WHO criteria for RA postmenopausal
patients, 46.8% of the patients were considered to have osteoporosis (t-score ≤ −2.5) [25]. However,
in another study using the FRAX criteria for RA patients, in which the population of this study was
similar to our study population, only 17.4% of the patients were reported to meet the FRAX criteria for
pharmacological interventions [27]. Therefore, a large prospective study of all RA patients is needed to
more accurately evaluate the prevalence of the high-risk group of osteoporotic fractures in patients
with RA.
Another limitation is that only bisphosphonate and SERM were evaluated as treatments for
osteoporosis. Recently, new drugs such as teriparatide and denosumab are being used to treat
osteoporosis [11,28,29], but there is no data evaluating these drugs in this study. Nevertheless,
this study has important implications, in that bisphosphonate and SERM are still widely used as
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primary drugs in the treatment of osteoporosis [11,14]. Another limitation is that 88.9% of patients
enrolled in this study were female. The final limitation is that our study did not measure vitamin
D levels. Lower levels of vitamin D, which are known in addition to regulating bone homeostasis,
regulate the differentiation and activities of immune cells [30]. So, vitamin D deficiency can stimulate
inflammatory status influencing disease status other than increasing bone erosion. Moreover, mutation
and polymorphism in vitamin D metabolism genes are associated with serum 25(OH)D levels [30].
Therefore, these factors might have been associated with the results of our study.
5. Conclusions
The proportion of RA patients with a high risk of osteoporotic fractures was 33.4% for WHO
criteria, 47.2% for FRAX criteria with BMD, and 61.0% for FRAX without BMD. Only 69.2%–77% of
candidate patients were receiving osteoporotic treatments when applying the FRAX criteria, in contrast
to 91.3% when applying the WHO criteria. Older age, higher doses of glucocorticoid, and longer
disease duration were independent risk factors for osteoporotic fractures in patients with RA.
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Abstract: We aimed to assess the subjective sleep quality in patients with rheumatoid arthritis (RA)
and its correlation with disease activity, pain, inflammatory parameters, and functional disability.
In a cross-sectional study, patients with confirmed RA diagnosis responded to a questionnaire
(consisting of socio-demographic data, the Health Assessment Questionnaire Disability Index, and the
Medical Outcome Study Sleep Scale). Disease activity was assessed with the Clinical Disease Activity
Index, and pain levels using the visual analogue scale. In addition, inflammatory markers (C-reactive
protein, interleukin-6, and tumor necrosis factor alpha) were analyzed. Ninety-five patients were
analyzed, predominantly female, with an average age of 50.59 (9.61) years. Fifty-seven percent
reported non-optimal sleep duration, where functional disability (92.7% vs. 69.8%; p = 0.006) and
higher median pain levels (3.75 (2.3–6.0) vs. 2.5 (2.0–3.5); p = 0.003) were also more prevalent.
No differences in sociodemographic variables, disease duration or activity, inflammatory parameters,
or use of biological and corticosteroid therapy were observed. The multivariate regression analysis
showed that more intense pain was associated with a lower likelihood of optimal sleep (odds ratio
(OR) = 0.68, 95% confidence interval (CI) 0.47–0.98, p = 0.038). Patients with RA report a high
prevalence of non-optimal sleep, which is linked to pain level. Clinicians need to be aware of this
issue and the potential effects on health and functional status.
Keywords: rheumatoid arthritis; sleep; sleep disorders; pain
1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by changes in the
synovium followed by joint swelling, pain, cartilage and bone destruction, and subsequent systemic
inflammation [1]. The exact etiology is still unknown; however, 50% of the risk is attributable to
genetics [2]. The incidence of RA has proven difficult to determine due to the wide variety of symptoms
with which patients seek medical help and the associated delay in seeking medical help. However,
the prevalence of RA has been reported at around 1% globally, with some countries showing reduced
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prevalence [3]. Overall, the disease is more prevalent in women and has been found to increase in
prevalence with age, with the highest rates found in women older than 65 years [2]. Patients with RA
have a higher mortality and morbidity burden, reduced quality of life, and higher disability [4].
As in other pain conditions, issues of sleep disturbance are of major concern in RA patients,
who often report problems with poor sleep quality, issues with falling asleep, as well as feeling unrested
and fatigued after sleep [5–8]. These subjective findings have been supported by polysomnographic
studies where, compared to healthy controls, patients with RA showed lower overall sleep efficiency
and more awakenings [9]. Sleep problems in people with chronic illness are associated with a variety
of problems, including lower quality of life, psychological issues, cognitive decline, as well as higher
morbidity and mortality [10]. In addition, patients with RA have reported that issues with sleep are of
high personal importance [6].
A commonly reported symptom of RA is fatigue, which is described as an overwhelming
feeling and different from normal tiredness, and is a multifactorial phenomenon associated with
sleep issues, pain, depression, and functional limitations [11–13]. RA patients that experience fatigue,
pain, and depression also have higher levels of physical disability. Several studies have indicated
that pain and depression, as well as sleep quality through its relationship with pain and fatigue,
are associated with functional disability [7].
Studies have shown that most sleep issues experienced in patients with RA stem from pain.
In particular, difficulties with falling asleep and feeling tired after sleep have been found to be
associated with lower pain threshold, pain severity, depression, and inflammation in patients with
RA [14–17]. Pain has also been found to predict sleep disturbance over time, even without sleep issues
affecting pain. Both pain and sleep issues were found to be associated with depression after a 2-year
follow-up [18]. Interestingly, poor clinical management and increased disease activity of RA were found
to be associated with lower daytime sleepiness (but also, as expected, with sleep problems), which may
be explained by pain-related alertness [19]. However, the exact mechanisms of disease activity and
sleep issues are not known. Sleep problems may also be of concern for clinicians working with RA
patients, as reduced sleepiness was found in studies of patients taking certain biopharmaceutical
therapies [17,20]. For instance, studies on abatacept have shown a positive influence on some aspects
of sleep quality [21].
Sleep quality and its associations with disease activity parameters has not yet been researched
in Austria. This paper presents the results of a larger cross-sectional study in patients with from RA.
The complete study protocol was previously published [22]. The aim of the present study was to
determine the prevalence of problems with sleep and its association with disease activity, pain levels,
inflammatory parameters, and functional disability in patients with RA.
2. Materials and Methods
2.1. Participants
One hundred participants visiting the rheumatology outpatient clinic of the Kaiser Franz Josef
Hospital in Vienna during their regularly scheduled visits were recruited for the purposes of this
study [22]. Inclusion criteria were: age between 18 and 65 years; and fulfilled the RA diagnostic
criteria according to the 2010 European League Against Rheumatism (EULAR) classification at
the time of inclusion [23]. Additionally, patients with severe comorbidities (fibromyalgia, cancer,
severe cardiovascular illness) as well as those that could affect handgrip strength measurements,
and patients who refused or were not able to sign the informed consent were excluded from the study.
The study took place from November 2015 to August 2016.
2.2. Methods
In this monocentric cross-sectional study, patients were approached during their regularly
scheduled visits to a rheumatology outpatient clinic, and if they fitted the inclusion criteria, were asked
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to participate in the study. After informed consent was given, the participants were asked to fill out
a questionnaire, after which measurements were taken.
2.3. Questionnaire
The questionnaire was made up of four parts and had 49 items in total—multiple choice
and open-end questions—and took around 10 min to finish. The questionnaire was designed for
self-reporting, with measurements of disease activity undertaken by a member of the study team.
The questionnaire was provided in several languages, including German, English, and Turkish, and one
with a combination of both Serbian and Croatian.
2.3.1. Socio-Demographic Data
This part consisted of multiple choice and open-end questions and was made up of 13 items
covering socio-demographic characteristics of the sample (age, sex, marital status, education level,
and current occupation). Additional questions on disease duration, as well as current therapy and
comorbidities, were also asked.
2.3.2. Functional Disability
The Health Assessment Questionnaire Disability Index (HAQ-DI) was used to assess the patients’
self-reported functional disability. This validated instrument consists of 20 questions divided into eight
categories of functioning: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities.
The overall functional disability index is given as a final score, with values between 0 (no functional
disability) and 3 (severe functional disability) [24].
2.3.3. Sleep Quality
Quality of sleep was assessed using the Medical Outcome Study Sleep Scale (MOS-SS).
This questionnaire is recommended for use in RA patients and is made up of 12 items regarding the
patient’s sleep over the last 4 weeks. MOS-SS is a self-report questionnaire that scores six different sleep
dimensions as scales and two additional indices: sleep disturbance (four items), daytime somnolence
(three items), snoring (one item), awakening short of breath or with a headache (1 item), sleep adequacy
(two items), and quantity of sleep (one item, which is not scored, but is an average number of hours
spent asleep over the past 4 weeks). Optimal sleep is an added dichotomized variable derived from
the quantity of sleep, where sleep is considered optimal if the reported duration is between 7 and
8 h, otherwise it is non-optimal. All items in the MOS-SS, expect for quantity of sleep, are given a
numerical score, and the result is the sum of the individual scores, with the minimum value being 0 and
the maximum 100. Higher scores indicate more of the named dimension, i.e., more sleep problems.
The two indices—sleep problem indices I and II—are derived from several items, with sleep problem
index I being derived from six items and sleep problem index II from nine items of the MOS-SS.
As with the other items, higher values indicate more sleep problems [25]. Patients were also asked
about their use of sleeping pills or pain medication.
2.4. Measurements
2.4.1. Disease Activity
Overall disease activity was measured by the Clinical Disease Activity Index (CDAI), which is
a widely used and validated instrument. The CDAI score is derived as a sum of the subscales (Swollen
28-Joint Count, Tender 28-Joint Count, Patient Global Disease Activity, and Evaluator’s Global disease
Activity). Scores ≤ 2.8 are considered as remission, >2.8 and ≤10 as low disease activity, >10 and ≤22
as moderate, and >22 as high disease activity [26]. For the purposes of our study, we grouped the
participants into two categories: remission and low disease activity in one group, and moderate and
high disease activity as the other group.
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2.4.2. Pain Intensity
Pain was assessed using the visual analogue scale (VAS), ranging from 0 to 10, whereby a higher
number indicates a higher pain intensity [27].
2.4.3. Inflammatory Parameters
The inflammatory parameters of C-reactive protein (CRP; mg/dL), interleukin-6 (IL-6; pg/mL),
and tumor necrosis factor alpha (TNF-alpha; ng/mL) were obtained through analysis of the patients’
blood samples at the Department of Laboratory Medicine of Kaiser Franz Josef Hospital, where the
research was conducted on the same day.
2.5. Statistical Analysis
Kolmogorov-Smirnov tests, Shapiro-Wilk tests, and histogram analysis were employed to
determine the data distribution. Descriptive statistics were recorded for each variable, with the
quantitative variables shown as mean values and standard deviation, and in the case of a non-normal
distribution, as median and 25–75 percentile values. Differences between groups were calculated with
T-tests or Mann-Whitney U-tests, depending on the data distribution. Chi-square tests were used for
the differences between categorical variables. Spearman’s rank order correlation was used for the
possible correlations between the dimensions of sleep quality, as derived from the MOS-SS, and the
other scores (age, disease duration, pain, CDAI score and HAQ-DI score). A multivariate logistical
regression analysis was performed in order to assess the characteristics that were associated with the
MOS-SS-derived dichotomized variable of optimal sleep (reported sleep between 7 and 8 h was deemed
“optimal”, while reported sleep under 7 h and more than 8 h was deemed “non-optimal”). Variables
which showed significant correlations in the univariate correlation analysis were included in the
multivariate logistic regression model. All p-values under 0.05 were considered statistically significant.
The analysis was performed using SPSS for Windows version 24.0 software (IBM, Armonk, NY, USA).
2.6. Ethics Approval
The study complied with Good Clinical Practice standards and the Helsinki Declaration. The study
was approved by the Ethical Committee of the City of Vienna (number: EK 15-173-0915).
3. Results
A total of 140 patients that fulfilled the inclusion criteria were approached and asked to participate.
However, 14 (10%) were not interested to take part, 6 (4.3%) declined due to time constraints, 4 (2.9%)
didn’t speak any of the languages the surveys were available in and 22 (15.7%) did not complete
the necessary measurements, which left 95 (67.9%) patients available for analysis. Approximately
two-thirds of the study population were female, with an age range from 22 to 65 years. The mean
duration of the disease in our population was around 9 years, with 80% receiving therapy with
disease-modifying anti-rheumatic drugs (DMRAD). According to the HAQ-DI score, 21.4% of the
participants had a level of functional disability, and the median pain score was 3.0 (2.0–5.0) out of
10. Differences according to optimal sleep duration were found in pain intensity, level of functional
disability, and use of non-steroidal anti-inflammatory drugs (NSAID) and disease-modifying drugs.
Additional information about the study participants is provided in Table 1.
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Table 1. Sociodemographic and disease-related variables stratified by optimal sleep duration.
Variable Total (n = 95) Non-Optimal Sleep
Duration (n = 54)
Optimal Sleep
Duration (n = 41) p
Age; mean (SD) 50.59 (9.61) 49.98 (9.14) 51.39 (10.25) 0.482
Sex
Male 32.6% 33.3% 31.7%
0.867Female 67.4% 66.7% 68.3%
Relationship status
In a relationship 73.7% 77.8% 68.3%
0.298Not in a relationship 26.3% 22.2% 31.7%
Education level
Primary level 15.8% 13.0% 19.5%
0.434Secondary level 72.6% 77.8% 65.9%
Tertiary level 11.6% 9.3% 14.6%
Employment status
Employed 61.1% 63.0% 58.5%
0.661Unemployed 38.9% 37.0% 41.5%
Disease duration in months;
median (Q25–Q75)
72.0
(36.0–141.0) 78.0 (36.0–144.0) 60.0 (28.50–138.0) 0.452
Pain intensity; median (Q25–Q75) 3.0 (2.0–5.0) 3.75 (2.3–6.0) 2.5 (2.0–3.5) 0.003
Functional disability
No disability 79.8% 69.8% 92.7%
0.006Disability 20.2% 30.2% 7.3%
Disease activity
Remission 29.5% 29.6% 30.8%
0.726
Low 33.7% 31.5% 38.5%
Moderate 26.3% 27.8% 25.6%
High 8.4% 11.1% 5.1%
Inflammatory parameters
CRP (mg/dL); median (Q25–Q75) 3.20 (1.10–6.70) 3.05 (1.07–7.05) 2.70 (1.00–5.55) 0.594
TNF-α (g/mL); median (Q25–Q75) 1.60 (0.56–2.35) 1.65 (0.54–2.89) 1.60 (0.64–2.32) 0.884
IL-6 (pg/mL); median (Q25–Q75) 3.89 (1.98–7.91) 4.47 (2.04–9.67) 3.44 (1.72–6.18) 0.179
Therapy
Disease-modifying drugs 81.1% 72.2% 92.7% 0.012
Biologicals 43.2% 50.0% 34.1% 0.122
Corticosteroid 16.8% 18.5% 14.6% 0.616
Non-steroidal anti-inflammatory 14.7 7.4% 24.4% 0.021
Other medication 55.8% 55.6% 56.1% 0.958
SD = standard deviation. Differences between groups were calculated with the T-test, Mann-Whitney U test
dependent on data distribution. Chi-square test was used for differences between categorical variables.
Overall, our patients reported non-optimal sleep duration in 56.8% of cases, with a mean duration
of sleep over the past 4 weeks of 6.5 (1.3) h. The median score of sleep problem index I was 30.0,
with the score of sleep problem index II being slightly higher at 32.2 points. The highest reported
median value of the six items was in sleep adequacy, which indicates that our patients, in general,
feel well rested and have enough sleep during the night. Furthermore, most of the participants did not
take pain medication or sleeping pills. Other results regarding the MOS-SS score and the other sleep
quality variables are presented in Table 2. In terms of disease activity, patients with moderate and high
disease activity reported fewer hours asleep in comparison to patients with low disease activity or in
remission (6.7 (1.2) vs. 6.0 (1.2); p = 0.009).
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Table 2. Sleep characteristics of the study participants.
Sleep-Related Variables n = 95
Sleep disturbance median (Q25–Q75) 32.5 (15.0–51.2)
Snoring; median (Q25–Q75) 40.0 (20.0–60.0)
Shortness of breath or headache; median (Q25–Q75) 20.0 (0.0–30.0)
Sleep adequacy; median (Q25–Q75) 60.0 (30.0–80.0)
Somnolence; median (Q25–Q75) 26.6 (13.3–46.6)
Sleep problem index I; median (Q25–Q75) 30.0 (16.6–46.6)




Pain medication for sleep
Daily 8.2%
Up to 3 times a week 7.2%
More than 3 times a week 5.2%




Up to 3 times a week 2.1%
More than 3 times a week 1.0%
Up to 3 times a month 4.1%
Never 83.5%
Hours asleep; mean (SD) 6.5 (1.3)
SD = standard deviation.
The relationship between the sleep domains of the MOS-SS and age, disease duration in months,
pain intensity, disease activity, and functional disability scores was investigated, as seen in Table 3.
Pain intensity was the only variable that was correlated with all the MOS-SS domains, with the highest
coefficient being a medium positive correlation with sleep problem index II (r = 0.406; p < 0.001).
Overall, the strongest relationship was found between functional disability and sleep problem index
II (r = 0.516; p < 0.001). Disease activity had significant small to medium positive correlations
with sleep disturbance, snoring, shortness of breath or snoring, and sleep problem indices I and II,
while a significant negative correlation was observed between sleep duration and the sleep adequacy
domains of the MOS-SS, as seen in Table 3.





















Age 0.077 −0.007 0.204 * −0.012 0.043 −0.027 −0.050 −0.040
Disease duration −0.177 0.201 * −0.037 0.134 −0.066 0.184 0.173 0.149
Pain intensity
(VAS) −0.350 ** 0.379 ** 0.228 * 0.279 ** −0.297 ** 0.305 ** 0.374 ** 0.406 **
CDAI Score −0.304 ** 0.324 ** 0.210 * 0.249 * −0.275 ** 0.148 0.293 ** 0.322 **
HAQ-DI Score 0.247 * 0.459 ** 0.090 0.298 ** −0.436 ** 0.390 ** 0.495 ** 0.516 **
* p < 0.005; ** p < 0.001; VAS: visual analogue scale, CDAI: Clinical Disease Activity Index, HAQ-DI: Health
Assessment Questionnaire Disability Index.
According to the multivariate logistical regression analysis, pain intensity was the only variable
that was significantly associated with optimal sleep duration, where more severe pain was associated
with a reduced likelihood of optimal sleep, as seen in Table 4.
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Table 4. Logistic regression model of variables associated with optimal sleep duration.
Variable OR 95% CI p
Age 1.03 0.99–1.09 0.162
Pain VAS scale 0.68 0.47–0.98 0.038
HAQ-DI score 0.53 0.19–1.45 0.215
CDAI score 1.02 0.95–1.11 0.544
Disease duration 1.00 0.99–1.01 0.756
OR: odds ratio, 95% CI: 95% confidence interval, VAS: visual analogue scale, CDAI: Clinical Disease Activity Index,
HAQ-DI: Health Assessment Questionnaire Disability Index.
4. Discussion
Our study showed that, in an investigated sample of patients with RA, problems with sleep
are common, with 56.8% of the participants reporting non-optimal sleep duration. Interestingly,
the MOSS-SS sleep adequacy scale showed high results, meaning that our participants were, overall,
satisfied with their sleep quality. Studies have shown that up to 70% of patients with RA suffer
from problems with sleep, ranging from difficulty falling asleep to difficulty maintaining sleep or
suffering from daytime sleepiness [6,28]. Several studies found that higher disease activity is associated
with sleep problems [9,29,30]. A study by Wolfe et al. [8] showed that sleep disturbance could
be attributed to RA in up to 42% of cases, linking sleep disturbance to pain, mood, and disease
activity. Similarly, a Korean study found decreasing subjective sleep quality as the disease activity was
increasing [30]. Conversely, studies have also found that reducing the active inflammatory disease and
the arthritic process have a positive effect on sleep quality [31]. However, a connection between disease
activity and sleep quality has not been universally reported in studies. For example, Hirsch et al. [5]
reported overall disturbed sleep in patients with RA, but found no association with inflammatory
disease activity. These results have often been questioned as the study population was very small
(only 19 patients), which may be the reason for the lack of association. Our study, although five
times larger in terms of the sample size, also found no difference in sleep quality in patients with
different disease activity, as shown in Table 1. In terms of the relationship between the CDAI scores
and the sleep domains of the MOS-SS, seen in Table 3, only low to moderate correlations were found.
The only significant difference in sleep characteristics between patients with different disease activity
was found in sleep duration, where patients in the moderate/high disease activity group reported
shorter sleep duration.
The mechanism of how disease activity influences sleep quality is not completely clear; however,
most studies have suggested the connection with joint stiffness and pain. In a study by Wolfe and
Michaud [8], pain was shown to be one of the most common underlying reasons leading to problems
with sleep, with a recent study of Austrian patients with chronic pain also reporting notable sleep
disturbance [32]. Chronic pain and associated sleep issues are a risk for developing depressive
symptoms in patients with RA, which in turn may have an additional influence as depression has
been reported as being a predictive factor for poor quality of sleep [15,19]. In our study population,
pain levels were generally low; however, there was a significant difference based on reported optimal
sleep duration, as seen in Table 1, where lower pain levels were found in those patients who reported
optimal sleep duration. The multivariate logistic regression model showed pain intensity to be
a predictor for non-optimal sleep in our population, as shown in Table 4. Furthermore, pain was found
to be correlated with all the domains of sleep quality in the MOS-SS, having a negative relationship
with hours spent sleeping and the sleep adequacy domain. More pain intensity is positively correlated
with sleep disturbance, snoring and shortness of breath, somnolence, and both sleep problem indices.
Recent evidence shows that lower sleep quality lowers the threshold of pain and increases the pain
intensity in patients with RA [9,16,19].
The relationship between RA therapy and medication used for sleep quality is ambivalent.
Some studies have reported the use of biological medication as having a positive effect on sleep
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quality, with longitudinal observations of anti-TNF substances also reporting greater sleep quality
improvements in patients on abatacept in comparison to methotrexate. A trial investigating the
effectiveness of indomethacin on sleep quality showed indomethacin to be superior to placebo in
a questionnaire-based study. However, polysomnographic studies investigating sleep patterns in
patients using NSAIDs showed no changes in sleep patterns or sleep quality in patients with RA.
In our study, as presented in Table 1, patients who reported optimal sleep duration were found to
more often use disease-modifying drugs and NSAIDs, which is probably connected to their analgesic
effect. More research, especially blinded longitudinal studies, should be done to investigate the
effects of medication on sleep quality of RA patients, as most cross-sectional studies have reported no
connection [8,30,33].
Functional disability was found to be associated with sleep quality, as patients with RA often
experience difficulties with the activities of daily living, which was found to be associated with
fatigue and sleep disturbance. In addition, disability often leads to greater depression, which in turn
leads to sleep disturbance. A relationship between pain, depression, sleep, and functional disability
has been shown in numerous studies, which may mean that there is a casual relationship, as pain,
fatigue, and depression inhibit normal daily productivity, causing sleep disorders and disability,
which then contribute to pain, fatigue, depression, and disability [8,9,33]. In our study, patients who
were categorized as having functional disability reported significantly non-optimal sleep duration,
as seen in Table 1. However, the HAQ-DI score showed no association with optimal sleep in the
multivariate logistic regression model and, interestingly, was found to have a positive relationship
with sleep duration. Furthermore, functional disability was found to be significantly correlated with
somnolence, shortness of breath, sleep adequacy, sleep disturbance, and both sleep problem indices as
shown in Table 3.
The relationship between age and sleep quality in patients with RA is unclear, but some studies
have reported lower sleep quality in older patients [30,33]. Our study showed only a small positive
correlation with age and snoring, but no correlation with other dimensions of the MOS-SS as seen
in Table 3. Other studies have often failed to report an association between age and sleep problems
in patients with RA [8,19]. This was confirmed by our logistic regression model, where there was no
significant association found between optimal sleep duration and age.
Finally, the study limitations need to be addressed. The cross-sectional study design does not
allow for causal conclusions on the relationships between variables. Longitudinal studies need to be
performed in order to examine the possible casual associations. Secondly, although the MOS-SS is
recommended for use in RA, it refers to a time frame of the previous 4 weeks, which may affect the
results due to recall bias. Additionally, we haven’t reported on the body mass index (BMI) which is
also a potential confounder. Finally, as patients were recruited to the study by their physicians, it is
possible that the results are an underestimation due to reporting bias. The relatively small sample size
might prevent the generalizability of the study results, as well as the higher proportion of women;
however, this is to be expected in a RA patient population. Furthermore, our population consisted of
men and women of working age, which may also contribute to the reduced sleep problems.
Given our results and the noted associations of pain and non-optimal sleep in patients with RA it is
important to alert the clinical community working with RA patients. Sleep as well as pain assessments
should be systematically included in the clinical assessments [34]. However, such monitoring will
not be effective in reducing the burden of pain and sleep problems in RA patients, unless appropriate
treatment is also not provided. Albeit research indicates the associations of pain and sleep disturbances,
pharmacotherapy for these comorbidities receives little attention, and there is yet to be a consensus
or evidence based treatment algorithms [35]. Additionally, a recent meta-analysis indicated that
non-pharmacological sleep treatments (including physiotherapy, meditation, massage, sleep restriction
therapy and sleep scheduling, imagery exercises, and others) were associated with large improvements
in sleep quality [36]. In conclusion, there is a high frequency of non-optimal sleep duration in
patients with RA of working age; however, these patients are mostly satisfied with their overall
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sleep quality. Our study further shows the association between higher pain levels and non-optimal
sleep. Physicians working with RA patients need to be aware of the sleep issues in this population
and include pharmacological and psychological interventions as these may have a positive effect on
sleep quality, and in turn on psychological wellbeing, physical wellbeing, and functional disability.
Future studies could focus on sleep quality in newly diagnosed patients, as well as longitudinal studies
need to be implemented in order to see if improvements in sleep contribute to reduction of depression,
pain, and functional disability.
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Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic
inflammation of the joints. Untreated RA leads to a destruction of joints through the erosion of
cartilage and bone. The loss of physical function is the consequence. Early treatment is important to
control disease activity and to prevent joint destruction. Nowadays, different classes of drugs with
different modes of action are available to control the inflammation and to achieve remission. In this
review, we want to discuss differences and similarities of these different drugs.
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1. Introduction
Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of
the synovial membrane. Untreated RA can lead to progressive joint destruction, resulting in disability,
poor quality of life, and increased mortality. About 1% of the population is affected, and the disease
onset generally occurs between 30 years and 50 years of age, with a higher incidence in women.
The therapy is complex and includes different classes of drugs with different routes of application
but also nonpharmacologic interventions. The most important are patient education followed
by exercise and physical and occupational therapy. Because of an increased risk of coronary
atherosclerosis, efforts should be made to reduce risk factors such as smoking, hyperlipidemia,
hypertension, and obesity.
To relieve pain and swelling fast and to gain control of the inflammation, glucocorticoids (GC) are
used widely in acute disease flares either orally or as intraarticular injections. Oral GC is for short-term
use (up to 3–4 month) only and should be tapered to prevent side effects as soon as possible [1].
To control inflammation in the long run, Disease Modifying Anti-Rheumatic Drugs (DMARD) to spare
GC are needed. Nowadays, there are a bunch of opportunities that can be challenges or chances.
The treatment of patients with RA aims to relieve pain and to control inflammation, and the final
goal is to achieve remission or at least low disease activity for all patients. In this context, the European
League Against Rheumatism (EULAR) has composed 10 international recommendations on how to
treat patients [2]. An algorithm based on the EULAR recommendations is shown in Figure 1. In 2010, an
international committee developed the treat-to-target (T2T) initiative. The centerpiece of this initiative
is the shared decision-making and regular patient revaluation that targets remission or at least low
disease activity (LDA) [3].
By now, there is evidence from different studies that the T2T principle is superior, and it forms part
of the treatment guidelines of the European League Against Rheumatism and the American College of
Rheumatology. The core principles of T2T are shown in Table 1. Even more important is that an early
start of therapy is required in order to achieve optimal outcomes.
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Figure 1. Algorithm adapted from the 2016 European League Against Rheumatism (EULAR)
recommendationson rheumatoid arthritis (RA) management. bDMARD, biological; bsDMARD,
biosimilar DMARDs; csDMARDs, conventional synthetic DMARDs; DMARDs disease modifying
amtirheumatic drug; IL, Interleukin; MTX, methotrexate; TNF, tumor necrosis factor; tsDMARDs,
targeted synthetic DMARDS.
184
J. Clin. Med. 2019, 8, 938
Table 1. Overarching principles of the T2T strategy (modified after Smolen J.S., et al. Ann Rheum Dis
2016;75:3–15). [3].
Overarching Principles of the T2T Strategy
1 Basis for the treatment is a shared decision making between patient and doctor
2
Major treatment goals are: maximization of quality of life, normalisation of function and
participation in social and professional life
3 The elimination of inflammation is essential to achieve the treatment goals
4 Outcomes in rheumatoid arthritis are improved by implementing T2T
2. Treatment Guidelines: Conventional Synthetic DMARD (csDMARD)
As soon as the diagnosis of rheumatoid arthritis is made, a treatment with a csDMARD should be
started [4].
A controlled comparison between csDMARDs for the first-line therapy does not exist; however,
within this group, methotrexate should be the first choice because, for this drug, most clinical experience
exists in monotherapy and as a combination partner with other DMARDs [5]. Methotrexate is usually
started at a dose of 15 mg/week and can be stepwise increased up to 25 mg/week. The combination
with glucocorticoids is recommended [3]. Due to the decreased bioavailability, a subcutaneous way of
administration is recommended [5].
The induction of remission with a combination of conventional synthetic DMARDs at this stage is
not superior to methotrexate monotherapy; however, these combinations are associated with more
adverse events and a higher rate of drug discontinuation [4,6]. Patients with a higher baseline disease
activity and Rheumatoid factor (RF)-positive patients have an increased risk of methotrexate (MTX)
failure due to inefficacy [6].
If MTX cannot be used, e.g., due to intolerance or contraindications, leflunomide (20 mg/week) or
sulfasalazine (2 g/day) should be started. In a placebo-controlled randomized controlled trial (RCT),
both substances showed a similar efficacy [7].
If by week 12 after the start of MTX therapy no adequate response is achieved or no remission
is reached with optimum doses after 24 weeks, the therapy should be adjusted [5]. To find the
best individual treatment strategy, patients should be categorized using prognostic markers. Poor
prognostic markers such as the presence of autoantibodies, early joint damage, and high disease
activity are associated with rapid disease progression; therefore, a biologic DMARD or a targeted
synthetic DMARD should be added at this stage [4]. In the absence of poor prognostic markers and
with moderate disease activity, a second csDMARD should be added to the therapy [5].
2.1. MTX
Unlike targeted DMARDs, conventional synthetic DMARDs came into clinical practice based on
empiric observations and their mechanisms of action are still incompletely understood [4].
The mode of action of high-dose methotrexate via the depletion of thymidine and purine residues
and cell-cycle arrest at S1 are well-known [8]. However, this mechanism does not seem to play a major
role in the clinical effect of low-dose MTX, as folate co-therapy does not result in a loss of clinical
benefit. Methotrexate has pleiotropic therapeutic effects on various immune cells and mediators,
resulting in an overall dampening of the inflammatory response. The main mode of action of low-dose
MTX in rheumatoid arthritis is thought to be via the potentiation of adenosine signaling. Adenosine
acts as a paracrine signaling agent via four distinct purinergic G-protein-coupled receptors, which
in rheumatoid arthritis are overexpressed. In addition to downregulating the production of tumor
necrosis factor (TNF) and NF-kB, adenosine might be one of the main mediators of the downregulation
of the activation and proliferation of T-lymphocytes, creating an immunotolerant environment [8].
Side effects of MTX are usually dependent on dose, mode of application, and duration
of methotrexate therapy. Unlike high-dose MTX, the side effects of low-dose MTX are rarely
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life-threatening and can often be relieved by substituting folate. Common side effects of low-dose
MTX are hematologic abnormalities (thrombocytopenia and leucopenia), stomatitis, gastrointestinal
problems (e.g., anorexia, loose stools, nausea, or stomach upset), elevation of liver enzymes, or central
nervous system symptoms like fatigue or headache [9]. The substitution of folate significantly lowers
the risk for side effects like hepatotoxicity (relative risk reduction of 77%) and decreases the number
of serious adverse events (by 61%) [5,10]. If side effects occur, substituting folate acid regularly and
gradually increasing the dose up to 5 mg daily can help to control the symptoms. Overall, fewer than
5% of patients have to stop using methotrexate because of adverse events [4].
MTX therapy can, in many cases, be safely continued perioperatively; however, a potentially
decreased kidney function in this setting should be taken into account. In addition, to decrease the
risk of pneumonia, the treatment should be paused if pulmonary comorbidities exist. At high doses
(25 mg/week), a temporary dose reduction should be considered [11].
MTX exposure during pregnancy can induce multiple congenital deformities. Therefore, MTX
therapy during pregnancy is not recommended. MTX should be withdrawn prophylactically 3 months
before conception. Daily folate supplementation should be continued antenatal and throughout
pregnancy. At the present stage of knowledge, it is not clear whether MTX transiently influences male
fertility and sperm DNA integrity [12].
2.2. Leflunomide
The primary mechanism of action of leflunomide (LEF) is the reversible inhibition of the
mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), the rate limiting step in the de novo
synthesis of pyrimidines. Activated lymphocytes expand their pyrimidine pool by approximately
eightfold during proliferation. Therefore, the inhibition of DHODH prevents activated lymphocytes
from moving from G1 to the S phase, hence triggering apoptosis [13]. The leflunomide effect seems to
be rather lymphocyte-specific on other cells, can reuptake pyrimidines, and can thereby overcome the
DHODH blockade.
The rate of discontinuation due to side effects is similar with methotrexate [14]. Potential side
effects include diarrhea and nausea as well as the elevation of liver enzymes. The changes in liver
function are generally reversible with dose reduction or a discontinuation of the drug, but in rare cases,
hepatotoxicity can be severe. However, transaminase elevation mainly occurs if other comorbidities
contributing to hepatotoxicity, e.g., concomitant non-steroidal anti-inflammatory drugs (NSAID) or
MTX therapy, previous or concurrent alcohol abuse, or viral or autoimmune hepatitis, are present [15].
A small percentage of patients with RA develop hypertension when taking LEF; therefore, blood
pressure monitoring is recommended during treatment [14].
The active metabolite of leflunomide is detectable in plasma until 2 years after the discontinuation
of the drug; therefore, a discontinuation of leflunomide perioperatively is generally not recommended.
Only at a high risk of infection or if a greater intervention is planned, a wash out with cholestyramine
should be initiated as recommended [11].
Leflunomide is contraindicated during pregnancy. Safe contraception during therapy in both
women and men is recommended. Before conception, leflunomide must be withdrawn and a washout
should be carried out until the drug is undetectable in the blood [12].
2.3. Sulfasalazine
Sulfasalazine SSZ was specifically designed in 1938 for the treatment of rheumatoid arthritis.
The idea behind the drug was to combine an antibacterial and an anti-inflammatory agent [16].
Sulfasalazine is effective in the treatment of rheumatoid arthritis; however, the mode of action
is incompletely understood. The main pharmacological effects of SSZ include effects on the gut
bacterial flora, on inflammatory cell functions, and on immunological processes [16]. Several plausible
mechanisms of action have been observed in vitro, such as the inhibition of NF-kB and osteoclast
formation via modulatory effects on the receptor activators of NF-kB (RANK), osteoprotegerin (OPG),
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and RANK-ligand. In addition, SASP can inhibit tumor necrosis factor (TNF)-alpha expression and
may reduce the secretion of inflammatory cytokines such as interleukin (IL)-8 as well as may suppress
B-cell function [17]. An additional mechanism that has been suggested is the increased production of
adenosine at sites of inflammation similar to the mode of action of methotrexate.
Adverse reactions, including idiosyncratic (e.g., hypersensitivity-/immune-related) and
dose-related effects, are common with sulfasalazine, especially gastrointestinal, central nervous
system, cutaneous, and hematologic adverse effects. The withdrawal rate for adverse events is
about 25%, two thirds of which are due to gastrointestinal and central nervous system toxicity. If
dose-related side effects occur, treatment can be paused for a week and after a resolution of the
symptoms, the treatment can be restarted at a lower dose [18]. However, if idiosyncratic effects like
skin reactions, hepatitis, pneumonitis, or hematologic side effects like agranulocytosis and hemolytic
anemia occur, immediate discontinuation of the drug is necessary; patients with this type of adverse
effect should not be rechallenged with the drug [18].
As sulfasalazine only has a short half-life of about 4–5 h and only a minimal immunosuppressive
effect, it can usually be continued perioperatively. If there is a risk of interaction or a potential additive
hepatotoxic effect with medication used preoperatively, sulfasalazine can be paused on the day of the
operation [11].
If treatment of rheumatoid arthritis is required during pregnancy, SSZ is an acceptable therapeutic
option, as the continuation of SSZ during pregnancy is very unlikely to cause fetal harm [12,19].
To increase safety, a concomitant folate supplementation before and throughout pregnancy is advised
and the dose of SSZ should not exceed 2 g per day to prevent neutropenia in the newborns. SSZ
can cause reduced male fertility; however, spermatogenesis recovers at about 2–3 months after a
withdrawal of the drug [12].
3. Biologic DMARDs (bDMARD)
According the EULAR guidelines, a bDMARD should be considered if remission or LDA is not
achieved with the first DMARD strategy, if poor prognostic factors (i.e., high acute phase reactant
levels, high swollen joint counts, or the presence of early erosions) exist, or if the patient responds
inadequately to MTX and/or other csDMARD strategies.
Before starting a therapy with bDMARD, active or latent infections with hepatitis or tuberculosis
must be ruled out. Patients, if possible, should be brought up to date with all immunizations before
initiating therapy. Blood cell counts and liver and kidney function also need to be evaluated prior
to treatment.
3.1. Tumor Necrosis Factor-Alpha Inhibitors (TNFi)
Until now, five TNFi were available. Although all anti-TNF drugs bind TNF-α, there are differences
in their molecular structures, their administration regimens, and their modes of action.
The first preclinical studies using antibodies against TNF- α were performed in animal models
of sepsis in 1985. About 6 years later, Keffer et al. provided the first evidence that TNF plays a role
in developing arthritis [20]. In 1994, The Lancet published the first RCT showing that the blockade
of a specific cytokine can be an effective treatment in patients with rheumatoid arthritis [21]. Since
then, antibodies against TNF-alpha have gotten an important cornerstone in the treatment of RA and
changed the lives of our patients.
Nowadays, we could not think of a world without antibodies against TNF-α or other cytokines.
For our patients, this changed the game.
The first TNF-α-inhibitor, approved in 2000 for the therapy of RA, was the chimeric murine/human
IgG1 monoclonal antibody Infliximab (IFX) that binds to both soluble and membrane-bound TNF-α [21].
The administration is intravenous every 8 weeks at a dosage between 3–5 mg/kg. Another TNF-inhibitor
also approved in 2000 is Etanercept (ETN), a recombinant fusion protein compound of the soluble
TNF-alpha receptor linked to the Fc portion of human IgG. ETN binds to the TNF receptor, preventing
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TNF-mediated cellular responses. ETN is administered subcutaneously at a dose of 25 mg twice
a week or 50 mg weekly [22,23]. The third inhibitor approved in 2003 by the European Medicines
Agency (EMA) is Adalimumab (ADA) [24]. It is a recombinant human IgG1 monoclonal antibody that
binds to soluble and membrane-bound TNF-α with a high affinity. It is administered by subcutaneous
injection once every 2 weeks. Golimumab (GOL) is a human IgG1 monoclonal antibody neutralizing
both soluble and membrane-bound TNF-α. GOL was approved in 2010 and is administered as a
subcutaneous injection at an initial dose of 50 mg every 4 weeks that can be increased to 100 mg if
there is no response after 4 doses (in patients with a body weight > 100 kg) [25]. Certolizumab Pegol
(CZP) was approved by the EMA in 2007. CZP is a recombinant humanized Fab’ fragment of a TNF
antibody coupled to polyethylene glycol (PEG) that prolongs its plasma half-life to approximately
2 weeks. It has an initial loading dose of 400 mg every 2 weeks for 6 weeks, followed by 200 mg every
2 weeks [26,27].
Only certolizumab, adalimumab, and etanercept are approved as monotherapy as well as in
combination with methotrexate [27–31].
Adverse effects include skin reactions characterized by itching, pain, and redness at the site of
medication injection. Such injection site reactions characteristically occur during the first weeks
of treatment. For intravenously administered agents, acute infusion reactions can occur with
hypotension, bronchospasm, wheezing, and/or urticaria. Acute reactions may, in some cases, represent
immunoglobulin-E-mediated type I reactions. The majority of acute infusion reactions that occur are
anaphylactoid reactions and not immunoglobulin E mediated. These reactions can be managed by just
reducing the rate of infusion [32,33].
However, delayed infusion reactions can also occur, and they are associated with skin rash,
diffuse joint pains, myalgia, and fatigue and sometimes accompanied by fever. Delayed reactions
may represent mild type III (immune complex-mediated) reactions [34]. It has been shown that the
formation of Anti-monoclonal antibodies may lead to a greater risk of infusion reactions and also
may limit the long-term efficacy of the drug. It has also been shown that the use of concomitant
immunomodulators prior to starting a TNF-α-inhibitor is effective in reducing antibody production
and therefore decreasing immunogenicity [32,34].
As TNF-alpha is a key player of the immune system during infections, this treatment has been
associated with an increased risk of serious infections. These include bacterial infections (particularly
pneumonia), herpes zoster, tuberculosis, and opportunistic infections [35]. As mentioned above,
screening for latent tuberculosis infections should be performed before the initiation of TNF-alpha
inhibitor therapy. If there is an indication of latent tuberculosis, a treatment for latent tuberculosis
should be initiated before starting therapy with a TNF-alpha inhibitor [36]. Another side effect occurring
in a few cases is neutropenia. Other cytopenias are uncommon [37]. The association between TNF-alpha
inhibitors and demyelinating diseases remains uncertain. However, anti-TNF-alpha agents should
generally be avoided in patients with established diseases that are associated with demyelination and
should be discontinued directly in any patient with suspected demyelination [38]. Treating patients
with NYHA III or IV cardiac failure is not recommended [2,39]. However, data regarding cardiac
failure in patients treated with anti-TNF-alpha agents are inconclusive [40]. While Kwon et al. reported
38 patients who developed new-onset heart failure and 9 patients who experienced heart failure
exacerbation after therapy [39], others report a reduced risk of cardiovascular events in patients treated
with TNF-alpha inhibitors [40].
Pregnancy
Observational studies and case reports of women exposed to TNF inhibitors during pregnancy
suggest that their pregnancy outcomes, including rates of preterm birth, spontaneous miscarriage, and
congenital anomalies, are similar to those in women with RA who have not received a TNFi [41].
Complete immunoglobulin G (IgG) antibodies—maternal as well as therapeutic—cross placenta
via active transport facilitated by the neonatal fragment crystallizable (Fc) receptor on the placenta.
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IgG1 is the most effectively transported of the four subclasses of IgG (G1–G4) [42]. This is relevant to
adalimumab, golimumab, and infliximab which are complete IgG1 anti-TNF. Etanercept is comprised
of the Fc domain of human IgG1 fused with the extracellular ligand binding domain of human tumor
necrosis factor receptor-2. Transplacental transport via the neonatal Fc receptor would theoretically be
plausible. In contrast to the complete IgG1 anti-TNF antibodies certolizumab pegol differs structurally
as it is a humanized PEG (polyethylene glycol)-ylated antibody Fab’ fragment lacking the IgG1 Fc
portion. Without the Fc portion it should, in theory, not be transported actively across the placenta [43].
So passive diffusion would be the only option for any detectable concentrations in exposed infants.
This was shown in two trials. Based on these trials the EMA has approved a label change for CZP,
making it the first anti-TNF for potential use in women with chronic rheumatic disease during both
pregnancy and breastfeeding [44].
TNFi may have different structures, morphology, pharmacokinetic properties, and activity, but
their clinical efficiency is comparable. If drug survival and safety are similar or different is still a matter
of debate.
3.2. Interleukin 1 Inhibitor
Anakinra was first approved in the US in 2001 and in Europe in March 2002. It is a recombinant
human IL-1 receptor antagonist with a short half-life (4–6 h), administered subcutaneously at a dose of
100 mg once a day. It was first developed for use in RA and showed some effects in early trials. A big
systematic review of the literature in 2009 showed only a moderate effectiveness [45,46]. Anakinra plays
not a very great role in RA therapy; today, it is much more effective in the therapy of auto-inflammatory
diseases, gout, or polyserositis [45–50].
Adverse effects include injection site reactions characterized by itching, pain, and redness at the
site of medication injection and lasting days to weeks. Between one and ten percent of people have
severe infections, decreased white blood cells, or decreased platelets [51].
Pregnancy
There have been no adequate studies for the safety of Anakinra in Pregnancy, although several
case reports of women with adult-onset Still’s disease treated through pregnancy resulted in healthy
neonates [52].
4. Interleukin 6 and Interleukin 6 Receptor Inhibitors
Interleukin-6 (IL-6) was identified in 1986 as a key cytokine in the pathogenesis of RA with
proinflammatory activity. It is able to enhance the production of acute-phase proteins involved in the
systemic inflammation process. Tocilizumab (TCZ) is the first humanized recombinant IgG1monoclonal
antibody that binds to both the soluble and membrane-bound IL-6 receptor, blocking its action and
leading to the decrease of the inflammatory response cascade. Its half-life (10–13 days) allows
its administration intravenously (8 mg/kg) every 4 weeks. A subcutaneous formulation of TCZ
(162 mg/week) has been approved, with an efficacy and safety profile comparable to intravenous
administration [52,53]. A second agent, Sarilumab is a human immunoglobulin G1 anti-interleukin-6
(IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble
IL-6 receptor alpha [54].
Events of gastrointestinal (GI) perforations have been reported in Phase III clinical trials, primarily
as complications of diverticulitis, including generalized purulent peritonitis, lower GI perforation,
fistula, and abscess. Tocilizumab or Sarilumab should be used with caution in patients who may be at
increased risk for GI perforation. Patients presenting with new-onset abdominal symptoms should be
evaluated promptly for the early identification of GI perforation. It is important to keep in mind that,
during IL-6 blockade, C-reactive protein or other acute phase reactants will increase slowly and less
pronounced [55,56].
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Other side effects are neutropenia or thrombocytopenia as well as hyperlipidemia. Also, serious
infections and liver enzyme elevations were observed and can require dose adjustments or drug
discontinuation [56].
4.1. Pregnancy
Based upon animal data, tocilizumab may cause fetal harm, but there are no adequate studies of
its effects on human pregnancy to allow an assessment of its risk. There are a few case series available.
No teratogenic effects were observed. In a case series of 50 pregnancies exposed to tocilizumab with
known outcomes, 36 resulted in live births, while there were five low-birthweight infants born and one
case of neonatal asphyxia [57,58].
4.2. CD80/86-CD 28 Inhibitor
Abatacept is a fusion protein constituted by an immunoglobulin fused to the extracellular domain
of cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a molecule that binds with a high affinity to
the CD80/86 ligand on antigen-presenting cells. Therefore, abatacept is able to block the interaction
between the antigen-presenting cell’s CD80/86 ligand and the CD28 ligand on the T cell [59]. This results
in decreased T cell proliferation and cytokine production. Abatacept is administered intravenously
once every 4 weeks or subcutaneously once a week [60,61].
Adverse effects including cases of hypersensitivity and anaphylaxis or anaphylactoid reactions
have been reported with iv administration. As in other bDMARDs, serious infections (including
tuberculosis and sepsis) have been reported, particularly in patients receiving concomitant
immunosuppressive therapy [59].
The use of CTLA-4 Inhibitors due to its T cell inhibition affect defenses against malignancies.
As compared to the general population, an increased risk of lymphoma has been noted in clinical trials;
however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma.
Abatacept itself seems not to further increase this risk [62].
Pregnancy
Abatacept is not teratogenic in animals, but there are no adequate studies of its effects on human
pregnancy to allow an assessment of its risk.
5. Anti-CD 20 Antibody
Rituximab (RTX) was initially developed for the treatment of hematologic malignancies. Since
2006, RTX is approved for the therapy of RA refractory to a combination therapy of anti-TNF-alpha, an
MTX [60]. RTX is a chimeric murine-human monoclonal antibody that binds to the CD20 membrane
receptor, leading to the depletion of circulating B cells. It is also able to inhibit the activation of T
cells that produce proinflammatory cytokines. A cycle of RTX consists in 1000 mg by intravenous
infusion, followed by a second 1000-mg intravenous infusion two weeks later. This is then repeated
every 6 months. Different studies showed that particularly patients who are autoantibody-positive
benefit from RTX [63,64].
According to results of different studies, patients benefit more from switching to RTX when an
initial TNFi was discontinued due to inefficacy.
One of the common side effects is an infusion reaction especially during the first infusion,
occurring in up to 30 to 45 percent of patients. Symptoms include headache, fever, skin rash, dyspnea,
hypotension, nausea, rhinitis, pruritus, and mild angioedema [65].
Repeated courses of RTX are associated with an increasing risk of hypogammaglobinemia.
A meta-analysis in 2009 found no increase in serious infections associated with the use of rituximab
with or without MTX compared with MTX plus a placebo, but other studies have found that repeated
courses may be associated with a higher rate of serious infections. The risk of serious infections seems
to increase with age [65].
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Pregnancy
There is only limited information about the use of RTX during pregnancy. Rituximab has been
detected in high concentrations in umbilical cord blood. There are case reports available, but in most
cases, the mother took RTX due to hematologic malignancies. Congenital anomalies were not reported.
As for all babies indirectly exposed to immunosuppressant biologics during pregnancy, immunization
with live vaccines should be postponed until the age of 6 months [66].
6. Targeted Synthetic DMARDS: JAK-Inhibitors
Recently, with the Janus–Kinase (JAK) Inhibitors, a new group of drugs for the treatment of
rheumatoid arthritis was introduced. These targeted, synthetic DMARDS (tsDMARDS) are effective in
inflammatory diseases by intracellularly blocking tyrosine kinase [67].
The JAK are cytoplasmic protein tyrosine kinases that are critical for signal transduction to the
nucleus from the common gamma chain of the plasma membrane receptors for interleukin (IL)-2, -4, -7,
-9, -15, and -21. JAK are receptor-associated intracellular proteins, with a tyrosine-kinase component.
They are important downstream mediators of many pro-inflammatory cytokines, e.g., interferons
or interleukin 6. Once a ligand binds to its receptor, the intracellular kinase is phosphorylated,
which further leads to the phosphorylation and activation of the signal transducer and activator of
transcription (STAT)-pathway. Accordingly, blocking these enzymes with a targeted molecule affects
multiple inflammatory pathways [65,66]. How JAKs transmit signals from cytokines and thereby
activates gene transcription is shown in Figure 2.
 
Figure 2. Cytokines bind to the receptors, which then undergo a change in their configuration into a
dimeric structure, thereby activating their ability to work as a kinase. Consequently, they phosphorylate
the STAT molecules (Signal Transducer and Activator of Transcription). Phosphorylated STATs also
form dimeres that travel to the cell core, where they activate transcription processes, which further fuel
inflammatory processes.
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Pharmacological aspects: JAK-inhibitors are referred to as small molecules, meaning that these
compounds carry a low molecular weight and bind to a macromolecular target, altering their activity
and function [68,69].
To date, two JAK-inhibitors are approved for therapeutic use in rheumatoid arthritis: Tofacitinib
and Baricitinib.
Tofacitinib was approved by the FDA (Food and Drug Administration) in the US in 2012. In 2017,
the European Medicines Agency (EMA) approved the drug for use in the European Union. Tofacitinib
is an inhibitor of JAK 1 and 3, with only little affinity to JAK 2 and Tyrosine-Kinase 2. It has been
shown effective in moderate and severe rheumatoid arthritis in monotherapy or in combination with
methotrexate. Several phase III clinical trials showed efficacy in DMARD naïve patients as well
as in patients with insufficient responses to csDMARDs and even bDMARDS. Tofacitinib is taken
orally twice daily with a dosage of 5 mg. The elimination is mostly hepatic; therefore, an adaption to
impaired kidney function is not necessary up to a GFR > 30 mL/min. Consequently, the treatment of
patients with end-stage renal failure with a GFR < 30 mL/min with Tofacitinib is possible with reduced
dosage [70,71].
The second JAK-inhibitor currently approved is Baricitinib which is an inhibitor of JAK 1 and 2. It was
approved by the FDA as well as the EMA in 2017. Baricitinib can be administered as monotherapy or
in combination with methotrexate. Several phase III clinical trials showed efficacy in the treatment
of DMARD naïve patients as well as in patients with insufficient responses to csDMARDS or even
bDMARDS [72–75].
Baricitinib is taken orally once daily. There are two dosages available: 4 mg or 2 mg. The elimination
for Baricitinib is mostly renal, which makes it necessary to reduce the dosage for patients with impaired
kidney function (estimated GFR 30–60 mL/min) from 4 mg to 2 mg daily. For patients with an estimated
GFR < 30 mL/min, the use of Baricitinib is not recommended [2].
According to the EULAR-Guidelines, both JAK-Inhibitors can be used in rheumatoid arthritis
once a therapy with csDMARDs has been insufficient or had to be discontinued due to adverse
events. Both Tofacitinib and Baricitinib have been shown to be more efficient than a placebo in the
treatment of rheumatoid arthritisl; both could show non-inferiority compared with the TNF-inhibitor
Adalimumab [2,71,73].
Side Effects
Tofacitinib: Increased susceptibility to infections including especially herpes zoster are the most
common side effects of Tofacitinib as well as headaches, hypertension, nausea, and diarrhoea. Elevated
levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol, and liver
enzymes have also been reported. In a post-marketing study, higher dosages of Tofacitinib showed an
increased risk of deep vein thrombosis and pulmonary embolism. The recommended dosage of 5 mg
twice daily should, therefore, not be exceeded [76,77].
Baricitinib: The most common side effect of Baricitinib was an increase of cholesterol levels.
Elevated cholesterol levels return to normal once the medication is paused or be treated with statins
effectively. This has been seen with other immunosuppressants as well. Other side effects include upper
respiratory tract infections and nausea. Other infections, such as herpes zoster or pneumonia are also
associated to Baricitinib. Patients treated with Baricitinib (0.3%) show significant neutropenia [78,79].
Screening pre-treatment: Active or latent infections with hepatitis or tuberculosis should be ruled
out before initiating treatment with JAK-inhibitors. Blood cell counts and liver and kidney function
also need to be evaluated prior to treatment.
Screening during treatment: neutrophil levels, lymphocyte levels, hemoglobin, and kidney and
liver function should be screened; 8–12 weeks after the initiation of treatment, HDL, LDL, overall
cholesterol, and triglycerides should also be screened.
Contraindications: JAK-inhibitors should not be prescribed for patients with neutropenia
(<1/nL), active tuberculosis or severe infections, or severe liver impairment and during pregnancy.
192
J. Clin. Med. 2019, 8, 938
A combination with other bDMARDs or strong immunodepressants as azathioprine, cyclosporine,
or tacrolimus should be avoided due to the elevated risk of infection and the lack of experience.
Use during Pregnancy: drugs from the JAK-inhibitor family have not been tested in pregnant
women yet. As both drugs are small molecules, it seems likely that cross the placenta. Women taking
JAK-inhibitors should be instructed to use safe contraceptive methods throughout the treatment and
up to one week (Baricitinib) to four weeks (Tofacitinib) after a discontinuation of the drug.
Perioperative management: Although there are not enough long-term data for a conclusive
recommendation on perioperative management, JAK-inhibitors in general have a short elimination-time.
It therefore seems possible to continue treatment until shortly before surgery. The therapy should then
be paused until proper wound-healing is achieved.
Ongoing development: Two selective JAK-1-Inhibitors are currently undergoing Phase 3 trials
for clinical approval: Upadacitinib and Filgotinib. Both drugs show promising results in terms of
efficacy and safety. Another JAK-inhibitor currently being evaluated in Phase 3 trials is the selective
JAK-3-Inhibitor Peficitinib, with limited data available so far [80,81].
7. Conclusions
The therapeutic strategies of RA have improved dramatically over the past 3 decades. At that time,
only a few drugs were available and therapy started late in disease course. With the T2T strategy and
the possibility to choose from different mode of actions, the aim of stable remission can be reached and
joint destruction can be prevented. Equally important to the choice of drugs is to diagnose the disease
early and to start therapy within 6–12 weeks after disease onset. Early arthritis clinics headed by
experienced rheumatologists are a good tool to achieve this. T2T further improves the prognosis of RA.
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Abstract: During the last decade, important advances have occurred regarding understanding of the
pathogenesis and treatment of rheumatoid arthritis (RA). Nevertheless, response to treatment is not
universal, and choosing among different therapies is currently based on a trial and error approach.
The specific patient’s genetic background influences the response to therapy for many drugs: In this
sense, genomic studies on RA have produced promising insights that could help us find an effective
therapy for each patient. On the other hand, despite the great knowledge generated regarding the
genetics of RA, most of the investigations performed to date have focused on identifying common
variants associated with RA, which cannot explain the complete heritability of the disease. In this
regard, rare variants could also contribute to this missing heritability as well as act as biomarkers
that help in choosing the right therapy. In the present article, different aspects of genetics in the
pathogenesis and treatment of RA are reviewed, from large-scale genomic studies to specific rare
variant analyses. We also discuss the shared genetic architecture existing among autoimmune diseases
and its implications for RA therapy, such as drug repositioning.
Keywords: rheumatoid arthritis; pharmacogenomics; methotrexate; anti-TNF; personalized medicine
1. Introduction
Human diversity includes, among other things, differential responses to environmental stimuli
and stress and differential drug metabolism and responses to treatments [1]. This diversity has
been in part revealed since the completion of the Human Genome Project, which has improved our
knowledge on the underlying biology of disease and its impact on healthcare. Since the completion
of this project, a developing field called “personalized medicine” has aimed to adapt medical care
to the genetic background of individuals, including diagnosis, therapeutic decision-making, health
outcomes, and policy implications of clinical use (National Human Genome Research Institute (NHGRI),
https://www.genome.gov/).
The most common variations in human DNA are single-nucleotide polymorphisms (SNPs), which
are simple substitutions of one nucleotide for another at a given position [2]. These variants can map
into gene coding or noncoding sequences of the genome, and the most studied to date have been
biallelic SNPs [3]. These genome variations have been the objects of study of personalized medicine,
which has revealed how subtle variations on the genome are responsible for large differences in health
outcomes [1]. The main goal of these studies has been to detect associations between genetic variants
and a trait or disease [4]. Under the common disease/common variant hypothesis, where common
diseases are likely influenced by common genetic variants in the population, traditionally these studies
have been focused on candidate gene association studies by comparing the allele frequency of the SNPs
in affected and unaffected individuals. If the observed differences were not due to random chance,
then they were considered to be associated with the disease or trait. Gene selection was based on
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the plausible mechanisms involved in disease pathogenesis [1]. At present and thanks to advances
in genotyping technology and information on the haplotype structure of the genome, these studies
are now directed toward the entire genome in so-called genome-wide association studies (GWAS).
These studies are hypothesis-free (where no prior knowledge of the biological pathways is needed)
and hypothesis-generating, as the new associations may pinpoint new molecular mechanisms never
anticipated before. However, larger sample sizes are needed to fulfill the stringent threshold for
statistical significance due to multiple testing adjustments (p-value < 5 × 10−8).
Since the completion of the first GWAS in 2005 [5], human genetic research has been a key player
in the discovery of new biological pathways underlying complex diseases. Furthermore, genomic
information may allow for the identification of patients with differential abilities to metabolize drugs,
assess drug reactions, and eventually develop individualized treatments [6,7], which is the aim of the
“treat-to-target” approach, where the therapeutic goal is to reach a state of disease remission or at least
lower disease activity [8]. Many challenges continue to exist in the interpretation of GWAS findings.
However, it has become fairly clear that drug development with genetic support from GWAS data is
twice as likely to reach approval for its use as without this support (from phase I to approval in the
different phases of drug development) [9]. In a recent paper by Nelson et al., the authors assessed
publicly available GWAS results and combined them with the commercial Informa Pharmaprojects
database. They found that those genes associated with a broad spectrum of human diseases were
enriched in target genes for drugs approved in the United States or the European Union, highlighting
the importance of the provided genetic knowledge in different drug mechanisms. The authors
commented that this correlation may be explained by genes with prominent phenotypic changes that
might be the most responsive to drug-induced alterations [9].
Interestingly, there have been several cases of genes associated with diseases that were effective
drug targets. The most recognized examples have come from cholesterol metabolism: For instance,
the gene HMGCR, which is associated with serum cholesterol levels [10], is a known target for statins.
Additionally, loss of function mutations on the gene PCSK9 have been described [11], and drugs
targeting this gene have been developed to lower cholesterol levels [12,13].
2. Genetics and Therapy Development in Rheumatoid Arthritis
In the largest genetic study of rheumatoid arthritis (RA) conducted to date [14], the authors
performed a three-stage transethnic meta-analysis in a total of 100,000 subjects of European and Asian
ancestry by evaluating ~10,000,000 SNPs. Stage 1 revealed 57 associated loci, including 17 that had
never been associated with the disease before. Afterward, the authors conducted a two-stage replication
study for the suggestive loci (p-value < 5 × 10−6), and in a combined analysis of the three stages, they
were able to identify 42 novel loci in the transethnic meta-analysis, increasing the total number of RA
risk loci to 101. These loci represented a total of 377 associated genes, which were then prioritized.
Interestingly, the authors assessed if the associated loci were useful for drug target validation and
how approved drugs for other diseases could be linked to RA risk genes, evaluating not only the
protein products of the RA-associated genes but also the protein that directly interacts with them in a
protein–protein interaction network. From this assessment, the authors found a significant overlap
among approved drugs for the treatment of RA that targeted genes that were considered RA risk genes
in genetic studies. Additionally, the authors assessed if approved drugs for other diseases might be
linked to RA risk genes for drug repurposing and found, for instance, the cases of CDK4 and CDK6,
which are targets for different types of cancer treatment [15] and have been shown to weaken disease
activity in animal models of RA [15]. All of the above evidence has shown how human genetic data
have the potential to be integrated with other biological information to enable personalized treatments.
3. Pharmacogenomic Studies in Rheumatoid Arthritis
Personalized medicine offers fully customized drugs for each person, attending to different
conditions (such as genetics), and pharmacogenomics may identify the individual patient’s signature,
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which could help guide treatment selection mostly based on an assessment of genomic variants
associated with drug response [16]. In the case of RA, even though routine compounds are suitable for
most patients, some of them may not have the desired effect when taking these drugs [17], and patients
may remain with high disease activity and irreversible joint damage as a possible consequence [18].
Thus, biomarkers are needed that help us differentiate between good and bad responses to a specific
treatment. Although great progress has been made in this field, the objective of finding predictive
genetic biomarkers that clearly define the grade of response to specific treatments is still far away.
The use of genetic variants as biomarkers that could predict the response to a specific treatment has
several advantages, as these variants are stable and would remain unaltered, unlike changes in gene
expression and epigenetics, which are highly dependent on the environment.
3.1. Genomic Predictors of Methotrexate
Methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) used as first-line
therapy in RA [19], and great efforts have been directed toward finding predictive biomarkers of
MTX response. These investigations have been centered on analyzing genes involved in the key
molecular pathways affecting MTX absorption and metabolism, such as cytokine production, drug
transport, or nucleotide synthesis. Most of these studies have been carried out in common variants,
and the strongest and most replicated association discovered was for the solute carrier family 19
member 1 (SLC19A1) gene, a transport carrier that allows MTX to enter cells. In this sense, several
studies have reported the association of rs1051266 with intracellular MTX levels. Indeed, a recent
meta-analysis that included 12 studies confirmed the association of this polymorphism with MTX
treatment response [20]. The methylene tetrahydrofolate reductase (MTHFR) gene has also been one of
the most studied genes, as the encoded enzyme is key in the MTX pathway (C677T and A1298C are the
most commonly studied SNPs associated with MTX response and toxicity [21,22]): However, there
were conflicting results in two meta-analyses [23,24]. Another commonly studied polymorphism is
the 347 C/G in the 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (ATIC) gene,
which was recently meta-analyzed in six studies that confirmed its association with responses to and
the toxicity of MTX [23]. Although many other SNPs have been associated with MTX response and
toxicity in RA patients, most of them could not be replicated, and the studies had a low sample size.
To date, two GWAS have been performed involving MTX activity: Senapati et al. [25] suggested
multiple novel risk loci involved in thymidylate synthase (TYMS) regulation, and Taylor et al. [26]
conducted the largest GWAS on MTX response, including 1424 early RA patients and finding a
suggestive association in neuregulin 3 (NRG3). However, the authors were not able to replicate
their findings. Thus, the existence of predictive models, including several SNPs from different genes
associated with MTX response, could help in the creation of specific treatments associated with
pharmacogenomics. In this regard, the clinical pharmacogenetics model of response to MTX (CP-MTX)
combined clinical data and genotypes from four SNPs in MTX-relevant genes (MTHF1D rs2236225, ATIC
rs2372536, AMPD1 rs17602729, and ITPA rs1127354). This model has been validated in independent
samples, and its benefits and costs have been addressed in informing MTX prescription [27–30].
However, it is expected that many more genes and many more variants with modest effects contribute
to response to treatment, and therefore the model could be further improved by including other clinical
variables and updating the list of associated genetic variants.
The major RA susceptibility region corresponds to the human leukocyte antigen (HLA) locus,
concretely the HLA-DRB1 shared epitope, which is associated with a more severe disease [31]. In this
regard, there have been conflicting results regarding the association of the shared epitope with a
lower MTX efficacy in monotherapy [32,33]. An additional HLA-DR locus, HLA-DRB4, is present in
nearly all haplotypes containing the strongest associated HLA-DRB1 alleles [34]. In this sense, a recent
study compared MTX responders and nonresponders after stratification for HLA-DRB4 expression,
highlighting that response to MTX is characterized by preponderant innate and adaptive immune
activation, respectively [35].
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3.2. Genomic Predictors of Tumor Necrosis Factor (TNF) Inhibitors
Biomarkers able to predict responses to biological drugs have received lots of attention. In this
line, tumor necrosis factor inhibitors (TNFis) remain the most commonly prescribed first-line biologics,
even when these drugs are ineffective in up to 30% of patients [36]. Thus, more than 40 candidate gene
studies and 6 GWAS regarding the response to TNFi have been performed to date [37,38]. One of the
most commonly studied SNPs is G308A in the tumor necrosis factor (TNFA) gene, which has been
associated with increased efficacy of adalimumab, infliximab, and etanercept [39,40]. In addition,
Krintel et al. [41] suggested an association with PDE3A–SLCO1C1, and their results were replicated in
a Spanish independent sample, reaching genome-wide significance [42]. Other SNPs linked to clinical
responses in anti-TNF therapy are located on protein tyrosine phosphatase receptor type C (PTPRC):
This has been consistently replicated in independent study samples [43–45]. Other studies have
assessed the involvement of the fragment C gamma receptor (FCGR) [46], the TNF receptor superfamily
1B (TNFRSF1B) [47], and mitogen-activated protein kinase 14 (MAPK14) [40] in associations with
TNFi response.
There have been many research efforts regarding the HLA region and its implication for TNFi
therapies, as it happens with MTX response. One of the first associations observed involved two
HLA-DRB1 alleles encoding the shared epitope, including * 0101 and * 0404, in response to etanercept [48].
Subsequent studies confirmed the association of this locus with anti-TNF treatments, specifically
with amino acid positions 11, 71, and 74 [31]. Furthermore, another study identified polymorphisms
within the nonclassical HLA-E gene associated with clinical outcomes of anti-TNF therapy in female
RA patients [49]. Unfortunately, the majority of studies that have been performed to date regarding
pharmacogenetics of anti-TNF therapies have revealed inconsistent results, and very few of them have
been robustly replicated [50,51]. This lack of replicability might be due to a lack of consensus on the
criteria to differentiate the good versus bad responders [51].
Interestingly, a recent study by Sieberts et al. [52] showed that common SNP information did not
improve significantly predictive models in contrast to other clinical information. They performed a
community-based open assessment and tested a wide range of state-of-the-art modeling methodologies.
However, the authors acknowledged some limitations when the number of risk loci was in the order of
hundreds or when heritability was better explained by rare variations or copy number variants, which
could be the case for TNFi response.
3.3. Other Genomic Predictors
DMARDs such as MTX and biologic agents are the drugs mainly used to treat RA. Nevertheless,
there are other concomitant therapies used to reduce inflammation and relieve pain, including steroids
and nonsteroidal anti-inflammatory drugs (NSAIDs). In this regard, two studies observed a better
response to the combination therapy of MTX and glucocorticoids in RA patients carrying the mutant
allele of the C3435T SNP of the multidrug-resistance 1 (MDR1) gene [53,54]. In addition, a subsequent
study observed that carrying the SNP G2677A/T of the MDR1 gene was significantly associated with
response to glucocorticoid treatment [55].
On the other hand, like other DMARDs, one-third of patients fail to respond to MTX treatment,
either because of inefficiency or adverse events. In those cases, leflunomide represents a potential
drug to replace MTX as a treatment [19]. Pharmacogenetic studies have indicated an impact of the
CYP1A2*1F mutation of the cytochrome P450 family 1 subfamily A member 2 (CYP1A2) gene in
leflunomide toxicity [56]. Another study observed that rs3213422 of the dihydroorotate dehydrogenase
(DHODH) gene was associated with leflunomide toxicity and therapeutic effects [57]. Finally, estrogen
receptor gene SNPs could influence the response to leflunomide therapy in females [58].
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4. Genetic Studies and Rare Variants
International collaborative efforts have enabled the recruitment of unprecedented sizes of study
participants: However, despite the increase in statistical power, today many challenges still exist in the
interpretation of findings from GWAS, which cannot account for much of the heritability of diseases
(the “missing heritability” paradigm) [59]. The possible contribution of rare variants (minor allele
frequency (MAF) < 0.5%) with larger effects on this missing heritability has been much discussed,
and this may require composite association tests of overall “mutational load” in cases and controls.
These genetic variations are not well captured by genotyping arrays. Therefore, whole-exome (WES)
and whole-genome sequencing (WGS) is the technology of choice: It generates millions of sequence
reads in parallel, increasing the speed and generated volume of data [59]. This technology will provide
a deeper characterization of genetic variants within the entire frequency spectrum and their relationship
to disease susceptibility.
The impact of rare human variations on complex diseases is still limited, but for most traits, there
is an inverse relationship between allele frequency and effect size, with the rarer alleles being those
with a higher odds ratio, resembling those in Mendelian disorders [6]. A limited number of studies
have assessed these rare genetic variations with success in RA. Li et al. [60] performed a WES study on
124 subjects from an Asian population. The authors identified genes enriched in deleterious variants
using a gene burden test that were involved in innate immunity pathways and contributed to the risk
of RA in a Han Chinese population. In the case of Bowes et al. [61], the authors utilized an interesting
approach by exploiting low-frequency GWAS data by partitioning the data into gene-centric bins and
collapsing their genotypes into a single count. The authors were able to prioritize signals mapping to
TNFAIP3, a known RA risk gene, with replicable results in independent study samples. This study
highlighted a previously known hypothesis where genes harboring common variants also harbored
rarer variants with larger effects that had not been captured in previous GWAS [59]. To further
confirm this hypothesis, Diogo et al. [62] assessed the contribution of rare and common variants in
candidate genes from GWAS on RA by deep-sequencing their protein-coding regions. The authors
exome-sequenced 25 RA risk genes from GWAS and found an aggregation of rare variants in IL2RA
and IL2RB. They additionally assessed the aggregate contribution of low-frequency and common
coding variants and observed an enrichment of coding variants with a nominal signal of association.
The authors finally acknowledged the need for increased sample sizes to comprehensively identify
variants distributed across the allele frequency spectrum associated with RA.
Interestingly, Eyre et al. [63] evaluated if previously associated linkage peaks were enriched
with rare variants. They found that the distributions of rare variants differed significantly among
regions showing linkage evidence, but that this effect depended on associations in the HLA region.
Along the same line, Bang et al. [64] performed targeted exome sequencing in Korean RA patients.
They comprehensively analyzed 10,588 variants of 398 genes and identified 13 nonsynonymous
variants with nominal associations and 17 genes with nominal burden signals. However, the authors
did not find a significant enrichment of coding variants associated with RA. As mentioned before, there
has been little success in confidently identifying rare variants associated with RA, and in the majority of
cases, studies have been performed on biological candidate genes. Only completely resequencing the
whole exome or genome will eventually pinpoint novel genes harboring rare variants and significantly
contribute to the proper assessment of RA heritability.
Interestingly, rare variants have also been evaluated in responses to treatment, as in the case of
TNFi. Cui et al. [65] sequenced the coding region of 750 genes in 1,094 RA patients treated with anti-TNF.
The authors applied single-variant association, gene-based associations, and gene set analyses in
TNF pathway genes: However, they were not able to identify rare and low-frequency protein-coding
variants that significantly contributed to anti-TNF treatment response.
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5. Shared Genetics in Autoimmunity and Drug Repurposing
Autoimmune disorders, such as RA, are very heterogeneous and share symptoms, risk genes,
comorbidities, and familial aggregation, suggesting a common genetic architecture that is extensively
recognized in autoimmunity [66,67]. Several studies have revealed these shared genetics through
simple comparisons of the associated genes [68], as was the case in a study conducted by our group,
where González-Serna et al. [69] considered the association of a rare variant in the TNFSF13B gene
with RA and replicated this association in systemic lupus erythematosus (SLE) patients. TNFSF13B
encodes the (B-cell activating factor) BAFF cytokine, which is essential for B-cell homeostasis and
the regulation of B-cell maturation, differentiation, and survival [70]. The assessed risk variant is
functional and results in a shorter transcript that escapes microRNA inhibition, leading to an increase
in the production of the BAFF cytokine. Additionally, it has been observed that this variant is strongly
associated with high levels of total IgG and IgM and with reduced monocyte counts [71]. Our reported
association with RA highlights the BAFF variant as a common genetic risk factor in autoimmunity.
Interestingly, belimumab is a monoclonal antibody targeting human BAFF and was the first targeted
therapy approved for SLE [72–74], highlighting the potential for drug repurposing for genetically
related conditions.
Recently, a combination of large-scale studies including different phenotypes has proven to be a
very useful tool in the identification of shared genetic risk variants and shared pathways involved in
these diseases in a systematic fashion [75–77]. The first example is a meta-GWAS that combined 10
pediatric autoimmune diseases and revealed new shared loci with immunoregulatory functions [78].
Another big study by Ellinghaus et al. [79] combined immunochip data from five chronic inflammatory
diseases and also found shared genetic loci in seronegative conditions, such as ankylosing spondylitis,
psoriasis, primary sclerosing cholangitis, Crohn’s disease, and ulcerative colitis. Furthermore, two
recent studies by Marquez et al. [80] and Acosta-Herrera et al. [81] assessed the genetic overlap in
autoimmune diseases by combining Immunochip and GWAS data, respectively. The authors identified
shared risk variants in autoimmunity and common biological mechanisms and suggested novel genes
as drug targets as well as promising candidates for drug repurposing. These studies highlighted how a
combination of different related phenotypes can contribute to the determination of causal variants in
disease and might help in the establishment of personalized treatments.
6. Future Perspectives
Most RA treatments are nonspecific and are based on a trial-and-error approach. Ineffective
treatments affect the quality of life of patients, increasing the probability of adverse events and the
eventual development of greater disabilities. It is therefore crucial to develop mechanisms to deliver
the right drug to the right patients, which is the ultimate goal of precision medicine. In this sense,
a small number of associated loci have been consistently replicated regarding treatment response:
One of the reasons might be the lack of statistical power of these assessments. RA is a complex and
heterogeneous disease, and therefore the response to treatment in RA patients might be influenced
by multiple effects of many genetic variants with moderate effect sizes. Thus, larger studies with
proper statistical power and more homogeneous classifications of phenotypes are needed to validate
previous findings.
Moreover, response to treatment is normally measured with several composite scores, including
the disease activity score (DAS-28), American College of Rheumatology, or EULAR response criteria,
hindering the possibility of validating the results. Well-described and homogenous measures of
responses are critical in pharmacogenetic studies. Additionally, most studies have investigated
common genetic variations in treatment response, and a broader assessment of the frequency spectrum
might be necessary.
Establishing the association of genes should continue with discoveries of the functional implications
of such associations. As commented before, genetic variants alone do not fully explain the risk of
suffering the disease, making complementary strategies necessary, including transcriptomic and
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epigenomics approaches: For example, Plant et al. [82] identified differentially methylated positions
on DNA as biomarkers of response to TNFi therapy. Additionally, Spiliopoulou et al. [83] showed that
the CD39 and CD40 pathways could be relevant to targeted drug therapy by evaluating the relations
of TNFi responses with locus-specific scores, constructed from GWAS data.
Finally, the integration of all of this information with clinical and environmental data will
eventually help us to identify the biological mechanisms underlying the development of the disease, to
establish accurate biomarkers for patient stratification, and to tailor treatment to genetic architecture,
increasing the probability of obtaining an adequate response to a particular drug and eventually
achieving disease remission.
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Abstract: Since the advent of infliximab for the treatment of rheumatoid arthritis (RA),
new genetically-engineered molecules have appeared. This review aims to present the current
data and body of evidence for golimumab (GLM). Safety, efficacy, tolerability and immunogenicity
are all being investigated, not only through phase III trials (GO-BEFORE, GO-FORWARD, GO-AFTER,
GO-MORE, GO-FURTHER, GO-NICE), but also through studies of real-world data. It seems that
GLM in the subcutaneous form is an efficacious molecule with a good safety profile at the standard
dosage scheme, but a 100 mg subcutaneous dose is associated with a higher risk of opportunistic
infections, lymphoma and demyelination. Furthermore, when compared to other tumor necrosis
factor-α molecules, it is non-inferior, and, at some points, such as when it comes to immunogenicity
and persistence of the drug, it has a better profile. In summary, GLM is an effective, well-tolerated
option for the treatment of RA, for both the clinician and patients who are seeking a convenient
dosage scheme.
Keywords: rheumatoid arthritis; TNFα; golimumab; efficacy; tolerability; immunogenicity
1. Introduction
Nowadays, rheumatology has been transformed into one of the most impactful specialties in
the field of medicine, mainly due to a better understanding of the way our immune system responds
to different internal and external stimuli [1]. The idea of neutralizing tumor necrosis factor (TNF)α
via a specific antibody emerged in the mid-1980s. The hypothesis was that reducing TNFα levels
would restore the balance in the cytokine system. Thus infliximab (INF), a chimeric human-murine
monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of
TNFα, but not to lymphotoxin α (TNFβ), was developed with the employment of genetic engineering
techniques. Since the advent of INF, four more genetically engineered molecules have been marketed:
etanercept (ETN), adalimumab (ADA), certolizumab (CTZ) and golimumab (GLM), each employing a
slightly different compositional and pharmacodynamic approach. In addition, anti-TNFα biosimilars
have come of age and are already on the market [2,3]. Nevertheless, even with the appearance of
different molecules targeting rheumatoid arthritis (RA), the unmet needs for the treatment of the
disease remain high [4].
2. Golimumab
GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with
recombinant DNA technology [5], which has been shown to improve the signs and symptoms of RA
in adults in large, randomized, placebo-controlled phase III trials [6–10]. It is the latest anti-TNFα
approved by the Food and Drug Administration (FDA), in 2009, under the brand name Simponi.
In Europe, a once-monthly 50-mg subcutaneous (s.c.) formulation of the TNFα GLM is approved as
monotherapy and/or in combination with methotrexate (MTX). Other approved indications of GLM
are for the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA)—comprising
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ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-AxSpA) in adults,
and polyarticular juvenile idiopathic arthritis (pJIA) in children (50 mg/month if body weight > 40 kg).
In patients with body weight greater than 100 kg and for all the above indications who do not achieve
an adequate clinical response after 3–4 doses, increasing the dose to 100 mg once a month may be
considered, taking into account the increased risk of certain serious adverse drug reactions. Finally,
GLM has been also approved for ulcerative colitis. The initial dose should be 200 mg, followed by
100 mg at week two. Patients who have an adequate response should receive 50 mg at week six and
every four weeks thereafter, whereas for those with an inadequate response or with body weight
greater than 80 kg, 100 mg at week six and every four weeks thereafter.
3. Pharmacological Properties of GLM
GLM acts principally by targeting and neutralizing TNFα with the ultimate goal to prevent
inflammation as well as cartilage degradation and bone destruction [11]. In pivotal phase III
trials (but also in different sub-studies in patients with RA and other inflammatory arthritides),
when administered alone or in combination with MTX, it showed that there is a significant reduction
in serum acute phase reactants and other inflammatory biomarkers [12–15].
GLM exhibits dose-proportional pharmacokinetics and this is why patients with different body
weights should receive different dosage schemes. The median time to maximum plasma concentration
is 2–7 days following a single s.c. injection. Steady-state plasma concentrations can be achieved
at 12 weeks of repeated injections and the mean absolute bioavailability is approximately 50% [16].
The mean elimination half-life is estimated to be approximately 12 days. In patients receiving MTX
with GLM, the mean steady-state trough concentrations were 30% higher than those receiving GLM
alone. The concomitant use of MTX reduces the apparent clearance of GLM by approximately 35% [17].
4. Clinical Efficacy
The clinical efficacy of GLM in inflammatory arthritides has been shown in a series of phase III
trials but also in several sub-studies (Table 1) [8–10,18–23]. More specifically, in RA there is sufficient
data supporting the therapeutic efficacy of the drug.
In the GO-BEFORE study (NCT00264537), a total of 637 MTX-naïve patients with active
RA were randomized (1:1:1:1) to placebo + MTX (group 1), GLM 100 mg + placebo (group 2),
GLM 50 mg + MTX (group 3), or GLM 100 mg + MTX (group 4). This study did not detect significant
differences in ACR50 response (primary endpoint) between the combination therapy groups (3 and 4)
of GLM (50 mg/100 mg) every four weeks plus MTX and MTX as monotherapy. A difference would
have been seen if the ACR 20 response had been considered. Thus, the modified intend-to-treat (ITT)
analysis of the primary endpoint and other prespecified efficacy measures demonstrated that the
efficacy of GLM + MTX is better than, and the efficacy of GLM alone is similar to, the efficacy of MTX
alone in reducing RA symptoms in MTX naïve patients, with no unexpected safety concerns [8,18].
In the GO-FORWARD study (NCT00264550), a total of 444 patients with active RA despite MTX
therapy were randomly assigned (3:3:2:2) to placebo injections + MTX capsules (group 1), GLM 100 mg
injections + placebo capsules (group 2) GLM 50 mg injections + MTX capsules (group 3) and GLM
100 mg injections + MTX capsules (group 4). The co-primary endpoints were the proportion of
patients with >ACR20% improvement at week 14 and change from baseline in the health assessment
questionnaire-disability index (HAQ-DI) score at week 24. In the aforementioned groups ACR20
response at week 14 was achieved by 33.1%/44.4%/55.1%/56.2%, respectively, whereas at week 24,
median improvements from baseline in HAQ-DI score (0.13) were: 0.13 (p = 0.240); 0.38 (p < 0.001);
0.50 (p < 0.001), respectively [9,19]. The conclusion of this study was that the addition of GLM to MTX
in patients with active RA despite MTX therapy, significantly reduced the signs and symptoms of RA
and improvement of physical function.
The GO-AFTER study (NCT00299546) evaluated the efficacy and safety of GLM in subjects who
have active RA and have been treated previously with >1 dose of a biologic anti-TNFα agent (ETN,
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ADA, INF). A total of 461 patients from 10 countries were randomly allocated to receive s.c. injections
of placebo (group 1), GLM 50 mg s.c. (group 2) or GLM 100 mg s.c. (group 3) every four weeks.
MTX, sulfasalazine (SSZ), hydroxychloroquine (HCQ), oral corticosteroids (CS) and non-steroidal
anti-inflammatory drugs (NSAIDs) were carried on at stable doses. As primary endpoint, an ACR20
improvement at week 14 should be achieved by patients who discontinued previous anti-TNFα
treatment due to lack of effectiveness or reasons unrelated to effectiveness, such as intolerance
and accessibility issues. In groups 1–3, 18%/35%/38% respectively achieved ACR 20 at week 14.
The conclusion of this study was that GLM reduces the signs and symptoms of RA in patients with
active disease who had previously received >1 anti-TNFα [10,20].
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spondylitis; nr-AxSpA: non-radiographic axial spondyloarthritis.
In the GO-MORE study (NCT00975130) a total number of 3366 patients were enrolled in order to
evaluate the efficacy and safety of s.c. GLM as add-on therapy in patients with active RA in typical
clinical practice settings (use of csDMARDs and Cs). A four-weeks add-on of 50 mg s.c. GLM for
a period of six months were given in part one of the study whereas in part two, patients not on
remission were randomly assigned to receive intravenous (i.v.) + s.c. (group 1) or s.c. GLM to month
12. Neither in part one nor part two of the study a statistically significant difference was observed
apart from the efficacy and safety of GLM as an add-on therapy for csDMARD-refractory RA in a
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typical clinical practice population. This study concluded that there is no additional efficacy of the
i.v. + s.c. scheme of GLM over the s.c. regimen [21].
The GO-FURTHER study (NCT00973479) evaluated not only the safety and efficacy but also
the radiographic progression through two years of treatment with i.v. GLM + MTX in an open-label
extension of a phase III trial of patients with active RA despite MTX therapy. A total number of
592 patients with active RA were randomized (2:1) to i.v. GLM 2 mg/kg + MTX (group one), or placebo
+ MTX (group 2) at weeks 0 and 4, and every eight weeks thereafter. ACR 20/50/70 response
criteria were measured as well as the 28-joint count disease activity score using the C-reactive protein
(DAS-28-CRP), physical function and quality of life, and changes in the modified Sharp/van der
Heijde scores (SHS). The ACR responses at week 100 were 68.1%/43.8%/23.5% respectively. Physical
function, quality of life and clinical response were maintained throughout the study period (two years).
The SHS score was 0.74 in group 1 and 2.10 in group 2 (p = 0.005). As far as it concerns the AE, 79.1%
had at least one and 18.2% had a serious AE. This study demonstrated that in patients with active RA,
despite MTX, i.v. GLM + MTX showed significant inhibition of structural damage at weeks 24 and 52
and substantial clinical improvement with no safety signs up to one year [22].
The GO-NICE study (NCT01313858), aimed to document patient and treatment characteristics as
well as clinical effectiveness and safety in adult patients newly treated with the 50 mg s.c. GLM every
four weeks under real-life conditions. Of the 1613 patients, 1458 were eligible for final analysis and
of those 474 patients were suffering from RA. The mean age of those patients was 54.9 ± 13.4 years,
72.8% were females and 64.7% biologic-naïve. The DAS-28-erythrocyte sedimentation rate (ESR)
decreased from 5.0 to 2.9 after 24 months (p < 0.0001). As reported, most AE were of mild or moderate
nature, and no new safety signals were detected [23].
Finally, there are several other studies regarding the persistence of GLM treatment in patients
with RA. Thomas et al. [24] in a retrospective, observational study of all patients treated with GLM
in four Academic centers in Greece during a four-year period examined the long-term survival on
drug (SOD) of patients not only with RA (166 patients) but also PsA (82 patients) and AS (80 patients).
The estimated SOD at two and three years was 68% and 62% respectively (69% and 60% for RA
patients) concluding that GLM showed a high three-year SOD with a low rate of discontinuation due
to AEs. Furthermore, Rotar et al. [25] analyzed prospectively the collected data of all patients treated
with GLM and other TNFs for seven years and were suffering from RA, AS, and PsA. The authors
concluded that the persistence of GLM in RA-treated patients is lower compared with the AS and PsA
patients but it is higher among those patients treated with other anti-TNFs. Svedbom et al. [26] in
a systematic review of real-world evidence in immune-mediated rheumatic diseases including RA,
examined the persistence to treatment with s.c. GLM but also to other anti-TNFα molecules. Of 376
available references identified, 12 studies with a total of 4910 patients met the inclusion criteria. In four
studies that included comparisons to other biologics, GLM was either statistically noninferior or
statistically superior to other treatments. Serrano et al. [27] in a prospective monocentric cohort of RA
patients treated with GLM and a total number of 61 patients (mean age 55.1 ± 14.1 years; 85.2% females;
RF + 70%; anti-CCP + 78%) showed that GLM survival time was better when used as first or second
biological and with concomitant use of csDMARDs. Aaltonen et al., based on Kaplan-Meier survival
analysis in a systematic review regarding the anti-TNFα, showed that the probability of discontinuing
the treatment within 6, 12, 24, and 36 months was 16%, 27%, 37%, and 43%, respectively in patients
with RA. SOD was better among the patients with no prior bDMARD therapy than among those
using anti-TNFα as their second or third bDMARD. CTZ (41%) and INF (38%) were associated with
higher probability of treatment discontinuation within 12 months compared to ADA (25%), ETN (25%),
and GLM (25%) [28].
5. Tolerability and Immunogenicity
Data from the pivotal phase III trials in adults with RA but also the open-label extension studies,
support that s.c. GLM is generally a well-tolerated therapeutic option [8–10]. Overall, in these
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trials, upper-respiratory infections (32.0% vs. 8.8% with placebo), nasopharyngitis (17.4% vs. 6.4%),
followed by elevated aminotransferase levels (11.9% vs. 5.2%) and hypertension (9.8% vs. 2.7%)
were the most common AE in the 50 mg s.c. dose. Injection-site reactions (ISRs) were reported
by 11.0% vs. 2.8% of GLM and placebo recipients, the most common being injection-site erythema
(5.8% vs. 1.1%) [29]. Tuberculosis, opportunistic infections, lymphoma, and demyelination incidence
appeared to be higher among patients receiving GLM 100 mg s.c. dose.
As far as it concerns the immunogenicity, Thomas et al. documented in a systematic review for
the immunogenicity of TNF inhibitors that GLM and ETN were the least immunogenic (3.8% and 1.2%
respectively) whereas the most immunogenic were INF (25.3%), followed by ADA (14.1%) and CTZ
(6.9%). The clinical significance of the anti-drug antibodies (ADAbs) in the sera of patients with RA is
associated with decreased clinical response [30].
6. Conclusions
GLM is one of five anti-TNFα inhibitors approved for the treatment of RA, but also other
inflammatory arthritides [31]. It is a newer, second-generation anti-TNFα and for this reason the
clinical experience is less in comparison with the older ones such as INF, ETA and ADA (first generation
TNFα inhibitors). On the other hand, the growing body of evidence through the open-label extension
trials of pivotal studies and those from several medical centers in patients with RA, confirm the efficacy
and safety of the drug. Furthermore, with clinical and radiological benefits being sustained and no
new safety signals being identified, GLM seems an attractive choice for the treatment of RA. Other,
important elements that make this choice attractive, are the low levels of immunogenicity, the low
rate of drug discontinuation in comparison with the other anti-TNFs and the dosage scheme (every
four weeks) which seems to be a point of major significance when a physician-patient sharing decision
occurs. One concern is the tendency of higher incidence of opportunistic infections, lymphoma and
demyelination in the 100 mg s.c. injection, and it should be used with caution in patients with higher
body weight or poor response to treatment with the 50 mg dosage scheme.
As there are no head-to-head trials comparing it with the other anti-TNFα inhibitors, the indirect
comparison of all five agents suggests that possibly GLM is better tolerated than ADA, CTZ and INF in
terms of the risks of serious infection and of discontinuing treatment due to AEs. In summary, GLM is
an effective, well-tolerated option for the treatment of RA for both the clinician but also for the patients
seeking a convenient dosage scheme.
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Abstract: Methotrexate (MTX) is a remarkable drug with a key role in the management of rheumatoid
arthritis (RA) at every stage of its evolution. Its attributes include good overall efficacy for signs
and symptoms, inhibition of structural damage and preservation of function with acceptable and
manageable safety, a large dose-titratable range, options for either an oral or parenteral route of
administration, and currently unrivalled cost-effectiveness. It has a place as a monotherapy and
also as an anchor drug that can be safely used in combination with other conventional synthetic
disease-modifying antirheumatic drugs (csDMARDs) or used concomitantly with biological DMARDs
or targeted synthetic DMARDs. MTX is not without potential issues regarding toxicity, notably
hepatotoxicity and bone marrow toxicity, as well as tolerability problems for some, but not all,
patients. But many of these issues can be mitigated or managed. In the face of a welcome expansion
in available targeted therapies for the treatment of RA, MTX looks set to remain at the foundation
of pharmacotherapy for the majority of people living with RA and other inflammatory rheumatic
diseases. In this article, we provide an evidence-based discussion as to how to achieve the best
outcomes with this versatile drug in the context of a treat-to-target strategy for the management of RA.
Keywords: methotrexate; rheumatoid arthritis; tolerability; efficacy; posology; titration; oral route;
subcutaneous route; bioavailability; effectiveness
1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation, pain,
stiffness, and progressive joint destruction with a detrimental impact on joint function, work ability, and
health-related quality of life (HrQoL) [1]. The primary goal of treating patients with RA is to maximize
long-term HrQoL through control of symptoms, prevention of structural damage, normalization
of function, and participation in social and work-related activities. Abrogation of inflammation is
considered the most important way to achieve optimal outcomes [2], and its achievement is facilitated
by Treat-to-Target (T2T) recommendations [2].
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The T2T paradigm has emerged during the last decade and was incorporated in recommendations
issued primarily in 2010 and recently updated [2]. The T2T paradigm relies on five principles: the
definition of a treatment target; the close and regular assessment of disease activity using composite
measures that include joint counts; the regular adaptation of therapy, if the target is not achieved within
a particular timeframe; the consideration of individual patients’ aspects; and shared decision-making
with the patient. A T2T strategy is more effective in terms of reducing disease activity compared to
routine care [3], and has a beneficial effect on working ability. T2T principles underpin the current
recommendations of European League Against Rheumatism (EULAR) Task Force [4], American
College of Rheumatology (ACR) guidelines [5], and the Canadian Rheumatology Association (CRA)
recommendations [6] and the Asian APLAR guidelines [7]. T2T overarching principles affirm the
necessity of a shared decision between patient and the whole team involved in the care of RA [2].
The ideal treatment target is remission [8], or, if remission cannot be achieved, low disease activity
(LDA). Remission is associated with the best achievable outcomes including limitation or prevention
of joint damage [9], preservation of physical function, and work capacity as well as optimizing overall
quality of life [10,11]. Furthermore, remission reduces comorbidity risks [12]. Treatment targets
should however be adapted according to the presence of comorbidities, individual patient factors
and drug-associated risks [2] to ensure the most favorable benefit: risk ratio for any given patient.
Treatment should be titrated to the therapeutic response assessed by composite measures of disease
activity, ideally with therapy adjustment at least every three months [2] if the patient is not in remission,
a recommendation based on evidence provided by clinical trials [13–15], until the desired treatment
target is reached.
Early treatment [16] and rapid attainment of the targeted endpoint are critical. Disease-modifying
anti-rheumatic drugs (DMARDs) are the main therapy of RA. The most commonly prescribed
conventional synthetic (cs) DMARDs are methotrexate (MTX), leflunomide, sulfasalazine, and
hydroxychloroquine [6]. Based on its efficacy, safety, large dose-titratable range, options for either
an oral or parenteral route of administration, and cost-effectiveness, MTX holds a unique place in
the management of RA, with a role at every stage of the evolution of this chronic condition. MTX
monotherapy is recommended as an initial pharmacological strategy [4–6], but it can also be used as an
“anchor drug” in combination with another conventional synthetic disease-modifying antirheumatic
drugs (csDMARD), any biological DMARD (bDMARD), or targeted synthetic DMARD (tsDMARD) [4].
MTX is currently the most commonly used first-line therapy for RA in the world [17].
While recommendations advocate the use of methotrexate at various positions in the contemporary
treatment paradigm, the heterogeneity of presentation of RA and versatility of approaches to effective
MTX use are such that there is need for evidence- and experience-based supplementary information to
enable clinicians to get the most out of MTX for their patients in the T2T era. Notably, this process
includes allaying any misconceptions that patients may have concerning this therapy, adapting dose
and administration routes for optimal efficacy, mitigating toxicity and tolerability issues, and taking
into account the relatively slow kinetic of response, which can be managed by the use of bridging
steroids as appropriate.
In this position paper, we address these and other issues regarding the optimal use of MTX in
a target population comprising adult (age ≥ 18 years) patients meeting current classification criteria




MTX (4-amino-10-methylfolic acid), an antifolate agent that was licensed for a RA indication
in the 1980s [18], is a prodrug that becomes active when glutamated within cells, exhibiting a high
binding activity for dihydrofolate reductase (DHFR) [19].
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Oral MTX is absorbed from the small gut by an active transport mechanism involving the
proton-coupled folate transporter. Bioavailability ranges from 30% to 70% [20] and plateaus for
single oral dose >15 mg [21], suggesting an absorption limitation [22]. Intracellular MTX is gradually
polyglutamated (MTXGlun). There is a competitive process between glutamation and deglutamation
and steady-state levels of intracellular MTX are reached in a median time of 28 weeks with variability
between patients due to different polyglutamation rates [23,24]. The major determinants of MTXGlun
concentrations are age, renal function, and MTX dose [25]. Serum concentration of MTX falls rapidly
following an intravenous administration [26]. The plasma half-life is 4.5 h to 10 h [27] but MTX is
retained within cells long after its serum clearance. Excretion of MTX is mainly renal, occurring
through glomerular filtration and active tubular excretion. Seventy-five percent of MTX is excreted
unchanged in the urine with large interpatient variability [28].
The active transport mechanism limits oral MTX absorption resulting in lower bioavailability
of higher MTX doses. Interestingly, bioavailability may increase by splitting the oral dose [22] or
switching to a parenteral route [22]. Polyglutamation is progressive, explaining the slow onset of the
action of MTX [19] and the delay before maximal benefit. In some patients with low glutamation
rates, a relatively low dosing strategy will lengthen the time required for adequate drug concentration
to be achieved [23]. This may be detrimental, as higher intracellular MTXGlun levels have been
associated with better clinical response [29]. The subcutaneous (SC) administration route is associated
with a significant increase in long-chain MTXGlun when compared to the oral route [30]. Renal
function impacts the generation of MTXGlun. The anti-inflammatory effects of MTX in patients with
RA are much more prolonged than its plasma half-life might suggests due to the accumulation of
polyglutamated metabolites in tissues. Since the MTX excretion mainly involves the kidney, renal
failure, or competitive excretion with other drugs in patients receiving multiple treatments will prolong
MTX serum half-life [31].
2.2. Mode of Action
The mechanisms by which low-dose MTX exerts its therapeutic effect in RA remain incompletely
understood [19]. MTX has several important anti-inflammatory actions mediated through a variety of
pathways that do not involve folate antagonism. The main putative mechanisms are the promotion of
adenosine release, inhibition of purine and pyrimidine synthesis, inhibition of methyl donors, generation
of reactive oxygen species, downregulation of adhesion-molecule expression, modification of cytokine
profiles, and downregulation of eicosanoids and matrix metalloproteinases [19]. Adenosine exerts
an anti-inflammatory activity by down-regulating the activation and proliferation of T-Lymphocytes.
Adenosine receptors are overexpressed on immune cells and synoviocytes of patients with RA, probably
because of the high tumor necrosis factor (TNF) levels. Inhibition of DHFR prevents the regeneration
from dihydrofolate to tetrahydrofolate, an essential factor for the production of folate cofactors required
for purine and pyrimidine synthesis [32]. Inhibition of DHFR also inhibits the production of methyl
donors and attenuates the formation of polyamines.
Since the anti-inflammatory properties of MTX are not mediated by folate antagonism, some toxic
effects may be prevented or minimized by folic acid supplementation (not taken on the same day as
MTX) without loss of therapeutic benefit.
In the future, pharmacogenetic advances may help to predict non-responses to MTX, thus
directing patients to combination therapy as initial treatment. Promising results have recently been
published [33,34].
3. MTX: A Forefront Position among csDMARDs
3.1. Flexible
More intensive treatment interventions provide the best chance of achieving remission in RA
patients [35]. However, potential benefits need to be balanced against potential risks and every
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effort must be made to ensure acceptable tolerability of any given therapeutic regime. The most
frequent strategy for management of early RA is a “step-up” approach, where MTX is initiated at a
dose estimated to be well tolerated and then titrated up according to therapeutic response. Current
recommendations for management of RA [5,36] advocate the initial use of MTX as a monotherapy
with a bridging steroid to give more rapid symptomatic relief before the clinic benefits of MTX become
apparent. Some authors have advocated a step-down approach to treatment, initiating MTX at a
high dose and arguing that this takes advantage of a “window of opportunity” for best outcomes
early in the disease [37]. However, this process has the potential disadvantage of making tolerability
issues more challenging to manage. Whatever the strategy, MTX has a central role to play, both
as a monotherapy and as an “anchor drug”, for many successful DMARD combinations whether
conventional, targeted synthetic, or biologic [38]. Some unique attributes of MTX contributing to
this versatility include the wide dose titratable range, choice of administration routes, the favorable
efficacy:toxicity ratio, utility in DMARD combinations, potential ancillary benefits, and outstanding
cost-effectiveness. Unfortunately, despite treatment guidelines, up to 50% of patients [39] do not
continue MTX when treatment with a biologic is initiated. Over the last few years there has been a
discussion about tsDMARD or bDMARD monotherapy. Some authors suggest that MTX administered
in a tolerated dose should be continued as a combination partner until remission is achieved [40]. This
process is recommended because the highest benefits for all targeted therapies are generally observed
when they are used with concomitant MTX.
MTX is marketed in the form of tablets with increments of 2.5, 5, or 10 mg/tablet, and as
prefilled syringes or auto-injectors with various doses per injection, allowing one to finely tune the
weekly dose. Oral and (SC) are the most widely routes used in RA patients. SC injections should
be considered for weekly doses of 15 mg or higher due to the better bioavailability of MTX when
administered parenterally.
3.2. Clinically Efficient
The TEAR study has demonstrated that low disease activity illustrated with the Disease Activity
Score-28 with the erythrocyte sedimentation rate (DAS28-ESR) can be achieved by 28% of patients
with early RA treated with MTX monotherapy [41]. It was a 2 × 2 factorial design comparing four
treatment arms (immediate combination of MTX + etanercept (ETN); immediate combination of MTX
+ hydroxychloquine (HCQ) + sulfasalazine (SSZ)); initial MTX with step-up treatment adding ETN;
initial MTX with step-up treatment adding HCQ and SSZ. The study aimed to assess if it was better to
intensively treat all early RA cases with drug combinations or to reserve this procedure for those who
do not achieve low disease activity (DAS28-ESR < 3.2) after 24 weeks. At week 24, 28% of the patients
from step-up groups achieved the treatment target. Similar results were achieved in the BeST study [42].
An even higher rate was demonstrated by Mueller et al in real-life [43]. Moreover, no difference was
found between groups with respect to disease activity after 48 weeks and 102 weeks of treatment.
Favorable results obtained with initial MTX monotherapy in the step-up groups were maintained
until week 102. Moreover, there was no difference in radiologic progression when comparing step-up
with combination therapy in a post-hoc analysis [38]. Since differences in outcomes were negligible
between patient groups that were started at a baseline on an aggressive combination therapy regimen,
or were delayed before stepping up (by 6 months), the authors concluded that there is no penalty
for delaying step-up therapy until it is clinically indicated [38]. In comparison with those patients
exhibiting a sustained, good response to MTX monotherapy, aggressive combined treatment would
only result in a higher risk of side effects and higher costs. Importantly, these results were obtained
employing a strict MTX dosage escalation regime (10 mg/w, escalated to 15 mg/w at week 6 and
20 mg/w at week 12, unless the patients had zero tender joints and zero swollen joints at that visit).
LDA, but not remission, was the key factor that determined whether to step-up to combination therapy
at week 24. The SWEFOT study reported similar results with 29.8% of patients meeting EULAR criteria
for response after 3 months of MTX monotherapy [44].
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3.3. Ancillary Benefits
Besides its efficacy in ameliorating arthritis, MTX may have ancillary benefits. Patients with
RA have a higher risk of cardiovascular disease, infection, and cancer [45–47], resulting in reduced
survival. Low-dose MTX is reported to reduce all-cause mortality in RA by 60% and cardiovascular
mortality by 70%, while other DMARDs have no effect on mortality. Protective effects appear to be
independent of MTX dose [48]. Another study reported that all-cause mortality was reduced by 70% in
a vast cohort of RA patients treated with MTX when compared to those receiving other treatments [49].
Protective effects were evident only after one year of MTX use and were independent of the effect on
RA activity [49]. The biological mechanisms underpinning this protection are not fully understood.
Effects of MTX on the survival of RA patients are likely to be mediated by its anti-inflammatory
properties, since MTX failed to demonstrate any protective effects on cardiovascular events in patients
with previous myocardial infarction or multivessel coronary disease who additionally had type 2
diabetes or metabolic syndrome but no major inflammation [50].
Interstitial lung disease (ILD) is a common extra-articular manifestation of RA [51], affecting
around 10% of patients [52]. Chronic lung disease (CLD) and ILD increase the risk of death in RA
patients [53,54]. Methotrexate has been associated with severe lung toxicity, including ILD [55].
However, there is recent data that questions the results of case studies or observational studies
linking methotrexate to pulmonary damage. Two meta-analyses also failed to associate methotrexate
with ILD; in the first one [56], a meta-analysis of clinical trials (22 studies with 8584 patients with
RA), the use of MTX in patients with RA was associated with an increased risk of total respiratory
complications (RR 1.10), mainly due to an increased risk of respiratory infections (RR 1.11) and acute
pneumonitis (RR: 7.81) but it was not observed that treatment with MTX increased the risk of death
due to lung disease (RR 1.53, 0.46–5.01). In the second one [57], a meta-analysis of the clinical trials of
psoriasis, psoriatic arthritis, and inflammatory bowel disease, all clinical conditions without pulmonary
manifestations, did not find an increase in lung disease in patients treated with MTX. A recent analysis
of a large prospective cohort of predominantly male US Veterans showed no increase in mortality risk
in RA-CLD patients treated with MTX or biologics [54]. Moreover, in a recent study, MTX was a strong
predictor of survival in RA patients with ILD [53].
The role for MTX in the prevention of dementia remains controversial. Inflammation is a common
feature of both RA and dementia [58]. Despite the blood brain barrier, systemic inflammation is
associated with cerebral inflammation [58]. A retrospective population-based study involving more
than 11,000 RA patients, including 70.6% of csDMARD users, revealed that csDMARDs users had a
40% risk reduction of dementia. The strongest effect was with the use of MTX [59].
Felty’s syndrome comprises a triad of RA, neutropenia, and splenomegaly, occurring in less
than 1% of RA patients. Pseudo Felty’s syndrome is characterized by RA, monoclonal expansion of
lymphocytes, and neutropenia. The main complication is infection, whose risk increases with the
depth and duration of neutropenia [60]. MTX is the first-line treatment of Felty’s syndrome and is
indicated, despite neutropenia [61,62].
3.4. Cost-Effectiveness
Therapeutic decisions should also be guided by cost-effectiveness considerations. Based on a
decision analysis model extended to lifetime duration, early MTX monotherapy was more cost-effective
than the early combination of MTX and TNF Inhibitor (TNFi)-based biologics [63]. The cost-effectiveness
ratio of the early MTX strategy was less than $5,000/quality-adjusted life year (QALY) and more than
$150,000/QALY for TNFis. In patients who failed to respond or to tolerate oral MTX; switching to SC
MTX was described as more cost-effective than adding bDMARDs [64], since a large proportion of
these patients achieved adequate response with SC MTX and, therefore, did not require more expensive
therapy [65]. A cost-minimization analysis based on UK costs indicated that a routine use of SC MTX
following oral MTX failure had the potential to save an estimated £7,197 (5536 US$) per patient in
the first year of therapy [64]. Prefilled syringes and auto-injectors facilitate self-administration of SC
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MTX by the patients, thus increasing costs savings. In addition, in some countries, the prescription of
bDMARDs can be reimbursed only if the patient did not adequately respond to at least 2 csDMARDs,
if not contra-indicated [66,67].
3.5. Combinable with Other Treatments
MTX is a great combination partner with other csDMARDs and bDMARDs. The most popular
csDMARDs combinations are MTX and HCQ and the triple combination of MTX, HCQ, and SSZ.
The combination of MTX and HCQ is synergistic and gave better results than MTX alone in a
head-to-head comparison after 6 months of treatment, but the difference was no longer significant after
12 months [68]. Combining MTX and HCQ may be useful in patients who have a good response to
MTX, attaining LDA but not remission [69]. The efficacy of this combination may be explained by
pharmacokinetic interactions. Concomitant administration of HCQ increases the mean area under
the curve (AUC) of MTX blood concentration, decreases the maximum MTX concentration (Cmax),
and extends the time to reach Cmax [67]. A reduced Cmax may also explain the diminution of acute
liver adverse effects. However, extra vigilance for MTX adverse events is recommended, especially
in patients with impaired renal function [67]. Triple therapy combining MTX, HCQ, and SSZ may
be a valuable alternative to the addition of bDMARDs to MTX, in cases of inadequate response
to MTX and in the absence of poor prognosis factors. In a randomized trial comparing a triple
combination of csDMARDs versus a regimen of MTX and etanercept (ETN), patients receiving triple
therapy adhered for a longer time to their regimen than patients receiving MTX + ETN, despite similar
outcomes [70], thus reflecting better acceptability. Infections were more frequent with the MTX+ETN
regimen, whereas gastrointestinal side effects were more frequent with the triple combination [71].
Conversely, in a network meta-analysis of 33 studies, the odds of remission were lower with triple
therapy than with the combination of MTX and TNFi [72]. However, the analysis considered both
patients with inadequate response to MTX and MTX-naïve patients. These results were contested
by a recent meta-analysis showing that triple association of csDMARDs and the combination of
MTX and bDMARD as a second-line treatment in patients with insufficient response to MTX gave
similar results [69]. Nonetheless, this result provides additional evidence supporting conventional
combinations over bDMARDs after an inadequate response to MTX.
MTX is also a valuable partner in combined therapy with tsDMARD and bDMARDs. Such
combinations have been shown to significantly improve clinical manifestations of RA [73–76]. Around
two thirds of patients will have to step-up from MTX monotherapy to combined strategies [41].
In addition, RA patients with severe presentation and poor prognostic factors may require combined
therapy upfront to prevent irreversible joint damage and functional impairment. The efficacy of
targeted therapies is enhanced when the bDMARD is administered in combination with MTX. This
may be due to complementary mechanisms of action, pharmacokinetic interactions, and reduction of
the immunogenicity of the biologic agent.
The CONCERTO study was the first blinded, controlled trial to address the relationship between
MTX dose and serum drug concentrations in RA patients treated with adalimumab. Steady-state trough
serum concentrations of adalimumab were almost two-fold higher in patients concomitantly receiving
MTX [77]. Patients were randomized into four groups with an increasing MTX dose (from 2.5/week
to 20 mg/week, orally). There was no difference between the two highest MTX doses on clinical,
radiographic, and functional response, whereas both doses were associated with better outcomes when
comparing to the two lowest doses [77]. In parallel, adalimumab serum concentrations were higher
with 10 or 20 mg MTX than with 2.5 or 5 mg MTX, mimicking the clinical findings. These results
suggested that MTX at a dose of 10 mg/w reduced the clearance of adalimumab and increased the
adalimumab serum level, thereby enhancing its efficacy. The MUSICA study [78] evaluated the effects
of low and high MTX doses in combination with the initiation of adalimumab in patients who did not
adequately respond to MTX. Patients with a stable MTX dose of at least 15 mg/week prior to screening
were randomized to receive blinded MTX, at either 7.5 or 20 mg/week in combination with open-label
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40 mg of adalimumab every other week. Since low-doses of MTX associated to adalimumab failed to
show non-inferiority as compared to high doses for most clinical, functional, and ultrasound outcomes,
the MUSICA study results do not support routine MTX reduction at the moment of adalimumab
initiation. However, in a proportion of patients who may need to reduce MTX for toxicity reasons,
much of the clinical efficacy in association with adalimumab may be retained, particularly when MTX
dose reductions are modest.
Secondary failure to bDMARDs after an initial response can occur in as many as 30% of
patients [79]. Development of anti-drug antibodies (ADAb) is one of the main drivers of loss of
treatment efficacy [80–84]. ADAb have been described with infliximab, adalimumab, but not with
etanercept. In a recent cross-sectional study on Spanish RA patients experiencing secondary failure
while receiving TNFi, the prevalence of adalimumab ADAb was 29.3%, the one of infliximab ADA
was 27.3%, and none of the patients treated with ETN developed ADAb [84]. Randomized-controlled
trials reported ADAb in a small proportion on patients on golimumab and certolizumab [80]. ADAb
either neutralize the active drug or decrease the serum drug concentration, resulting in a loss of clinical
response [85]. Around 80% of patients who tested positive to ADAb had no detectable drug in the
serum [84]. In a retrospective cohort of RA patients who were biologic-naïve at the time of enrolment,
and were then treated with infliximab for a median time of 5.75 years, ADAb against infliximab were
found in 33% of patients, in 24% of responders, and in all non-responder patients [83].
MTX may prevent [84,86] or reverse [87] the formation of ADAb and so maintain efficacy to TNFi,
prolong drug survival, and prevent immune complex-mediated adverse events [80,83]. The pooled
risk ratio for the formation of ADAb in patients receiving combined therapy with immunomodulators
versus that of patients receiving anti-TNF monotherapy was 0.49 in a meta-analysis of 35 studies
involving 6790 patients with inflammatory bowel disease [88]. The development of ADAb is reduced
by the concomitant use of MTX in a dose-dependent manner [89]. It is, therefore, desirable to prescribe
bDMARDs in combination with concomitant MTX when it is satisfactorily tolerated with toxicity.
However, in the event of tolerability issues with MTX, the dose can be lowered while still providing
efficacy benefits in combination, as illustrated in the CONCERTO [77] and MUSICA [90] studies.
3.6. Challenges Associated with MTX Use
When prescribing MTX as first-line therapy in RA patients, the physician has to face several
challenges, such as explaining the time-course of the clinical benefits to the patient, improving
patient compliance and adherence to therapy and monitoring, and avoiding unnecessary premature
discontinuation of MTX are at the forefront of physician concerns.
The collective findings of combination therapy studies with MTX monotherapy arms, such as
SWEFOT [44], CAMERA [14], TEAR [41], OPTIMA [91], and PREMIER [74], illustrate that, in general,
it takes 6 months to see a full response to MTX. In patients with early RA and no poor prognostic
factors, the relatively slow onset of action of MTX does not jeopardize clinical or functional outcomes.
During this period, and especially during the first months, patients do not experience the full clinical
benefit of MTX but are maybe exposed to adverse events. This is a crucial period in which too many
patients discontinue MTX. The risk of premature stopping can be mitigated by the provision of clear
and complete information to the patient. The slow kinetic of onset of symptomatic improvement with
MTX can be mitigated by co-prescription of corticosteroids as a bridging therapy.
The best outcomes with the use of MTX are achieved when a shared decision-making approach
to treatment is used in which the patient is an active participant. Patients need to understand and
take responsibility for attendance for blood tests to ensure close monitoring of laboratory parameters,
as well as following recommendations for folic acid supplementation in order to reduce the likelihood
of certain adverse events. Reassuring tolerability and safety of low-dose MTX have recently been
studied confirmed in the large placebo-controlled CIRT study aimed at determining if low-dose MTX
could reduce the incidence of atherosclerotic events in patients with metabolic disorders and a history
of myocardial infarction or multivessel coronary disease [50]. The study included 2391 patients who
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were allocated to the MTX arm. The median follow-up was 2.3 years before the study was stopped
because of its futility. Most frequent AEs were infections, mouth sores and oral pain, unintended
weight loss, leukopenia, and elevation of liver enzymes more than three times the normal range.
Severe AEs are far less frequent. No case of marrow depletion was reported, even if leukopenia was
frequent [50]. However, the report of more non-basal skin cancers in the MTX group was unexpected
and deserves further exploration.
Elevations of liver enzymes must alert the physician to potential hepatotoxicity, in which case
it may be prudent to temporarily reduce the MTX dose or even to discontinue the drug. Acute
elevations of liver enzymes occur relatively frequently but are usually transient and generally resolve
spontaneously. Rarely, persistent abnormal liver function tests reveal hepatotoxic effects of MTX,
justifying treatment cessation. Among 41 patients receiving low-dose MTX for rheumatic diseases,
experiencing elevation of liver enzymes, and underwent liver biopsy, only 2 patients had histological
signs of direct hepatic MTX toxicity. Most frequently, liver biopsies revealed autoimmune hepatitis-like
lesions, especially in patients with RA [92]. However, it is important to avoid the unnecessarily
premature discontinuation of MTX for reasons of small elevations in transaminases. It is important to
bear in mind other causes of transaminitis, such as alcohol consumption or over-the-counter use of
nonsteroidal anti-inflammatory drugs (NSAIDs). The limited data available on the effects of alcohol
consumption on the risk of liver toxicity in patients with RA who are receiving MTX are insufficient
to draw firm conclusions on the amount of alcohol that patients receiving MTX can safely consume.
International guidelines vary. The American College of Rheumatology recommends that alcohol
should be avoided whilst on MTX [93], while EULAR advises avoiding MTX in patients with a history
of alcohol abuse, without specifying a restriction of alcohol consumption otherwise [94]. A systematic
literature review found little evidence to provide specific guidelines regarding alcohol consumption [95].
Following their analysis, they estimated a 3% risk for the development of severe liver disease in
patients who drink over 100 g of alcohol (12.5 units) per week in the absence of additional risk factors
such as obesity, diabetes, or hepatitis. The authors advised caution in using MTX in patients with risk
factors. A more recent study suggested that a weekly consumption of <14 units of alcohol per week
does not appear to be associated with an increased risk of hepatotoxicity as defined by transaminitis
based on aspartate transaminase (AST) or alanine transaminase (ALT), >3 times the upper limit of
normal. Consuming between 15 and 21 units is associated with a “possible risk”, and over 21 units
with a significantly increased risk of transaminitis [96]. However, this definition of hepatotoxicity
is somewhat arbitrary as it is not supported by the use of hepatic scans or histology. Furthermore,
allowing alcohol consumption of up to 14 units/week may place patients at risk of hepatotoxicity,
such as hepatic fibrosis and cirrhosis [97]. In practice, many rheumatologists allow patients without
additional risk factors for hepatotoxicity to consume small to moderate amounts of alcohol while taking
MTX, preferably avoiding alcohol consumption on the days that they take MTX. Decisions regarding
alcohol consumption should be made on an individual patient basis after taking into consideration the
presence of other risk factors.
The next section of this position-paper will detail how to deal with these challenges in real-life
conditions in order to get the most out of MTX as a first-line treatment.
4. How to Get the Most out of MTX as a First-Line Treatment?
Despite the many advantages of MTX, it may still be used suboptimally. Studies indicate that
half of patients discontinue oral MTX within 2 years and that MTX is still frequently stopped rather
than combined with bDMARDs or tsDMARDs when these target therapies are initiated. The risk of
discontinuation is higher in older patients [98–100]. Patients should be treated early since a longer
duration of RA decreases the probability of response [101]. Baseline high disease activity increases the
probability of non-response in most studies [102,103].
When initiating MTX, the choice of dose, route of administration, and approach to subsequent
dose escalation is not an exact science. Choices may depend on several factors, including the age,
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gender, ethnicity, weight, and renal function of the patient. These choices will be made with the
intent to minimize any tolerability issues and drug-related toxicity, as well as to optimize efficacy and
maximize adherence to MTX.
4.1. Dealing with Modifiable Predictors of Response to MTX
Some factors have been shown to impact the response to MTX. Of these, many such as age [104],
gender [104], and pharmacogenetic profile [34] cannot be modified. However, others such as smoking
may be modifiable, and physicians should endeavor to address this.
Smoking may affect the pharmacokinetic and pharmacodynamics properties of MTX [25]. Smoking
habits are predictors of poor response [102,104,105] in a dose-dependent manner [103], with heavy
smokers being at higher risk of non-response. In addition, given the higher cardiovascular risk attached
to RA patients, smoking cessation is highly desirable [106,107]. Even if it is a demanding objective [107],
smoking cessation should be a priority for physicians.
Alcohol consumption, particularly when excessive, has been implicated in the risk of inadequate
response to MTX [103]. For most patients, a modest alcohol intake is acceptable, provided that hepatic
monitoring remains within safe limits.
Setting realistic but positive expectations about the likely magnitude of benefit, speed of onset, and
mitigation strategies to limit toxicity and tolerability issues for MTX may favorably influence the drug’s
efficacy via improved compliance. High quality education plays a crucial role in achieving this goal.
The impact of patient anxiety has also been underscored in limiting the potential benefits of MTX and
can be accentuated by the ready availability of misinformation through the internet and other sources.
In a multivariate model predicting non-response to MTX in a real-life setting, the risk of non-response
was higher in patients who were negative for rheumatoid factor, had a higher Health Assessment
Questionnaire (HAQ) score, a higher tender joint count, a lower DAS28 score, and a higher anxiety
score [108]. Nonetheless, anxiety is a modifiable risk factor. This issue should be addressed during
the shared decision-making process. This process should include exploring the patient’s expectations
regarding the disease and its treatment, providing honest and positive messages about achievable
outcomes, and allaying unfounded fears about adverse effects of therapy. Educating the patient may
lower the level of anxiety and improve clinical outcomes.
4.2. Choosing the Route of Administration
When starting MTX, the physician has the choice between oral or parenteral administration.
Although MTX can be given by intramuscular (IM) injection, the subcutaneous route is the preferred
parenteral administration mode.
Depending on the MTX dose, the bioavailability differs between oral and subcutaneous routes.
Oral MTX at a dose of 7.5 mg/week has a 100 percent bioavailability. However, bioavailability is
reduced by 30% starting at just 15 mg/week due to gut absorption limitations [22,109]. This threshold
is also the point where the bioavailability of oral MTX reaches a plateau in RA patients [21,110].
Consequently, for a patient receiving a weekly dose of 20 mg, intestinal absorption may be reduced by
30% and the effective dose actually received by the patients may be only 14 mg/week. Despite this fact,
orally administered doses greater than 15 mg/week are frequently used to control disease activity.
By contrast, the bioavailability of SC MTX is greater than that of oral MTX and does not depend
on the MTX dose with a linear increase in systemic exposure for increasing doses [21]. The ratio
of dose-normalised AUC0–24 h of the SC MTX compared to oral MTX was 127.61 (90% CI 122.30 to
133.15) in a cross-over study comparing the two administration routes of the same MTX dose [21].
The AUC ratio between SC and oral MTX increases with higher doses [110]. Therefore, upon switching
from an oral to SC MTX formulation, a patient may experience a bioequivalent increase of more than
6 mg MTX per week. The practical implication of this is that for many patients, there may be no
advantage to increasing oral MTX dose above 15 mg/week [21]. Rather, RA patients with an inadequate
clinical response to orally administered MTX may benefit from the higher drug exposure offered when
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switched to the SC formulation [21]. Initiating the MTX regimen with SC administration has been
associated with better clinical outcomes at the same dosages [111]. Initial treatment with SC MTX has
been associated with lower rates of treatment change, no difference in toxicity, and some improvements
in disease control compared to oral MTX over the first year, in a large cohort of early RA [112].
4.3. Starting at the Right Dose
As monotherapy, the dose of MTX can range from 7.5 to 25 mg/week, depending on national
guidelines and physician’s preference. Such a range allows a wide variety of practices. Indeed,
considerable heterogeneity exists in rheumatologist prescribing behaviours [113].
The recommended MTX dose at initiation is generally 10–15 mg/week [94] but should be
personalized, depending on age, ethnicity, body weight and prior history of intolerance to other
medications. In the interventional C-OPERA study involving Japanese patients, the initial MTX dose
was 8 mg/week [114]. Considering the average patient body weight in the Japanese population, a MTX
dose of 8 mg/week gave a similar MTX dose, per pound of body weight, to a 10 mg MTX dose in the
USA or Europe [114]. In the French ESPOIR cohort involving 813 patients recruited in 14 regional
centres the median MTX dose at initiation was 12.5 mg/week [113] with two peaks in the distribution at
10 mg and 15 mg/week. An optimal treatment defined by a starting dose of at least 10 mg/week during
the first 3 months, with escalation to at least 20 mg/week at 6 months, has been associated with better
clinical outcomes at two years in this cohort [113]. Of note, only 26.3% of patients were considered to
have had an optimal dose.
Clinical response is associated with longer-chain polyglutamates, which take 3–8 weeks to become
detectable in erythrocytes [23]. These data raise the question as to whether a more rapid attainment of
a steady state could be achieved with alternative dosing strategies, such as more rapid dose escalation
or starting therapy with higher doses. Starting with a high oral dose does not make pharmacologic
sense due to the reduced bioavailability of oral MTX above 15 mg/week. Recent trials have used higher
initial MTX dosage (20–30 mg/week) [115]. However, combining the results of 31 studies involving
5589 patients, a meta-regression analysis did not support higher effectiveness of increasing MTX dose
in monotherapy [116]. In the CONCERTO study which investigated the effects of starting with various
dosages of oral MTX in combination with adalimumab 40 mg every other week, there was no difference
in clinical or radiographic outcomes of patients starting with a 10 mg/week MTX dose, compared
to those starting with a 20 mg/week dose [77]. Starting with higher oral doses may also result in
discontinuation due to adverse events, such as nausea.
In patients who reintroduce MTX after previous discontinuation for tolerability problems, the MTX
dose selection should be determined by the last tolerated dose.
4.4. Escalating and Adapting the MTX Dose
In the context of a treat-to-target strategy, the large dose-titratable range of MTX offers numerous
possibilities of dose adjustment before combining with bDMARDS and tsDMARDs. Around one third
of DMARD-naïve patients will respond to MTX monotherapy and maintain favourable outcomes
for several years as reported in the SWEFOT study [117]. The MTX dose should be increased until
remission or at least LDA. In clinical trials comparing bDMARDs to MTX monotherapy, 25% of the
patients allocated to the MTX arm reached ACR70 criterion within 6 months, bringing them in the
range of LDA [118]. With the subcutaneous route [111], the proportion of patients reaching LDA was
even higher.
Titration is highly influenced by the starting dose and initial response to treatment. An optimal
treatment defined by a starting dose of at least 10 mg/week during the first 3 months with escalation
to at least 20 mg/week at 6 months has been associated with better clinical outcomes at two years
in the ESPOIR cohort [113]. In the C-EARLY study comparing certolizumab +MTX and placebo +
MTX in DMARD-RA patients with poor prognostic factors, MTX was started at 10 mg/week and
escalated by 5 mg every 2 weeks, if tolerated, to a maximum of 25 mg/week by week 8. In the MTX
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monotherapy group, 39.4% of patients reached LDA at week 52. Withdrawals due to AEs occurred for
9.2% of patients [119]. These results suggest that the MTX dose should not be less than 10 mg/week
and that dose escalation should be as rapid as tolerated. Maximum dose varies according to the
region. The usual maximum MTX dose is 25 mg/week in USA and Europe although some patients may
benefit from higher doses. The maximum recommended dose in China is 20 mg/week [120] and in
Japan, 16 mg/week [114]. In a randomized controlled trial in patients with active RA despite oral MTX,
intramuscular (IM) MTX, starting at a dose of 15 mg/week then increasing to 45 mg/week, did not
improve disease control; however, higher doses were generally well tolerated [121]. The CRA 2012
Working Group recommends individualized dosing (oral or parenteral) titrated, to a usual maximum
dose of 25 mg/week, by rapid escalation [6]. The French Society for Rheumatology recommends
rapid dose escalation (e.g., 5 mg increments every 1–4 weeks) reaching an optimal dose of MTX (15 to
25 mg/week) within 4–8 weeks [122], depending on effectiveness and safety, as well as individual
characteristics. The use of split oral dosing (2 half-doses at 8 h interval on one day of the week) has
been reported to improve bioavailability, tolerance, adherence, and efficacy [123]. Given the higher
bioavailability of SC MTX beyond 15 mg/week, as compared to oral MTX, switching to SC MTX before
increasing the MTX dose beyond 15 mg/week could be good practice. In addition, switching to SC
MTX may also prevent dose-dependent gastrointestinal side effects [124].
When remission without structural progression is achieved in a patient who is not taking
glucocorticoid therapy, and sustained for many months or even years, therapy de-escalation according
to tight control principles could be considered [122]. However, withdrawing MTX bears the risk of
losing the state of remission and difficulties in regaining a good outcome after a post-withdrawal
flare [118].
4.5. Switching to SC Route
In patients with an inadequate response or intolerance to oral MTX, parenteral administration
should be considered [6]. In Germany, the 2012 adapted EULAR Task Force recommendations
and treatment algorithm in RA support optimization of MTX monotherapy with parenteral
administration [125]. Similarly, the British Society for Rheumatology 2008 guidelines for DMARD use
recommends switching to IM or SC MTX if oral MTX is ineffective or not tolerated [126].
Parenteral administration has been reported to reduce disease activity in patients who have an
inadequate response to oral MTX [127]. Conversely, a change from parenteral to oral MTX has been
associated with disease flare [128], increased disease activity, and greater frequency of gastrointestinal
side effects. Switching back to intramuscular MTX improved disease manifestations and reduced side
effects [129].
Switching patients treated with oral MTX to an SC formulation should be considered when
the maximum tolerated dose has been reached without achieving LDA. The SC route may also be
proposed upfront to the patient at the time of MTX initiation, although this has relatively greater
economic implications. However, data from a randomized controlled trial of 375 MTX-naïve RA
patients favoured initiation of 15 mg once weekly MTX therapy by the SC route, which resulted in
higher ACR20 and 70 response rates than oral MTX with a similar safety profile at 24 weeks [111].
Furthermore, in a large retrospective cohort study, Harris et al. reported that patients taking SC MTX
received higher starting and maximum doses than those on oral MTX (>15 mg starting dose and >20
mg maximum dose) [130], perhaps reflecting the better tolerability of the parenterally delivered drug.
There have been advocates in Canada, Germany, and the United Kingdom for the use of SC MTX
in order to optimize achievable efficacy of MTX prior to commencing biologic treatment or even to
prevent or delay the need for biologic therapy with attendant health economic benefits [6,125,126].
Indeed, multiple lines of evidence suggest that SC MTX, which bypasses first-pass metabolism in the
gastrointestinal tract, appears to be an effective option in patients who have had an inadequate response
or are intolerant to oral MTX. Switching such patients to SC MTX has been shown to result in higher
and more constant bioavailability [22], to be more effective at the same dosage [111], and to have less
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intense gastrointestinal side effects compared to oral MTX [124]. Higher bioavailability and increased
long-chain MTXGlun may translate into efficacy [30,65,131,132]. A retrospective population-based
study in 156 patients who were intolerant or unresponsive to oral MTX found that switching to SC
MTX (n = 78) resulted in a decrease in RA disease severity, with good tolerability reported in these
patients [65]. In the retrospective analysis of the US Veterans Affairs database of patients treated with
injectable MTX after failing prior oral MTX, higher doses of MTX (>20 mg/wk) were achieved more
readily with SC administration, and were associated with a significantly longer duration of MTX
monotherapy before therapeutic change or the addition of other DMARDs/biologic agents, as compared
to the oral formulation [133]. In the previously mentioned clinical trial comparing SC and oral MTX
in 375 RA patients, after 16 weeks, patients from the oral group not fulfilling ACR20 criteria were
switched from 15 mg of oral MTX to 15 mg of SC MTX following which 30% went on to achieve ACR20
responses [111]. In keeping with this observations, but in a real-world setting, retrospective analysis
of 103 RA patients who switched from oral to SC MTX showed significant improvements in DAS-28
scores in patients who switched due to inefficacy or intolerability to prior oral MTX [132].
A prospective survey (i.e., office questionnaires) study evaluating patients (n = 70; each serving as
their own control) with long-lasting RA who were switched from oral MTX to SC MTX due to side
effects reported that when receiving the SC formulation, patients experienced less intense GI side
effects, with no patients reporting vomiting or diarrhoea AEs [124].
SC MTX should also be considered in patients with poor compliance to oral MTX. There is
currently no clear biomarker available to measure adherence to MTX in daily practice, despite some
data suggesting a strong correlation between MTXGlun and compliance assessed by the electronic
monitoring of treatment intakes with the Medication Event Monitoring System [134].
4.6. Giving Time for MTX to Achieve its Maximum Clinical Benefit and Using Bridge Therapies
Whether MTX is initiated at a higher dose, or a lower dose with upward titration, it will still take
up to six months to achieve a maximum clinical benefit. Nevertheless, therapeutic response to MTX
should be assessed after 3 months of treatment with the objective of a clinical improvement at least
50% [4]. If this short-term target is not reached, treatment adjustment should be considered.
Intra-articular glucocorticoids or short term systemic glucocorticoids may be used as part of the
initial treatment strategy while waiting for MTX to take effect [6]. When MTX and intra-articular
glucocorticoids were used with a treat-to-target approach in patients with early RA in the context
of a clinical trial, this strategy effectively decreased synovitis, osteitis, and tenosynovitis and halted
structural damage progression, as judged by MRI [135]. The EULAR Task Force recommends
using glucocorticoids in combination with csDMARDs primarily as bridging therapy until the
csDMARD reaches its maximum effect but corticosteroids should be tapered as rapidly as clinically
feasible [4,6]. Intra-articular glucocorticoid application may be considered in residually inflamed or
reactivated joint [4].
4.7. Preventing or Dealing with Adverse Events by Folic Acid Supplementation
In clinical practice, MTX-related toxicity may limit optimum treatment. Mild toxicity occurs in
about 60% of patients and roughly seven to 38% of patients discontinue MTX within the first year of
treatment due to toxicity [18,136,137]. Predisposing factors include existing folate deficiency, advanced
age, cumulative MTX dose, renal insufficiency, and concomitant use of other folate inhibitors. A folate
deficiency may cause side effects, such as mouth sores, abdominal pain, elevation of liver enzymes,
or bone marrow depletion. Folate deficiency is frequent in RA patients and even more in those treated
with MTX [138]. In a meta-analysis of six clinical studies, RA patients treated with low-dose MTX and
“dummy” folic or folinic acid frequently experienced side effects: nausea and vomiting were reported
by 35% of patients, abnormal liver blood tests were reported by 21% of patients, 22% of patients
experienced mouth sores [139]. By contrast, genuine folic acid and folinic acid supplementation
greatly reduced discontinuation of MTX compared to placebo supplementation in a placebo-controlled
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double-blind clinical trial. This was mainly due to the MTX stopping rules based on elevations of
liver enzymes [137]. By delaying or preventing a premature switch from MTX to a far more expensive
bDMARD or tsDMARD, folate supplementation may contribute to health costs savings [140].
There is a large variability of folate supplementation practices amongst rheumatologists. In a
study of 2467 incident users of MTX in the Veterans Health Administration database, 27% of patients
were not prescribed folic acid within 30 days of MTX initiation. After 20 months, only 50% of patients
continued to receive folic acid [141].
In a Cochrane review of patients on MTX therapy for RA, folic acid or folinic acid supplementation
reduced the risk of gastrointestinal side effects (nausea, vomiting, and abdominal pain) by 26% (not
statistically significant); abnormal serum transaminase elevations were decreased by 77%; the risk
of premature discontinuations from MTX for any reason was reduced by 61%. A trend towards
a reduction in stomatitis was demonstrated but did not reach statistical significance [139]. Folate
supplementation did not negatively impact the efficacy of MTX. These results were confirmed by a
recent meta-analysis of seven studies involving 709 patients [142]. A third meta-analysis of 68 studies
(not limited to RA) of patients taking MTX revealed that MTX increased the risk of nausea and vomiting,
elevated transaminase levels, mucosal ulcerations, leucopenia, thrombocytopenia and infectious events.
The concomitant prescription of folic acid or folinic acid was associated with a significantly lower risk
of any adverse events [143].
No evidence of a significant difference between folic or folinic acid has been reported, but given
its low-cost, folic acid may be the most cost-effective therapy [139]. Prescription of at least 5 mg folic
acid per week with MTX therapy is strongly recommended [94] to avoid or prevent side effects. Taking
folic acid two days before MTX intake may improve its tolerability. Folic acid supplementation can
be increased to 5 mg/day, other than the methotrexate dosing day, if needed. However, a pilot study
recently compared two folate supplementation regimens with folic acid (5 mg/week and 0.8 mg/week)
with similar results [144]. Folinic acid should be administered on a weekly basis the day after MTX.
Although daily use of folic acid other than the MTX day does not appear to affect MTX efficacy, dosing
of folinic acid close to MTX administration or dose of folinic acid over 7.5 mg/week may hinder
MTX efficacy.
4.8. Potential Toxicities
Most frequent adverse events of MTX are gastrointestinal and there is a correlation between
the MTX dose and the intensity of side effects [124]. Other possible side effects include anaemia,
neutropenia, increased risk of bruising and dermatitis. Gastric side effects can be reduced both by
switching patients to the SC route [124] and by folate supplementation [139]. Elevation of transaminases
is frequent, but MTX treated patients are not at increased risk of symptomatic or severe liver related
adverse events [55]. The incidence of clinically important cytopenia in patients treated with low dose
MTX is estimated to be less than 1%. A complete blood count, liver and renal biochemistry, and a chest
radiograph should be ordered prior to initiating MTX therapy [6]. Screening for hepatitis B and C
should be considered and HIV testing is recommended in high-risk patients [6].
MTX is excreted via the kidneys and is contraindicated in patients with an estimated glomerular
filtration rate of less than 30 mL/min. Patients with impaired renal function should be closely monitored
particularly for hematologic toxicity.
Concomitant intake of NSAIDs may reduce renal function, thereby increasing MTX bioavailability.
In a registry-based analysis, concomitant use of NSAIDs and MTX increased the risk of serious adverse
events with a higher risk of renal failure and cytopenia [145]. However, it should be remembered
that NSAIDs, per se, may increase liver enzymes. Therefore, if raised transaminases are observed
in patients taking concomitant MTX and NSAIDs, it is worth considering a decrease (or cessation)
in the dose of NSAIDs rather than diminishing the MTX dose. The physician should pay attention
to self-medication with NSAIDs. MTX should not be used with trimethoprim-sulfamethoxazole
when used in a twice-daily regimen for treatment of an infection since the combination may result in
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significant bone marrow toxicity. However, it can be used for patients taking prophylactic doses of
trimethoprim-sulfamethoxazole (dosed three times per week) for prevention of Pneumocysis Carinii.
The main drug interactions are summarized in Table 1.
Table 1. Drug interactions. MTX, methotrexate.
Interactions Source of Interactions
Increase MTX levels
• Allopurinol, triamterene
• Decrease renal MTX clearance: ciprofloxacin, cephalothin,
penicillin, probenecid, sulfonamides
• Decrease MTX excretion: diuretics, proton pump inhibitors
• Increase MTX reabsorption by the kidney tubule: probenecid
Decrease MTX levels • Decrease intestinal absorption of MTX:
chloramphenicol, tetracyclines
Increase the risk of bone
marrow suppression • Chloramphenicol, co-trimoxazole, pyrimethamine,
sulfonamides, trimethoprine-sulfamethoxazole
Increase liver toxicity • Alcohol, leflunomide
MTX-induced pneumonitis is a potentially life-threatening adverse effect [146]. It is an idiosyncratic
hypersensitivity reaction due to activated T-cell-mediated (CD4 and CD8) stimulation of type 2 alveolar
cells to release cytokines which lead to the recruitment of inflammatory cells, resulting in alveolitis.
Acute or subacute pneumonitis related to methotrexate usually occurs during the first year of
treatment [55,147]. It appears rapidly with low grade fever or high fever, nonproductive cough, and
dyspnea that usually progresses to respiratory failure. The presence of eosinophilia in peripheral
blood but not in bronchoalveolar lavage is common (50%). A diffuse interstitial pattern or a mixed
interstitial-alveolar pattern (nodular or patchy infiltrates) is observed in the chest radiograph and
high-resolution CT usually reveals the pattern of a usual interstitial pneumonia or a nonspecific
interstitial pneumonia. Risk factors for this complication are age (>60 years), previous use of other
DMARDs, hypoalbuminemia, the presence of diabetes mellitus, and a history of pleural disease and/or
prior ILD related to AR (OR: 7.1), the latter being a great confounding factor when establishing a causal
relationship with the drug [148]. It could be difficult to distinguish MTX-induced pneumonitis and
pneumonitis related to Pneumocystis [149]. In a systematic review, 15 of 3463 RA patients (0.43%) who
were receiving MTX developed MTX-induced pneumonitis [150]. Even if rare, this complication needs
to be known and should not be neglected. Its treatment includes withdrawal of MTX, supportive
therapy, and adjunctive steroids. The outcome is good if the condition is recognized early, and if
appropriate treatment is given [146].
Although the overall benefit:risk ratio for MTX is remarkably favourable, as with any drug,
adverse events can occur. Based on known adverse events of MTX treatment, we propose that it is good
practice to assess the patient for several potential risk factors (Table 2). Among these precautions are the
assessment of pre-existing infections, immunosuppression, haematological, kidney or liver diseases,
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neoplasms, the cardiovascular risks, potential interactions with concomitant therapies. In parallel the
psychological status of the patient should be judged or assessed including the coping strategies and
the internal resilience.
Table 2. Preparation of MTX therapy.
Diagnosis of rheumatoid/inflammatory arthritis and/or need for treatment
Diagnosis of chronic kidney or liver diseases
Assessment of cardiovascular risks
Assessment of a neoplastic disease
Discussion on smoking habits and the advantage of smoking cessation
Evaluation/judging of depression and resilience/coping strategies
Assessment of anemia, leukopenia, or thrombocytopenia
Documentation of concomitant drug therapy
Defining therapeutic aim
Shared decision making with the patient
Evaluation of alcohol-consumption
Diagnosis of active/chronic infection with herpes zoster, tuberculosis, hepatitis, HIV, relevant fungal infection
Diagnosis of immunodeficiency
Documentation of vaccination status
Consider testing for tuberculosis
Anticonception/assessing wish of conception/family planning
4.9. Placing MTX as an Anchor Drug
MTX is considered the initial drug of choice in RA pharmacotherapy with subsequent use as
an anchor drug when used in combination due to its efficacy (when used optimally), safety, large
dose-titratable range, and cost-effectiveness [4,5,94].
If the patient is unable to achieve treatment targets on maximally tolerated doses of oral MTX, and
after a switch to the SC route, other treatment strategies must be considered. These include adding
other csDMARDs, and adding or switching to biologic therapies or tsDMARDs, depending on the
absence or presence of poor prognostic factors [4]. In routine practice, several combinations can be
considered with some variations in preference according to country. As an example, physicians may
take advantage of the combination with probenecid [151], the synergistic action of MTX and HCQ [69],
or the triple combination MTX, HCQ, and SSZ [69,70]. In UK or Canada, rheumatologists are required
to use at least two csDMARDs before the application of bDMARDs is approved by the payers [4].
The EULAR Task Force strongly recommends that bDMARDs and tsDMARDs should primarily be
added to csDMARDs, such as MTX, since all bDMARDs have better efficacy when combined with MTX
than as monotherapy [4]. This may be due to complementary mechanisms of action, pharmacokinetic
interactions, and reduction of immunogenicity of the administered biologic agent.
If MTX is well tolerated in combination with concomitant csDMARDs or targeted therapies,
the dose does not need to be tapered while waiting to achieve the desired treatment target. In case of poor
tolerability, MTX can be used at 7.5–10 mg/week to provide additional efficacy to TNF-inhibitors [77]
and intolerance at these low doses leading to discontinuation is very rare. Stopping MTX should be
limited to patients with contraindications or very poor tolerance to MTX.
Current application of these guidelines is far from optimal. Analysing a database of 35,640 US
patients with RA starting oral MTX, Rohr et al. [152] reported that over the 20,041 patients who had to
change the treatment over a 5 year follow-up, only 13% switched to SC MTX. In those who added
or switched to a biologic, only 37% were on >15 mg/week of oral MTX when a biologic was started.
The addition or switch to a biologic occurred in the first 3 months of MTX therapy in 41% of patients,
and in the first 6 months in 51% of patients. As stated by the authors, this study revealed that the MTX
was dramatically underutilized as an efficacious anchor drug in clinical practice
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4.10. Conception and Pregnancy
This section applies to RA patients who are planning to become pregnant and/or breastfeeding,
men planning to conceive and patients who have accidentally conceived while taking MTX.
MTX is pro-abortive and teratogenic but does not decrease fertility [153]. Therefore, MTX at
any dose should be avoided during pregnancy [154]. The optimal delay between the last MTX dose
and conception is still a matter of debate and may vary between countries. Guidelines from the
British Society for Rheumatology (BSR) and the British Health Professionals Society in Rheumatology
recommend to stop MTX three months in advance of conception [154]. On the other hand, MTX is
recommended to be stopped between 48 h and 6 months before conception, in France and in Spain,
respectively. Thus, to avoid medicolegal issues, we recommend following the legal label of your country.
In the case of accidental pregnancy on low-dose MTX, the drug should be stopped immediately [154].
MTX cannot be recommended in breastfeeding because [154] MTX is excreted into breast milk
and may be toxic for the neonate.
If a woman has received MTX within 3 months prior to conception, or in the case of accidental
pregnancy on MTX, folate supplementation should be continued prior to and throughout pregnancy at
a dose of 5 mg/day [154].
Data regarding preconception exposure to MTX in men are reassuring, and, indeed, recent BSR
guidelines state there is no need for men wishing to father children to stop MTX [154]. A study involving
a very large cohort concluded that paternal exposure to MTX within 90 days before pregnancy was not
associated with congenital malformations, stillbirths, and preterm birth [155]. Older recommendations
suggest to stop MTX three months prior to conception, but this is not evidenced by an understanding
of the impact of MTX on spermatogenesis or paternal-mediated teratogenicity, but rather relies on the
timeframe of spermatogenesis [156].
4.11. Vaccinations
RA patients are more prone to infections than healthy subjects due to the immune dysfunction
associated with the condition. DMARDs inhibit cellular and humoral immunity, thus aggravating
the susceptibility to infections. For these reasons, vaccines against preventable diseases should be
counselled in patients with RA. Influenza, pneumococcal, and shingles are important for all patients
with RA whereas human papilloma virus, hepatitis B virus, and yellow fever (YF) vaccines are relevant
only in selected patients, such as those living in or traveling to a YF-endemic country [157]. Protection
is far from optimal. In 2012, in the United States, only 28.5% of patients older than 60 with rheumatic
diseases were vaccinated against pneumococcal pneumonia; 45.8% were optimally vaccinated against
influenza, and only 4.0% of patients were vaccinated against shingles [158].
MTX significantly decreases vaccine response to pneumococcal [159,160] and seasonal influenza
vaccines [159] in a dose-dependent manner [161]. A recent randomized controlled trial showed that,
in order to impair the response to vaccines, MTX had to be present just before or at the same time
of vaccination [162]. It is, therefore, recommended that vaccination be done before a DMARD is
started, where practically feasible [5]. However, it may be necessary to prioritize control of the disease.
In such circumstances, and for seasonal vaccinations, MTX dosing can be temporarily interrupted.
In a prospective randomized parallel-group trial, patients with RA taking a stable dose of MTX were
randomly assigned at a ratio of 1:1:1:1 to continue MTX (group 1), suspend MTX for 4 weeks before
vaccination (group 2), suspend MTX for 2 weeks before and 2 weeks after vaccination (group 3), or
suspend MTX for 4 weeks after vaccination (group 4). All participants were vaccinated with trivalent
influenza vaccine. Temporary MTX discontinuation improved the immunogenicity of vaccination. No
difference was found between groups three and four [162]. These results were confirmed in another
study [161] that demonstrated improvement in immunogenicity of seasonal influenza vaccination
in patients receiving methotrexate in whom the drug was withheld for 2 weeks immediately after
immunisation, compared with those who continued to receive methotrexate with a satisfactory vaccine
response seen in 76% of the former compared with 55% of the latter group. However, there was a
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slightly higher incidence of flares in those patients who withheld methotrexate compared with those
who had remained on methotrexate (11% vs. 5%). Therefore, suspending MTX administration for
2 weeks after the vaccination seems to be good practice.
Shingles vaccine can be used safely with low-dose MTX (i.e., up to 25 mg/week) [157].
Live vaccines, such as yellow fever, measles/mumps/rubella, varicella, and oral typhoid
vaccinations, are contra-indicated in patients receiving MTX. Information remains too scarce to
question the current guidelines.
4.12. No Need for MTX Discontinuation in Case of Surgery
Despite the efficacy of DMARDs, 58% of RA patients will ultimately undergo orthopaedic surgery,
with nearly 24% undergoing large-joint arthroplasty [163]. Patients receiving DMARD are potentially
at higher risk of infections and delay in wound healing due to the anti-inflammatory properties of
these compounds. A study involving 388 patients with RA who underwent surgery found that patients
who continued MTX through surgery had fewer complications, infections, and RA flares than patients
who discontinued MTX for 2 weeks before and after surgery [164]. A special consideration should
be given to patients who develop renal dysfunction postoperatively, since the risk of MTX toxicity is
increased in cases of renal failure.
4.13. Sharing the Decision Making with the Patient
Adherence to treatment has been shown to depend on the level of appropriate information
provided to patients and the amount of good interaction with the rheumatologist [165]. Non-adherent
patients flare four times more frequently than adherent patients [100]. Most arthritis patients prefer to be
involved in decisions about their medication [166], and this has been linked to higher patient satisfaction.
Patients exhibit a complex range of beliefs related to DMARD therapy [167]. Furthermore,
the degree to which patients desire to be directed by their physician regarding treatment choice
varies tremendously and may evolve over time to become more collaborative [168]. Sympathetic
understanding will facilitate the provision of appropriate information to allow the patient to make
informed decisions [169]. Furthermore, it is crucial to educate patients about the importance of a T2T
strategy, since it has been shown that patient preference is among the leading barriers to treatment
adjustment to T2T in RA [170].
The EULAR Task Force recently reiterated the relative safety of MTX and recommended that
the frequent fears of patients after reading the package insert should be addressed by providing
appropriate information [4]. The overemphasis on the risk of side effects that are widely spread on
social media can generally be overcome by an open, balanced, and reassuring discussion regarding
the benefits/risks and risk mitigation at the time of the first prescription. The other crucial points
to address are the importance of maintained therapy, especially in those patients in remission who
want to stop MTX, and patient adherence (in particular, for patients who tell their practitioner that
they are taking MTX when, actually, this is not the case). Available data suggest that adherence to
RA therapy does not exceed 66% [171], but this proportion is enhanced by the belief in the necessity
of the medication. For this reason, when explaining the achievable goals of treatment to the patient,
the rheumatologist should emphasise the availability of long-term observational data demonstrating
the numerous benefits and good overall tolerability of MTX.
When initiating MTX, we recommend that rheumatologists adopt a shared decision-making
approach to the recommended regime. Key points to be emphasised in dialogue with the patient are
summarized on Table 3.
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Table 3. Key points patients will need to be counselled about when rheumatologists adopt
a shared decision-making approach to the recommended regime. NSAIDs, non-steroidal
anti-inflammatory drugs.
Topics to Discuss with Patients
• The choice of routes of administration and the advantages of each
• Expected time to experiencing benefits (this is very important as a patient may experience transient
tolerability problems such as nausea prior to experiencing and improvement in symptoms and there will
therefore be a danger of non-adherence if there has not been appropriate counselling)
• Potential toxicities with reassurance about the capability to mitigate these risks through regular and
appropriate blood monitoring
• The potential tolerability issues, especially nausea with appropriate reassurance that this can be lessened or
mitigated with use of folic acid supplementation or parenteral administration
• Women of childbearing potential need to be counselled about pregnancy and family planning.
• Vaccinations and how to ensure optimum outcomes of vaccination
• Alcohol consumption
• Interactions between MTX and other medication with particular advice about NSAIDs
5. Conclusions
In conclusion, MTX is a remarkable drug with a unique place in the pharmacotherapeutic
management of RA. Key recommendations for clinical use are listed in Table 4. In the last 2 decades,
the cumulative experience of rheumatologists has helped to refine the possibility of achieving the
best outcomes with MTX. It has a large dose titratable range and can be administered as a once
weekly dose regimen by either oral or subcutaneous routes. Parenteral administration of MTX has
the advantages of maximising bioavailability, reducing gastrointestinal intolerance, and potentially
enhancing compliance and adherence. MTX is recommended as the first-line csDMARD treatment for
RA and can also be used in combination with other csDMARDs, bDMARDs, or tsDMARDs. In the
case of concomitant use with targeted therapies, MTX facilitates optimum achievable efficacy, and
also has the advantage, when used with bDMARDs, of reducing ADAb responses to administered
biologic. MTX is also highly cost-effective and has a favourable benefit/risk profile overall. Nonetheless,
adverse events associated with MTX are well-described and tolerability issues can be a troublesome
complication of this treatment. However, with appropriate risk-mitigation strategies, including folic
acid supplementation, blood monitoring, and patient education, one can optimise achievable outcomes.
Table 4. Key recommendations for clinical use of MTX. csDMARD, conventional synthetic
disease-modifying antirheumatic drugs; bDMARDs, biological DMARDs; tsDMARDs, targeted
synthetic DMARDs; SC, subcutaneous.
Key Points for Clinical Use of MTX
Modify predictors of response to MTX
Encourage smoking cessation
Limit alcohol consumption
Ensure appropriate education on how to optimise outcomes
Manage anxiety and depression
Start at the right dose
Generally 10–15 mg/week, but should be personalized
There is no need to start with higher dose
Choose between oral and parenteral route.
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Table 4. Cont.
Key Points for Clinical Use of MTX
Escalate as quickly as tolerated
Titrate dose according to individual clinical response
Generally aim to reach a dose of at least 20 mg/week after 6 months
Consider local recommendations and clinical context
Switch to SC route for doses higher than 15 mg/week to enhance MTX bioavailability
Prevent side effects
Start folic acid supplementation at a dose of at least 5 mg/week and up to 5 mg/day other than the day of
methotrexate (or folinic acid at a dose lower than 7.5 mg/week)
Instruct the patient to not take folic acid on the day of MTX administration
Folinic acid should be administered on a weekly basis the day after MTX administration
Counsel patients about risk mitigation through blood monitoring according to local protocols
Be aware of potential drug to drug interactions
Instruct the patients to seek advice from their rheumatologist about compatibility with methotrexate of
self-medicated drugs or drugs prescribed by another physician
In case of poor tolerability
Diminish gastrointestinal side effects by switching to SC route
In case of inadequate response
Enhance MTX bioavailability by splitting oral dose or switching to SC route
Consider combination with csDMARD, bDMARDs or tsDMARDs
Do not stop MTX nor reduce MTX dose unless there are toxicity or tolerability concerns
Give time for MTX achieving maximum clinical benefit
Use intra-articular or systemic glucocorticoids as bridging therapies
Educate the patient and adopt a shared decision-making approach
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